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ABSTRACT:

Diagnosis for neurodevelopmental disorders poses numerous challenges, related to the
lack of specific findings and limited understanding of clinical impact of the majority of genetic
variation. Epigenomics mechanisms involve chemical modifications in DNA that involve a range
of cellular mechanisms. DNA methylation is an epigenetic mechanism involving addition and
removal of methyl groups to cytosine residues. These methylation signals form episignatures;
patterns of methylation that can be used as biomarkers capable of differentiating
neurodevelopmental disorders. EpiSigns have enabled molecular diagnosis of a number of
genetic conditions, classification of variants of unknown significance, and provided insights into
the pathophysiology of neurodevelopmental disorders. I hypothesized DNA methylation can
provide classifications of neurodevelopmental disorders, and identify epigenetic patterns that
relate the phenotypic and genotypic variations seen in these patients. Main objectives of this
work include 1) determination of syndrome specific episignatures, 2) analysis of domain specific
variants and their effects on the methylation profiles and ensuing phenotypes 3) determine
effectiveness of episignature assessment in classifying neurodevelopmental disorders in
paralogous genes, 4) assessing phenotypic overlap between distinct neurodevelopmental
disorders and correlation to their methylation profiles. My thesis demonstrates that these
episignatures are robust biomarkers that inform effective methods to diagnose complex
neurodevelopmental disorders and provide evidence of shared functional pathways highlighted
by the various genomic and phenotypic contexts episignatures have been derived from.
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LAY SUMMARY:
Within each cell, genetics acts as a blueprint to provide instructions for the creation and
maintenance of various cellular structures and functions, however, given how this genetic blueprint is
identical across all cells in an organism, additional methods of control must exist. While the blueprint
remains the same, different levels of expression of genes within the genome allow for differentiation,
resulting in the various different types of cells available in the human body. Additionally, cells can
change over time, at different developmental periods, where particular genes are expressed, and
eventually turned off when their function is complete. The study of this phenomenon, where the genome
is not altered, but instead has the expression of different regions turned on and off, is referred to as
epigenetics. One method for this type of epigenetic change is DNA methylation, a chemical mark that can
be attached to parts of the genome that changes how genes at that region of the genome are expressed,
similar to an on/off switch. When defects in the genome or epigenome occur, disorder of the cell’s control
systems is caused, and disease ensues, as switches supposed to remain off are switched on, or vice versa.
This thesis works to observe how they differ from persons with disease compared to those without them,
to create episignatures, chemical fingerprints of gene defects. In particular I have assessed DNA
methylation in relation to neurodevelopmental disorders, syndromes that present with a complex set of
characteristics related to intellectual development, and cognitive abilities. By cataloging and describing
the genome of persons with neurodevelopmental disorders, we can identify which on/off switches are in
disarray compared to their healthy counterparts, helping to better understand the ways in which these
disorders present themselves, and provide ways to identify them in new persons.
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CONTRIBUTION TO ORIGINAL KNOWLEDGE

The work described in this thesis represents significant contributions to the field of
genetics and neurodevelopmental disorders in several ways. First and foremost, I describe
several novel episignatures, in chapter 2, an episignature for GADEVs, In chapter 3, an
episignature for the newly describe K2BNDD, in Chapter 4, an episignature for KAT6A
syndrome, and finally an episignature shared between ADNP and SMARCA2 cohorts. These
signatures are effective biomarkers shown to have a high degree of sensitivity and specificity,
and can be used in both clinical and research settings to better understand the disorders in
question, and their molecular etiologies. Furthermore, I have integrated various sources of
clinical information, including genetic phenotypic and epigenetic data, for assessment and
refinement of the related episignatures. My work provides further evidence of the genotype and
phenotype correlations with the consequent epigenetic patterns and provides further insights into
the molecular pathophysiology of genetic neurodevelopmental disorders.
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1.1 LITERATURE REVIEW

1.1.1 DEFINING EPIGENETICS
Epigenetics refers to the study of cells ability to control gene activity without changes to
the underlying genetic sequence [1,2]. The prefix “Epi-” from Greek, means above, or upon, and
provides an effective insight into the mechanisms that epigenetics uses to modify the ensuing
phenotypic expression of cells, namely, through modifications in the form of added molecular
groups, such as methyl tags, and histone protein modifications. These chemical modifications
involve DNA and the adjacent chromatin structures, allowing for regulation of gene expression
through compaction of DNA elements, and restriction or easement of protein machinery access
to the genetic sequence. Therefore, although no change is made to the composition or sequence
of nucleotides, significant changes in expression of the various proteins and molecular signals
that instruct the cells can be made.

1.1.2 ALTERNATE EPIGENETIC MECHANISMS: HISTONE MODIFICATIONS AND
CHROMATIN REMODELERS
In this thesis, my research has focused primarily on the assessment of DNA methylation,
which will be discussed in detail, however it is important to acknowledge the importance of other
epigenetic modifiers, namely, histone modifications and chromatin remodeling complexes. Many
of the previously established episignatures have been associated with the disruption of these
machineries (See Figure 1-1), and they play an important part in the establishment of the
epigenome. My primary assessment method throughout this project was based on DNA
methylation biomarkers, however, the syndromes and cohorts of patients I will discuss further on
concern disruption of genetic mechanisms related to several important histone modifying
proteins, DNA methylation interactors, and chromatin remodeling complexes.
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Figure 1-1. Episignatures associated with histone modifications. Outline of 23 disorders
included in the Episign Version 3 paper [12] that involved direct modification of histone
residues. Disorder names are paired with the histone modification for which the associated gene
is responsible. 21 disorders were associated with histone 3 modifications, while an additional
two disorders were associated with histone 4 modifications.
Histones are protein octamers that are organizational units that DNA is wrapped around,
allowing for compact storage of the near 3 billion base pairs within the human genome [2]. This
form of wrapped and compacted DNA is referred to as chromatin, comprising both the DNA
sequence and its eight complexed organizational histone proteins. The compaction of chromatin
into its transcriptionally inactive state; heterochromatin, or decompacted, transcriptionally active
state; euchromatin is regulated by a plastic system of chemical modifiers. The addition or
removal from the “tail” residues of the histone complexes results in changes to the histone's
compaction, and therefore gene regulation activities. Histone tail modifications include but are
not limited to, methylation, acetylation, phosphorylation, acylation, and ubiquitination, with each
modification resulting in different chromatin states depending on the type and pattern of
modification [3]. These changes, in concert with other epigenetic mechanisms, result in
genetically identical cells within an organism being able to differentiate into the myriad of cell
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lines and phenotypes, as well as providing a reversible plastic system of gene regulation, capable
of interacting with and responding to environmental stimuli [4]. The interactions of histone
modification and DNA methylation allow for an organism to differentiate both spatially, creating
diverse and unique cell lines, as well as temporally, as epigenetic machinery can be recruited at
various developmental timepoints to allow for preferential gene expression.
Chromatin remodelers are protein complexes capable of providing large scale changes to
nucleosomes and their associated chromatin, promoting changes in nucleosome spacing and
density, or facilitating histone variant exchange [5,6]. Disruption of these chromatin remodelers
causes widespread changes to gene expression, which in the context of neural development,
disrupts the tightly regulated network of factors which determine cell fates, resulting in the
neurodevelopmental disorder (NDD) phenotypes observed. Proper reorganization of chromatin
states, regulated by these complexes, allows for fine tuning of gene expression, making them
essential [7,8]. Major actors include the Adenosine triphosphate (ATP) dependent chromatin
remodeling enzyme family, which consists of four subgroups, the Switch/Sucrose nonfermentable (SWI/SNF), Imitation Switch family (ISWI) , Chromodomain-Helicase-DNA
binding family (CHD), and the Inositol 80 family (INO80), which have been implicated in a
number of neurodevelopmental disorders including Coffin Siris (CSS), Nicolaides Baraitser
(NCBRS). The SWitch/Sucrose Non-Fermentable (SWI/SNF) complex, also known as the
BRG1/BRM associated factor (BAF) is one such example of chromatin remodeler, which utilizes
ATP dependent hydrolysis to alter the nucleosome, ultimately resulting in flexible changes
between hetero-chromatin and euchromatin states. This SWI/SNF complex is involved in a
number of epigenetic regulatory roles that impact developmental processes, particularly in the
central nervous system (CNS). Lethality has been associated with complete knockout models of
SWI/SNF, and even in the case of conditional knockout, severe neural agenesis was observed,
indicating its essential status in proper development of neural structures[7,9,10]. Nevertheless,
due to their complexity in terms of how they assemble their various subunits, and function in
vivo, the exact role of each actor remains difficult to study, and future work remains to determine
how these remodeler proteins can be accurately described and targeted for therapeutic
interventions. [11]
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1.1.3 DNA METHYLATION TECHNOLOGIES
DNA methylation can be assayed by several methods, including bisulfite conversion,
restriction-enzyme digestion, DNA binding proteins with differential affinity for methylated
sequences, pulldown antibody assays, and most recently, enzymatic methyl sequencing
techniques [13, 14, 15, 16]. Microarray-based and sequencing methods have been built using
these principles and allowed for extensive investigations into the epigenome. The current gold
standard technique makes use of sodium bisulfite, which involves chemically modifying
unmethylated cytosines. Bisulfite deaminates unmethylated cytosines to uracils, which are then
converted to thymines following polymerase chain reaction (PCR) amplification, allowing for
the identification of the remaining methylated cytosines through traditional sequencing or
microarray methods. Whole genome bisulfite sequencing (WGBS), makes use of this technique,
providing a genome wide view of methylation levels at single base resolutions [17, 18, 19]. This
technology has shortcomings however, as the bisulfite conversion process can result in damage
to the DNA sequence, as well as resulting in low levels of cytosine within the samples, making
polymerase reactions required for sequencing difficult [20, 21]. This makes WGBS in tissues
with limited genetic starting material difficult, as the margin of error for the amount of
acceptable loss of DNA is quite small, and can create biases in the estimates of methylation
levels.
Microarray technologies, such as the Illumina EPIC array used in my assessment of
episignatures, make use of similar principals in the assessment of genome methylation levels. In
DNA methylation microarrays, DNA is bisulfite converted to differentiate between methylated
and unmethylated cytosines, as unmethylated cytosines are converted to uracil residues. The
ensuing converted DNA is then provided to the microarray, wherein oligonucleotide probes,
short sequences of DNA complementary to the processed DNA, are available for hybridization.
For differentiation, probes specific to the methylated and unmethylated sequences are associated
with different dyes, whose intensity can be measured to identify the distribution of methylated
cytosines at each probe. Recent years have seen widespread adoption of microarray analysis in
methylation research, due to its cost-effectiveness, versatility, high resolution at individual base
pairs, and low amount of required DNA (~500ng) [22,23]. In comparison to sequencing
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methods, microarrays only assay a selected portion of the genome, depending on the associated
probeset, however it does so at a high level of coverage, providing a high level of precision [24].
Microarray methods suffer from the same shortfalls of WGBS, as the bisulfite conversion
process can damage DNA, and requires significant amounts of starting material to proceed.
Furthermore, the hybridization process is limited by bisulfite conversion, as bisulfite treated
DNA only has 3 bases (A,T, and G) with which to create oligonucleotide probes for effective
hybridization [25]. Nevertheless, microarray-based assessment of DNA methylation profiles
remains a popular choice in research and clinical settings, representing a significantly more cost
effective approach when compared to WGBS. Microarrays only assay a small proportion of the
genome, they offer a high level of precision through high levels of coverage at these selected
sites [24], furthermore, large increases in assayed regions have occurred over the past decade of
technological advancements, with the latest version of the microarray platform from Illumina,
the EPIC beadchip array covering over 850,000 CpG methylation sites [23].
Recently developed enzymatic methyl-sequencing techniques have been developed in
response to the difficulties associated with the bisulfite conversion step of WGBS and
microarray techniques, and validations of the process seem to indicate it to be an effective
method of genomic methylation levels [15]. This technique makes use of epigenetic eraser
proteins, known as ten-eleven translocases (TET), more specifically TET2 (OMIM# 612839), to
oxidize methylated cytosines within the genome, which are then converted to uracils using an
additional enzyme, apolipoprotein B mRNA editing enzyme catalytic subunit 2 (APOBEC2,
OMIM# 604797) to convert them to thymines. This essentially mirrors the process of bisulfite
conversion, but uses enzymatic modifiers, rather than chemical, and as a result has several
improvements. These enzymatic modifiers do not have the same cross reaction with the DNA
backbone, and do not cause DNA degradation, allowing this process to be used on smaller
amounts of starting material. Furthermore, since the end products of these processes are the
same, analytical tools based on bisulfite conversion techniques can be used [13,26].
1.1.4 DNA METHYLATION; MACHINERY, MECHANISMS AND MODULATION
The most well studied and understood epigenetic mechanism is DNA methylation, that is,
the addition of a methyl group to nucleotide residues within the DNA sequence. First
demonstrated in bacterial models in 1925, the presence of methyl (CH3) chemical groups on
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nucleotide bases remained poorly understood for several decades [27]. In 1975, researchers
characterized the biological function of methyl groups connected to the 5’ carbon of the cytosine
residue skeleton, identifying these 5-methyl-cytosine (5mC) residues as important epigenetic
modifiers that influence gene expression [28,29]. DNA methylation in humans occurs almost
exclusively on cytosine residues, in cytosine-guanine dinucleotides (aka CpG). These CpG
dinucleotides are interspersed throughout the human genome, and include randomly interspersed
genomic CpGs, and gene promoter associated CpG islands, where large clusters of CpGs occur
in high density [4]. Most of the interspersed CpGs in the human genome are methylated,
however a subset of CpGs, termed CpG islands, are predominately unmethylated and associated
with transcriptionally activated euchromatin configurations [30]. In these CpG islands, located
near promoters, or promoter regulatory regions of genes, hypermethylation corresponds to a
heterochromatin state, which lessens the ability of proteins to interact with the proximal DNA
sequence, thereby reducing and/or silencing the expression of nearby genes [31]. However,
epigenomic structures or profiles display regional differences across the human genome. For
example, most CpGs in the epigenome, with the key exception of CpG islands of gene promoters
for housekeeping genes [32], are methylated during development. Once cells are differentiated
into separate cell lines, specific genes are differentially methylated in appropriate cells, allowing
for expression of genes that are necessary for the unique functions of the given cell line, and
subsequently maintain their function in these specialized tissues.
This plastic system requires several key functions for effective regulation of gene
expression, necessitating several families of important proteins to carry out epigenetic
modification. Components that interact with the epigenome are named “epigenetic machinery”
and can be sorted into several classes according to their function, namely, readers, writers and
erasers [33,34,35].
Writers, such as the DNA methyltransferase (DNMT) family, are responsible for the
addition of methyl tags to cytosine bases. In the process of DNA methylation, methyl (CH3)
groups are added onto the C5 position of the carbon skeleton of the cytosine residue, and is
carried out by a family of proteins known as the DNA methyltransferases (DNMTs). The DNMT
family has 3 key proteins, DNMT1, DNMT3A, and DNMT3B (OMIM#126375, OMIM# 602769,
OMIM# 602900). DNMT1 was the first of the DNMT family to be researched and isolated, and
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is referred to as a maintenance methyltransferase. This refers to its role transferring methyl
groups to hemimethylated DNA, that is, DNA with methylation tags on one strand of the DNA
helix, following parental DNA replication. To maintain proper methylation patterns in the
daughter cells, DNMT1 must methylate the opposing strand’s CpG [30]. The presence of this
enzyme is therefore integral during embryonic development, and genetic disruption results in
embryonic lethality in mouse embryo models [30,36]. DNMT3A and DNMT3B perform
methyltransferase activity without the need for the DNA strand to be hemimethylated (although
they also methylate hemimethylated DNA with similar efficiency), and as such are termed “de
novo'' methyltransferases. Capable of modifying methylation patterns throughout the genome,
these genes are integrally linked to developmental processes, particularly those related to
genomic imprinting. Although they both perform similar activities, DNMT3A is expressed
ubiquitously, while DNMT3B is expressed at its highest levels within the testis, thyroid, bone
marrow and thymus [37]. Disruption of these DNMT enzymes is implicated in a number of
neurodevelopmental conditions, including adult-onset autosomal dominant cerebellar ataxia,
with deafness and narcolepsy (ADCADN) and Tatton-Brown-Rahman syndrome (TBRS). In
ADCADN, mutations in DNMT1 result in a degenerative condition characterized by hearing loss,
narcolepsy, cataplexy and cerebellar ataxia, highlighting the myriad of CNS developmental
processes affected by the loss of this maintenance methyltransferase [38].
Erasers, on the other hand, reverse this process, removing methyl groups to reduce
compaction of chromatin and promote a more transcriptionally active state. One group of erasers,
the Ten-Eleven Translocation (TET) enzymes, can perform this activity, removing methyl
groups through their cytosine dioxygenase activity. TET proteins convert 5mC to 5hydroxymethylcytosine (5hmC), then 5-formylcytosine (5fC), and finally 5-carbocylcytosine
(5caC), with each step in the process carried out by TET1, TET2, and TET3 respectively [39].
The methyl groups of 5mC derivatives are more readily removed and repaired using base
excision repair (BER) processes, resulting in an unmethylated cytosine residue [40]. This
interaction between DNA methylation associated proteins creates a plastic network of epigenetic
fine tuning, allowing for modulation of gene regulation throughout an organism's life. Marks can
be added and removed in different cells, or at particular developmental periods, fostering a great
deal of transcriptional flexibility.
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Finally, readers, such as MECP2, MBD1, MBD2, MBD3 and MBD4 (OMIM#300005,
OMIM#156535, OMIM#603547,OMIM# 603573, OMIM#603574), can recognize the presence
of methyl groups with specialized methyl binding domains within their structure [30,35,41],
allowing the body to accurately assess and modulate methylation at key developmental stages,
resulting in spatial and temporal differentiation through manipulation of transcription [42, 43].
MECP2 binds to methylated CpG sites, and promotes interaction with several histone modifying
enzymes, including histone deacetylase complexes (HDAC)[44, 45] as well as chromatin
remodeling complexes, such as the cAMP response element binding protein (CREB)[46]. The
effects of these interactions vary depending on the associated complex and genomic context,
with transcriptional activation resulting in some instances [44, 46] while others promote
transcriptional repression [44, 47]. Epigenetic reader proteins exhibit a wide range of effects on
the regulation of epigenetic activity, and the downstream effects of their disruption lead to
significant alterations in transcriptional activity. Disruption of MECP2 results in Rett syndrome
(RTT), while duplication of MECP2 results in MECP2 duplication syndrome, each characterized
with significant intellectual disability, autism and developmental regression, highlighting large
scale developmental consequences [48].
Interaction with the micro and macroenvironmental exposures further increases the
complexity of the epigenetic landscape, and this network of epigenetic machinery allows the
body to react to these stimuli. For example, epigenetic mechanisms have been shown to respond
to changes in diet, exercise, exposure to chemicals, and a myriad of other environmental stimuli
[49]. Epigenetic mechanisms can therefore be described as a conduit between the environment,
the genotype, and through their effects on the transcriptional landscape, the ensuing phenotype of
the cell, playing a key role in cellular and organismal responses to adaptation to their
environment.
My investigation of epigenetic machinery and its effects on the biology of human
development focuses on mendelian neurodevelopmental disorders, (NDDs). By assessing the
recurrent DNA methylation patterns, I aimed to develop accurate epigenetic biomarkers that can
help in resolving ambiguous genetic findings and variable phenotypes, and provide further
insights into the molecular pathophysiology of genetic NDD disorders.
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1.2 MENDELIAN NEURODEVELOPMENTAL DISORDERS
1.2.1 DEFINING NEURODEVELOPMENTAL DISORDERS
The term neurodevelopmental disorder is a broad one, referring to a large cohort of
complex, heterogeneous conditions that involve some form of disruption to brain development,
resulting in highly variable difficulties in cognition, learning, speech, motor function and various
sensory capabilities. Under the current criteria of Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), NDDs are defined as a group of conditions with onset in the development
period, inducing deficits that produce impairments of functioning [50]. This necessarily broad
definition results in grouping a large group of disorders that includes intellectual disability
disorders, communication disorders, autism spectrum disorders and neurodevelopmental motor
disorders.
1.2.2 CURRENT DIAGNOSTIC GUIDELINES
NDDs have a global prevalence of approximately 2-3% of the population. Application of
whole exome sequencing (WES) and whole genome sequencing (WGS) has greatly improved the
diagnostic rate in these conditions [6], however successful diagnosis rates remain relatively low.
Current diagnostic guidelines use a combination of genetic information, and assessment by
qualified clinicians to aid in the diagnosis of these conditions. Causes of NDDs are highly
heterogeneous, including environmental factors, single gene mutations and chromosomal
aberrations, with a large number of genes involved in the epigenetic machinery being implicated
[51]. Nevertheless, the complexity of the observed phenotype, and a high degree of genetic
variability, resulting in low penetrance and expressivity makes diagnosis of these conditions
extremely difficult. Overlapping phenotypes, low penetrance, and the inability of current next
generation sequencing (NGS) techniques to identify and interpret non-coding regions of the
genome all contribute to lack of genetic diagnosis in an estimated two thirds of patients [52-56].
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1.2.2.1 AMERICAN COLLEGE OF MEDICAL GENETICS GUIDELINES FOR VARIANT
INTERPRETATION
NGS assessment, including targeted gene analysis and WES, provide a conclusive
diagnosis in approximately 15-35% of cases in patients with rare neurodevelopmental disorders
[52-56]. Although this is an improvement over previous gold standard chromosomal microarray
(CMA) techniques, most patients with a suspected diagnosis do not reach a conclusive diagnosis
for their condition. Current American College of Medical Genetics (ACMG) standards and
guidelines for variant interpretation rely on various sequence interpretation tools and variant
classifications, grouping variants detected on NGS platforms based on their perceived
pathogenicity. This classification falls into one of five categories for any detected variant,
pathogenic, likely pathogenic, uncertain significance, likely benign and benign, depending on the
observed effects of the variant in question. These classifications are based on a number of
criteria, including mode of inheritance (inherited or de novo), analysis of previously published
literature including similar variants, in silico prediction tools, variant type (frameshift, missense,
nonsense, splice-site etc.) and functional evidence of variant expression. Genetic testing in
NDDs often results in the classification of variants as variants of unknown significance (VUS),
with some estimations at upwards of 25% of diagnostic assessments resulting in VUS
classification [57,58]. Although the ACMG guidelines can help interpret the effects of a variant
following detection in WES, the ability to classify the downstream effects of epigenetic
perturbation is low. Interpretations of these variants can be aided with population databases, and
in silico prediction tools, but reclassification of genetic VUS in these patients, if possible, is
directed by functional studies such as DNA methylation assessments.
1.2.2.2 CLINICAL FEATURES ASSESSMENT
Clinical features are an important source of information for the diagnosis of NDDs.
Clinician’s role in the process is indispensable, providing an assessment of intellectual
disabilities, dysmorphisms, speech pathologies and the various other etiologies of NDDs.
Methods of assessment include self-reported surveys from patients or their caretakers,
dysmorphic features assessment carried out by clinicians, patient history review and a myriad of
tests for various aspects of neurodevelopmental pathology, including fine and gross motor skills,

11

written and oral communication, socio cognitive impairment, eating habits, self-care and daily
living proficiencies and many others [59,60]. One such example of gross motor assessment is the
Gillette functional activity level, which measures the ability of patients to be mobile in various
environments on a ten-point scale, providing an assessment of overall capacity for activity and
independence [59,60]. Communication methods and frequency is often assessed, with the
Communication Function Classification System (CFCS) providing a scale-based reporting
method for patients and their caregivers on a patient's communication abilities [59, 61].
Additional assessments of academic abilities (reading, writing, etc.), and medical history are
assessed through checklists in clinics, with some guidelines available through governmental
agencies, such as the CDC guidelines on developmental milestones [62] Assessment and
identification of the myriad of NDDs currently identified is a difficult and complex process,
confounded by many factors, such as sex, age, and ethnicity. Facial gestalts vary greatly between
disorders, with specific identifying features for disorders occurring rarely, as many of these
NDDs involve highly overlapping phenotypes [35] requiring additional genomic findings to
provide a definitive classification or diagnosis.
1.2.3 DISRUPTION OF THE EPIGENETIC MACHINERY THEORY OF NDDS
The term “Epigenetic Machinery'' refers to the extensive network of proteins involved in
modulating the key epigenetic functions throughout the genome, that in turn have considerable
downstream effects on the expressed genome as they modulate expression [35]. As such,
disruption of these proteins can result in significant changes to not only the protein in question,
but the myriad of genes and protein networks that they interact with. For example, when
mutations occur within one of the DNMTs, the effects are widespread, and complex, as it affects
the entire cell's ability to effectively translate and transcribe its contents [63]. These epigenetic
processes are integral to the normal functioning of many organisms, including humans. Targeted
DNMT mutation of embryonic stem cells in mouse models were found to result in embryonic
lethality when introduced to the germline [64]. When a mutation occurs in protein machinery
related to reading, writing or erasing methylation marks, histone modifications or chromatin
remodeling complexes, epigenetic and gene expression profiles are consequently disrupted. The
EpiSign project has identified a large number of syndromes associated with the disruption of
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these epigenetic machineries, highlighting their importance in the establishment of the healthy
functioning epigenome. (See Figure 1-2)

Figure 1-2. A comparison of the phenotypic overlap across conditions associated with disruption
of epigenetic machinery. Disorders were categorized into 6 classifiers based on descriptions
provided in their MIM profile: intellectual disability (n= 42), facial anomalies (n= 36), growth
abnormalities (n=28), limb/nail abnormalities(n= 20), speech pathologies (n= 12), and
overgrowth disorders (n= 5). Intellectual disability classifier was applied to disorders whose
clinical phenotype contained key words such as intellectual disability, cognitive disability, and
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mental retardation. Facial anomalies were assigned to disorders described to have malformations
of facial features, including descriptions of abnormal nose, eye, eyelid, and mouth features.
Growth abnormalities covered a description of deficiencies in development, including short
stature, microcephaly, retardation of somatic development, and poor postnatal growth.
Overgrowth disorders were assigned to disorders containing descriptors of acromegaly,
macroorchidism, and gigantism. Limb/nail abnormalities category contained disorders associated
with malformations of the appendicular skeleton, such as brachydactyly, and absence or
hypoplasia of various limb features. The speech pathology category was assigned to disorders
that were described with speech delay or absence of speech. Other phenotypic keywords,
including epilepsy, cardiac malformations, immune dysfunction, dental malformation,
narcolepsy/dementia and blood disorders, were also observed but were excluded from
visualization because of low occurrence (n <4). (Figure produced by Gavin Riddolls,
Guildenthaw Design.)

1.3 DNA METHYLATION EPISIGNATURES AS DIAGNOSTIC BIOMARKERS
Using genomic DNA methylation analysis in conditions that exhibit unique epigenetic
signatures associated with specific genetic defects enables resolution of ambiguous findings and
uncertain phenotypes in these patients [65]. Changes in DNA methylation are closely related to
the variation in the expression of genes within the human genome and connected to a wide
network of genes that directly or indirectly modulate the epigenome through chromatin
remodeling, DNA methylation, histone modifications, or more indirect and complex molecular
pathways [12, 66, 67, 68]. Variants that occur in early stages of development can therefore have
widespread changes in gene expression, and be propagated through cell differentiation and tissue
development, which allows for assessment of methylation perturbations in easily accessible
tissues such as peripheral blood [12,65]. Peripheral blood samples extracted using standard
techniques can be processed using bisulfite conversion techniques and assessed using microarray
technology to determine methylation signal intensities at various CpGs throughout the genome.
[63,65].
This methylation data is then processed and filtered using established protocols, and a set
of age and sex matched controls are identified for comparative analysis. Methylation levels are
14

then modeled, accounting for blood cell proportions as confounding variables, and significantly
differentially methylated probes (>5% methylation signal intensity change and p-value <0.05)
are identified in the case cohort and used to create the “episignature”. Probe selection parameters
included the probe “score”, the area under the receiver operating characteristic curve, and a
probe-to-probe methylation correlation value. The probe score was derived from the absolute
value of the mean methylation difference multiplied by the negative value of the log-transformed
adjusted P values for each probe. This score identified the top 1000 probes with distinct
methylation changes at statistically significant levels. The 1000 probe threshold is somewhat
arbitrary but has proven effective at identifying a large enough set of probes that subsequent
filtering steps result in episignatures comprising of ~150-500 probes [12]. This episignature size
maintains the ability to provide a flexible biomarker that is informed by biological information
from several genomic regions, while remaining computationally efficient. Increasing the number
of probes could provide an increase in the number of informative regions identified, however the
ensuing increase in computational complexity results in inefficient analysis times. These 1000
probes were then filtered by the AUC derived from ROC analysis of the level of methylation
change at the specific probe, identifying probes with a high level of sensitivity and specificity for
differentiating cases from controls. Finally, Pearson’s correlation coefficients for the remaining
probes were conducted, and highly correlated probes were removed, in a pseudo random manner,
to avoid over reporting of probes which assay identical regions of the methylome. Additionally,
due to the sex related differences in chromosomes, probes on the X and Y chromosomes are
filtered from probe selection. Although this reduces the ability of the episignature pipeline to
determine sex specific DNA methylation changes, the ensuing methylation patterns can be
applied to a larger population, without the need to differentiate samples based on their sex. The
resulting episignature is modeled and assessed using supervised machine learning methods to
assess the sensitivity and specificity of the probeset to differentiate between case and control
samples, as well as the large number of non-case syndrome classified cases, determining the
specificity of this episignature for the syndrome of interest (See Figure 1-3).
Modeling methods include multidimensional scaling (MDS), principal component
analysis (PCA) and hierarchical clustering heatmaps. Principal component analysis, or PCA, is
used primarily in quality control steps of the statistical pipeline, to assess global changes in DNA
methylation to identify possible batch effects or improperly labeled samples. This process is a
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dimensionality reduction method that reduces the complexity of large datasets to allow for
effective visualization of trends in the data, while maintaining as much of the information
contained in the larger set as possible. PCA attempts to reduce the complexity of datasets
through analysis and detection of orthogonal vectors which represent the variance in data, with
the first principal component being one such orthogonal vector which represents the most
variance, the second principal component representing the second most variance etc. [118].
Multidimensional scaling or MDS, has a similar goal, reduction of large datasets into more
simple and easily visualized mediums, however it differs in how it achieves that goal. MDS uses
the pairwise distances in Euclidean space, i.e. the relationships between distinct data points, to
create a low dimensional model of the high dimensional dataset, and then uses a stress test to
assess whether or not the new model maintains those pairwise distances well [119]. The result is
a similar reduction in dimensions, providing a two- or three-dimensional dataset that can be
easily visualized and assessed, however the focus of MDS is on maintaining the relationships
between data points, while PCA focuses on the preservation of the dimensions through
measuring their associated variance.
Where traditional genomic technologies fail to encompass the complexity of phenotypes
in relation to the mutation observed in the epigenetic machinery, analysis and comparison of the
methylation profile described as an episignature, allow for robust classification of the disorder.
Rather than assigning the source of pathogenic condition to a given mutation or set of mutations,
the episignature instead provides a genome wide view of the downstream epigenetic effects of a
defect in a specific gene involved in the epigenetic machinery.
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Figure 1-3. Overview of the Episignature statistical analysis pipeline. Adapted from
https://www.diagenode.com/en/categories/bisulfite-conversion,
https://en.wikipedia.org/wiki/Support-vector_machine, Haghshenas & Bhai 2020 [15] and Zweig

& Campbell 1993 [112]
Investigations of episignatures in the context of inherited disorders has been ongoing for
several years, with the earliest reports describing observed patterns of differentially methylated
regions (DMRs) in trisomy 21 (Down syndrome) [69]. Expansion of this work has greatly
increased in recent years with the current literature reporting 65 episignatures, [12]. These
individual episignatures are unique to the disorder in question, which permits the use of a
multiclass classification algorithm for concurrent analysis of each methylation pattern. These
discoveries, in combination with the previously clinically validated imprinting and trinucleotide
repeat disorders has introduced the first clinical genome-wide DNA methylation assay known as
EpiSign [63, 70-74].
As previously mentioned, the low diagnostic rate of WES practices in NDDs, and large
number of VUS variants indicates the need for improvement in the diagnostic criteria of these
complex conditions. DNA methylation assessment can be a powerful functional assay for
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resolving these complex cases, benefiting from the ability to identify the unique methylation
patterns associated with these conditions from peripheral blood samples.

1.3.1 PERIPHERAL BLOOD AS DIAGNOSTIC TISSUE IN DNA METHYLATION
ASSESSMENT
In the context of neurodevelopmental disorders, analysis of brain tissue would provide
the clearest identification of biological processes associated with disorder related changes in
DNA methylation, however, access to brain tissue is greatly limited, and often derived from
postmortem samples. As such, alternate surrogate tissues such as peripheral blood have been
explored in research, and eventually implemented for the purposes of our study. It is important to
know then, that the comparison of epigenetic markers from peripheral blood is effective in
predicting those seen in brain tissues. Several studies have found high concordance between
tissues, with Horvath et al, 2013 [113] reporting a correlation of 0.85-0.91 with genome wide
methylation patterns from publicly accessed datasets. Additional studies from Davies et al, 2014
[114] and Braun, 2019 [115] found similar results, with high levels of correlation between
peripheral blood and brain tissue derived methylation patterns. Due to the emergence of
mutations at fertilization, differences in DNA methylation are carried throughout the germline
into the various specialized cells that go on to form the brain and other structures, leading to
common patterns observed between tissues. Given the ease of access, and cost efficiency of
peripheral blood, as well as it’s demonstrated value as an effective mirror of the changes in DNA
methylation observed at disease associated tissues such as brain tissue, the use of peripheral
blood as a surrogate measure provides biologically relevant, and reliable assessment of DNA
methylation patterns. Nevertheless, our statistical pipeline utilizes an additional method to
account for the variability associated with a heterogenous cell mixture such as peripheral blood.
Implementation of the Houseman method involves the estimation of blood cell proportions
within a whole blood sample through analysis of cell lineage specific DNA methylation patterns
[117]. As each of the various leukocyte lineages have been differentiated into specific roles from
their hematopoietic stem cell originators, DNA methylation changes occur at specific loci to
modulate gene expression, resulting in a number of differentially methylated regions that can be
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used to define a specific cell lineage. These cell proportions can then be considered in the linear
modeling of differentially methylated probes as confounding factors to reduce methylation
“noise” caused by heterogenous cell mixtures. [117]

1.3.2 EPISIGNATURES IN THE CONTEXT OF INHERITED DISORDERS
Recent studies involving DNMT1 mutations in a cohort of patients with ADCADN
(MIM# 604121), demonstrates the effects of disruption of the epigenetic machinery on the
genome [75], Peripheral blood samples from patients with DNMT1 mutations were shown to
have significant differences in genomic methylation when compared to unaffected controls,
primarily increased in areas that normally remain unmethylated throughout development [75].
Such hypermethylation of gene promoters can be associated with disruption of gene expression
and likely plays a part in the observed pathophysiology of this disorder, namely large-scale
multi-organ disruption, particularly in brain tissue. A large and continually growing number of
human neurodevelopmental disorders are caused by mutations in the epigenetic machinery
genes, each presenting significant difficulties in their diagnosis. Overlapping phenotypes,
confounding results from current genetic sequencing techniques, and a limited ability to detect
and interpret non-coding genomic regions all contribute to a particularly challenging diagnostic
landscape in these conditions.

1.3.3 EPISIGNS AS DIAGNOSTIC MARKERS IN COMPLEX DISORDERS
When variants classified as VUS are matched with an episignature, the variant can be
reclassified into likely pathogenic (matching the epigenetic signature). In a recent study, out of
36 patients with VUS variants in a cohort of KMT2D, 7 (19%) of the patients were predicted to
have a methylation profile matching the episignature for Kabuki syndrome (MIM# 147920),
whereas the remaining 29 samples that matched the control cohort methylation profile were
predicted to carry likely benign variants [76]. In the same study, 8 out of 16 (50%) of patients
with VUS in NSD1 (OMIM #606681), were predicted as having Sotos syndrome (MIM
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#117550) [63]. Assessment of Coffin Siris (CSS; MIM# 135900, 614607) and Nicolaides
Baraitser (NCBRS; MIM# 601358) syndromes classified 4 of 18 (22%) of patients with VUS,
in genes encoding subunits of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin
remodeling complex, as good clinical matches [77]. Two additional cohorts of patients with VUS
in genes associated with the epigenetic machinery were assessed with the Episign multiclass
classification algorithm and matched a signature with a predicted pathogenic phenotype in 17/44
(39%) [71] and one out of 9 (11%) patients [70]. As such, episignature assessment is not only
enabling reclassification and interpretation of genetic variants, but also expanding the knowledge
of the types of genetic variants that can cause genetic disorders. Until recently, variant reports for
the ADNP gene, associated with Helsmoortel Van der Aa syndrome (HVDAS), (MIM #615873),
have been restricted to truncating variants [78,79]. By matching the episignature defined by
patients with truncating LOF mutations, 2 unrelated patients with different ADNP missense
mutations were shown to be affected by HVDAS [80]. Characterizing VUS cases is one way in
which episignature analysis is increasing the molecular diagnostic yield. Another approach is to
systematically screen patients with NDDs that show negative genomic findings. Genomic
analyses, including copy number variation (CNV) arrays and exome sequencing have limitations,
including identification of balanced translocations [81,82], allele phasing, mapping problems due
to guanine cytosine bias, repetitive elements, and homologous sequences, and are normally
restricted to the assessment of coding regions with minimal coverage of intronic or regulatory
elements [83]. Methylation profiling can be used as a biomarker to assess patients with negative
genetic findings. Methylation profiling can also help to stratify NDDs with phenotypic overlap
when diagnosis based on clinical features is difficult. For example, in the case of CHARGE
syndrome (MIM#214800) caused by variants in the CHD7 gene includes Kabuki syndrome
(MIM#147920, 300867) as one of the differential diagnoses [84,85]. In this case, matching a
given patient’s methylation patterns to one of the episignatures associated with these conditions
can provide functional evidence supporting diagnosis. In one study, a cohort of 51 patients with
phenotypes suggestive of CHARGE syndrome, but lacking a definitive molecular confirmation
underwent genome wide DNA methylation analysis. Epigenomic signatures were consistent with
CHARGE in 23 patients; 27 patients were ruled out for both signatures, and a final patient had an
episignature consistent with Kabuki syndrome [63]. In this case, DNA methylation analysis
provided a novel avenue for diagnosis, providing effective classification when traditional
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practices of genomic investigation and clinical classification were insufficient. A larger cohort of
965 subjects with a spectrum of neurodevelopmental delays and congenital anomalies, but
negative for routine genetic investigations by CMA, and in some cases, targeted gene panels or
WES, underwent genome wide methylation profiling. Of the 34 episignatures screened, 16
different conditions were matched across 24 unique samples [63,65], further highlighting the
effectiveness and utility of episignature analysis.
1.3.4 EPISIGNATURES AS PHENOTYPIC BIOMARKERS IN NDDS
Disorders involving either direct or indirect perturbation of proteins that regulate
epigenetic machinery display significant phenotypic overlap with one another, which may be
associated with the downstream effects of altered gene expression that arise when epigenetic
patterns are disrupted [86]. The differentially methylated regions in this group of NDDs are
genome wide, and can range in numbers from hundreds to thousands with both hypermethylation
and hypomethylation changes observed. Changes are interspersed both within and outside gene
coding regions, affecting active protein sequences, upstream regulatory elements or deep intronic
regions. The extent of change can vary as well, with DMRs that cover areas of single CpGs, to
entire CpG islands. The pattern of DMRs within one condition is highly reproducible, which
permits mapping of their profile for use as potential diagnostic biomarkers alongside genome
wide methylation signatures [63, 70,75, 84-96]. There are shared DMRs across the epigenetic
machinery subclass of neurodevelopmental disorders, but typically, less than 10% are linked to
more than one condition, and machine learning approaches have been used to accurately classify
one condition from another as well as controls using this DMR focused approach. Episignature
mapping involves using a training cohort of patients with known pathogenic variants to provide
evidence for feature selection and model training, demonstrating accuracies of up to 99.9% [63,
65,70]. Once mapped, an episignature can be validated with a testing cohort of similarly affected
individuals. The high accuracy demonstrated by the episignature is further expressed through the
high level of sensitivity with these validation cohorts, with over 99% sensitivity in classifying
validation cohorts into the correct category, and a high level of specificity, with unaffected
control cohorts demonstrating 100% correct classification as control subjects. [63, 65,70]. The
importance of accurate diagnosis in these closely related conditions is necessary for creating an
appropriate and direct treatment plan for these patients. It has been shown that genetic findings
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have changed clinical management in up to 55% of individuals with multiple congenital
anomalies, developmental delay, intellectual disability and autism spectrum disorders [97].
1.3.5 INVESTIGATIONS OF PHENOTYPIC AND GENOTYPIC OVERLAP
Episignatures can distinguish conditions from one another, but are also providing insight
into the phenotypic variability observed within conditions, or perhaps more specifically, the
range of phenotypes observed from variants within the same gene. For example, HVDAS is a
common cause of ASD and intellectual disability, with patients with variants in the associated
ADNP gene for this disorder comprising around 1.7% of ASD cases [78, 79, 98, 99].
Interestingly, a large amount of phenotypic variability is seen within these cohorts however, with
a high amount of variable expressivity [78]. Variants in the causative ADNP gene have been
shown to cluster into two distinct episignatures dependent on the location of the variant,
translating to a spectrum of downstream gene expression effects and ultimately offering a
possible explanation of the varied phenotypic range observed in HVDAS [80]. In a similar case,
variants in SMARCA2 have historically been associated with NCBRS, but methylation profiling
for a subset of SMARCA2 variants has recently identified an episignature that is predominantly of
an opposite pattern to those observed in NCBRS patients, and linked to a divergent phenotype
[100].
Although gene level information is often associated with a definitive clinical diagnosis,
specific examples of ADNP and SMARCA2 show that nucleotide level variant features, such as
location, variant type, or mechanism of action may be required for reaching an accurate
diagnosis. Furthermore, in addition to defining a distancing phenotype, variant location can be a
factor in milder or less expressive variation of the phenotype associated with these conditions.
Revisiting the SMARCA2 gene as a causative factor in NCBRS, most pathogenic variants map to
the ATPase/c-terminal helicase domain of the protein [101]. Patients with variants in SMARCA2
distal to the helicase domain present with milder neurodevelopmental and atypical features
compared with typical NCBRS patients. Downstream methylation effects have been shown to
represent an intermediate profile that matches neither NCBRS, nor unaffected controls, but
overlaps with a significant number of control DMRs, nearly 50% [87]. This intermediate
signature further indicates the possibility of a distinct phenotype, or the possibility of a
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“signature scale” corresponding to different levels of methylation perturbation that could explain
the variable expressivity observed in some conditions.
Episignatures have begun to guide us towards a more accurate method of determining a
patient's diagnosis, while providing insight into the inherent biology that dictates their ensuing
phenotype and shedding light on the variable expressivity seen within cohorts that share the same
gene of interest. Additionally, DNA methylation provides evidence of overlap between disorders
that share molecular interactions, providing common episignatures across multiple genes. BAF
complex in CSS and NCBRS syndromes, cohesin complex in Cornelia DeLange Syndrome
(CDLS) (MIM# 122470, 300590,610759, 614701,300882) and Cohen Gibson syndrome (MIM
#601573), are all examples whereby variants in multiple distinct genes map to common
methylation patterns detectable by the episignature process [65].

1.4 MACHINE LEARNING IN EPIGENOMICS
The use of machine learning approaches in bioinformatics has expanded greatly in recent
years, making use of “machines”, aka algorithms or modeling techniques that employ statistical
approaches to find relationships between complex sets of data, and evaluates them, providing
interpolated or extrapolated predictions of variables, or classifications [102]. In this way, these
machines “learn” continuously improving their ability to provide predictions in each iteration of
their use, identifying trends in complex datasets. Machine learning is particularly helpful in the
context of complex conditions, such as NDDs, where the classification of a given observation, in
this context, the identity of a given NDD, is based on a complex set of characteristics, whose
interactions are multifactorial and interconnected, making them difficult to interpret via
traditional data analysis [35,86]. In this thesis, I made use of one such machine learning method,
known as Support Vector Machines (SVM) based on our previously described methods [63].
SVM can analyze groups of observations, and attempts to find a hyperplane, a boundary within
the observed dataset that can separate observations into distinct groups based on their
characteristics. The hyperplane is derived through providing observations, in this context
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representing methylation profiles form patient samples, to the machine learning algorithm, and
mapping them based on similarity of their characteristics, within n-dimensional space, where n is
the number of features used to differentiate observations, in this context, DNA methylation
probes. Once mapped, the SVM uses support vectors, the most proximal samples within the
mapped space to create a hyperplane which splits the sets of observations into the desired
categories, i.e., cases vs controls, while maintaining the largest margin between support vectors.
This method, also known as a maximal margin classifier, creates a decision boundary, wherein
samples on one side of the boundary, represented by a hyperplane spanning the # of desired
features in the n dimensional space, are classified as one group, for example controls, while those
found on the other side of the boundary are identified as cases. This classifier can then be
expanded beyond the dataset used to train it, providing a method for classifying new
observations based on their relation to the derived hyperplane with new testing samples [103107]. This classification method is a binary one, and needs to be modified to provide a
continuous scale of the similarity between observations, allowing for more nuanced and detailed
results, as such, I then employed Platt’s scaling method, which converts the classification into a
probability distribution over the classes [108]. Probabilities of being assigned into a given class,
either resembling the methylation profile of the disorder training cohort, or not, can provide a
more nuanced understanding of different sample types, and allows us to identify samples that are
similar to the methylation profile on a continuous scale, rather than a binary one. However,
probabilities can differ greatly across different training sets, meaning that without an effective
training method, the modeled probabilities are unlikely to reflect empirical probabilities observed
in new samples. Platt’s scaling method was created specifically for support vector machines to
provide a way to create classification probabilities that are trained on a subset of samples to
reduce bias and allow for effective classification of new samples. This procedure uses a training
set of samples to generate probabilities, which are then calibrated with a logistic regression to the
observed scores derived from the SVM classifier. The calibrated probability curve can then be
used to evaluate the effectiveness of this calibration, providing a testable model of probabilities
that reflect the training group it was based on. For our classifier, we split the training cohort into
groups, and provide them as training, calibrating and testing in several iterations, such that each
group of samples is used in the training, testing and calibrating categories at least once. Once
complete, these scores are then combined into a final MVP score which reflects each iteration,
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and provides a highly robust score which reflects each sample's similarity to the methylation
profile of the given training group. In this way, we can provide not only a classification into a
given disease group following analysis of a selected probeset, but a score for each sample in
terms of its similarity to the methylation profile observed in the training group, allowing for
substratification of case groups and further avenues of research to identify subgroups with
differentiated methylation characteristics within a given disease group.

1.5 CHALLENGES IN DNA METHYLATION ANALYSIS
Episignature detection works on the model that an inherited pathogenic variant in a gene
is associated with a unique methylation profile. The assumption with this model is that the
inherited changes originated early in development, and an episignature observed in our
diagnostic tissue, peripheral blood, is also present in other tissues. The evidence to support this
theory is limited, but it has been demonstrated in Sotos syndrome whereby fibroblast samples of
affected patients which underwent DNA methylation assessment showed similar patterns to the
episignature derived from the peripheral blood tissue of those same patients [92]. Blood is a
readily available surrogate tissue that can be used as a biomarker for direct testing when the
critical tissues, such as brain tissue in the context of neurodevelopmental disorders , are
unavailable. The use of peripheral blood can be limited by tissue mosaicism when the affected
tissues for the disorder in question does not include blood, such as in the case of Beckwith
Wiedemann syndrome [109], or if the level of mosaicism produces an episignature that is below
the threshold of differences of the positive population. This outcome is predicted by the milder
profiles observed by carriers of recessive conditions [110] or of carriers with intermediate
patterns when compared to affected individuals [87]. In the case of Claes Jensen syndrome
(MIM # 300534) caused by variants on the X chromosome gene KDM5C [111], healthy female
carriers were shown to exhibit one such intermediate pattern. This intermediate pattern showed
some similarities to the affected male patients, as well as with the unaffected control cohorts
[111]. The exact limit of detection of mosaicism for episignature analysis will likely be specific
to each new signature, and will require systematic investigation to fully understand.
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Episignature work has thus far focused primarily on cohorts involving disruption of genes
of the epigenetic machinery. The utility of these episignatures is dependent not only on the
robustness of methylation changes but also on the diversity of variants and number of positive
vases in the cohort. Specific genetic neurodevelopmental disorders are rare, and collection of
appropriate numbers of cases or of cases with a diverse variant profile is not always feasible. The
type of variant and location of it within genes and their associated domains have been shown to
impact the episignature profile [64, 80, 87] and therefore, episignatures based on variants of the
same type or within the same protein domain offer challenges in the interpretation of results
when alternate variants or regions of the gene are introduced for investigation.
Each of these challenges I have addressed so far are controlled through several quality
control steps and statistical processes. These steps are an important part of our statistical
pipeline. In the case of batch effect, we assess drift between different batches through the use of
a PCA plot which displays the overall methylation profile of all probes assayed upon the EPIC
array. This plot displays a low dimension presentation of the trends in DNA methylation across
the genome, and allows for identification of particular batches that differ significantly in their
global DNA methylation changes. PCA plots which display a dense, homogenous mixture of
samples indicate the overall change in methylation between batches is small, while scattered
PCA batch plots may flag certain batches for regeneration or further assessment. Overall, the
methylation differences between batches are kept low, due to many of our batches being run on
site at LHSC, or in collaborating labs which also maintain a high level of adherence to
established protocols. Other steps that are key to generating new samples on the classifier
include checking the number of failed probes, ensuring that the methylation predicted age (via
Horvath clock predictions [113,116]), and predicted sex match the information provided for each
patient, and ensuring that the provided sample is from peripheral blood and not some other
surrogate tissue, such as fibroblast.
Although DNA methylation signatures or EpiSigns have now evolved beyond scientific
concepts to the use in diagnosis of patients with a growing number of neurodevelopmental
disorders, much more work remains before this technology can reach its full potential. Collecting
cohorts of patients with each of these conditions will take effort and international collaboration
for years to come. As technology continues to evolve, it can be expected that targeted approaches
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such as methylation microarrays may be expanded by the more comprehensive genomic
approaches, such as bisulfite genome sequencing. In that context, reference databases will need
to evolve to account for the growing data complexity, which may provide an opportunity to
reassess conditions with no existing EpiSigns based on methylation microarray analysis.
Mapping DNA methylation profiles based on other tissue types, such as buccal swabs,
fibroblasts and so forth will provide further understanding of the biology and underpinning
mechanisms, as well as providing additional opportunities for clinical utilization of this
technology.
1.6 STUDY RATIONALE, HYPOTHESIS AND OBJECTIVES
1.6.1 CONCLUDING REMARKS
The analysis of DNA methylation episignatures provides an important level of epigenetic
information that can inform not only more effective diagnosis of complex NDDs, but is
inherently implicated in their underlying biology, elucidating mechanisms, pathways and shared
characteristics of various conditions. Nevertheless, many questions remain to be explored. Are
there readily identifiable episignatures for every genetic disorder? Can the episignature
differentiate between syndromes caused by paralogous genes? Can the shared phenotype
observed in disorders with distinct genomic origins be correlated to overlapping changes in DNA
methylation? Although the identification of effective diagnostic biomarkers in the form of
episignatures has been well described, my work expands on the current body of knowledge by
assessing genomic and phenotypic correlation of episignatures in Mendelian NDDs.
1.6.2 HYPOTHESIS
I hypothesized that DNA methylation episignatures can be used to provide sensitive and
specific classifications in neurodevelopmental disorders, and further stratification of these
episignatures can identify key epigenetic patterns that relate to the phenotypic and genotypic
variations seen in patients with these disorders.
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1.6.3 OBJECTIVES
To achieve my goals of testing this hypothesis, I identified several specific aims that
relate to each chapter of my thesis, based on my work over the past several years. 1) I sought to
identify syndrome specific episignatures, relating Yin Yang 1 (YY1, OMIM#600013)
transcription factor variants associated with Gabriele De Vries syndrome (GADEVS,
OMIM#617557) , providing a baseline interpretation of episignature development. 2) In an
attempt to resolve the effects of gene domain specific variants on the ensuing methylation
profile, I investigated variants within the lysine demethylase 2B gene (KDM2B, OMIM#609078)
, and then stratified the cohort based on specific domains affected by variants within this disease
cohort, focusing particularly on those which disrupted the CxxC DNA binding domain within the
KDM2B sequence. 3) Next, I sought to identify whether or not paralogous genes, Lysine
acetyltransferase 6A (KAT6A, OMIM#601408) and lysine acetyltransferase 6B (KAT6B,
OMIM#605880) , with significant shared genetic character and function could be effectively
differentiated from one another on the basis of the DNA methylation profiles derived from
KAT6A patients. 4) Finally, through the analysis of a cohort of two distinct molecular entities, the
activity dependent neuroprotector homeobox protein (ADNP, OMIM#611386) and the
SWI/SNF-related matrix associated actin dependent regulator of chromatin, subfamily A
member 2 (SMARCA2, OMIM#600014) which both exhibited a particular phenotype.
This work is by no means a comprehensive list of possible avenues of episignature
assessment, but provides an extensive expansion of the ways in which researchers can combine
genetic, phenotypic and epigenetic evidence that is rapidly rising in prominence and accessibility
across the world to inform research. By using DNA methylation assessment, in tandem with
traditional methods of genetic and clinical diagnosis, we can further elucidate how changes in the
epigenome relate to the specific diagnosis of complex conditions, and the molecular etiologies of
disease.
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PREFACE

In exploring diagnostic avenues available to DNA methylation episignature assessment, one of
the most common outcomes observed has been a relationship involving a single gene disruption resulting
in a shared episignature for all patients with such a disruption. Although I did identify a single case which
indicated the possibility of alternate phenotypes based on variant type and location, due to low sample
size, I was unable to fully research the underpinning biology associated with this atypical case in the
context of DNA methylation. Nevertheless, it does indicate that future avenues of research, along the lines
of the more specialized and stratified episignatures describe in the later chapters of this thesis may indeed
be present in Gabriele De Vries (GADEV) patients.
Additionally, with all case samples (with the exception of the atypical case) clustering strongly
together in all models, and no evidence of further overlap with other neurodevelopmental disorders,
indicted by high scores on the support vector machine-based methylation variant pathogenicity (MVP)
scores, this discovered episignature has been shown to be highly sensitive and specific to the disorder in
question. This is by no means a new finding, and has been firmly established in a number of our
published works over the past several years. Nevertheless, in providing an epigenetic roadmap
assessment, it is important to include this baseline outcome to better understand how my work has since
expanded on the overall complexity of episignature assessment.
As such, in this chapter, I will be discussing the discovery of a highly sensitive and specific
episignature for the neurodevelopmental disorder Gabriele De Vries syndrome. DNA methylation patterns
derived from patient samples showed to be effective biomarkers for this disorder, and provided interesting
insights into alternate forms of the condition.
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ABSTRACT

PURPOSE
Gabriele-de Vries syndrome (GADEVS) is a rare genetic disorder characterized by developmental delay
and/or intellectual disability, hypotonia, feeding difficulties, and distinct facial features. To refine the
phenotype and to better understand the molecular basis of the syndrome, we analyzed clinical data and
performed genome-wide DNA methylation analysis of a series of individuals carrying a YY1 variant.

METHODS
Clinical data were collected for 13 individuals not yet reported through an international call for
collaboration. DNA was collected for 11 of these individuals and 2 previously reported individuals in an
attempt to delineate a specific DNA methylation signature in GADEVS.

RESULTS
Phenotype in most individuals overlapped with the previously described features. We described 1
individual with atypical phenotype, heterozygous for a missense variant in a domain usually not involved
in individuals with YY1 pathogenic missense variations. We also described a specific peripheral blood
DNA methylation profile associated with YY1 variants.

CONCLUSIONS
We reported a distinct DNA methylation episignature in GADEVS. We expanded the clinical profile of
GADEVS to include thin/sparse hair and cryptorchidism. We also highlighted the utility of DNA
methylation episignature analysis for classification of variants of unknown clinical significance.

KEYWORDS
DNA methylation, Epigenetics, Gabriele-de Vries syndrome, Intellectual disability, YY1
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INTRODUCTION
Alteration of proteins involved in chromatin regulation is a well-established cause of
many neurodevelopmental disorders. Among these conditions, Gabriele-de Vries syndrome
(GADEVS, OMIM# 617557) is a rare congenital disorder characterized by variable intellectual
disability (ID), various neurological disorders (hypotonia, abnormal movements, behavioral
disorders, brain abnormalities), feeding difficulties, ophthalmological abnormalities, significant
but not specific facial features, and more rarely cardiac or renal malformations [1-5]. GADEVS
is mainly caused by pathogenic missense variants in Ying Yang 1 Transcription Factor gene
(YY1, OMIM# 600013) and less frequently by truncating variants or whole gene deletions,
suggesting haploinsufficiency as the underlying mechanism [1].
YY1 encodes the Ying Yang 1 Transcription factor, which is a ubiquitously expressed
transcription factor in mammals. Its name comes from its ability to be both an activator and a
repressor of transcription [6]. YY1 is characterized by four highly conserved C2H2 Zinc fingers
located in its C-terminal domain. The N-terminal region corresponds to the transcriptional
activation domain. A transcriptional repression domain, including the REPO domain allowing
the recruitment of the polycomb complex, is located between the N-terminal region and Zinc
fingers domain[7-9].
It has been demonstrated that genetic disorders involving genes related to chromatin
regulatory functions exhibit specific DNA methylation signatures, referred to as episignatures
[10-12]. DNA methylation episignature analysis has recently been implemented as the diagnostic
clinical genomic DNA methylation test EpiSign, in patients with rare disorders, providing strong
evidence for clinical utility including the ability to provide conclusive diagnostic findings in the
majority of subjects tested[13] In this study, we describe the clinical phenotype of 13 previously
unpublished individuals carrying a pathogenic or likely pathogenic variant or a complete deletion
of YY1, as well as a specific epigenetic signature associated with GADEVS.
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MATERIALS AND METHODS

SUBJECTS AND SERIES
We contacted clinicians about 19 individuals carrying a pathogenic or likely pathogenic
variant or a deletion of YY1 through clinical networks (Groupe DI France, AnDDI-RARES
http://anddi-rares.org/, ERN ITACHA https://ern-ithaca.eu/) and GeneMatcher
(http://www.genematcher.org)[14]. We collected clinical and molecular data, DNA samples,
brain MRI and neuropsychological assessment data of individuals from this series, when
available. Referring physicians provided the data by filling in a standardized table.
This study was approved by the Institutional Review Board of Montpellier University
Hospital (IRBMTP_2020_05_202000459, ClinicalTrial.gov identifier: NCT04381715) and the
Western University Research Ethics Board (REB 106302). We obtained informed written
consent from all individuals or their legal guardians to participate in the study and to publish
their photographs. All samples and records were de-identified. The research was conducted in
accordance with the Declaration of Helsinki.

MOLECULAR STUDIES
Diagnostic laboratories performed genetic tests on DNA from blood samples using nextgeneration sequencing or microarrays. The pathogenicity of point variants was verified according
to American College of Medical Genetics and Genomics (ACMG) recommendations [15], using
the varsome interface (https://varsome.com/)[16]. The visualization of the variants on the protein
sequence was performed with the ProteinPaint tool (https://proteinpaint.stjude.org/), using the
canonical isoform NM_003403.

STATISTICAL ANALYSIS
To describe the continuous variables (SD of growth parameters, age of milestones
acquisition), we calculated medians, minimums, maximums and interquartile ranges in order to
construct corresponding boxplots. We also included data from the literature in these graphs.
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METHYLATION ARRAY AND QUALITY CONTROL
DNA methylation analysis and episignature classifier development was performed using
a previously established protocol [11,12,17,18]. Genomic DNA was extracted from peripheral
blood samples using standard techniques and followed by bisulfite conversion and hybridization
to the Illumina Infinium methylation EPIC bead chip arrays, according to manufacturer’s
protocol. Idat files, containing methylated and unmethylated signal intensity plots (beta values)
were produced from these microarrays, and used for analysis in R 4.0.2. Normalization was
performed using the Illumina Infinium methylation EPIC array with background correction from
the minfi package [19]. Previously defined exclusion criteria [12,17] were used to exclude
probes with detection p values >0.01, probes on the X and Y chromosomes, probes known to
contain SNPs at the site of CpG interrogation or single nucleotide extension, and probes known
to cross react with chromosomal locations other than their target regions. All samples were
examined for genome-wide methylation distribution and those deviating from a bimodal
distribution were excluded. Factor analysis using a principal component analysis (PCA) was
performed to examine batch effects and identify outliers.

DNA METHYLATION PROFILING
Probe methylation levels (beta values), were calculated as the ratio of signal intensity in
methylated probes versus total sum of unmethylated and methylated probes, resulting in values
ranging from zero to one. To allow for linear regression modeling, beta values were logit
transformed using the limma package [20], allowing for the identification of differentially
methylated probes. Data were adjusted for the blood cell type composition as per Houseman et al
[21]. Estimated blood cell proportion was added to the model matrix of the linear models as a
confounding variable [22] Using the eBayes function in the limma package [23], p values were
moderated and corrected for multiple testing using the Benjamini Hochberg (BH) method.
Probes with the most significant methylation differences were selected using two items from this
dataset: the level of methylation difference (relative methylation signal intensity), and the
probability that an observed difference is due to random chance (p values). Evaluation of this
interaction was carried out by multiplying the absolute methylation difference between affected
cases and controls by the negative value of the log transformed p values, and ranking the top
1000 probes with the highest values from this transformation. Next, receiver operating
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characteristic analysis (ROC) was performed on each probe, to measure the pairwise correlation
coefficient between probes. Probes with low area under curve values from ROC analysis were
removed, as well as highly correlated probes, eliminating probes with low sensitivity and
specificity, and probes with highly correlated characteristics using Pearson’s correlation
coefficient. This ensures that the final probeset contains the most differentiating, non-redundant
probes that are not influenced by random data structures. Only probes with a methylation
difference greater than 5% were included in this analysis. This probe filtering process was
designed to avoid reporting of probes with low effect size, and those influenced by technical or
random variations as conducted in previous studies [11,12].

SELECTION OF MATCHED CONTROLS FOR METHYLATION PROFILING
For episignature characterization, mapping of probes and feature selection, matched
controls were randomly selected from the LHSC EpiSign Knowledge Database (EKD)[12]. All
of the GADEVS samples were assayed, therefore all the controls selected for episignature
identification were analyzed using the same array type. Samples were matched by age, sex and
batch using the MatchIt package. A 4:1 ratio of controls to cases was deemed optimal for this
analysis, as previously described [11]. PCA analysis was performed after each attempt at
matching to detect outliers and determine data structures for the presence of batch effect. Outlier
samples, and those with highly aberrant data structures were removed, and subsequent matching
trials were performed until consistent iterations with no outliers in the first two components of
the PCA were derived. No such samples were identified for removal in this cohort.

CLUSTERING AND DIMENSION REDUCTION
Hierarchical clustering and multidimensional scaling were used after each iteration of
analysis to examine the data structure of the identified episignature. Hierarchical clustering was
performed using Ward’s method on Euclidean distance by the base stats package in R, and
visualized with the ggplot2 package [24,25]. Multi-dimensional scaling provides a visual
representation of sample methylation profile similarity based on the scaling of the pairwise
Euclidean distances between each sample.
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DISCOVERY/TRAINING COHORT SELECTION
Identification of disease-specific episignatures was performed using a randomly selected
sub-set of the database, on a 75:25 ratio of discovery: training, using the caTools package in R.
Testing samples were used to assess the performance of the classification model developed later
in the study. For every disease group in the discovery cohort, a sex and age-matched control
group with a sample size at least four times larger was selected from the reference control group
using the MatchIT package, and methylation profiles were compared between the two.

CROSS VALIDATION
For each round of validation, one of the 13 selected GADEVS samples was removed
from probe selection, alongside matched controls. The remaining GADEVS samples were
designated as testing samples, and all three groups were modeled using multidimensional scaling
to determine how they cluster/segregate with one another. This process was repeated with
different combinations of assigned training and testing samples until all cases had been removed
from probe selection and used for testing once (see Figure 2-S2).

CLASSIFICATION MODEL
Specificity of the episignature was assessed using the Methylation Variant Pathogenicity
(MVP) score, using all the identified probes. A support vector machine (SVM) used a linear
kernel for training on GADEVS cases and controls. Once again, a 4:1 ratio of controls to cases
was used to divide both the case and control samples previously matched and used for probe
selection into training and testing cohorts for the SVM. Furthermore, the remaining unselected
samples from the EKD were also divided similarly (75% training, 25% testing) to allow for
comparison and testing of signature robustness against all of the samples in the EKD. Using the
e1071 R package, we performed 10-fold cross validation to determine hyperparameters optimal
for episignature classification. In this process, the training set was divided into ten folds by
random assignment, where the first nine are used for training, and the last used for testing the
accuracy of the model. The mean accuracy over all rounds was then calculated, and
hyperparameters with the best performance by this metric were selected. The model provides a
score ranging from 0-1 for each subject, representing the model’s confidence in predicting
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whether the subject has a DNA methylation profile similar to the GADEVS probe set or not.
Conversion of these SVM decision values was done using Platt’s scaling method [26], and the
class obtaining the greatest score determined the predicted phenotype. A classification as
GADEVS was made when a sample received the greatest score for that class (normally greater
than 0.5). Finally, the model was applied to both a training set of a large cohort of individuals
with clinical and molecular diagnoses of neurodevelopmental disorders, as well as a group of
healthy controls to determine its effective specificity.

VALIDATION OF CLASSIFICATION
To ensure the model is not susceptible to the batch structure of the methylation
experiment, the classifier was applied to samples assayed on the same batch as the cases used for
training. Using methylation data from individuals without a confirmed diagnosis of GADEVS
within the EKD and assayed on the same microarray chip as case samples, methylation profiles
were modeled to ensure the classifier was not confounded by technical artifacts unique to the
given microarray. Specificity was determined by supplying a large number of DNA methylation
arrays from unaffected subjects to the model. To further assess the specificity of the GADEVS
classifier relative to other neurodevelopmental disorders, we applied it to cases with other patient
cohorts exhibiting distinct episignatures within the EKD.

RESULTS
CONSTITUTION OF THE SERIES
We contacted the referring clinicians of 19 individuals carrying a pathogenic or likely
pathogenic variant in YY1. We excluded three individuals either because they refused to
participate in the study or because neither clinical data nor a DNA sample was available. Another
individual was excluded because the YY1 variant was inherited from a healthy parent. We
therefore included 15 individuals in this study. For details see Table 2-S1.
Among these 15 individuals, 13 were not previously reported; these 13 individuals were
labeled YY1-1 to YY1-13 and constituted the clinical series that allowed us to refine the
phenotypic data related to YY1 variants. The two remaining individuals, “individual 5” and
“individual 8,” were initially reported by Gabriele et al, 2017 [1]. Regarding the episignature
series, we used DNA samples from 11 individuals of the clinical series (samples from
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individuals YY1-8 and YY1-9 were not available) along with DNA samples from “individual 5”
and “individual 8.” The episignature series is detailed in Table 2-S2.

CLINICAL SPECTRUM ASSOCIATED WITH YY1 PATHOGENIC VARIANTS
Clinical data were collected for the 13 individuals (YY1-1 to YY1-13) not previously
reported. Detailed clinical data are available in Table 2-S3. Among this series, 12 individuals
had a phenotype overlapping with that previously described in the literature. Unfortunately,
individual YY1-6 (father of individual YY1-7) died accidentally before being clinically assessed.
The only data concerning individual YY1-6 is the presence of ID. Due to the clearly unusual
phenotype that was observed in individual YY1-10, we chose to describe him separately. Table
2-1 summarizes the clinical data from this series and the literature. The 12 individuals with
phenotype overlapping with the literature presented with variable ID and/or developmental
delay. All these individuals presented with craniofacial features among which the most frequent
were long face, broad forehead, simple ears, malar hypoplasia and full nasal tip. They also
frequently had thin and/or sparse hair. (figure 2-1A).
We also observed various neurological disorders such as hypotonia, behavioral disorders
(ASD, low frustration tolerance, anxiety, self-harm, ADHD), and abnormal movement
(dystonia). Feeding disorders were present in 10/10 individuals. Frequent additional features
include skeletal abnormalities, ophthalmologic abnormalities, and cryptorchidism.
Overall distribution (including data from literature) of ages of growth parameters and
milestones achievement is represented in figure 2-1 (respectively B and C). Individual YY1-10
was considered to have an unusual YY1 phenotype because of overgrowth and obesity
(BMI=41kg/m²), slight macrocephaly (HC at 53cm [+2.3SD]) and moderate craniofacial features
(See figure 2-1A). Full clinical features of individual YY1-10 are detailed in Table 2-S3.
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Atypical
phenotype

Classical YY1 phenotype
Present study
(n=12)

Literature
(n=14)

Total
(n=26)

YY1-10

IUGR

1/9

4/13

5/22 (23%)

-

Short stature

2/11

2/14

4/25 (16%)

Overgrowth

BMI < -2SD

4/10

3/10

7/20 (35%)

Obesity

Microcephaly

2/10

1/12

3/22 (14%)

Macrocephaly

Motor delay

8/11

11/14

19/25 (76%)

+

Language delay

10/11

10/12

20/23 (87%)

+

ID

11/12

11/12

22/24 (92%)

+

Hypotonia

5/11

5/13

10/24 (42%)

+

Behavioral disorders

10/11

7/12

17/23 (74%)

+

Abnormal movement

4/11a

7/12

11/23 (48%)

-

Abnormal brain MRI

4/8

8/13

12/21 (57%)

+

Cardiac abnormalities

1/9

4/11

5/20 (25%)

-

Cryptorchidism
Skeletal
abnormalities
Feeding disorders

3/7

1/5

4/12 (33%)

-

9/10b

8/13

17/23 (74%)

-

10/10

12/13

22/23 (96%)

-

Constipation

4/11

NR

4/11 (36%)

-

Sparse hair
Endocrine
abnormalities
Recurrent infections
Ophthalmologic
abnormalities
Deafness

6/10

NR (9/12)*

15/22 (68%)

-

2/9

3/14

5/22 (16%)

-

2/10

3/14

5/24 (21%)

-

9/10c

7/13

16/23 (70%)

+

1/10

NR

1/10 (10%)

-

Long face

8/11

NR (7/12)*

15/23 (65%)

-

Facial asymmetry

3/10

9/14

12/24 (50%)

-

Broad forehead

9/11

14/14

23/25 (92%)

-

Ears abnormality
Up slanting palpebral
fissures
Down slanting
palpebral fissures
Full nasal tip

11/11

12/12

23/23 (100%)

-

4/10

1/11

5/21 (24%)

-

2/10

6/11

8/21 (38%)

-

8/10

11/13

19/23 (83%)

+

Malar hypoplasia

6/10

11/13

17/23 (74%)

-

Smooth philtrum

3/9

NR (2/12)*

5/21 (24%)

Deep

Thin upper lip

5/10

NR (1/12)*

6/22 (27%)

Thick

Thick lower lip

2/10

5/13

7/21 (33%)

+

Pointed chin

3/10

5/12

8/22 (36%)

-

Micrognathia

3/10

NR (3/12)*

6/22 (27%)

-

Growth

Development

Neurological features

Miscellaneous

Morphological
features

Table 2-1: Summary of clinical features of individuals carrying a pathogenic variant of YY1 (this series
and the literature). Individuals with an atypical variant are described separately. Frequencies marked by
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an * are based on our own interpretation of the pictures available in literature. +: feature present; - :
feature absent; NR: not reported; NK: not known. a: dystonia, dyskinesia; b: camptodactyly, joint
hyperlaxity, scoliosis, plagiocephaly, turricephaly; c: Hyperopia, superficial punctatae keratitis,
nystagmus, strabismus
(5/12), astigmatism, myopia, cortical vision abnormalities.

Figure 2-1: Representation of some clinical features related to YY1. A: Front and lateral view of individuals
from this series. Common facial features are long face, broad forehead, simple ears, malar hypoplasia, full
nasal tip and sparse hair. B: Boxplots showing distribution of ages at sitting alone, walking alone and first
words in standard deviation. C: Boxplots showing distribution of height, head circumference (HC) and
BMI, in standard deviation.
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YY1 VARIANTS SPECTRUM
We collected molecular data from 13 unpublished individuals including a father-son pair
(individuals YY1-6 and YY1-7). Except for this pair, all variants were de novo. The variants of
the series and from the literature are represented on the YY1 protein sequence in Figure 2-S1.
Among these 13 individuals, 12 carried a pathogenic or likely pathogenic sequencing variant (10
were missense and two were truncating variants). All missense variants were located in zinc
finger domain except for individuals YY1-10. The variant p.(Gly176Asp) from individual YY110 was located in the transcriptional repression domain. Missense variants located in this
domain has never been previously described in the literature to our knowledge. The last
individual YY1-3 had a microdeletion encompassing YY1, WARS1 and the 3' end of EML1.

DETECTION AND VERIFICATION OF AN EPISIGNATURE FOR YY1/GADEVS
DNA methylation profiles from 13 individuals peripheral blood samples, which all had
confirmed molecular variants in the YY1 gene and clinical presentation of GADEVS, were used
to establish a DNA methylation episignature for this disorder. Overall methylation patterns in all
13 patients were assessed for several key features, including sample quality, and similarity of the
sample methylation profiles to case samples versus controls. Of these, one sample, YY1-10
segregated consistently with controls, exhibiting methylation patterns more similar to age and
sex matched control samples than the rest of the disorder cohort, and was removed from probe
selection. Comparisons were carried out, matching GADEVS samples with age, sex and batchmatched controls at a ratio of 4:1 (4 matched controls for each case sample). When compared to
controls, significant differences in methylation patterns across 487 probes, which are visualized
using a volcano plot (Figure 2-S2) were detected. Selected probes had a minimum methylation
difference of 10%, and a multiple testing corrected p value of <0.01 (limma multivariable
regression modeling).
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VISUALIZATION OF METHYLATION PROFILES INDICATES DISTINCT CLUSTERING
PATTERNS OF YY1 CASES
Hierarchical clustering was used to visualize methylation differences based on the
selected probes, and was plotted using Ward’s method alongside 56 age and sex-matched control
samples. This model demonstrated a clear separation of the control and case samples, with the
exception of the YY1-10 sample. This sample grouped with control samples in all iterations of
the model, indicating that the associated variant in this sample results in a methylation profile
more similar to control samples than the other cases with confirmed YY1 variants. The location
and characteristics of the variant are atypical, with a missense mutation within the transcriptional
repression domain of YY1, and reported presentation of overgrowth characteristics. Multiple
dimensional scaling (MDS) showed similar findings, with cases grouping tightly together away
from the control cohorts (see Figure 2-2B). Cross validation using GADEVS samples was
performed, showing in the majority of cases that the remaining testing samples clustered with the
other GADEVS samples, and segregated from the controls. In three cases, samples YY1-6, YY17 and YY1-11, cross validation showed less specific clustering along with lowered MVP scores,
suggesting a level of signal heterogeneity and further data structure within the observed common
episignature. However, all samples consistently segregated with the case cohort in hierarchical
clustering and multidimensional scaling plots, and received high MVP scores when provided to
the finalized SVM classifier (see Figure 2-2D and Figure 2-S2).
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Figure 2-2: DNA Methylation Profile for GADEVs
A: DNA methylation signal intensity plot for 13 patients with identified YY1 mutations sorted by
hierarchical clustering. Cases in red represent GADEVS cases, those in blue indicate cases with no
phenotypic or genotypic presentation of GADEVS, including samples with confirmed presentation of
other syndromes, and the final case in orange, refers to sample YY1-10, which was removed from probe
selection following segregation with control samples. B: Multidimensional scaling plot representing the
dimensions of variation in methylation signal intensity at informative CpG identified for GADEVS.
Represents similarity of methylation profiles of GADEVS patients, marked in red. C: SVM classifier
model for GADEVS. Each sample receives scores for the probability of having a DNA methylation
profile similar to cases as compared to samples with a confirmed Episignature in the EKD. Higher value
on Y-axis indicates that a sample presents a methylation profile more similar to cases compared to the
methylation profiles of patients with other disorders. Thirty-six other syndromes with confirmed
Episignatures from the EKD are plotted based on this relative scale of similarity to indicate probeset
specificity for the case disorder. D: Cross Validation summary representing the MVP scores received for
each sample during their respective testing round. Case samples are marked in red, while the remaining
samples from the EKD are marked in black. Left side plot contains MVP scores for the EKD samples
following training the SVM against controls, while the right contains MCP scores for EKD samples
following training the SVM against all samples within the EKD.
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MVP SCORE DEMONSTRATES SENSITIVITY AND SPECIFICITY OF GADEVS
EPISIGNATURE
Samples were provided to a support vector machine binary classifier with a linear kernel
to assess the sensitivity and specificity, and the ability of the selected probe set to classify
samples. For each sample, the classifier provides a methylation variant pathogenicity (MVP)
score between 0 and 1. When plotted against control samples, all GADEVS samples received
high scores (>0.8) close to 1, while the control scores remained near 0, indicating the classifier
has a high sensitivity for the detection of the GADEVS episignature (see Figure 2-2C).
Furthermore, specificity of the classifier was tested by providing it with a large number of
subjects with a confirmed diagnosis of a neurodevelopmental disorder of various types with
existing episignatures within the EKD. 75% of both case and control samples from other
syndromes in the EKD were used for training, with the additional 25% reserved for testing. Case
samples scored >0.8, while the remaining non-GADEVS cases scored very low, with no case
exceeding a score of 0.5 to be classified as a GADEVS sample, indicating a very high level of
specificity for the selected probe set.

DISCUSSION
We describe the phenotype of 12 new individuals carrying a pathogenic or likely
pathogenic variant in YY1, proposed to lead to YY1 loss-of-function as reported by Gabriele et al,
2017 [1]. In addition, missense variants in the zinc finger domains and truncating variants both
lead to an overall decrease in the occupancy of YY1 on the genome and a loss of H3K27
acetylation at the active enhancers linked by YY1, and consequently to a differential expression
of target genes [1]. It was therefore postulated that YY1 could have an impact on DNA
methylation especially since YY1 has been demonstrated to have the ability to recruit the
Polycomb complex [27,28] known to be involved in the control of DNA methylation [29].
We observed a similar phenotype in our series to that described in the literature, such as
variable ID and developmental delay, behavioral and abnormal movement disorders, skeletal
abnormalities, and ophthalmological abnormalities, associated with craniofacial features and
feeding difficulties with a consequent low BMI in individuals with the classical variants.
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We also observed some differences including additional clinical features not previously
described in the literature, including thin and/or sparse hair (6/10). Looking at pictures from the
literature it seems that collectively, 15/22 (68%) of YY1 individuals had this clinical feature.
In addition, congenital malformations and cardiac malformations seem less frequent in
this series. We also observed cryptorchidism in 3/7 males, whereas this feature has been
described only once in the literature. However, YY1-related disorders are very rare, and it is
difficult to make conclusions on such a small number of individuals. Indeed, despite an
international call for recruitment we could only identify 13 new individuals with YY1 pathogenic
or likely pathogenic variants according to ACMG classification criteria. This condition is
probably still underdiagnosed since the involvement of YY1 in neurodevelopmental disorders
only became recognized in 2017. As the severity of ID seems to be variable in GADEVS, we
wanted to study the neurocognitive profile of individuals carrying a YY1 variant in order to
highlight a possible specific pattern. However, data from neuropsychological assessments were
largely insufficient, because the data were incomplete or uninterpretable. Additional studies
should be performed to this point.
In addition to the clinical features, here we demonstrate the first evidence of a peripheral
blood DNA methylation episignature, as a common molecular phenotype in patients presenting
with classical features of GADEVS. All samples provided evidence of a common methylation
profile for GADEVs, with of limited signal heterogeneity within the cross-validation model for 3
samples (YY1-6, YY1-7, and YY1-11) which received more moderate scores compared to the
rest of the cohort. These findings, alongside the atypical sample (YY1-10) indicate the
possibility of additional data structure, or sub-signatures, associated with variants in the YY1
sequence, similar to what is observed in some other genetic conditions [17,18]. Further research
with larger sample size will be necessary to study this hypothesis.
Individual YY1-3 carrying a deletion encompassing YY1 plus two other genes (WARS1
[MIM 191050] and EML1 [MIM 602033]) has a similar epigenetic signature to that observed in
individuals with pathogenic missense variants, suggesting that his phenotype can be at least
partially attributed to YY1 haploinsufficiency. In addition to dystonia previously described by
Gabriele et al, 2017, Carminho-Rodrigues et al, 2020 [3] and Zorzi et al, 2021 [4], individual
YY1-3 also has severe spasticity, as well as short stature (-3.9 SD). One of the other two genes,
WARS1, could explain the additional neurological feature as this gene is associated with a
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dominant distal motor neuropathy phenotype, however WARS1 variants described in this
condition are all missense [30-32] so this is unlikely.
Regarding individual with atypical localization of missense variant (individual YY1-10
with p.(Gly176Asp), located in in the transcriptional repression domain), we observed some
major differences in phenotype than GADEVS, i.e., overgrowth, obesity and macrocephaly.
Moreover, his DNA methylation profile is not specific and does not fit with the GADEVS
episignature. The p.(Gly176Asp) variant was initially considered as likely pathogenic according
to the ACMG classification (de novo variant absent from gnomAD exomes and genomes) but the
result of the DNA methylation analysis has allowed us to reclassify this variant to unknown
significance related to GADEVS. However, whether this variant is likely benign is not certain,
given the possibility of yet to be defined alternate episignatures or lack thereof. The utility of
EpiSign analysis in the reclassification of variants of uncertain clinical significance has been
recently demonstrated in the clinical setting in a large number of Mendelian disorders with
established episignatures [13]. Several studies have been published from our lab thus far
involving additional substratification of episignatures [17-18] further highlighting the importance
of methylation profiling in elucidating complex presentations of phenotype that remain
unexplained by genetic diagnosis alone.
Considering the phenotype of overgrowth in individual YY1-10, the pathophysiological
mechanism could be the selective alteration of the transcriptional repression function. However
functional analysis or additional individuals with the same p.(Gly176Asp) YY1 variant should be
necessary to definitively rule out or confirm this variant to be responsible for a novel YY1-related
disorder.
In conclusion, we describe 12 novel individuals with Gabriele-de Vries syndrome. We
identified novel features (i.e., thin and/or sparse hair and cryptorchidism in males). We also
describe for the first time a highly sensitive and specific DNA methylation episignature for
GADEVS and demonstrate the utility of EpiSign in the clinical assessment of variants of
uncertain clinical significance. Additional research is necessary to support the expanded clinical
spectrum and genotype-phenotype correlations in GADEVS.
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SUPPLEMENTARY FIGURES AND TABLES

Figure 2-S1: Cross validation. For each round of validation, one of the 13 selected GADEVS
samples was removed from probe selection, alongside matched controls. The remaining GADEVS
samples were designated as testing samples, and all three groups were modeled using
multidimensional scaling to determine how they cluster/segregate with one another. This process
was repeated with different combinations of assigned training and testing samples until all cases
had been removed from probe selection and used for testing once. Green, control; Blue, probe
selection (training); Red, testing/validation. Red samples should cluster with blue samples.
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Figure 2-S2: Graphical representation of the YY1 protein and its functional domains.
Variants from the series (top) and from the literature1–5 (bottom) are indicated by tags. The
missense variants from this series are mainly located in the Zinc finger domain, with the exception
of one variant, which is located in the glycine and lysine rich domain, involved in transcription
repression.
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Figure 2-S3: YY1 MVP Score ROC Graph: Receiver operating characteristic curve demonstrating the
sensitivity and specificity of the generated MVP scores for the YY1 cohort and the remaining EKD samples used for
training.
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Recruited individuals

Included individuals

3

3

Groupe DI

2

2

Anddi-RARES

2

2

ERN ITHACA

1

1

Clinical trial

1

0

GeneMatcher

8

5

Other

2

2

19

15

Montpellier University
Hospital

Total

Table 2-S1: number of individuals recruited and included according to the network used
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Episignature ID

Individual
ID

Label

Sex

Age at sample
collection
(years)

Genotype

MS3563

YY1-6

YY1

m

33

YY1(NM_003403.5):c.1067C>T,
p.(Thr356Met)

MS3564

YY1-7

YY1

m

2

YY1(NM_003403.5):c.1067C>T,
p.(Thr356Met)

MS3565

YY1-3

YY1

m

28

arr[GRCh37]14q32.2(100402364101351127)x1

MS3567

YY1-2

YY1

f

17

YY1(NM_003403.3):c.1112G>A,
p.(Arg371His)

MS3568

YY1-1

YY1

f

5

YY1(NM_003403.4):c.1007A>G,
p.(Glu336Gly)

MS3569

Individual 5+

YY1

f

17*

YY1:c.535A>T,p.(Lys179*)

MS3570

YY1-5

YY1

f

4

YY1(NM_003403.4):c.1151_1154dup,
p.(Pro386Valfs*7)

MS3571

YY1-4

YY1

f

1

YY1(NM_003403.4):c.1001T>C,
p.(Phe334Ser)

MS3575

YY1-10

YY1
Negative

m

2.5

YY1(NM_003403.4):c.527G>A,
p.(Gly176Asp)

MS4008

YY1-11

YY1

m

7

YY1(NM_003403.5):c.690dup,
p.(Asn231Argfs*3)

MS4447

YY1-12

YY1

m

25.6

YY1(NM_003403.5):c.1124G>A,
p.(Arg375Gln)

MS4828

YY1-13

YY1

m

19

YY1(NM_003403.4):c.908G>T,
p.(Cys303Phe)

MS4881

Individual 8+

YY1

f

34

YY1(NM_003403.4):c.385delG,
p.(Asp129Ilefs*127)

Table 2-S2: GADEVS samples with accompanying genetic and phenotypic information. DNA
was derived from peripheral blood taken from patients with features of GADEVS previously
identified through genomic sequencing and clinical assessment. Individuals marked by (a) are
individuals already described in Gabriele et al., 2017 [1] Missing age information, marked by (b)
was calculated using methylation based molecular estimates based on the Horvath Clock CpGs
[6].
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Protein change

YY1-1

YY1-2

YY1-3

YY1-4

YY1-5

YY1-6

YY1-7

YY1-8

YY1-9

YY1-10

YY1-11

YY1-12

YY1-13

p.Glu336Gly

p.Arg371His

NR

p.Phe334Ser

p.Pro386Val
fs*7

p.Thr356Met

p.Thr356Met

p.Val374Gly

p.His320Arg

p.Gly176Asp

p.Asp231Arg
fs*3

p.Arg375Gln

p.Cys303Phe

Growth
Genre
Age at
examination
Birth weight in g
(p)
Weight in kg (p)
Height in cm (Zscore)
BMI in kg/m² (Zscore)
HC in cm
(Z-score)

F

F

M

F

F

M

M

M

M

M

M

M

M

18y2m

16y7m

31y9m

6y

6y2m

33y

5y9m

4y9m

2y1m

2y10m

8y1m

25y7mo

20y6m

1760 (37)

2940 (25)

1560 (0.3)

2880 (10)

1885 (3)

NP

2820 (NP)

3908 (50)

3160 (35)

4167 (94)

2515 (27)

2720 (7)

2920 (NP)

34.6
(-5 SD)
162,5
(0,2 SD)
13.2
(-6 SD)

39.5
(-2,7 SD)
151,5
(-1,7 SD)
17.2
(-1,5 SD)
54.5
(0,1 SD)

54
(-1,9 SD)
148,5
(-3,9 SD)
24.5
(+0,4 SD)
54.5
(-1,4 SD)

18.6
(-0,6 SD)
115
(+0 SD)
14.1
(-0,9 SD)
49
(-1,7 SD)

15.2
(-2,5 SD)
111
(-1 SD)
12.3
(-3,2 SD)
50.5
(-0,5 SD)

15
(-2,4 SD)
101.5
(-2,4 SD)
14.6
(-0,7 SD)
48
(-2,5 SD)

18
(+0 SD)
110
(+0,6 SD)
14.9
(-0,5 SD)
48 (1y9m)
(-0,3 SD)

9.2 (1y7m)
(-2,4 SD)
78 (1y4m)
(-0,6 SD)

48
(-0,8 SD)

45.3
(+7,9 SD)
105
(+2,7 SD)
40.8
(+6,8 SD)
53
(+2,4 SD)

20.5
(-1,7 SD)
118
(-1,8 SD)
14.7
(-0,6 SD)
50,7
(-1,4 SD)

44.2
(-3,6 SD)
169.4
(-1 SD)
15.4
(-4,43 SD)
53
(-2,4 SD)

56.2
(-1,6 SD)
176.5
(-0,1 SD)
18
(-2,3 SD)
59
(+2,1 SD)

NP

9

15

11

>9

NP

19

NP

NP

8

NP

9

8

29

22

54

18

20

NP

66

54

Absent

18

18

18

15

NP

NP

NP

24

30

NP

NR

NR

NP

15

12 to 24

18

12

NP

NP

NP

33

36

NP

NR

NR

NR

36

36 to 48

36

NP

Delay

Simple
sentences

Normal

Simple
sentences

Words

Simple
sentences

Normal

Normal

Simple sentences

+

+

NP

NP
NP
NP
NP

NR

Psychomotor development
Age of sitting
alone (months)
Age of walking
alone (months)
1st words
(months)
1st sentences
Language

Delay

NP

Absent

Absent

+

+

+

+

+

+

+

+

+

+

Learning
difficulties

Hypotonia

-

-

+

+

+

NP

+

-

+

-

-

-

Behavioral
disorders

Anxiety, selfharm

Anxiety, selfharm,
stereotypies

-

ADHD

Low frustration
tolerance

NP

ASD

Autism

+
ADHD, low
frustration
tolerance,
stereotyped
behavior

ASD,
aggressiveness

Trouble
focusing

Anxiety

ADHD, ASD, OCD,
anxiety,
aggressiveness

Abnormal
movement

-

-

Severe
dystonia,
spasticity

Dystonia

-

NP

-

-

-

-

Facial tics,
Tourette
syndrome

-

Generalized dystonia

-

Enlargement
of
subarachnoid
spaces,
perimesencephalic
lipoma

NP

NP

Suspected focal
cortical dysplasia,
aspecific T2
hyperintensity foci

Congenital
torticollis,
week tendon
reflexes

-

Gait
imbalance,
exerciseinduced

-

-

ID
Neurologic features

Brain MRI

Other

NP

-

-

-

Aspecific
FLAIR hyperintensities

NP

Focal lesions
of white
matter

benign
enlargement
of
subarachnoid
spaces

Dysmetria

Febrile
seizures

Oculomotor
disorders

-

Amyotrophy

NP

-

--
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YY1-1

YY1-2

YY1-3

YY1-4

YY1-5

YY1-6

YY1-7

YY1-8

YY1-9

YY1-10

YY1-11

YY1-12

YY1-13

Cardiac
abnormalities

-

-

-

AtSD, VSD

NP

NP

-

-

NP

-

-

-

-

Urologic
abnormalities

-

-

Cryptorchidism

-

NP

NP

Unilateral
cryptorchidism

-

Bilateral
cryptorchidism

-

-

-

-

Skeletal
abnormalities

Camptodactyly,
hyperlaxity,
scoliosis,
long fingers

Hyperlaxity

Finger
hyperlaxity,
long fingers

NP

Occipital
plagiocephal
y hyperlaxity

-

Turricephal
y

-

Joint
hyperlaxity

Scoliosis,
joint pain

Scheuerman’s
kyphosis
(spinal
fusion)

NP

Feeding
disorders

Feeding
disorders,
constipation

NP

Feeding
disorders in
infancy
Chronic
constipation

Feeding
disorders,
G-tube

Miscellaneous

Gastro-intestinal
abnormalities

Feeding
disorders,
constipation

Hyperlaxity

Severe
constipation,
Feeding
disorders

NP

Feeding
disorders in
infancy

Feeding
disorders in
infancy

Feeding
disorders

Feeding
disorders

Feeding
disorders

Hair abnormalities

-

-

-

Thin hair

Thin hair

NP

Thin hair

Thin hair

Sparse hair

-

Sparse hair

Facial
hirsutism

-

Endocrine
abnormalities

-

-

-

-

NP

NP

-

-

NP

-

-

Hypothyroidism

Thyroid
nodule

Immune
abnormalities

-

-

-

-

NP

NP

-

-

Recurrent
infections

-

-

Recurrent
infections

-

Hyperopia
superficial
punctuated
keratitis,
nystagmus

Hyperopia,
astigmatism

-

+
(unspecified)

Convergent
strabismus

NP

NP

Convergent
strabismus,
cortical
vision
abnormalities

Convergent
strabismus

Strabismus,
amblyopia,
astigmatism

Strabismus

Strabismus
Myopia

+
(unspecified)

-

Conductive,
bilateral
20-35dB

-

-

NP

NP

-

-

-

-

-

-

-

Ophthalmologic
abnormalities

Deafness

Table 2-S3: Full description of 12 previously unpublished individuals with YY1 pathogenic variants.: the 13th individual, YY1-6, for
whom we have no clinical information, is not reported in this table +: feature present; -: feature absent; ADHD: attention deficit
hyperactivity disorder; ASD: autism spectrum disorder; AtSD: atrial septal defect; ID: intellectual disability; NP: not provided; p:
percentile; NR: not relevant; SD: standard deviation; VSD: ventricular septal defect
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CONCLUSION

This second chapter in my thesis lays the groundwork for the ensuing works described in later
chapters. In exploring the identification of a sensitive and specific biomarker for GADEVs, I found a
robust episignature capable of classifying a number of patients with YY1 variants on the basis of their
distinct methylation profiles. This biomarker can greatly improve the ability to detect this disorder in
clinical contexts, adding to the already powerful genetic and phenotypic features that currently help guide
diagnosis. Within ClinVar, 78 YY1 variants have been identified, with 20 currently identified as variants
of unknown significance (20/78, 26%, See Appendix Table 1). DNA methylation profiling of patients
with these variants could provide the functional evidence required to provide an effective diagnosis of
GADEVs, thereby increasing the diagnostic yield for this gene sequence.
Furthermore, this episignature’s interesting presentation of an atypical sample dissimilar in
methylation profile and phenotype provides an interesting insight into the possibility of further
subsignatures within the YY1 sequence. This atypical sample was classified as not having a methylation
profile similar to other case samples by the hierarchical clustering heatmaps and multidimensional scaling
models, as well as receiving low MVP scores within each iteration of our classifier, guiding us to look
further into the possible reasons for this atypical presentation. These investigations led to novel insights
into the patient in question, revealing phenotypic differences in the presentation of the disorder,
characterized with symptoms of overgrowth not seen in other patients. This atypical phenotype was
unknown to me in the preliminary stages of the analysis, and was identified through methylation
profiling. Further research into the methylation differences observed in this sample, and samples with
similar variants may reveal similarly affected pathways that explain the alternate phenotype observed, and
should be explored to better understand these patients, as well as those presenting with the more typical
phenotype of GADEVs.
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PREFACE
In the previous chapter, we discussed the discovery of a novel episignature for Gabriele
De Vries syndrome, which encompassed a number of variants within the associated YY1
transcription factor gene sequence. This episignature was common to the entirety of the cohort
across the spectrum of genetic variants with the exception of a single atypical case. Due to the
small sample size of this atypical signature, I hypothesized the possibility of an additional
episignature, associated with an alternate phenotype of overgrowth, requiring further research
and similar samples to effectively classify this potential subsignature. Expanding on this
potential avenue of multiple episignatures within a cohort of patients involving disruptions of the
same gene sequence, I now present to you my findings within a cohort of patients with KDM2B
variants, associated with a novel NDD we have coined as KDM2B-related-neurodevelopmental disorder or K2BNDD. Within this cohort, we identified not only an episignature for variants
within the KDM2B gene, similar to the one described in my previous chapter, but a specific
DNA methylation pattern associated with disruption of a particular gene domain within the
KDM2B sequence.
Disruption of the CxxC DNA binding motif domain within the KDM2B sequence
resulted in a distinct DNA methylation subsignature, characterized a much larger magnitude of
change in methylation signal intensity with distinct multidimensional scaling models when
compared to the matched controls and other KDM2B cases with variants outside this particular
domain. Furthermore, phenotypic differences were also observed in these CxxC domain patients,
with considerable increases in the incidence of congenital anomalies, not seen in other KDM2B
cases. Gathering these findings, I propose the existence of multiple domain specific episignatures
that are robust diagnostic biomarkers, unique not only to a particular gene sequence, but even to
specific domains within those gene sequences. This chapter demonstrates the assessment of
multiple episignatures with multiple specific phenotypes, as a result of domain specific
differences, within a cohort derived from a single gene origin.

71

ABSTRACT
Mutations in genes involved in the epigenetic machinery are an emerging cause for
neurodevelopmental disorders (NDDs). Lysine-demethylase 2B (KDM2B) encodes an epigenetic
regulator but has not been recognized as an NDD gene to date. Here we present a cohort of 21
individuals with heterozygous –likely- pathogenic variants in KDM2B. These individuals present
with developmental delay and/or intellectual disability, autism, attention deficit /hyperactivity
disorder, AD(H)D), congenital organ anomalies and facial dysmorphism. To establish this
cohort, we assessed 24 variants in 33 individuals. We applied methylation arrays on bloodderived DNA samples to establish a KDM2B-specific epigenetic signature characterized by
hypermethylation of CpG-dinucleotides. We identify the CxxC-domain as a mutational hotspot
and identify a specific episignature for this subgroup. Importantly, we were able to detect the
KDM2B-episignature even in the context of a dual diagnosis with the presence of another
episignature, demonstrating the robustness of this assay.

INTRODUCTION
Many genes encoding for epigenetic regulators have been implicated as monogenic
disease genes in neuro-developmental disorders (NDDs). This group of disorders, collectively
referred to as ‘Mendelian Disorders of the Epigenetic Machinery’ (MDEMs) , is characterized by
intellectual disability (ID) and/or growth abnormalities [1]. For an increasing number of
MDEMs, distinct genome-wide methylation signatures (or episignatures) have been identified
[2]. These signatures are emerging as valuable tools in clinical practice, as they are unique for
each disorder and can be detected in peripheral blood samples, providing a robust and easily
accessible diagnostic tool [3]. The KDM2B gene (lysine-demethylase 2B, a.k.a FBXL10, NDY1,
CXXC2 and JHDM1B; OMIM #609078) encodes for a well-studied component of the
epigenetic machinery. The canonical, full-length KDM2B protein (KDM2B-Long Form;
KDM2B-LF) acts by demethylating lysine residues K4, K36 and K79 of Histone 3
[4,5,6,7,8,9,10,11]. This catalytic activity is provided for by the JmjC-domain , which is
conserved from yeast to humans [11,12]. Interestingly, an alternative transcript produces a
shorter KDM2B isoform (KDM2B-SF), which lacks the JmjC domain and thus lacks catalytic
activity [13]. This short form is highly expressed in mouse embryonic stem cells (mESC) [14]
suggesting important functions of KDM2B not directly related to lysine demethylation activity.
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Apart from the JmjC-domain, both KDM2B isoforms share the same architecture, consisting of
four additional domains. The first is the CxxC-domain, a DNA-binding domain that specifically
binds unmethylated CpG-dinucleotides and directs KDM2B to promoter regions [15, 16, 17].
The CxxC-domain is stabilized by the adjacent PHD-domain [17], a protein interacting domain
that binds to methylated H3K4 and H3K36 residues [8]. The KDM2B proteins are completed
by the F-box and LRR domains which are implicated in protein-protein interactions, most
notably the CUL1-RING complex and Polycomb Group proteins [18, 19, 20].
KDM2B has been implicated in many biological processes, including cell cycle regulation,
metabolic regulation and DNA-damage repair [5, 15, 21, 22]. Moreover, in line with a central
role in epigenetic and transcriptional regulation, KDM2B is essential for organism development
and regulates cellular differentiation [15]. For instance, KDM2B can immortalize cells and
maintains stemness in mESC [7, 23]. In addition, KDM2B is essential for survival of neuronal
progenitor cells, and full knock-out causes aberrant neuronal development in mice, and
ultimately embryonic lethality [14,15]. Interestingly, re-expression of only KDM2B-SF in a
Kdm2b knock-out background resets the methylation of CpG-islands to baseline levels and
rescues embryonic lethality [15]. Although the molecular mechanisms by which KDM2B
operates -and the contributions of each isoform to these functions- remain to be determined,
these findings suggest that the functions of KDM2B are not limited to lysine demethylation
alone.
Despite scarce reports describing individuals carrying KDM2B germline variants [24, 25, 26, 27,
28], a KDM2B-related human disorder has not been delineated to date and the significance of
reported variants remains uncertain. Here, we present a series of 33 individuals with
heterozygous KDM2B variants, collected through international collaborations and literature
review. We establish a KDM2B-related episignature and apply this for further characterization of
the identified variants. For 21 individuals (representing 16 different variants), variants were
classified as (likely) pathogenic. We delineate a novel NDD with or without congenital
anomalies, and propose to refer to this novel syndrome as ‘KDM2B-related NDD’ (K2BNDD).
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RESULTS

GENETIC VARIANTS IN KDM2B

The present study was initiated after the identification of a de novo c.1912G>A
(p.Gly638Ser) variant in KDM2B (NM_032590.4; Table 3-1, Extended Data Table 3-1) by
diagnostic trio-exome-sequencing (trio-ES) in the index patient (#1). KDM2B presented as an
outstanding disease gene candidate as the gene is intolerant for both putative loss-of-function
(pLoF; o/e=0.09 [0.05-0.18]) and missense (Z=3.44) variants in the general population [29].
Furthermore, KDM2B is a known epigenetic regulator and the patient’s phenotype fitted with
known MDEMs (Table 2, Extended Data Table 3-2) [1]. In addition, the identified variant was
absent from the gnomAD database [29], predicted damaging by multiple algorithms (Table 3-1,
Extended data Table 3-1) and affects a well conserved residue (Supplementary Figure 3-S1A) in
a known functional domain (i.e. the CxxC-domain; Figure 3-1A & 3-1B). We therefore aimed to
collect additional cases carrying KDM2B variants and formed the present cohort after online
matchmaking using the Genematcher platform [30], literature search, personal communication
and in-house database searches.
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Figure 3-1: A cohort of heterozygous KDM2B variant carriers. A: Schematic representation of the KDM2B gene,
its known domains and the variants included in this study. Lollipops representing individual variants indicate location,
classification of (predicted) impact on the transcript and/or protein (shape) and the classification based on the first
analysis of the methylation arrays (color; Supplementary Figure 3-S2). Larger deletions (i.e. cases 25.1, 25.2, 29 and
30) are not shown. B: CxxC-domain missense variants on the known crystal structure. Purple spheres represent Zn2+
ions. Sidechains of relevant residues are included. C: Pedigrees depicting all cases of inherited variants of which the
pedigree has not been published before (families 3, 4, 5 and 25). All remaining pedigrees can be found in
Supplementary Figure 3-S1. ADHD: Attention Deficit Hyperactivity Disorder; ID: Intellectual Disability; LD:
Learning Difficulties; WT: Wild Type . D) Projection of the p.Val316Ile (family 4) variant on the structure of the
mouse KDM2A JmjC structure (yellow). The predicted human KDM2B JmjC structure as determined by AlphaFold
is shown in green. Orange sphere indicates Fe2+ ion and the aKG cofactor is shown as yellow sticks. Purple line
indicates target peptide (Histone 3).
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We collected data of a total of 33 individuals from 25 families representing 24 different
heterozygous variants in KDM2B (Figure 3-1, Table 3-1& 3-2, Supplementary Figure 3-S1,
Extended data tables 1&2). Our cohort encompasses seven pLoFs (7/24), sixteen missense
variants (16/24) and one in-frame deletion (1/24). Eighteen variants were confirmed de novo
(18/24). Of note, one of these variants was identified twice and thus occurred de novo at two
independent occasions (c.1847G>A, #18 and #31). Five variants are inherited (5/24; families 3,
4, 5, 24 and 25; Figure 3-1C and Supplementary Figure 3-S1B). Nine individuals have been
previously reported in other studies: family 25 [31], family 24 [28], individuals #29 and #30
[32], and #34 [26]. An overview of all variants, including inheritance, presence in gnomAD and
summarized results from prediction algorithms, is presented in Table 3-1 (details in Extended
Data Table 3-1). Of note, we observed a remarkable clustering of coding-altering variants (8
missense and 1 in-frame deletion) in the CxxC-domain (Figure 3-1A and 3-1B), of which seven
missense variants (7/8) were predicted to be damaging by all algorithms. The only exception is
p.Ile652Val, which is furthermore the only inherited variant and reported twice in gnomAD.

We performed additional structural modeling of the coding altering variants located in
areas where structural data is available. First, we projected the variants located in the CxxCdomain on the known crystal structure (Figure 3-1B) [17]. The missense variants located at
positions p.Cys616, p.Cys627 and p.Cys630 are predicted to be damaging as they are likely to
influence the interaction with the Zinc ions (Zn2+) located at the respective positions. The
p.Ile652Val variant is located near the same Zn2+ ion as p.Cys616, however this substitution is
less likely to affect the position of the ion as the sidechain is located towards the surface, and the
respective loss of a methyl group is not expected to influence the local structure. Functional
consequences of this variant are therefore questionable, furthermore strengthened by its presence
in gnomAD and inconsistent results from prediction algorithms (Table 3-1). The variants
affecting p.Gly638 are expected to impact on the torsion angle at this location, most likely
disrupting the local architecture and are therefore expected to be damaging. Finally, the
p.Asp632Tyr and p.Lys635del variants are located within an ɑ-helix and are likely to impact on
the function of this structure.
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Individual

Inheritance

Variant (NM_032590.4)

GnomA
D

In silico prediction

EpiSign

-

4/4

Y

1

c.1912G>A,

Pathogenic variants
p.(Gly638Ser)
de novo

3.1, 3.2
4.1, 4.2,
4.3
6

c.3370C>T

p.(Arg1124*)

Paternal

-

LoF

Y; Y

c.946G>A

p.(Val316Ile)

Paternal

1x

4/4

Y; U; Y

c.499C>T

p.(Arg167Trp)

de novo

-

4/4

Y

10

c.457delA

p.(Met153Cfs*24)

de novo

-

LoF

Y

11

c.3005_3023del19

p.(N1002Sfs*35)

de novo

-

LoF

Y

18, 31

c.1847G>A,

p.(Cys616Tyr)

de novo

-

4/4

Y; NA

20

c.1913G>A

p.(Gly638Asp)

de novo

-

4/4

NA

22

c.1846T>C

p.(Cys616Arg)

de novo

-

4/4

Y

23

c.1889G>C

p.(Cys630Ser)

de novo

-

4/4

Y

25.1, 25.2

12q24.31 deletion

Paternal

NA

LoF

Y

29

12q24.31 deletion

de novo

NA

LoF

Y

30

12q24.31 deletion

de novo

NA

LoF

Y

13

c.1903_1905delAAG

-

NA

NA

12

c.1244G>A

1/4

NA

17

c.1627G>A

p.(Ala543Thr)

de novo

2x

4/4

NA

24.1-4

c.2173G>A

p.(Ala725Thr)

inherited

-

4/4

NA

34

p.(Gly745Ser)
p.(Arg766Gln)

de novo
de novo

-

4/4

NA

2

c.2233G>A
c.2297G>A

2x, 7alt

3/4

N

5.1, 5.2

c.1954A>G

p.(Ile652Val)

Maternal

2x

3/4

N; U

14

c.3637C>T

p.(Arg1213Trp)

de novo

5alt

4/4

N

Likely pathogenic variants
p.(K635del)
de novo

Variants of unknown significance (VUS)
p.(Cys415Tyr)
unknown
-

c.777+5G>A
Splice site
de novo
3/3 reduced
N
19
Abbreviations: alt=alternative; LoF=Loss of Function; N=No/Negative; NA=Not Applicable/Not Assessed; U=Uncertain;
x=times; Y=Yes/Positive; - =absent
Table 3-1: Overview of KDM2B variants in the cohort. International collaborations resulted in a cohort of 33
individuals representing 24 variants in KDM2B. The table indicates genetic details of each variant, appearance of the
variant in gnomAD (or alternative variants affecting the same residue, alt), summary of in silico prediction results and
inclusion in the KDM2B episignature cohort. alt=alternative; LoF=Loss of Function; N=No/Negative; NA=Not
Applicable/Not Assessed; U=Uncertain; x=times; Y=Yes/Positive. Additional and supporting information per variant
can be found in Extended Data Table 3-
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Ind

Sex,
Variant
age
(NM_032590.4)
(year)
Pathogenic variants

Inheritance

ID/DD

Behavior/
psychiatry

Hypotonia

Microcephaly
(OFC < -2 SD)

Cardiac
anomalies

Kidney
anomalies

other

1

M, 7

De novo

-

-

Familial polydactyly

hyperactivity

+

-

VSD, ASD, fetal
atrial flutter
VSD, DORV

-

F, 7

Speech delay,
SON-IQ 86
Severe ID

Autism

3.1

c.1912G>A,
p.(Gly638Ser)
c.3370C>T,
p.(Arg1124*)

NA

3.2

M, 42

Unknown

NA

-

-

NA

M, 15

Learning
difficulties
Mild

ADD

4.1

-

NA

NA

epilepsy

M, 65

Autism, ADHD,
tantrums
NA

NA

4.2

c.3370C>T,
p.(Arg1124*)
c.946G>A,
p.(Val316Ile)
c.946G>A,
p.(Val316Ile)

Phelan McDermid
syndrome: 22q13
deletion
COPD

NA

-

NA

NA

decreased renal
function, osteoporosis
(adult age)

4.3

F, 21

c.946G>A,
p.(Val316Ile)

Paternal

NA

-

NA

NA

6

M, 9

De novo

-

-

-

-

7

M, 4

c.499C>T,
p.(Arg167Trp)
c.1894G>T,
p.(Asp632Tyr)

Autism,
tantrums,
anxiety
ADHD
Autism, ADHD,
impulsiveness

-

-

PVS, ASD

-

8

F, 6

De novo

Mild speech delay

-

-

-

10

M, 10

De novo

Mild ID, IQ 66

-

-

-

F, 5

De novo

-

M, 5

Autism,
hyperactivity
-

+

18

Global DD,
moderate ID
Moderate global
DD

ASD, MR, PDA,
PVS
Atrial septal
aneurysm, MR
-

Single
kidney
-

11

c.1880G>A,
p.(Cys627Tyr)
c.457del,
p.Met153Cysfs*24
c.3005_3023del19,
p.(Asn1002Sfs35)
c.1847G>A,
p.(Cys616Tyr)

-

+

-

Single
kidney

20

F, 14

c.1913G>A,
p.(Gly638Asp)

De novo

Mild autistic
features

NA

-

mild mitral
insufficiency

-

22

M,
16m

c.1846T>C,
p.(Cys616Arg)

De novo

Speech delay learning
difficulties
Global DD, speech
delay

-

Upper
limbs

-

PFO

Single
kidney

23

F, 3

c.1889G>C,
p.(Cys630Ser)

De novo

Severe DD, no
speech

-

+

NA

ASD

Single
kidney,
Right VUR

Paternal

Paternal
Unknown

De novo

De novo

Learning
difficulties - mild
ID
Moderate
Speech delay, nonverbal IQ 97
Learning
difficulties

78

NA

Congenital ptosis,
cryptorchidism
Hypertonia,
progressive
contractures, inguinal
hernia
Short stature
SHOC2-related
Noonan syndrome
Epilepsy, MRI
abnormalities (MCD)
Coloboma,
hypertrichosis, failure
to thrive
Short stature, R
oculomotor defect
enophtalmus
Brain MRI
abnormalities,
unilateral
anophthalmia,
bilateral SNHL, facial
asymmetry
Short stature, poor
weight gain, squint,

25.1

F, 12

12q24.31 deletion
(including KDM2B,
HNF1A)
12q24.31 deletion
(including KDM2B,
HNF1A)

Paternal

Severe, no speech,
cannot walk

Not specified

+

+

NA

Unknown

Normal

-

-

-

-

Normal
renal
function
-

25.2

M,
adult

29

F, 12

12q24.31 deletion
(including KDM2B &
SETD1B)

De novo

+

Autism, ADHD

-

-

NA

NA

30

M

12q24.31 deletion
(including KDM2B &
SETD1B)

De novo

+

Probable autism

+

OFC at 4th
percentile

NA

NA

31

M, 5

c.1847G>A,
p.(Cys616Tyr)

De novo

Speech delay,
mild- moderate ID

Stereotypies

-

+

ASD

-

-

+

+

-

Behavioral
difficulties

Hypotonia

Microcephaly
(OFC < -2 SD)

ASD (x2), PVS,
PDA, PFO
Cardiac
anomalies

Likely pathogenic variant (sample not available for methylation analysis)
13
F, 4
c.1903_1905delAAG,
De novo
Moderate speech
p.(Lys635del)
delay, mild ID
Ind
Sex,
Variant
Inheritance ID/DD
age
(NM_032590.4)
(year)

Kidney
anomalies

VUS (sample not available for methylation analysis)
12
M,
c.1244G>A,
Unknown
0,2
p.(Cys415Tyr)

UK

UK

+

-

UK

UK

17

F, 7

c.1627G>A,
p.(Ala543Thr)

De novo

+

Autism

+

-

PFO

NA

24.1

F, 32

c.2173G>A,
p.(Ala725Thr)

Maternal

Moderate

SCZ

NA

NA

Incomplete
RBBB, normal
echocardiogram

NA
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congenital obstructio
ductus nasolacrimalis
Epilepsy, hip dysplasia
Published by Chouery
et al; Krzyzewska et al.
Insulin-dependent
diabetes at 14y.
Published by Chouery
et al; Krzyzewska et al.
Preauricular tags,
oligodontia, umbilical
hernia, published
Krzyzewska et al.
Epilepsy, published
Krzyzewska et al.,
patient 10; Labonne et
al.
cryptorchidism, talus
pes, kyphosis.
congenital obstruction
of ductus
nasolacrimalis
Feeding difficulties at
birth
other

Macrocephaly,
polyhydramnios, club
foot, contractures,
multiple
arthrogryposis,
undescended testis;
published Monies et
al:
PMID: 31130284
History of failure-tothrive until age 2,
epilepsy, later obesity,
MRI abnormalities
IQ 39 after diagnosis
of schizophrenia.

24.2

F, 69

24.3

F, 39

24.4

M, 34

c.2173G>A,
p.(Ala725Thr)
c.2173G>A,
p.(Ala725Thr)
c.2173G>A,
p.(Ala725Thr)

Unknown

NA

SCZ

NA

NA

NA

NA

Maternal

+

SCZ

NA

NA

NA

NA

Maternal

Moderate - severe

SCZ

NA

NA

NA

NA

34
NA
p.Gly745Ser
De novo
NA
VUS (Variants not showing KDM2B specific episignature)
2
F,
c.2297G>A,
De novo
1,8
p.(Arg766Gln)

SCZ

NA

NA

NA

NA

-

-

NA

-

NA

5.1

M, 28

5.2

F, 58

14

M, 12

c.1954A>G,
p.(Ile652Val)
c.1954A>G,
p.(Ile652Val)
c.3637C>T,
p.(Arg1213Trp)

Maternal

Mild- moderate

Autism

NA

-

NA

NA

Unknown

-

NA

NA

NA

NA

NA

De novo

Global DD, limited
speech, mild ID (IQ
64)

Hyperactivity,
aggressive
behavior

+

-

-

-

published by
Yokotsuka-Ishida et al.
published by
Yokotsuka-Ishida et al.
Seizures. published by
Yokotsuka-Ishida et al.
CP, L opaque cornea, L
eye blindness.
published by
Yokotsuka-Ishida et al.
Published Girard et al.
CL/P, preaxial
polydactyly, finger
contractures, thumb
hypoplasia
Scoliosis, hearing loss
due to cholesteatoma
dyslexia

Macrocephaly,
epilepsy, brain MRI
abnormalities,
hand/finger
abnormalities
19
F, 1
c.777+5G>A
De novo
Severe DD, no
NA
+
+
ASD
Neonatal seizures,
speech
thrombotic
angiopathy, SNHL,
abnormal renal
vasculature
+= presence of feature, = absence of feature, ADHD= attention deficit hyperactivity disorder, ASD= atrial septal defect, CLP= cleft lip/palate, COPD= chronic obstructive pulmonary
disease, CP= cerebral paresis, DD= developmental delay, F, female= ID, intellectual disability, DORV= double outlet right ventricle, L= left; M= male; MR= mitral regurgitation; MCD=
malformation of cortical development, NA= not assessed, PDA= persistent ductus arteriosus, PFO= persistent foramen ovale, PVS= pulmonary valve stenosis, RBBB= right bundle
branch block, SNHL= Sensorineural hearing loss, VSD= ventricular septal defect, VUR= vesicoureteral reflux

Table 3-2: An overview of the phenotypes associated with K2BNDD. This table summarizes the clinical features of individuals with KDM2B
variants. More extensive data are presented in Extended Data Table 3-2 and the clinical summaries. Abbreviations: +=presence of feature, -=absence of feature,
ADHD=attention deficit hyperactivity disorder, ASD=atrial septal defect, CLP=cleft lip/palate, COPD=chronic obstructive pulmonary disease, CP=cerebral
paresis, DD=developmental delay, F=female, ID=intellectual disability, DORV=double outlet right ventricle, L=left; M=male; MR=mitral regurgitation;
MCD=malformation of cortical development, NA=not assessed, PDA=persistent ductus arteriosus, PFO=persistent foramen ovale, PVS=pulmonary valve
stenosis, RBBB=right bundle branch block, SNHL=Sensorineural hearing loss, VSD=ventricular septal defect, VUR=vesicoureteral reflux.
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Two other missense variants are located in known domains for which structural data is
available. The p.Ala725Thr variant is located at the border of the PHD-domain and affects a
residue located just outside the known structure [17]. This might indicate that this variant resides
in an unstructured area, and we are therefore unable to predict functional consequences. The
p.Val316Ile variant is located in the JmjC-domain. Since the structure of the KDM2B JmjCdomain remains to be resolved, we projected the variant on the known structure of the
homologous mouse Kdm2a domain [12] and the human KDM2B AlphaFold model [33]. This
residue is located within the active site of the JmjC-domain, near the catalytic metal ion and
cofactor alpha-ketoglutarate binding site (Figure 3-1D). The variant is expected to impact on
metal ion binding as it results in an increase in size, thus likely interfering with the catalytic
activity of the JmjC-domain.
In summary, we collected a total of 24 variants in KDM2B. Based on the absence from
controls and predicted functional impact on the gene product, the majority was considered
promising candidates to explain the patients’ phenotypes.

A GENOME WIDE EPISIGNATURE IN KDM2B PATIENTS
We next aimed to determine if the variants had an impact on KDM2B function. Due to its
role in the epigenetic machinery, we hypothesized that KDM2B deficiency leads to genome-wide
changes in DNA methylation; an effect which has been observed for >30 other monogenic
disease genes involved in chromatin organization [2, 3, 34]. These methylation changes present
as disease specific episignatures, which are detectable in peripheral blood. As such, episignatures
not only provide fundamental insights into the molecular consequences of genetic variants; they
provide easily accessible diagnostic tools to identify syndromes or re-classify variants of
unknown significance (VUS) [3].
Under the assumptions that such an episignature also exists for KDM2B and the majority
of the variants in our cohort disrupt gene function, we set out to determine a KDM2B-related
episignature. To that end, we generated genome-wide methylation array data for 21 individuals
(Table 3-1, Extended Data Table 3-1) according to previously established protocols. We
excluded two samples because of technical errors (#2 and #4.2, Supplementary Figure 3-S2D).
Another three samples were excluded for the establishment of the episignature, as they failed to
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group with case samples after cross validations (#5.1, #14 and #19; Supplementary Figure 3S2B, D and E). This suggests the respective variants do not impact on KDM2B function, or at
least not in a similar fashion as the majority of the variants. Of note, all these three variants were
marked uncertain based on inheritance and/or presence in gnomAD (Table 3-1, Extended Data
Table 3-1). As the #5.1 sample -representing the p.Ile652Val variant- did not pass cross
validation testing, we additionally excluded the sample from #5.2 from further analysis.
The remaining 15 samples, representing 13 variants, were used to establish a KDM2B
episignature (Figure 3-2). To this end, methylation patterns were assessed for sample quality,
degree of methylation change and statistical robustness of observed changes at each probe,
allowing for effective modeling of the methylation differences observed between case samples
and matched controls who do not carry KDM2B variants (see Materials and Methods).
Comparisons were performed against age and sex matched controls, leading to the identification
of 156 statistically differentially methylated probes (Figure 3-2A). Hierarchical clustering based
on this probe set showed distinct clustering of case samples away from controls, with all samples
presenting a more similar methylation profile to one another as compared matched controls
(Figure 3-2B and 3-2C). Cross validation assays, based on the removal of each single sample
from the probe selection training process, confirmed the probe set is able to effectively identify
KDM2B variant carriers, as all case samples remained grouped together on each iteration
(Supplementary Figure 3-S3B). In conclusion, we established an episignature able to
discriminate KDM2B variant carriers from controls. Interestingly, the KDM2B associated
episignature mainly consists of hypermethylated probes (Figure 3-2A).
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Figure 3-2: A KDM2B specific episignature. After initial analysis (Supplementary Figure 3-S2), fifteen
samples, identified as outliers in the initial analysis, were included for the training of a KDM2B specific episignature.
A: Volcano plot indicating selected probes (red) included in the KDM2B episignature. B: Multidimensional scaling
(MDS) plot for selected probes, representing the pairwise distance across samples (red) and controls (blue), based on
the top two dimensions. C: Heatmap of selected probes and unsupervised hierarchical clustering results indicating the
episignature’s ability to decipher KDM2B variant carriers (red) from controls (blue). D: Support Vector Machine
(SVM) classifier indicating specificity of the KDM2B episignature. Graph shows summary of 4-fold validation using
all fifteen case samples and 75% of unaffected controls and other episignatures for training (blue) and the other 25%
for testing (grey). Y-axis: MVP scores as determined by SVM. X-axis: different groups of samples, controls and other
known episignatures. Red arrowhead indicates the IDDSELD sample referred to in the text. *Note. Figure differs from
previously published version of the paper. Results were regenerated for figure quality improvement, and differ
somewhat in quantitative results, however, qualitative results (correct classification of KDM2B samples, outlier
IDDSELD sample) remain the same.

We next tested the sensitivity and specificity of the episignature using a support vector
machine. For each sample, we determined a methylation variant pathogenicity (MVP) score
between zero and one based on matching the KDM2B episignature. All KDM2B samples
included in the training set received scores >0.8 while control samples remained near zero,
indicating high sensitivity for the detection of the KDM2B episignature (Supplementary Figure
3-S3C). Specificity was tested using a similar classifier that was instead trained against a large
number of samples with confirmed diagnoses of a non-KDM2B related NDD from our Episign
knowledge database. 75% of both case and control samples were used for training the classifier
with the remaining 25% reserved for testing (Figure 3-2D). Case samples again scored high
(>0.85) while the remainder of samples scored low (<0.5), with few exceptions. The most
notable exceptions are cerebellar ataxia, deafness, and narcolepsy (ADCADN; OMIM 604121), a
disorder associated with DNMT1; Hunter–McAlpine syndrome (HMA; OMIM# 601379),
associated with NSD1 ; and Dystonia 28, childhood-onset (DYT28 ; OMIM# 617284), associated
with KMT2B (also see Discussion). One other sample amongst the control samples did score
remarkably high for the KDM2B signature (Figure 3-2D, red arrow head). This sample was
previously diagnosed with intellectual developmental disorder with seizures and language delay
(IDDSELD , OMIM# 619000), a disorder caused by variants in SETD1B . This gene is located
close to KDM2B at 12q24, and upon closer investigation we identified this sample to originate
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from a case reported to have a 12q24.31 deletion which does not include KDM2B but might
affect regulatory regions [32, 35]. For reference, we included the clinical description of this
individual (#33, Extended Data Table 3-2).
Of note, our cohort contains two cases (#29 and #30) that carry larger deletions
encompassing both KDM2B and SETD1B (Table 3-1, Extended Data Table 3-1 and 3-2) who
were previously reported based on the SETD1B deletion and its associated episignature [32]. In
these two samples, we have additionally identified the KDM2B signature. Another sample
showing co-existing episignatures is #3.1, which was previously diagnosed with PhelanMcDermid syndrome (PHMDS, OMIM 606232) due to a 22q13 deletion, which was also
confirmed based on the respective episignature. We here thus identify the KDM2B related
signature associated with a KDM2B nonsense variant as well. These results indicate that multiple
episignatures can coexist in a single individual and that the method is able to correctly identify
both syndromes independently.

A CXXC-DOMAIN SPECIFIC EPISIGNATURE DISCRIMINATES BETWEEN LOF AND
CXXC MISSENSE CARRIERS
Our cohort consists of both coding-altering and LoF variants, and we observed a
remarkable clustering of variants in the CxxC domain (Figure 3-1A). One could therefore
hypothesize that CxxC missense variants exert different or additional effects as compared to LoF
variants. We therefore asked whether CxxC missense variants resulted in a different episignature.
To this end, we performed the same analysis as before based on a selection of five samples
(Figure 3-3C; Extended Data Table 3-1) carrying missense variants in the CxxC domain for
which methylation data was available. The resulting probe set was then used for the hierarchical
clustering of these CxxC samples and the LoF samples within the cohort. Interestingly, this
probeset correctly differentiates between all KDM2B variant carriers (i.e. including the LoF
variants) and controls (Figure 3-3B and 3-3C), suggesting that LoF and CxxC variants affect the
same genomic regions. However, this probe set also segregates CxxC missense samples from
LoF variant samples (Figure 3-3B and 3-3C), indicating that CxxC variants have a distinct
impact on DNA methylation as compared to LoF variants. Most notably, 106 hypermethylated
probes amongst the 107 significant probes selected for the CxxC-trained episignature present
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with an on average increased methylation level even exceeding that of the hypermethylation
probes of the pan-KDM2B probeset (mean methylation difference of all hypermethylated probes:
16.56% ±4.21 vs. 10.38% ±3.68, respectively; Figure 3-2A and Figure 3-3A). Similar, yet less
pronounced, results were achieved using the LoF variant samples to train for probe selection
(Supplementary Figure 3-S4). In conclusion, CxxC missense variants cause a distinct
episignature that is associated with increased hypermethylation levels.
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Figure 3-3: A CxxC-variant specific episignature. All samples representing a CxxC-coding variant and
included in the KDM2B episignature training set, were used to train a CxxC-variant specific episignature. A: Volcano
plot indicating all selected probes (red) included in the CxxC episignature. B: Multidimensional scaling (MDS) plot
for selected probes, representing the pairwise distance across CxxC variants (orange), LoF variants (red) and controls
(blue), based on the top two dimensions. C: Heatmap of selected probes and unsupervised hierarchal clustering results
indicating the episignature’s ability to decipher KDM2B variant carriers (red and orange) from controls (blue), and to
decipher CxxC variants (orange) from LoF variants (red). D: Support Vector Machine (SVM) classifier indicating
specificity of the CxxC episignature. Graph as in Figure 3-2D.

CLASSIFICATION OF KDM2B VARIANTS BASED ON EPISIGNATURE
Based on the pan-KDM2B episignature (Figure 3-2), we established a functional effect
for 13 variants within our cohort, represented by 15 individuals. Four variants tested negative for
the signature. Among the negative samples are two missense variants of which the a priori
prediction was doubtful (i.e. p.Arg766Gln & p.Ile652Val, Table 3-1 and Extended Data Table 31). Although the remaining missense (p.Arg1213Trp) is de novo and predicted damaging by all
algorithms, two alternative substitutions (i.e. p.Arg1213Gln & p.Arg1213Leu) in five individuals
are reported in the gnomAD database. The other negative sample is that of the only splice-site
variant in our cohort, possibly indicating the predicted splice effects do not occur, or at least not
to a level that interferes with gene functionality. These four variants we consider to remain
VUSs, as a negative episignature result does not suffice to infer an absence of functional effects.
Based on the ACMG/AMP criteria [36], incorporating the functional evidence provided by the
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episignature (criterium PS3) [3], we classified the 13 positive variants as pathogenic (Table 3-1,
Extended Data Table 3-1).
As we now consider KDM2B as an established disease gene (including arguments from
the shared clinical phenotypes described below), we set out to re-classify the variants that were
not tested or returned inconclusive results for the episignature, based on the ACMG/AMP
guidelines [36] (Extended Data Table 3-1). Importantly, we considered the CxxC-domain as an
established hotspot for pathogenic variation in KDM2B (criterium PM1), as all tested de novo
variants within this domain returned positive for the episignature. Amongst the seven variants
not tested for the episignature, we re-classified two variants as pathogenic, as they involve de
novo variants located within the CxxC-domain and are absent from the gnomAD database. In
addition, one of these variants (p.Gly638Asp, #20) affects a residue at which a different
substitution was confirmed pathogenic based on the episignature (p.Gly638Ser, #1). One variant
was re-classified as likely pathogenic (p.K635del, #13); although this variant affects the CxxCdomain as well, it represents the only in-frame deletion in our cohort and no additional functional
evidence for pathogenicity can be collected. The four remaining variants we consider VUSs as
they are either inherited or of unknown inheritance, are not located in the CxxC-domain and/or
are reported in the gnomAD database. In conclusion, based on the ACMG/AMP guidelines and
supported by the functional evidence provided by the episignature, we classified 15 variants as
pathogenic, one variant as likely pathogenic and eight variants remain VUSs (Table 3-1,
Extended Data Table 3-1, Supplementary Figure 3-5).

CLINICAL FEATURES IN (LIKELY) PATHOGENIC KDM2B-VARIANT CARRIERS
We next determined the clinical phenotypes associated with the novel KDM2B-related
syndrome. Clinical data of all individuals were systematically collected (Table 3-2 and Extended
Data Table 3-2) and detailed clinical histories for all individuals are available as supplemental
material. To prevent confounding the clinical presentation, we here limit the clinical description
to patients that: 1) carry a pathogenic or likely pathogenic variant affecting KDM2B; and 2) for
whom KDM2B represents the only identified genetic disorder. Within this group of 15
individuals, all presented with speech delay, developmental delay (DD), learning difficulties
and/or ID. Behavioral concerns such as autism-spectrum-disorder (ASD) and attention-deficit
hyperactivity-disorder (ADHD) are common (9/14). Growth parameters were within the normal
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range for the majority. We observe several congenital defects, including congenital heart defects
(CHD; 7/15), unilateral kidney agenesis (4/15) and ophthalmological anomalies (6/14). Two
patients had cryptorchidism, two had epilepsy.
We collected facial photographs of 12 individuals, but no recognizable facial gestalt
could be identified by an experienced dysmorphologist (RO) (Figure 3-4). Facial features noted
in several individuals with CxxC-domain variants were a broad nasal tip, large ear lobes, and
exaggerated Cupid’s bow. Interestingly, in the individuals with LoF variants the nose was often
more prominent, with a narrow nasal ridge and malar flattening with the exception of #10, who
also has a diagnosis of Noonan syndrome.
The KDM2B related phenotype thus presents as a NDD of variable expression. Most
common features include DD/ID , behavioral abnormalities, congenital defects and facial
dysmorphisms. We propose to refer to this novel syndrome as ‘KDM2B-related NDD’
(K2BNDD).
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Figure 3-4: Facial photographs of individuals with KDM2B pathogenic variants. A-C) Individuals of
family 4 with the p.Val316Ile variant, located in the JmjC-domain. D-G) Individuals with loss-of-function variants.
Individual 10 (E) is also affected with Noonan syndrome H-L) Individuals with missense variants in the CxxC domain.

POTENTIAL GENOTYPE PHENOTYPE ASSOCIATIONS
As our methylation analysis revealed differences between CxxC and LoF variants, we
next performed genotype-based patient stratification in order to support detection of possible
genotype-phenotype relationships. Unfortunately, the current number of individuals available for
analysis is limited, precluding the establishment of a genotype-phenotype relationship.
Importantly, only two LoF variant carriers are not confounded by additional findings (i.e. dual
diagnosis or larger deletion affecting multiple genes). We note however that unilateral kidney
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agenesis and eye anomaly (coloboma/anophthalmia/congenital obstruction ductus
nasolacrimales) was only reported in those individuals carrying a CxxC variant. In addition,
congenital heart defects were present in six individuals with a CxxC variant, and only in two
with a LoF variant. Of note, both these LoF carriers were diagnosed with another, both of which
are associated with congenital heart defects. We thus note that congenital organ anomalies might
be overrepresented in CxxC variant carriers, however the currently limited number of available
cases precludes drawing any conclusions. Epilepsy did not occur in association with the CxxC
domain variants, and did occur in one patient with a JmjC domain variant, one patient with a
frameshift variant and two patients with a 12q24.31 deletion.

DISCUSSION

We describe a novel NDD caused by heterozygous pathogenic variants in KDM2B, which
encodes a well-studied epigenetic regulator with multiple molecular functions, including the
demethylation of H3 lysine residues. We collected a cohort of 33 individuals with 24
heterozygous KDM2B variants and performed genome-wide methylation profiling. In 15
samples, representing 13 unique KDM2B variants, we identified a shared episignature. We
utilized this episignature to re-classify the variants in our cohort based on the ACMG/AMP
criteria [36] and conclude that 16 variants are (likely) pathogenic. In line with other MDEMs,
pathogenic variant carriers present with variable phenotypic expression, including DD/ID,
congenital organ anomalies and/or facial dysmorphisms. We refer to this novel syndrome as
KDM2B-related NDD (K2BNDD).

Given that K2BNDD presents as a heterogeneous disorder with variable severity and
phenotypes, larger cohorts are needed to fully encompass the phenotypes associated with the
disorder. Furthermore, the limited number of individuals representing potential groups for
genotype-phenotype associations precludes drawing conclusions in this regard. We do however
observe potential hints towards such associations, especially for CxxC-domain variant carriers
and the presence of congenital anomalies. A more severe phenotypic expression of CxxC-
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variants would be in line with the enhanced DNA methylation levels observed in this subgroup
as compared to LoF-carriers (Figure 3-3).

The episignature identified for K2BNDD adds to the expanding toolbox offered by
methylation profiling. Not only can these signatures be used to provide functional evidence to
support the evaluation of VUSs; the increasing number of syndromes for which episignatures
have been established enables the diagnosis of uncharacterized individuals, as well as the
identification of novel pathogenic variants through pinpointing the causal gene [3]. The results
presented here furthermore emphasize its utility by demonstrating that multiple episignatures can
coexist within a single individual. Moreover, our analysis identified the K2BNDD related
signature in a case previously diagnosed with IDDSELD (Figure 3-2D). Upon closer
investigation, we noticed this sample carries a larger deletion on the 12q24 region, directly
affecting the coding region of SETD1B, but not KDM2B. We hypothesize therefore that this
deletion affects a regulatory region, causing mis regulation of KDM2B and thereby the
K2BNDD-signature. Alternatively, the presence of two samples with a deletion encompassing
both KDM2B and SETD1B in our episignature training cohort might cause the signature to
contain some traces of the IDDSELD signature as well. This sample remains of interest for
further investigation.
In line with the overall clinical performance of EpiSign testing [3], the KDM2B
episignature enables specific and sensitive detection of K2BNDD. For this episignature, we
noticed MVP scores over 0.25 for three other disorders (Figure 3-2D). The first is associated
with ADCADN, which is caused by mutations in DNMT1, a methyltransferase known as the
central player in the maintenance of CpG methylation [2, 37]. Interestingly, DNMT1 has been
suggested to regulate H3K4 methylation, providing a direct mechanistic link with KDM2B [38].
The second is HMA , a syndrome associated with duplication of 5q35 [39,40]. This region
includes NSD1, which encodes a lysine methyltransferase known to methylate H3K36 [41],
providing a direct functional link between HMA to K2BNDD as well. Finally, DYT28 is
associated with KMT2B [42], encoding another methyltransferase reported to methylate H3K4
[43], again suggesting a direct link with KDM2B. All three disorders might therefore be
associated with dysregulation of the same molecular process as for K2BNDD, and as such the
same genomic regions might be affected in all three disorders. Of note, the K2BNDD,
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ADCADN, HMA and DYT28 episignatures are all characterized by hypermethylation [2, 44,
45]. Alternatively, therefore, the elevated MVP scores might reflect a set of loci sensitive to
hypermethylation irrespective of the underlying mechanisms. Phenotypically, K2BNDD shares
features with HMA, e.g. mild – moderate delay, congenital heart defects and dysmorphism, but
present differently from ADCADN and DYT28. Future studies will have to determine if and how
K2BNDD, ADCADN, DYT28 and HMA are related, and might provide valuable insights into
the etiology of these disorders.
The majority of pathogenic variants are of de novo origin, however in three families the
variant was inherited from a mildly or unaffected parent (families 3,4 & 25). The more severe
presentation in the children could be explained by a second diagnosis in the child, as was
identified in family 3. Individual 25.2 is of special interest, he has a 12q24.31 deletion
encompassing KDM2B and the episignature is present, however does not seem to be clinically
affected. Individual #4.2 appears more mildly affected as compared to his affected children as
well. These observations might be explained by multiple hypotheses. First, the parents might be
mosaic carriers, resulting in a smaller percentage of affected cells and thereby reduced
expression of the phenotypes. Alternatively, all inherited pathogenic variants originate from the
father, possibly indicating that males are affected less severely. In mice, Kdm2b has been shown
to be involved in X-chromosome silencing [15], and as such a different clinical expression in
males versus females seems plausible. Future studies will have to inform on which hypotheses
are true, or whether different explanations underlie these observations.
In line with hypermethylation defining the episignature, elevated DNA methylation levels
have also been observed in a mouse Kdm2b knock-out model [15]. In addition, our cohort
contains several truncating variants and gene deletions, and KDM2B constraint metrics indicate
the gene is intolerant for LoF variants in the healthy population [29]. Collectively, these
observations argue that K2DNDD is likely caused by haplo-insufficiency of KDM2B. Codingaltering variants associated with K2DNDD are therefore expected to cause LoF as well. The
clustering of coding-altering variants in the CxxC-domain however suggests additional
mechanisms by which variants in this domain cause disease. Supporting this notion is the
identification of a distinct episignature associated with CxxC-variants and the elevated levels of
hypermethylation defining this episignature. These observations are suggestive of a (partial)
dominant-negative effect of CxxC-domain associated variants. Interestingly, the CxxC-domain
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has been specifically implicated in the developmental functions of KDM2B, as CxxC mutants fail
to rescue cellular differentiation induced by Kdm2b depletion in mESC [7] and specific deletion
of the CxxC-domain induces developmental defects in the heterozygous state, whereas
heterozygous knockouts appear healthy [18, 46]. Future studies will have to determine the
molecular mechanisms by which both LoF and CxxC-specific variants lead to hypermethylation
and how these mechanisms relate to the associated phenotypes.
In summary, we have delineated a novel syndrome that is caused by heterozygous
KDM2B variants and characterized clinically by DD/ID, behavioral challenges including autism
and ADHD, congenital anomalies mainly of the heart, urogenital system and eyes, and variable
facial dysmorphism. KDM2B directly affects gene expression by epigenetic processes, and
affected individuals show a distinct episignature. As such, K2BNDD represents a novel addition
to the emerging group of MDEMs [1]. The signature can aid in reclassification of VUSs, and the
detection of K2BNDD missed during routine diagnostic testing, e.g. due to intronic variants. We
observed both de novo and dominantly inherited pathogenic variants. As the latter might easily
be overseen by standard trio-ES based diagnostic testing, we suggest including the gene in
relevant gene panels in order to facilitate the identification of inherited variants.

MATERIALS AND METHODS

ETHICAL CONSIDERATIONS AND APPROVAL, INCLUSION CRITERIA AND DATA
COLLECTION

All individuals were included after informed consent forms, stating they agree to
participate in research efforts and do agree with publication of their clinical and genetic data, as
well as photos for relevant cases, were signed and received by the respective institutions. Patient
privacy was respected during the exchange of data amongst researchers and/or clinicians. This
study was approved by the medical ethical committee installed by the University Medical Centre
Utrecht (TCBIO 20/714, March 18th, 2021).
Individuals were included based on the identification of a heterozygous KDM2B
suspected to be pathogenic based on in silico predictions and/or inheritance. Individuals carrying
bi-allelic VUSs were not considered for this study. Individual 1 was the index patient, after a
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KDM2B variant was annotated to be of interest after diagnostic trio-ES. Families 2-5 were
included after local, in-house database searches. All remaining individuals were included after
personal communication, literature search, or resulting from searches using the Genematcher
platform [30]. For the published cases, we contacted the original authors for updated clinical
information. For all individuals, clinical and genetic data was collected through a standardized
spreadsheet which was completed by the respective physicians and/or researchers.

GENETIC VARIANT DETECTION

Variants in individuals/families 24, 25, 29, 30 and 34 were identified as described before
[26,28,31,32]. The variant of individual 4.3 was identified by targeted Sanger sequencing. All
other variants were detected through clinical and/or research-based exome-sequencing.

ANALYSIS AND CLASSIFICATION OF KDM2B VARIANTS

Structural analysis of variants was performed with Pymol (The Pymol Molecular
Graphics System, Version 2.5 Schrödinger, LLC). All figures were generated with Pymol. Four
in silico prediction algorithms were consulted: SIFT , Metadome, MutationTaster and Polyphen2 [47, 48, 49, 50]. All variants were manually analyzed using Alamut Visual v2.15 (Sophia
Genetics). Variants were classified according to the 2015 ACMG/AMP guidelines [36]. Episign
results were used as criterium PS3; PM1 as applied for CxxC-domain variants.

EPISIGN METHODS

METHYLATION ARRAY AND QUALITY CONTROL
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DNA methylation analysis and Episignature classifier development was performed using
previously established protocol [34, 51, 52, 53]. Stored genomic DNA samples extracted from
peripheral blood, previously used for genomic sequencing, were used for bisulfite conversion
and hybridization to the Illumina infinium methylation EPIC bead chip arrays, according to
manufacturer’s protocol. Idat files, containing methylated and unmethylated signal intensity plots
(beta values) were produced from these microarrays, and used for analysis in R 4.0.2.
Normalization was performed using the Illumina Infinium methylation EPIC array with
background correction from the minfi package [54]. Previously defined exclusion criteria [52,53]
were used to exclude probes with detection p values >0.01, probes on the x and y chromosomes,
probes known to contain SNPs at the site of CpG interrogation or single nucleotide extension,
and probes known to cross react with chromosomal locations other than their target regions were
removed. All samples were examined for genome wide methylation distribution and those
deviating from a bimodal distribution were excluded. Factor analysis using a principal
component analysis (PCA) was performed to examine batch effect and identify outliers.

DNA METHYLATION PROFILING

Probe methylation levels (beta values), were calculated as the ratio of signals intensity in
methylated probes vs total sum of unmethylated and methylated probes, resulting in values
ranging from zero to one. To allow for linear regression modeling, beta values were logit
transformed using the limma package [55] , allowing for the identification of differentially
methylated probes. Data was adjusted for the blood cell type composition as per Houseman et al
[56]. Estimated blood cell proportion was added to the model matrix of the linear models as
confounding variables [57]. Using the eBayes function in the limma package [58], p values were
moderated and corrected for multiple testing using the Benjamini Hochberg method. Probes with
the most significant methylation differences are selected using two facts from this dataset, the
level of methylation difference (relative methylation signal intensity), and the probability that an
observed difference is due to random chance (p values). Evaluation of this interaction is carried
out by multiplying the absolute methylation difference between affected cases and controls by
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the negative value of the log transformed p values, and ranking the top 1000 probes with the
highest values from this transformation. Next, receiver operating characteristic analysis (ROC)
is performed on each probe, to measure the pairwise correlation coefficient between probes.
Probes with low area under curve values from ROC analysis are removed, as well as highly
correlated probes, eliminating probes with low sensitivity and specificity, and probes with highly
correlated characteristics using Pearson’s correlation coefficient. This ensures that the final
probeset contains the most differentiating, non-redundant probes that are not influenced by
random data structures. Only probes with a methylation difference greater than 5% were
included in this analysis. This probe filtering process was designed to avoid reporting of probes
with low effect size, and those influenced by technical or random variations as conducted in
previous studies [52,53].

SELECTION OF MATCHED CONTROLS FOR METHYLATION PROFILING

For episignature characterization, mapping of probes and feature selection, matched
controls were randomly selected from the LHSC EpiSign Knowledge Database (EKD) [52]. All
of the KDM2B samples were assayed, therefore all the controls selected for episignature
identification were analyzed using the same array type. Samples were matched by age, sex and
batch using the MatchIt package. A 4:1 ratio of controls to cases was deemed optimal for this
analysis, as previously described [34]. Principal Component Analysis (PCA) analysis was
performed after each attempt at matching to detect outliers and determine data structures for the
presence of batch effect. Outlier samples, and those with highly aberrant data structures were
removed, and subsequent matching trials were performed until consistent iterations with no
outliers in the first two components of the PCA were derived.

CLUSTERING AND DIMENSION REDUCTION

Hierarchical clustering and multidimensional scaling were used after each iteration of
analysis to examine the data structure of the identified episignature. Hierarchical clustering was
performed using Ward’s method on Euclidean distance by the base stats package in R, and
visualized with the ggplot2 package [59, 60]. Multidimensional scaling provides a visual
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representation of sample methylation profile similarity based on the scaling of the pairwise
Euclidean distances between each sample. Observations of study samples’ methylation profiles
at this stage allowed for further refinement of the cohort used for probe selection training.

DISCOVERY/TRAINING COHORT SELECTION
Identification of disease specific episignatures was performed using a randomly selected
sub-setting of the database, on a 75:25 ratio of discovery:training, using the caTools package in
R. Testing samples were used to assess the performance of the classification model developed
later in the study. For every disease group in the discovery cohort, a sex and age matched control
group with a sample size at least 4 times larger was selected from the reference control group
using the MatchIT package, and methylation profiles were compared between the two.

CROSS VALIDATION
For each round of validation, one of the selected KDM2B samples was removed from
probe selection, alongside matched controls. The remaining KDM2B samples were designated as
testing samples, and all three groups were modeled using multidimensional scaling to determine
how they cluster/segregate with one another. This process was repeated with different
combinations of assigned training and testing samples until all cases had been removed from
probe selection and used for testing once.

EPISIGNATURE CLASSIFICATION MODEL
Specificity of the episignature was assessed using the Methylation Variant Pathogenicity
(MVP) score, using all the identified probes. A support vector machine (SVM) used a linear
kernel for training on KDM2B cases and controls. Once again, a 4:1 ratio of controls to cases
was used to divide both the case and control samples previously matched and used for probe
selection into training and testing cohorts for the SVM. Furthermore, the remaining unselected
samples from the EKD were also divided similarly (75% training, 25% testing) to allow for
comparison and testing of signature robustness against all of the samples in the EKD. Using the
e1071 R package, we performed 10-fold cross validation to determine hyperparameters optimal
for episignature classification. In this process, the training set was divided into ten folds by
random assignment, where the first nine are used for training, and the last used for testing the
99

accuracy of the model. The mean accuracy over all rounds was then calculated, and
hyperparameters with the best performance by this metric were selected. The model provides a
score ranging from 0-1 for each subject, representing the model’s confidence in predicting
whether the subject has a DNA methylation profile similar to the KDM2B probe set or not.
Conversion of these SVM decision values was done using Platt’s scaling method [61], and the
class obtaining the greatest score determined the predicted phenotype. A classification as
KDM2B was made when a sample received the greatest score for that class (normally greater
than 0.5). Finally, the model was applied to both a training set of a large cohort of individuals
with clinical and molecular diagnoses of neurodevelopmental disorders, as well as a group of
healthy controls to determine its effective specificity.

VALIDATION OF EPISIGN CLASSIFICATION
To ensure the model is not susceptible to the batch structure of the methylation experiment,
the classifier was applied to samples assayed on the same batch as the cases used for training.
Using methylation data from individuals without a confirmed diagnosis of KDM2B within the
EKD assayed on the same microarray chip as case samples, methylation profiles were modeled to
ensure the classifier is not confounded by technical artifacts unique to the given microarray.
Specificity was determined by supplying a large number of DNA methylation arrays from
unaffected subjects to the model. To further assess the specificity of the KDM2B classifier relative
to other neurodevelopmental disorders we applied it to cases with other patient cohorts exhibiting
distinct episignatures within the EKD.
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Supplementary Figure 3-1: A cohort of heterozygous KDM2B variant carriers. A) Conservation of
KDM2B residues affected by coding altering variants in the cohort. Purple color intensity is indicative of conservation
across the species included in the figure. B) Pedigrees for the individuals not included in Figure 3-1A and/or not
published before. Family 24 has been published elsewhere (Yokotsuka-Ishida et al., 2021).
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Supplementary Figure 3-2: A shared episignature amongst the majority of KDM2B variant carriers.
All samples for which methylation array data was available were used to train an episignature. A) Volcano plot
indicating all selected probes (red) included in the signature. B) Multidimensional scaling (MDS) plot for selected
probes, representing the pairwise distance across samples (red) and controls (blue), based on the top two dimensions.
C) Distribution of the (raw) p-values of all probes. D) Heatmap of selected probes and unsupervised hierarchal
clustering results indicating the clustering of the majority of variant carriers (red) apart from controls (blue). E) Crossvalidation of the episignature. Each test sample (red) was removed from the training cohort and was subsequently
tested against the resulting classifier.
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Supplementary Figure 3-3: Supporting data for figures 3-2 and 3-3. A) Distribution of the (raw) p-values
of all probes for the samples used to train the KDM2B episignature (Figure 3-2). B) Cross-validation of the KDM2B
episignature. Each test sample (red) was removed from the training cohort and was subsequently tested against the
resulting classifier. C) Support Vector Machine (SVM) model trained on the samples included in Figure 2. All case
samples and matched controls were used for training. Next, each sample was tested against the provided classifier. D)
As (A), E) as (B) and F) as (C) for the CxxC episignature (Figure 3-3).
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Supplementary Figure 3-4: Identification of a LoF associated episignature. All samples representing a
loss-of-function (LoF) variant and included in the KDM2B episignature, were used to train a LoF-variant specific
episignature. A) Volcano plot indicating all selected probes (red) included in the LoF episignature. B)
Multidimensional scaling (MDS) plot for selected probes, representing the pairwise distance across CxxC variants
(orange), LoF variants (red) and controls (blue), based on the top two dimensions. C) Distribution of the (raw) pvalues of all probes. D) Heatmap of selected probes and unsupervised hierarchal clustering results indicating the
episignature’s ability to decipher KDM2B variant carriers (red and orange) from controls (blue), and to decipher CxxC
variants (orange) from LoF variants (red). E) Cross-validation of the LoF episignature. Each test LoF sample (red)
was removed from the training cohort and was subsequently tested against the resulting classifier.
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Supplementary Figure 3-5: Patient inclusion flow chart. Flow chart indicating which samples/variants
were used in the different sub-cohorts used throughout this study.
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Supplementary Figure 3-6: KDM2B MVP Score ROC Graph. Receiver operating characteristic curve
demonstrating the sensitivity and specificity of the generated MVP scores for the KDM2B cohort and the remaining
EKD samples used for training.
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CONCLUSION
This chapter provides a definitive example of episignature substratification briefly
hypothesized in the first chapter, demonstrating the additional episignatures that can be derived
through analysis of specific domains. In the 2019 paper from Bend et al concerning the
identification of multiple episignatures within the ADNP gene sequence [53], researchers
determined two specific episignatures within the ADNP sequence, one associated with
disruptions of the central region of the gene, and another associated with the terminal ends of the
sequence. This provided evidence towards the existence of specific DNA methylation patterns
that result from disruptions of different loci within a given gene sequence, and helped guide my
analysis towards the identification of further substratified episignatures within a cohort of
patients with common genetic origins.
This research proved fruitful upon the analysis of the KDM2B cohort, and showed that
domain specific episignatures can exhibit a high level of sensitivity and specificity, and provide
interesting insights into the key mechanisms required for gene function. When a specific domain
is disrupted, analysis of the epigenome, phenotype and genotype can help compare and contrast
the affected individuals carrying mutations in different gene domains. Through this comparison,
we can identify how these domains interact with DNA methylation profiles, and the ensuing
phenotype through their presentation in not just case samples experiencing disruptions of the
domain in question, but cases presenting without domain disruption, and unaffected controls.
This approach can prove highly effective in the context of NDDs which are associated with
complex variable phenotypes, which may be better explained by the functional evidence that
domain specific episignatures provide, tying the variation in presentation to a more focused view
of genes and their important domain machineries.
Most importantly, this work provides evidence of a novel NDD. These findings can also
be applied to the reclassification of variants involved in the KDM2B sequence, representing
functional information that can identify evidence for pathogenicity in variants of unknown
significance. Within ClinVar, a number of such VUS’s have been reported amidst other KDM2B
variants (9/36, 25%, See Appendix Table 2) which could be reclassified following modeling with
the derived KDM2B signature.
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Further work is required to understand exactly how the disruption of the CxxC binding
domain results in the distinct methylation pattern observed in the KDM2B cohort, but given the
functional nature of this domain as a DNA binding motif, we can hypothesize the effect is due to
loss of specific DNA binding mediated by the CxxC domain. Functional studies, and an in-depth
analysis of how the KDM2B gene and it’s CxxC domain interact with DNA to perform
demethylase activities will potentially shed light into the exact mechanisms of this interaction,
and explain the phenotypic differences observed in the affected patients. Large scale changes in
DNA methylation observed in the CxxC patients could result in gene expression changes leading
to the increased incidence of congenital anomalies not seen in cases with variants outside this
domain. In this way, I describe, using the KDM2B cohort as an example, the analytical process
of identifying additional sub stratified episignatures within a single gene sequence, which has
resulted in an effective DNA methylation biomarker for a novel NDD, and insights into the
functioning and molecular relationships of KDM2B’s gene domains.
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PREFACE
Throughout this work, I have made reference to the intricate net of biological interactions
that tie the genome, epigenome and ensuing phenotype of neurodevelopmental disorders
together. In the context of a monogenic disorder, I have demonstrated the existence of multiple
methylation profiles that accompany changes in phenotype in line with alternate genetic variants
in terms of location, mechanism of effect, and type. It is therefore pertinent to discuss the effects
of DNA methylation profiles in patients with multiple genetic origins, and how episignature
profiles can guide assessment in the context of paralogous, but distinct molecular entities. As
such, I have chosen to describe my research concerning the discovery of an episignature for
patients with variants in the lysine acetyltransferase gene KAT6A, which shares a paralogous
gene, KAT6B. These two genes share a common genetic origin, each acting as a subunit in the
MOZ/MORF complex, and are associated with similar histone modifying activity however,
disruptions of the KAT6B sequence are associated with two distinct NDDs, Genitopatellar
syndrome (GTPTS) and Say-Beiber-Biesecker-Young-Simpson syndrome (SBBYSS), while
KAT6A is associated with KAT6A Syndrome (AKA Mental Retardation Disorder 32 (MRD32),
Arboleda-Tham Syndrome (ARTHS)). For GTPTS and SBBYSS, episignatures were derived in
2018, demonstrating that the disruption of lysine acetyltransferase activity can have distinct
effects on the methylation profiles of affected patients [3], however, such an episignature has not
been established for KAT6A so far. This context provides an interesting challenge to the
derivation of an episignature, with shared function and genetic character between these two
genes, but association with distinct syndromes that share considerable phenotypic overlap. These
confounding factors provide an interesting complexity to our episignature assessment practices,
posing several questions. To what degree can the DNA methylation profiles of these different
disorders overlap? To what extent can the differences in DNA methylation be correlated to the
distinct phenotypes seen in the three disorders? Finally, and most importantly, is there an
effective way to fully differentiate the methylation pattern of KAT6A syndrome, even in the
context of shared gene function and homology with GTPTS and SBBYSS? Data presented in this
chapter will address these questions and elucidate the epigenetic assessment of a disorder while
compensating for the confounding effects brought about by paralogous genes. This will provide
evidence towards a syndrome specific episignature for KAT6A syndrome, as well as potentially
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explaining the overlap in phenotypic characteristics of these lysine acetyltransferase disorders
through the lens of epigenetics.

ABSTRACT
Accurate diagnosis for patients living with neurodevelopmental disorders is often met
with numerous challenges, related to the ambiguity of findings and lack of specificity in genetic
variants leading to pathology. Genome wide DNA methylation analysis has been used to develop
highly sensitive and specific “episignatures” as biomarkers capable of differentiating and
classifying complex neurodevelopmental disorders. In this manuscript, we describe distinct
episignatures for KAT6A syndrome, caused by mutations in the lysine acetyltransferase A gene
(KAT6A), and the lysine acetyl transferase B (KAT6B) associated with two other
neurodevelopmental disorders. We demonstrate the ability of our models to differentiate between
highly overlapping episignatures, increasing the ability to effectively identify and diagnose these
conditions.

Keywords: Epigenetics; DNA Methylation; Episignature; KAT6A
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INTRODUCTION
Hereditary neurodevelopmental disorders (NDD) are relatively common, with a global
prevalence of approximately 3-5% [1,2]. A thorough clinical examination and genetic testing can
help pinpoint the underlying cause, but as more NDD-related genes are being discovered and
examined, more genetic variants of unknown significance are being identified. Segregation
analyses and functional assays can sometimes help determine pathogenicity [3,4], but in the
majority of cases, clinicians, patients and families are left without definitive diagnoses.
Assessment of DNA methylation profiles provides novel possibilities to confirm
diagnoses and explain pathophysiology. Epigenetics describes the heritable changes in gene
expression without altering the underlying nucleotide sequence [5]. Epigenetic mechanisms
include DNA methylation, histone modifications and the effects of non-coding RNAs (ncRNA)
[6,7] Mutations in genes involved in chromatin regulatory processes have been implicated in a
growing number of NDDs [3]. Predominantly related to neurobehavioral phenotypes, disorders
of the epigenetic machinery have the potential to cause widespread disruption of developmental
programs [8]. Chromatin regulatory genes, such as DNA methyltransferases play an important
role in modulating cell differentiation during development [8]. Unique DNA methylation profiles
have been described in patients with mutations in genes involved in epigenetic and chromatin
regulating processes [9]. Highly sensitive and specific algorithms based on disease-associated,
differentially methylated CpG dinucleotides, which are effectively detectible using microarray
technology, are referred to as “episignatures” or “EpiSigns”, and to date, over 50 have been
described. These episignatures provide a sensitive and specific molecular technique for diagnosis
and variant classification for a growing number of genetic conditions [3,10-22]. In certain
conditions, a significant overlap has been described between the methylation profiles of multiple
syndromes [20], as well as sub-gene level, or gene domain specific signatures. Recently, DNA
methylation testing has been adapted in a clinical setting demonstrating a significant diagnostic
yield and utility in diagnosis of Mendelian disorders [20,21].
Histone acetyltransferases (HATs) are enzymes that acetylate the lysine tails of histones.
Multiple HAT complexes have been described, including the Gcn5 N-acetyltransferases (GNAT)
and the MYST (Moz/Morf, Ybf2/Sas3, Sas2 and Tip60) families. MOZ or Lysine (K) Acetyl
Transferase 6A (KAT6A, OMIM#601408) and MORF or Lysine Acetyltransferase 6B (KAT6B,
OMIM#605880) form the catalytic subunits of a protein complex (together with BRPF1/2/3,
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ING5 and hEAF6) that specifically acetylates lysine residues on histone H3 tails [23,24,25]. This
acetylation alters chromatin structure and generally results in a more active gene expression. A
disruption of this KAT6A/B complex can result in widespread changes of gene expression.
KAT6A syndrome, caused by pathogenic mutations in the KAT6A gene, was first described by
Arboleda et al and Tham et al., in 2015 [26,27]. A reverse dysmorphology approach (first whole
exome sequencing (WES), sanger sequencing and array comparative genomic hybridization
(array-CGH) showing KAT6A mutations, followed by phenotyping) was used to first describe
KAT6A syndrome in seven patients. A large follow-up cohort to these studies, from Kennedy et
al. [28], identified truncating or nonsense variants, as well as a subset of missense variants
located within highly conserved residues in the KAT6A sequence. Intellectual disability and
speech delay were found in all patients; however the presentation was found to be more severe in
those patients with truncating variants in the last two exons of the gene (exons 16 and 17) when
compared to early truncating variants (located in exons 1-15) [26, 27,28]. It was found that 95%
of late truncating mutations were rated as moderate or severe for intellectual disability, while
60% of the early truncating cases were classified as mild intellectual disability. Interestingly,
mutations in the KAT6B gene, encoding the other catalytic subunit of the KAT6A/B protein
complex, can result in multiple distinctive syndromes (Genitopatellar Syndrome (GTPTS,
OMIM #606170), Ohdo Syndrome (Say-Beiber-Biesecker-Young-Simpson; SBBYSS variant,
OMIM #603736), which share a significant amount of phenotypic overlap with KAT6A
syndrome [29,30,31,32,33].
Research of diagnostic rates of genes involved in developmental disorders notes that
KAT6A syndrome is a common cause of syndromic intellectual disability [1], indicating the
importance of providing a reliable molecular biomarker for the identification and classification
of KAT6A variants. With overlapping clinical features with several disorders as described above,
particularly KAT6B related disorders, a specific molecular test, such as those we have
demonstrated previously with episignatures, could provide a significant improvement to the
accurate diagnoses of these conditions and can potentially help to explain the clinical features. In
this paper we demonstrate that a unique KAT6A syndrome classifier can be derived through the
assessment of DNA methylation patterns in patients with identified KAT6A variants, providing
evidence of this episignatures ability to differentiate between case and control samples.
Additionally, because of the partial overlap in clinical features and the similar roles of KAT6A
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and KAT6B as catalytic subunits of their MYST family HAT protein complex, we investigated if
clinical similarities and differences between these syndromes can be explained by their
methylation profiles.
MATERIALS AND METHODS
SUBJECTS AND CONTROL COHORTS
DNA samples were extracted from peripheral blood of 21 individuals with clinical and
molecular features of KAT6A syndrome (See Table 4-3), that are part of the EpiSign Knowledge
Databases (EKD) [20] housed at the London Health Sciences Centre (LHSC; Canada), and
recruited from Amsterdam University Medical Centers (AUMC, The Netherlands), University of
Western Australia, University of Queensland (Australia), University of Sydney (Australia),
Victoria Clinical Genetics Services (Australia), Royal Prince Alfred Hospital (Australia),
University of Montreal (Canada), Tartu University Hospital (Estonia), Scientific Institute for
Research, Hospitalization and Healthcare (IRCCS, Italy), Sheba Medical Centre (Israel) and Sant
Joan De Déu Hospital Barcelona (Spain). All samples and records were de-identified.
Additionally, 4 samples with confirmed KAT6B variants associated with GTPTS from University
of Montreal, as well as 10 SBBYSS samples with associated KAT6B variants from collaborators
at University of Montreal, AUMC and Greenwood Genetics Centre (USA), were included in our
models to assess the overlap in methylation profiles between these adjacent conditions.
The research was conducted in accordance with the Declaration of Helsinki. Study
protocol has been approved by the Western University Research Ethics Board (REB 106302).
Informed consent was obtained by physicians for use of the clinical information of the described
patients.

METHYLATION ARRAY AND QUALITY CONTROL
DNA methylation protocol, analysis and episignature construction were performed using
a previously established protocol [3,12,21,34]. Genomic DNA was extracted from peripheral
blood samples using standard techniques and underwent bisulfite conversion for analysis using
the Illumina Infinium methylation EPIC bead chip arrays, according to manufacturer’s protocol.
Methylated and unmethylated signal intensity plots (beta values) were processed to obtain the
idat files for analysis in R 4.0.2. Normalization of the Illumina Infinium methylation EPIC array
data was carried out with background correction from the minfi package [35]. Exclusion criteria,
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as previously defined [3,21] excluded probes with detection p values >0.01, probes on the x and
y chromosomes, and those known to contain SNPs at the site of CpG interrogation or single
nucleotide extension, and probes known to cross react with chromosomal locations other than
their target regions were removed. All samples were examined for genome wide methylation
density and those deviating from a bimodal distribution were excluded. Factor analysis using a
principal component analysis (PCA) was performed to examine batch effect and identify outliers.

DNA METHYLATION PROFILING
Methylation levels for probes were measured as beta values, based on the ratio of
intensity in methylated signals vs total sum of unmethylated and methylated signals from
microarray analysis, represented as a value ranging from zero to one. These values were used for
the biological interpretation and visualization of samples. To allow for linear regression
modeling, beta values were logit transformed using the limma package [36], allowing for the
identification of probes differentially methylated between cases and controls. Blood cell type
compositions were used to adjust analysis using an algorithm developed by Houseman et al [37].
Estimated blood cell proportions were added to the model matrix of the linear models as
confounding variables [38]. Using the eBayes function in the limma package, p values were
moderated and corrected for multiple testing using the Benjamini Hochberg method. The most
informative probes were selected using two factors from this dataset, the level of methylation
difference (relative methylation signal intensity), and the probability that an observed difference
is due to random chance (p values). The most informative probes are selected using two factors
from this dataset, the level of methylation difference (relative methylation signal intensity) and
the probability that an observed difference is due to random chance (p value distribution).
Evaluation of this interaction is carried out by multiplying the absolute methylation difference
between affected cases and controls by the negative value of the log transformed p values, and
taking a list of 1000 probes with the highest values from this transformation. Next, receiver
operating curve characteristic analysis (ROC) is performed on each probe, and measures
pairwise correlation coefficient between probes. Probes with low area under the curve values
from ROC analysis are removed, as well as highly correlated probes, eliminating probes with
low sensitivity and specificity, and probes with highly correlated characteristics using Pearson’s
correlation coefficient. This ensures that the final probeset contains the most differentiating, non123

redundant probes that are not influenced by random data structures. Furthermore, only probes
with a methylation difference greater than 5% were included in the analysis, as investigation of
Illumina microarrays has shown that methylation values are prone to technical error when
attempts are made to assess methylation differences below 5%. This probe filtering process was
designed to avoid reporting of probes with low effect size, and those influenced by technical or
random variations as conducted in previous studies [3,12].

SELECTION OF MATCHED CONTROLS FOR METHYLATION PROFILING
For mapping the episignature for probe and feature selection, matched controls were
randomly selected from the LHSC EpiSign Knowledge Database (EKD) [3]. All KAT6A samples
and controls were assayed using the Illumina EPIC array. Matching was done by age, sex and
batch using the MatchIt package. A ratio of 4:1 of matched controls to cases was used for each
analysis; previous efforts have found that increasing the ratio beyond this compromised the
ability of the model to effectively match samples [12]. First assessments found that there was
significant overlap between KAT6A case samples and the additional 14 KAT6B associated
samples, (see Figure 4-1B, and 4-1C) and as such, these KAT6B samples were added as control
samples for training the probe selection models. After each attempt at matching, a rudimentary
PCA analysis was performed to detect outliers and determine data structures for possible batch
effect and other characteristics. Outlier samples, and those with highly aberrant data structures
were removed, and subsequent matching trials were performed until we achieved consistent
iterations with no outliers detected in the first two components of the PCA. Overall, 4 samples
were removed from analysis due to significant divergence in methylation patterns exhibited,
identified in Table 4-1.
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Figure 4-1. Models of Episignature Discovery trained on KAT6A samples and match controls
A: Bimodal distribution plot of mean methylation difference vs -log p-value for each probe, represented
as circles on the plot. Probes highlighted in red indicate the probes chosen following preliminary analysis,
wherein the most highly differentiated probes with statistically significant p-values are selected for
representation
B: Multidimensional scaling plot representing the dimensions of variation in methylation signal intensity
at informative CpG identified for KAT6A. Represents comparisons of the similarity of methylation
profiles of KAT6A patients (marked in red) to control samples (marked in blue) which include cases
without a confirmed phenotypic and/or genotypic presentation of KAT6A, including the added KAT6B
samples and samples with confirmed presentation of other syndromes.
C: Targeted SVM classifier model for KAT6A without inclusion of KAT6B in training controls. Each
sample receives scores for the probability of having a DNA methylation profile similar to cases as
compared to controls. Higher value on Y axis indicates that a sample presents a methylation profile more
similar to cases compared to controls. SBBYSS and GTPTS samples from the EpiSign Knowledge
Database are plotted based on this relative scale of similarity to indicate probeset overlap between
adjacent disorders. Additionally, KAT6A samples removed from analysis have been plotted, labelled as
KAT6A (testing)
D: Multidimensional scaling plot representing the dimensions of variation in methylation signal intensity
at informative CpG identified for KAT6A without inclusion of KAT6B in training controls. Represents
comparisons of KAT6A patients with confirmed KAT6 related patients (Genitopatellar Syndrome-GTPTS,
Say-Barber-Biesecker-Young-Simpson Syndrome- SBBYSS). Cases marked in red represent KAT6A
cases, while purple represent SBBYSS cases, orange represent GTPTS cases, pink represents KAT6A
samples removed from analysis, blue indicate cases with no phenotypic or genotypic presentation of any
disorder (Control-Training), including samples with confirmed presentation of other syndromes.
E: DNA methylation signal intensity plot comparing confirmed KAT6A syndrome patients with
confirmed KAT6 related patients without inclusion of KAT6B in training controls (Genitopatellar
Syndrome-GTPTS, Say-Barber-Biesecker-Young-Simpson Syndrome- SBBYSS), sorted by hierarchical
clustering. Cases marked in red atop the figure represent KAT6A syndrome cases, while purple represent
GTPTS cases, yellow represent SBBYSS cases, blue indicate cases with no phenotypic or genotypic
presentation of KAT6A, including samples with confirmed presentation of other syndromes.
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CLUSTERING AND DIMENSION REDUCTION
Following each analysis, probes were examined with hierarchical clustering and multiple
dimensional scaling (MDS) to examine the structure of the identified episignature. Hierarchical
clustering was performed using Ward’s method on Euclidean distance by the base stats package
in R, and visualized with the ggplot2 package. MDS was performed by scaling of the pairwise
Euclidean distances between samples.

DISCOVERY/TRAINING COHORT SELECTION
Identification of disease specific episignatures was performed using a randomly selected
subset of the database, on a 75:25 ratio of discovery:training, using the caTools package in R.
Testing samples were used to assess the performance of the classification model developed later
in the study. For every disease group in the discovery cohort, a sex and age matched control
group with a sample size at least 4 times larger was selected from the reference control group
using the MatchIT package, and methylation profiles were compared between the two.

CROSS VALIDATION
For each round of validation, one of the 17 selected KAT6A samples was removed from
probe selection, alongside matched controls and added KAT6B samples. The remaining KAT6A
samples were designated as testing samples, and all three groups were modeled using MDS to
determine how they clustered/segregated with one another. This process was repeated 10 times
with different combinations of assigned training and testing samples (See Supplemental Figure
4-1).

CLASSIFICATION MODEL
The Methylation Variant Pathogenicity (MVP) score was created to assess the specificity
of the identified methylation signature using all of the identified probes. A support vector
machine (SVM) classifier used a linear kernel for training on KAT6A cases and controls. A 4:1
ratio of controls to cases, with cases and controls that had been used previously for probe
selection, paired with 75% of the remaining controls, and 75% of the other syndrome samples
from our EKD was chosen for modeling the episignature classification. Once modeled, we tested
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the classifier using the remaining 25% of controls and other syndrome samples from the EKD.
EKD samples include both 450k and EPIC array data, allowing the classifier to assess both array
types, however because the majority of the samples to be tested later were assayed using the
EPIC array, we limited the analysis to probes shared by both array types. Training used the
e1071 R package, we used 10-fold cross validation to determine hyperparameters optimal to
classification. In this process, the training set was divided into ten folds by random assignment,
where the first nine are used for training, and the last used for testing the accuracy of the model.
The mean accuracy was then calculated, and hyperparameters with the best performance by this
metric were selected. The model provides a score ranging from 0-1 for each subject, representing
the model’s confidence in predicting whether the subject has a DNA methylation profile similar
to the KAT6A probe set. Conversion of these SVM decision values was done using Platt’s scaling
method [39], and the class obtaining the greatest score determined the predicted phenotype.
Classification as KAT6A was made when a sample received the greatest score for that class
(normally greater than 0.5). Finally, the model was applied to both a training set of a large cohort
of individuals with clinical and molecular diagnoses of neurodevelopmental disorders, as well as
a group of healthy controls to determine the model’s effective specificity.

VALIDATION OF CLASSIFICATION
To ensure the model is not susceptible to batch structure of the methylation experiment,
the classifier was applied to samples assayed on the same batch as the cases used for training.
Using downloaded methylation data from isolated cell populations of healthy individuals from
the GEO online database to ensure the classifier is not sensitive to the blood cell type
compositions, we provided these samples to the classifier and examined the variance of scores
across different blood cell types. The model was then applied to the case cohort to evaluate its
predictive ability on affected subjects. Specificity was determined by supplying a large number
of DNA methylation arrays from healthy subjects to the model. To understand whether or not the
model is sensitive to detecting other medical conditions presenting with similar phenotypes of
neurodevelopmental disorder and intellectual disability, we tested a large number of subjects
with confirmed clinical and molecular diagnoses of similar syndromes with the KAT6A classifier
model.
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DIFFERENTIALLY METHYLATED GENES
To identify regions of significant methylation changes and the genes associated with
them, the DMRcate algorithm was used [40]. P values were calculated for each probe using
multivariable limma regression modeling, which were then kernel smoothed to identify regions
with a minimum of 3 probes no more than 1 kb apart and an average regional methylation
difference of greater than 10%. The Stouffer false-discovery rates (FDR) were used to select
regions across the identified differentially methylated regions (DMRs). Analysis was performed
on the same set of cases and controls used for methylation profiling and was also adjusted for
blood cell type composition.
RESULTS
COMPARISON OF PHENOTYPES
Common features of KAT6A syndrome include developmental (especially speech) delay
and intellectual disability, varying in severity, and specific dysmorphic features, like
microcephaly, eye abnormalities (ptosis, blepharophimosis and strabismus), low-set ears, a broad
nasal tip, a thin upper lip and small peg shaped teeth (see Table 4-1). The majority of patients
have a visual defect, heart anomaly and other congenital anomalies (see Table 4-2). Overlapping
phenotypic characteristics between KAT6A and KAT6B-related syndromes include
developmental delay and intellectual disability, microcephaly, hypotonia, and feeding problems
[31,32,33]. Typical features of GTPTS are, as the name implies, genital and patellar
abnormalities, but the vast majority of patients also have corpus callosum abnormalities
(agenesis or hypoplasia), heart and renal malformations and limb contractures. Other
(congenital) abnormalities have also been described in the literature (see Table 4-3). Facial
features partially overlap with KAT6A syndrome and include low set and/or posteriorly rotated
ears, a flat and/or broad nasal bridge with a broad and bulbous nasal tip and micro- or
retrognathia. Mask-like facies and eye abnormalities (ptosis, hypertelorism, strabismus) are
described in some patients with GTPTS (see Table 4-1). A characteristic feature of SBBYSS is a
long thumb or great toe, but other hand and skeletal abnormalities have also been described.
Teeth, thyroid, heart and genital defects are common, as well as hearing loss and lacrimal duct
abnormalities. Regarding facial features of patients with SBBYSS, ptosis or blepharophimosis
with mask-like facies and a cleft lip and/or palate are frequently seen (see Table 4-1 and 4-2).
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Facial
dysmorphism:
Microcephaly
Ptosis /
Blepharophimosis
Downslanting
palpebral fissures
Hypertelorism
Strabismus
Low-set and/or
posteriorly rotated
ears
Nasal bridge: flat
and/or broad
Nasal bridge:
prominent
Nasal tip: Broad,
fleshy, bulbous.
Philtrum
Short
Long
Lip
Thin
Micro/retrognathia
Mask-like facies

36% (27/75)
17% (13/78)

KAT6B –
GTPTS
(n=26)
65% (17/26)
8% (2/26)

KAT6B –
SBBYSS
(n=73)
30% (22/73)
45% (33/73)

1% (1/76)

-

8% (6/73)

5% (4/76)
55% (42/76)
32% (26/81)

12% (3/26)
8% (2/26)
19% (5/26)

11% (8/73)
5% (4/73)
12% (9/73)

1% (1/76)

12% (3/26)

16% (12/73)

-

8% (2/26)

3% (2/73)

85% (61/72)

31% (8/26)

23% (17/73)

‘Common’
62% (42/68)
9% (7/81)
-

4% (1/26)
4% (1/26)
23% (6/26)
8% (2/26)

1% (1/73)
10% (7/73)
7% (5/73)
12% (9/73)
42% (31/73)

KAT6A
(n=81)

4% (3/76)
19% (15/81)
65% (42/65)
9% (7/76)
5% (4/81)
3% (2/76)
22%* (17/76)
3% (2/76)
53% (42/79)
4% (3/81)
10% (8/81)
1% (1/76)

KAT6B –
GTPTS
(n=26)
96% (25/26)
31% (8/26)
15% (4/26)
8% (2/26)
23% (6/26)
12% (3/26)
19% (5/26)
65% (17/26)
81% (21/26)
88% (23/26)
27% (7/26)

KAT6B –
SBBYSS
(n=73)
8% (6/73)
18% (13/73)
8% (6/73)
18% (13/73)
16% (12/73)
26% (19/73)
40% (29/73)
33% (24/73)
38% (28/73)
4% (3/73)
40% (29/73)
1% (1/73)

10% (8/81)
2% (2/81)
3% (2/76)
10% (8/81)
3% (2/76)
10% (8/81)
-

19% (5/26)
8% (2/26)
31% (8/26)
88% (23/26)
69% (18/26)
19% (5/26)
15% (4/26)
31% (8/26)

3% (2/73)
1% (1/73)
8% (6/73)
26% (19/73)
15% (11/73)
62% (45/73)
16% (12/73)
11% (8/73)

KAT6A
(n=81)
Anomaly of:
Corpus callosum
Brain (other)
Visual
Hearing
Lacrimal duct
Cleft lip/palate
Teeth
Thyroid
Heart
Renal
Genital
Anus
Musculoskeletal
Craniosynostosis
Thorax
Spine
Respiratory tract
Contractures
Patella
Long dig I (hand)
Hand (other)
Skeletal (other)

Table 1. Overview of the dysmorphic features of patients with KAT6A and
KAT6B-related syndromes as described in literature. GTPTS =
genitopatellar syndrome. SBBYSS = Say-Barber-Biesecker-YoungSimpson syndrome. ‘-‘ means that the feature has not occurred or has not
been described in the specific group.

Table 2. Overview of the congenital and structural anomalies of patients
with KAT6A and KAT6B-related syndromes as described in literature.
GTPTS = genitopatellar syndrome. SBBYSS = Say-Barber-BieseckerYoung-Simpson syndrome. ‘-‘ means that the feature has not occurred or
has not been described in the specific group.
* mainly small, peg shaped teeth, dental crowding.

Table 4-1, 4-2. Overview o f phenotypes for patients with KAT6A and KAT6B Syndromes
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id

target

sex

age (years)

genotype

MS2563

KAT6A

f

6

KAT6A p.Met547Glufs*3

MS2564

KAT6A

m

3

KAT6A p.Gln1873*

MS2565

KAT6A

f

16

KAT6A p.Arg971Profs*5

MS2599

KAT6A

f

4

KAT6A c.3449dup p.Trp1152Metfs*23

MS2600

KAT6A

m

5

KAT6A c.3860_3861del p.Glu1287fs

MS2780

KAT6A

m

2

KAT6A: c.4645G>A p.Gly1549Ser

MS2782

KAT6A

m

1

KAT6A p.Ser1551Arg

MS3394

KAT6A

f

2

KAT6A: c.1961A>G p.Gln654Arg

MS3396

KAT6A

f

*21

KAT6A: c.3385C>T, p.Arg1129*

MS3397

KAT6A

f

*25

KAT6A: c.3820G>T, p.Glu1274*

MS3398

KAT6A

m

*2

KAT6A: c.3399_3400dup; p.Lys1134Argfs*14

MS3399

KAT6A

f

*4

KAT6A: c.3377delC; p.Ser1126Phefs*8

MS3400

KAT6A

m

*19

KAT6A: c.3631_3632delGT; p.Val1211*

MS3401

KAT6A

f

*2

KAT6A: c.4254_4257del; p.Glu1419Trpfs*12

MS3402

KAT6A

m

*13

KAT6A: c.3182T>A; p.Leu1061*

MS3403

KAT6A

m

*5

KAT6A: c.4224dup; p.Leu1409Ilefs*10

MS3404

KAT6A

m

*1

KAT6A: c.4502dup, p.Asn1501Lysfs*6

MS3405

KAT6A

f

*15

KAT6A: c.3070C>T, p.Arg1024*

MS3406

KAT6A

f

*1

KAT6A: c.3434del, p.Pro1145Leufs*2

MS3407

KAT6A

f

*36

KAT6A: c.3034C>T; p.Arg1012*

MS3422

KAT6A

m

9

KAT6A: c.3640A>T,p.Lys1214*

MS0673

GTPTS

f

1 month

KAT6B: c.3578_3585delTCCAGCAT; p.Phe1193Serfs*23

MS0677

GTPTS

m

3

KAT6B: c.3769_3772delTCTA; p.Lys1258Glyfs*13

MS1773

GTPTS

*m

*1

KAT6B: c.3788_3789del; p.Lys1263Argfs*7

MS1784

GTPTS

*f

*5

KAT6B: c.3788_3789del; p.Lys1263Argfs*7

MS0682

SBBYSS

f

6

KAT6B: c.3046del; p.Ser1016Alafs*98

MS1487

SBBYSS

*f

2

KAT6B: c.3147G>A; p.Ala1008Argfs*64

MS1641

SBBYSS

f

26

KAT6B: c.3349_3350del; p.Gln1117Valfs*19

MS1772

SBBYSS

*m

*8

KAT6B: c.3172C>T;p.Arg1058*

MS1785

SBBYSS

*m

*4

KAT6B: c.5492C>G;Ser1831*

MS1835

SBBYSS

*f

*17

KAT6B: c.5502C>G, p.Tyr1834*

MS1937

SBBYSS

f

1 month

KAT6B c.4617_4618del; p.Glu1540Aspfs*30

MS2253

SBBYSS

f

*14

KAT6B: c.4831delG

MS2557

SBBYSS

m

4

KAT6B: c.5795_5798del; p.Leu1932Hisfs*18

MS2788

SBBYSS

f

1

KAT6B: p.Arg9452*
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Table 4-3. Overview of the KAT6A (n = 21) and KAT6B (SBBYSS n = 10, GTPTS n = 4)
samples used in our analyses, including information about included patients gender, age and
KAT6A/B mutation. Samples highlighted in yellow were removed from probe selection following
preliminary analysis which indicated their methylation profiles were more similar to matched
control samples than other cases. Samples marked with an asterisk (*) did not have age or sex
information provided, and thus had their status calculated via methylation profile.

DETECTION AND VERIFICATION OF AN EPISIGNATURE FOR KAT6A
DNA methylation profiles from the peripheral blood of 17 individuals with confirmed
clinical and molecular presentations of KAT6A syndrome were used to derive the episignature.
Sample filtering steps removed 4 of the original 21 samples for several reasons, including sample
quality, sample type, and sample clustering patterns (samples clustering with controls based on
preliminary assessment are excluded). Samples had fewer than 1000 failed probes and passed
quality control requirements.
First analyses where KAT6A samples were compared to matched controls indicated the
presence of shared methylation patterns between KAT6A and highly related syndromic groups
based on 97 differentially methylated probes (See Figure 4-1A), namely GTPTS and SBBYSS,
neurodevelopmental disorders associated with mutations in the lysine acetyltransferase protein
6B (KAT6B) gene. Although the model was capable of differentiating KAT6A samples from
controls (See Figure 4-1B), MDS and heatmap models showed significant overlap in clustering
patterns between these three syndromes and both the KAT6B related disorders scored moderately
high scores in the classifier (See Figure 4-1C, 4-1D, 4-1E), representing the significant degree of
overlap between these conditions. Full delineation of these highly similar KAT6 family
syndromes was achieved when the 14 GTPTS and SBBYSS samples in our database were
provided as controls for probe selection, training the selected probeset against the features of this
cohort alongside age, sex and array matched controls. This allowed for distinct MDS and
heatmap separation of case and control samples, with corresponding high MVP scores for the
KAT6A cohort and low scores for the remaining syndrome’s samples.
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When compared to this control set, cases showed significant differences in methylation
patterns of 114 probes, which are visualized using a volcano plot (See Figure 4-2A). Probes with
a minimum methylation difference of 5% between the two cohorts, and a multiple testing
corrected p value of <0.01 (limma multivariable regression modeling) were used for the
episignature. P values were adjusted for blood cell type composition to ensure comparability
between heterogeneous peripheral blood sample sources. Hierarchical clustering and MDS
demonstrate that the selected probeset strongly separates cases and controls (See Figures 4-2B,
4-2D, 4-2E). Cross-validation using KAT6A samples was performed to validate the sensitivity of
the episignature, showing in each case that the remaining testing samples clustered with the other
KAT6A samples, and segregated from the controls. Plotting KAT6B samples associated with
GTPTS and SBBYSS conditions showed distinct clustering of KAT6A samples from the KAT6B
samples, where previous models showed adjacent clustering. Some minor overlap of the
SBBYSS cohort in the MDS model was observed, however hierarchical clustering heatmaps
showed the capability of the model in differentiating the two syndromes (See Figures 4-2D, 42E).

DEVELOPMENT OF AN MVP SCORE
Subjects with KAT6A variants, matched controls, and a number of samples from
syndrome cohorts previously established in the EKD were used for training a model to test the
sensitivity and specificity of the episignature created through previous probe selection steps. The
MVP score was set to generate a single score from 0-1 for each sample, with 1 being a
methylation pattern highly similar to the case samples, and 0 being a methylation pattern highly
similar to matched control samples. The class obtaining the highest score determined the
episignature classification. These results were validated by a series of tests to validate their
reliability. While all KAT6A samples received high scores close to 1, control scores remained
near 0, indicating the classifier has a high sensitivity for the detection of the KAT6A episignature
(See Figure 4-2C, Figure 4-3). Furthermore, specificity of the classifier was tested by providing
it with a large number of subjects with confirmed diagnosis of an NDD of various types,
including trinucleotide repeat expansion abnormalities, imprinting defect disorders,
BAFopathies, Mendelian disorders of the epigenetic machinery, down syndrome as well as
subjects with nonsyndromic autism spectrum disorders. The vast majority of EKD samples,
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including the KAT6B syndromes, GTPTS and SBBYSS, were classified as being highly similar
to controls using the KAT6A classifier, confirming its efficacy as a sensitive and specific model
for the identification of KAT6A related episignatures.

Figure 4-3. SVM classifier model for KAT6A. Each sample receives scores for the
probability of having a DNA methylation profile similar to cases as compared to every other
sample with a confirmed episignature in the EKD. Higher value on Y axis indicates that a sample
presents a methylation profile more similar to cases compared to the methylation profiles of
patients with other disorders. 53 other syndromes with confirmed episignatures from the EKD
are plotted based on this relative scale of similarity to indicate probeset specificity for the case
disorder. This classifier also clearly distinguishes KAT6A syndrome from the KAT6B syndromes
GTPTS and SBBYSS.
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DIFFERENTIALLY METHYLATED GENES
In the significantly differentially methylated regions (DMRs), we found a total of 36
differentially methylated genes (DMGs) in the assessed KAT6A syndrome, GTPTS and SBBYSS
samples, compared to control samples. For KAT6A syndrome, this included 15 genes, whilst
GTPTS samples had 25 DMGs and SBBYSS 8 DMGs.
The following genes were differentially methylated in KAT6A syndrome and GTPTS
samples, compared to controls: BMP4, HEY2, HOTAIRM1, HOXA1, HOXA3, HOXA5, HOXA6,
HOXA-AS3, RP11-357H14.17, RP1-170O19.22, RP1-170O19.23. The GLI2 gene was only
differentially methylated in KAT6A syndrome and SBBYSS samples compared to controls. For
a full list of all 36 DMGs in the DMRs of KAT6A syndrome, GTPTS and SBBYSS samples (all
compared to controls), see supplementary Table 4-1.

DISCUSSION
Recent advances in the assessment of DNA methylation profiles have provided
significant improvements to the diagnosis and discovery of rare diseases. To date, 65
neurodevelopmental conditions have been associated with specific DNA methylation profiles,
known as episignatures [20,41]. Often, genes with roles involving histone modifications, DNA
methylation and chromatin have been implicated, and the resulting downstream changes to the
epigenetic profile of these patients can be used to differentiate between conditions exhibited by
different patients [20,42,43,44]. These episignatures are complex representations of the
corresponding gene expression profiles affected by these various epigenetic modifiers, and in
several cases, have provided clarification for variants of unknown significance [43,44], and
refinement of the spectrum of variants associated with a given condition [20,41]. This study
focuses on a cohort of patients with variants within the KAT6A gene sequence, and further
expands upon the landscape of epigenetic classifiers, providing evidence of this technology’s
capability of differentiating syndromes with a high degree of phenotypic and genotypic overlap.
These findings provide novel avenues of research and expansion of diagnostic criteria for
patients with KAT6A variants, as well as it’s adjacent sister conditions, GTPTS and SBBYSS.
KAT6A syndrome is a relatively novel condition, first identified in 2015 by Arboleda et
al. [26], and shortly after by Tham et al. [27], and presents as an intellectual disability disorder
with additional features including facial abnormalities, skeletal abnormalities, speech pathologies
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and other (congenital) abnormalities. Based on DNA methylation data derived from the
peripheral blood of patients with clinically and molecularly identified KAT6A syndrome, we
have identified an episignature specific to the syndrome’s associated pathology. Our data
suggests that not only is there a specific DNA methylation signature for patients with variants in
the KAT6A sequence, but that significant overlap in methylation differences can occur between
similar conditions GTPTS and SBBYSS, potentially elucidating similar mechanisms of action.
DNA methylation signatures vary in genomic locations and intensities across different
disorders, with the identified KAT6A syndrome signature showing highly robust characteristics,
including distinct hierarchical clustering, segregation of case and controls following MDS
models, similar to previously described episignatures [3,10,11,12,13, 14, 15,16,17,18,19,20]. Of
the 21 samples with (likely pathogenic) variants in KAT6A, 17 samples, all with truncating
variants, showed a specific signature. Four KAT6A syndrome samples grouped predominantly
with control samples. Of these four samples, three had missense variants and one had a
truncating variant, located more upstream in the KAT6A gene than the other samples. This may
suggest that, similar to KAT6B, multiple episignatures exist for KAT6A syndrome, possibly
accompanied by a different phenotype, and that the four “negative” samples might have another
signature. However, the group number is too small to draw conclusions yet. Similar results
exhibiting multiple episignatures from variants within single genes have been described,
including ADNP, SMARCA2, SRCAP, and KMT2D [21, 45,46, 47]. Locations of variants plays a
major role in determining the subsequent methylation patterns seen when patients are assessed,
as such it is not unreasonable to suggest a similar phenomenon may be occurring within these
more “upstream” KAT6A variants. Variants outside previously established “canonical” loci
associated with KMT2D related Kabuki syndrome, and SRCAP related Floating Harbor
syndrome were found to exhibit methylation patterns distinct from those found in patients with
canonical variants in SRCAP exons 33 and 34 for Floating Harbor syndrome, and in KMT2D
exons outside 38 and 39 for Kabuki syndrome 1. Furthermore, in the assessment of Helsmortel
Van der Aa syndrome patient cohorts, patients classified with variants within the central domain
of the ADNP gene provide a different episignature than those exhibited by patients with variants
within the terminal domain [21]. Additionally, location, especially in terms of affected domains
associated with the syndrome may play a key role in determining methylation patterns as well, as
demonstrated in the assessment of non-Nicolaides Baraitser patients with SMARCA2 mutations.
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Assessment of these novel BIS patients identified large changes in the methylation pattern for
patients with variants outside of the helicase domain, that result in a recognizably distinct
syndrome from NCBRS, despite being associated with the same SMARCA2 gene [45]. Further
assessment of the variant loci, and the disruption of genetic and epigenetic machinery that comes
as a result of these changes in different loci may explain the distinct methylation patterns
exhibited by these non-compliant samples.

Evidence of highly sensitive and specific association of the selected probeset with KAT6A
syndrome was provided following cross validation and SVM classifier training. All case samples
received high MVP scores, while controls and individuals from other disorders provided to the
model scored very low scores. This indicates that the highly differentiated CpG probes selected
through training with the KAT6A cohort are capable of reliably classifying this condition in a
sensitive and specific manner. The first models were produced without the addition of KAT6B
samples to the control training cohort, to test the ability of the KAT6A derived episignature to
differentiate GTPTS patients using the DMRs derived from patients with KAT6A variants.
Providing four GTPTS samples to the episignature derived from probe selection using KAT6A
samples showed GTPTS samples clustered away from the KAT6A sample cluster, as well as
being visually separable from the remaining control samples. The selected methylated regions
seem to contain informative loci for both disorders, providing further evidence of the genetic
overlap of these disorders. Additionally, models created using the comparison of KAT6A samples
and SBBYSS samples, showed similar results, with SBBYSS samples intermixed with the
KAT6A samples. Interestingly, when GTPTS and SBBYSS were assessed separately in a
previous publication [20], it was discovered that despite being caused by mutations within the
same gene, the methylation profiles exhibited by these two syndrome groups were quite distinct
from one another, and resulted in episignatures for both conditions. When the probeset was
trained using KAT6A samples only, without the addition of GTPTS and SBBYSS samples to the
training control group, intermediate scores were produced in the MVP assessment for both
GTPTS and SBBYSS. This indicates a significant overlap in methylation profiles between these
similar disorders, a phenomenon which has been observed in assessments of other NDDs,
including the combined BAFopathy episignature derived from the assessment of NicolaidesBaraitser (NCBRS) and Coffin-Siris (CSS) cohorts [34].
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Further research is required to determine why these two distinct syndromes are showing
methylation profile overlap with KAT6A syndrome, a disorder associated with genetic variants in
KAT6A. As stated before, the two associated genes, KAT6A and KAT6B are both components of
the similar MOZ/MYST complexes, that exert lysine acetyltransferase activity [33]. In an
attempt to search for answers we compared the clinical features of these three syndromes (Tables
4-1 and 4-2) and tried to find an explanation for the overlap and differences of features of these
syndromes in the methylation profiles. We saw that the BMP4 gene (OMIM # 112262) is
differentially methylated in KAT6A syndrome and GTPTS [48]. Mutations in this gene can cause
a disorder characterized by cleft lip/palate, brain, eye and skeletal malformations. The BMP4
gene is also involved in tooth development. All of these features have been described in KAT6A
syndrome and GTPTS. The HEY2 gene (OMIM # 604674) is also differentially methylated in
both KAT6A syndrome and GTPTS samples. This gene is believed to be important for heart
development and its differential methylation could perhaps explain the high frequency of heart
anomalies in KAT6A syndrome (53%) and GTPTS (65%) patients. [49]

Multiple HOX-genes are differentially methylated in KAT6A syndrome and GTPTS
samples (HOTAIRM1, HOXA1, HOXA3, HOXA5, HOXA6 and HOXA-AS3) or only in GTPTS
samples (HOXA4, HOXA-AS2, HOXB3, HOXB6, HOXB-AS3 and HOXB-AS4). HOX genes are a
group of Homeobox genes, that are important for various developmental processes. A regulatory
effect of KAT6A on HOX gene expression has been described previously [50, 51]. Mutations in
some of the HOX genes are associated with specific malformations or syndromic disorders with
a wide spectrum of symptoms (hearing loss, developmental delay, cardiovascular and skeletal
malformations, dysmorphic features), but for other HOX genes the function and consequences of
mutations need to be further elucidated. Samples of KAT6A syndrome and SBBYSS patients had
a differentially methylated GLI2 gene (OMIM # 165230) in common. This gene is associated
with Holoprosencephaly 9 (OMIM # 610829) and Culler-Jones syndrome (OMIM # 615849) and
could explain some of KAT6A syndrome and SBBYSS features, like eye/visual abnormalities
and microcephaly. It would be interesting to perform deep phenotyping of the patients of which
samples are used in our current study and to specifically compare the differentially methylated
genes per patient to their clinical features.
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An important consideration to make is that the identification of DNA methylation
episignatures is achieved using peripheral blood samples from patients, rather than the tissues
most relevant to the particular syndrome, in this case neural tissue. Therefore it can be proposed
that the DNA methylation patterns seen in the peripheral blood do not necessarily match those
within the neural tissues of the same patients. Nonetheless, it has been shown that epigenetic
alterations in brain and peripheral tissues are correlated to changes in brain tissue [52,53], which
suggests that methylation patterns in peripheral blood appear to reflect methylation patterns in
other tissues for at least some genes. Although we have determined that the selected probes used
in the KAT6A signature are effective at providing evidence towards differentiation of KAT6A
samples from other cases, not all of them are necessarily related to the phenotype of the
condition, but still act as robust biomarkers for the condition. Further work on the overlapping
differentially methylated probes for the KAT6A and KAT6B related episignatures will provide
insights into how these differentially methylated probes relate to the pathophysiology of this
condition. Additionally, the Illumina EPIC bead chip array used for this assay covers nearly
860,000 human genomic methylation CpG sites, including 99% of published Refseq genes, and
96% of CpG islands [3,12]. Therefore, although the array does not represent the totality of
human methylation profiles, it assesses the vast majority of biologically relevant gene sequences
and other elements with significant effects on heredity. Further advances in microarray and
epigenetic assessment technologies may unveil more active methylation sites for assessment,
however with the present capabilities of the platform, reliable and comprehensive assessments of
human epigenetic change can be provided.

In conclusion, the discovery of a highly robust KAT6A syndrome episignature expands a
list of NDDs with DNA methylation episignatures that can be used for screening and diagnosis
of patients with rare neurodevelopmental conditions. The highly sensitive and specific DNA
methylation profile detected from peripheral blood of patients with KAT6A variants enables
effective diagnosis, screening and classification of suspected KAT6A variants and provides a
novel avenue of testing in diagnostic settings. Assessment of the epigenetic overlap between
KAT6A syndrome, GTPTS and SBBYSS has provided insight into common pathways, that
potentially result in the shared characteristics of these conditions. Additional work expanding on
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the number of cases with different types of KAT6A mutations, across multiple exons, will allow
for more extensive refinement of the episignature, and a further assessment of the diagnostic
overlap of this model with adjacent syndromes will provide further avenues of research and
greater understanding of these complex conditions.
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SUPPLEMENTARY FIGURES AND TABLES

Supplemental Figure 4-1. Multidimensional scaling plot for cross validation, representing the
dimensions of variation in methylation signal intensity at informative CpG identified for
KAT6A. Represents comparisons of the similarity of methylation profiles of KAT6A patients,
with those chosen for probe selection marked in blue, and the cross-validation sample marked in
red. Control samples (shown in green) include cases without a confirmed phenotypic and/or
genotypic presentation of KAT6A, including samples with confirmed presentation of other
syndromes.
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Supplemental Figure 4-2. KAT6A MVP Score ROC Graph. Receiver operating characteristic curve
demonstrating the sensitivity and specificity of the generated MVP scores for the KAT6A cohort and the remaining
EKD samples used for training.
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Differentially methylated gene

Syndrome(s)

ANK2

GTPTS

BMP4

KAT6A+GTPTS

COL18A1

GTPTS

CTC-340A15.2

KAT6A

DTNA

SBBYSS

GLI2

KAT6A+SBBYSS

HEY2

KAT6A+GTPTS

HLA-DPA1

SBBYSS

HLA-DPB1

SBBYSS

HOTAIRM1

KAT6A+GTPTS

HOXA1

KAT6A+GTPTS

HOXA3

KAT6A+GTPTS

HOXA4

GTPTS

HOXA5

KAT6A+GTPTS

HOXA6

KAT6A+GTPTS

HOXA-AS2

GTPTS

HOXA-AS3

KAT6A+GTPTS

HOXB3

GTPTS

HOXB6

GTPTS

HOXB-AS3

GTPTS

HOXB-AS4

GTPTS

KIAA1161

SBBYSS

LTBP3

SBBYSS

METTL11B

GTPTS

NKAIN1

SBBYSS

PCCA

GTPTS

PDE4D

KAT6A

PPP2R2C

SBBYSS

RP11-297J22.1

KAT6A

RP11-357H14.17

KAT6A+GTPTS

RP1-155D22.2

GTPTS

RP11-650J17.1

GTPTS

RP1-170O19.22

KAT6A+GTPTS

RP1-170O19.23

KAT6A+GTPTS

TJP1

GTPTS

ZDHHC14

GTPTS

Supplemental Table 4-1. Differentially Methylated Genes for KAT6A Episignature Probeset.
Differentially methylated genes for each syndromic group. Genes were termed as differentially
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methylated if a methylation signal intensity at 3 consecutive CpGs within the gene sequence exceeded a
5% change in value compared to controls.
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CONCLUSION
This chapter answers important questions often raised in the identification of
episignatures for NDDs. How does the presence of a highly similar gene, in this case the
paralogous counterpart to KAT6A, KAT6B, affect the derivation of a sensitive and specific
episignature? Does the similarity methylation of profiles in highly similar genes make
identification of specific DNA methylation biomarkers impossible? And finally, does the shared
methylation character coincide with shared phenotypic characteristics shared between the NDDs
associated with each respective gene? These are important distinctions to make, as it provides
evidence towards future assessment of episignatures in the context of homologous genes, but
provides a better understanding of DNA methylation profiling in the context of shared etiology.
Furthermore, assessment of the regions of overlap in terms of the genome and phenotype
provides functional evidence to elucidate the common molecular pathways which result in the
commonality seen in these disorders.
In my work, I demonstrated evidence of an episignature derived from the training of
classifier models with patients with KAT6A variants, and a cohort of age and sex matched
controls, however, when compared with data from patients carrying mutations in the paralogous
gene KAT6B reduced specificity was evident. Understandably, due to their nature as
exchangeable subunits within the MOZ/MORF complex, and common function as lysine acetyl
transferases, the disruption of both KAT6A and KAT6B resulted in significant changes in DNA
methylation at common loci, perhaps explaining the significant phenotypic overlap observed
between these conditions. Identification of a specific episiganture for KAT6A was made possible
through a modified statistical analysis pipeline by training against KAT6B samples along with
unaffected controls. Once this was performed, a KAT6A episignature with a high degree of
sensitivity and specificity was derived. This episignature can be applied to the reclassification of
the large number of variants of unknown significance currently reported in ClinVar for KAT6A
(89/410, 21%, See Appendix Table 4-3). This expansion of the analytical pipeline provides a
novel increase in diagnostic power for the derivation of DNA methylation episignatures,
providing a concrete example of episignature specificity, even in the context of multiple
confounders in terms of genetic and phenotypic overlap.
I believe this process can be further applied to future cohorts, with the understanding that
our ability to identify causative genes and explain their effects should be considered in the
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context of broader gene function and molecular pathways. KAT6A and KAT6B have shared
molecular function, resulting in a large degree of overlap in their methylation profiles, and
clinical phenotypes, which must be accounted for in the search for effective diagnostic
biomarkers. The interactions observed between KAT6A and KAT6B demonstrates a network of
molecular pathways that are well described by DNA methylation analysis. Data presented in this
chapter connects the genome, epigenome and phenotype in a way that mirrors the interconnected
nature of human biology, while providing highly sensitive and specific diagnostic biomarkers.
The functional information provided by DNA methylation analysis will be crucial in future work
when we begin to combine the layers of diagnostic evidence from genomic and phenotype
derived sources. This could result in the elucidation of common pathways that result in shared
phenotypes, identifying hitherto unknown molecular interactors, and evaluating the effects of
changes in regulatory and non coding sequences of DNA and how they relate to human health.
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PREFACE
Building on the evidence of epigenetic, genetic and phenotypic interactions discussed in
the previous chapter, in this chapter I expand on the connection of shared epigenetic profilies
between different genes, but partially overlapping phenotypes. To explore this, the final chapter
of this work will discuss DNA methylation patterns in a cohort of patients with variants in two
distinct genes that present with a partially overlapped phenotype. Specific variants in the activity
dependent neuroprotector protein (ADNP), commonly associated with Helsmoortel Van Der AA
(HVDAS), and the SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily A, member 2 (SMARCA2), commonly associated with both Nicolaides Baraitser
syndrome (NCBRS), and Blepharophimosis impaired intellectual development syndrome (BIS),
were assessed for evidence of a shared episignature in relation to their shared phenotypic
features. ADNP and SMARCA2’s interactions have been investigated, finding that ADNP
functions as a guide for the BAF complex that SMARCA2 is a subunit of [4]. Disruption of
ADNP’s sequence is hypothesized to result in similar disruption of the BAF complexes
chromatin remodeling activity, potentially explaining the partially overlapping phenotype seen in
this cohort of patients with variants in distinct genes.
In my work, I sought to describe this interaction in the context of the subsequent changes
in DNA methylation, attempting to identify a common episignature that would represent the
common changes in epigenome profiles. I describe the assessment of an episignature that is
common to two distinct molecular entities, united by a common phenotypic feature, providing a
novel example of a dysmorphology based approach towards episignature assessment. As I will
demonstrate, this episignature was found to be highly sensitive and specific to a subset of ADNP
variants in the central domain of the protein sequence, and BIS cases with SMARCA2 variants,
with the common blepharophimosis phenotype.
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INTRODUCTION
For this work, we describe a novel episignature, involving a novel method of discovery,
based on shared phenotype observed in patients with mutations in SMARCA2, and ADNP.
Blepharophimosis-Impaired Intellectual Development syndrome (BIS) is a recently recognized
disorder distinct from Nicolaides-Baraister syndrome that presents with distinct facial features of
blepharophimosis, and global developmental delay [1,2]. BIS is due to pathogenic variants in
SMARCA2, that encodes the catalytic subunit of the superfamily II helicase group of the BRG1
and BRM-associated factors (BAF) forming the BAF complex, the mammalian homolog of
switch/sucrose nonfermentable (SWI/SNF), a chromatin remodeling complex that regulates
expression of several genes involved in chromatin remodeling and gene expression regulation.
Individuals bearing variants within the bipartite nuclear localization (BNL) signal domain of
ADNP, the gene responsible for Helsmoortel-Van Der Aa Syndrome (HVDAS) present with
blepharophimosis and epicanthal folds, a striking overlap with the BIS phenotype. Interestingly,
ADNP was found to interact with several major proteins of the SWI/SNF complex, with proteinprotein interactions identified between ADNP and several of the BAF complex subunits
identified by Mandel and Gozes in 2007 [3,4,5] ADNP was found to bind directly to SMARCA2,
SMARCA4, and SMARCC2 through its C terminal end, providing a molecular pathway through
which disturbance of proper ADNP function can result in impacts on the BAF complex’s ability
to provide it’s chromatin remodeling capacity.
SMARCA2’s role within the cell is to encode a catalytic subunit of the superfamily II
helicase group of the BRG1 and BRM-associated factors (BAF), of which there are two [1]. The
BAF complex is involved in chromatin remodeling activity, regulating expression of a number of
genes, as such, disruption of the SMARCA2 gene has been seen to be involved in several NDDs,
including Nicolaides Baraitser syndrome, and our syndrome of interest, BlepharophimosisImpaired Intellectual Development syndrome (BIS). BIS is a congenital disorder, with distinct
facial features of blepharophimosis, and global developmental delay. Individuals living with BIS
exhibit delayed motor skills, difficulties in independent locomotion, and impaired intellectual
development with poor or absent speech.

155

ADNP, or the activity dependent neuroprotector homeobox, is a homeodomain zincfinger protein with transcription factor activity. This protein, integral to proper brain formation
[3] is known to interact with the SWI/SNF complex, and is commonly mutated in autism
spectrum disorder (ASD) cases, being detected in 0.17% of individuals with ASD. Individuals
with ADNP variants are commonly classified as Helsmoortel-Van Der Aa Syndrome (HVDAS),
classically presenting with intellectual disability, developmental delay, motor dysfunction, ASD
and facial dysmorphisms [6]. Previous work has shown that depending on the location of
variants within the ADNP sequence, different episignatures can be derived, resulting in two
episignatures for central domain and terminal domain regions respectively [8].
This manuscript focuses on the emergence of a potential third episignature derived from a
cohort of ADNP patients, derived by means of a phenotype first, dysmorphology approach. It has
been clinically observed that within a subset of patients with ADNP mutations, with variants
with the nuclear bipartite localization domain [7] , symptoms of blepharophimosis were
observed, a trait not seen in other ADNP patients, but common in SMARCA2 associated BIS
cohorts. This led to the assessment of these molecularly distinct, but phenotypically overlapping
cohorts via DNA methylation microarray testing, to determine whether or not the common
features seen in these patients could be explained by shared changes in methylation patterning.

METHODS
SUBJECTS AND CONTROLS COHORTS
DNA samples were extracted from peripheral blood of 25 individuals with molecular
variants identified in ADNP and SMARCA2. 10 ADNP samples, 8 of which were previously
published in Bend et al, 2017 [8], were assessed, with an additional 2 provided by the Telethon
Institute which featured characteristics of blepharophimosis. (See Table 5-1). The 15 remaining
samples were associated with SMARCA2 variants, and featured clinical features of BIS (See
Table 5-2). All samples and records were de-identified. Age and sex matched controls were
selected from the Episign Knowledge Database, and represented various other conditions not
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associated with ADNP or SMARCA2 related disorders, including NCBRS and other BAFopathy
conditions.
The research was conducted in accordance with the Declaration of Helsinki. Study
protocol has been approved by the Western University Research Ethics Board (REB 106302).
Informed consent was obtained by physicians for use of the clinical information of the described
patients.

Case ID

Blepharophimosis Gender

Age

ADNP variant

(years)
MS1167

+

Female

12

c.2157C>G (p.Tyr719*)

MS1182

-

Female

3

c.2157C>G (p.Tyr719*)

MS1254

-

Female

5

c.2157C>G (p.Tyr719*)

MS1255

-

Female

4

c.2157C>G (p.Tyr719*)

MS1262

NR

Male

13.4

c.2156dupA (rs1135401808 )

MS1265

NR

Male

4.2

c.2188C>T (p.Arg730*)

MS1276

-

Male

5.4

c.2157C>G (p.Tyr719*)

MS1277

-

Female

12

c.2156_2157insA (p.Tyr719*)

MS2687

+

Female

8

c.2157C>G:(p.Tyr719*)

MS4091

+

Female

6

c.2157del, p.(Tyr719*)

Table 5-1. BNL-ADNP Sample Table. +: present; -: absent, NR: Not Reported
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Case ID

Gender

Age

SMARCA2 variant

(year)
MS1982

male

7

c.1585C>G, p.(Leu529Val)

MS1984

male

12

c.2810G>A;p.Arg937His

MS1988

male

8

c.2810G>A;p.Arg937His

MS1989

male

8

c.2810G>A;p.Arg937His

MS2524

male

0.2

c.2810G>A;p.Arg937His

MS4929

male

0.5

c.2809C>T, p.(Arg937Cys)

MS5212

female

17.4

c.1538G>T, p.(Gly513Val)

MS5213

female

3

c.2809C>T, p.(Arg937Cys)

MS5214

female

3

c.1573C>T, p.(Arg525Cys)

MS5215

female

5.4

c.2566A>G, p.(Met856Val)

MS5216

male

5

c.1573C>T, p.(Arg525Cys)

MS6938

female

13

c.1574G>A, p.(Arg525His)

MS7249

female

11.4

c.1534G>A, p.(Glu512Lys)

MS7416

female

9

c.1585C>G, p.(Leu529Val)

MS7417

female

17

c.6286C>A, p.(Asp510Gly)

Table 5-2. BIS Sample Table. The clinical features of these cases have been previously
described in greater detail in Cappuccio et al.[1]
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CLINICAL CHARACTERISTICS
Patients were assessed by clinicians at several separate sites, with blepharophimosis
being identified in samples MS2687, and MS4091, by Dr Brunetti. An additional 8 samples,
previously published in Bend et al, 2017 [8], were assessed via photographs for characteristics of
blepharophimosis, however two samples, MS1262, and MS1265 did not have photographs
available, and were labeled as “Not Reported”. One additional sample was identified from
photograph analysis published in the original Bend cohort. This sample, MS1167, was identified
as having the blepharophimosis phenotype.
METHYLATION ARRAY AND QUALITY CONTROL
DNA methylation analysis and Episignature classifier development was performed using
previously established protocol [9-12]. Genomic DNA was extracted from peripheral blood
samples using standard techniques and followed by bisulfite conversion and hybridization to the
Illumina infinium methylation EPIC bead chip arrays, according to the manufacturer's protocol.
Idat files, containing methylated and unmethylated signal intensity plots (beta values) were
produced from these microarrays, and used for analysis in R 4.0.2. Normalization was performed
using the Illumina Infinium methylation EPIC array with background correction from the minfi
package [12]. Previously defined exclusion criteria [9,10,11] were used to exclude probes with
detection p values >0.01, probes on the x and y chromosomes, probes known to contain SNPs at
the site of CpG interrogation or single nucleotide extension, and probes known to cross react
with chromosomal locations other than their target regions were removed. All samples were
examined for genome wide methylation distribution and those deviating from a bimodal
distribution were excluded. Factor analysis using a principal component analysis (PCA) was
performed to examine batch effect and identify outliers.No case samples were identified for
removal.
DNA METHYLATION PROFILING
Probe methylation levels (beta values), were calculated as the ratio of signal intensity in
methylated probes vs total sum of unmethylated and methylated probes, resulting in values
ranging from zero to one. To allow for linear regression modeling, beta values were logit
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transformed using the limma package [13], allowing for the identification of differentially
methylated probes. Data was adjusted for the blood cell type composition as per Houseman et al
[14]. Estimated blood cell proportion was added to the model matrix of the linear models as
confounding variables [15]. Using the eBayes function in the limma package [16], p values were
moderated and corrected for multiple testing using the Benjamini Hochberg method. Probes with
the most significant methylation differences are selected using two facts from this dataset, the
level of methylation difference (relative methylation signal intensity), and the probability that an
observed difference is due to random chance (p values). Evaluation of this interaction is carried
out by multiplying the absolute methylation difference between affected cases and controls by
the negative value of the log transformed p values, and ranking the top 1000 probes with the
highest values from this transformation. Next, receiver operating characteristic analysis (ROC) is
performed on each probe, to measure the pairwise correlation coefficient between probes. Probes
with low area under curve values from ROC analysis are removed, as well as highly correlated
probes, eliminating probes with low sensitivity and specificity, and probes with highly correlated
characteristics using Pearson’s correlation coefficient. This ensures that the final probeset
contains the most differentiating, non-redundant probes that are not influenced by random data
structures. Only probes with a methylation difference greater than 5% were included in this
analysis. This probe filtering process was designed to avoid reporting of probes with low effect
size, and those influenced by technical or random variations as conducted in previous studies
[9,10,11].

SELECTION OF MATCHED CONTROLS FOR METHYLATION PROFILING
For episignature characterization, mapping of probes and feature selection, matched
controls were randomly selected from the LHSC EpiSign Knowledge Database (EKD)[11]. All
of the ADNP and BIS samples were assayed, therefore all the controls selected for episignature
identification were analyzed using the same array type. Samples were matched by age, sex and
batch using the MatchIt package. A 4:1 ratio of controls to cases was deemed optimal for this
analysis, as previously described [9,10,11]. PCA analysis was performed after each attempt at
matching to detect outliers and determine data structures for the presence of batch effect. Outlier
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samples, and those with highly aberrant data structures were removed, and subsequent matching
trials were performed until consistent iterations with no outliers in the first two components of
the PCA were derived.
CLUSTERING AND DIMENSION REDUCTION
Hierarchical clustering and multidimensional scaling were used after each iteration of
analysis to examine the data structure of the identified episignature. Hierarchical clustering was
performed using Ward’s method on Euclidean distance by the base stats package in R, and
visualized with the ggplot2 package [17,18]. Multidimensional scaling provides a visual
representation of sample methylation profile similarity based on the scaling of the pairwise
Euclidean distances between each sample.
DISCOVERY/TRAINING COHORT SELECTION
Identification of disease specific episignatures was performed using a randomly selected
sub-setting of the database, on a 75:25 ratio of discovery:training, using the caTools package in
R. Testing samples were used to assess the performance of the classification model developed
later in the study. For every disease group in the discovery cohort, a sex and age matched control
group with a sample size at least 4 times larger was selected from the reference control group
using the MatchIT package, and methylation profiles were compared between the two.
CROSS VALIDATION
For each round of validation, one of the 25 selected ADNP-BIS samples was removed
from probe selection, alongside matched controls. The remaining ADNP-BIS samples were
designated as testing samples, and all three groups were modeled using multidimensional scaling
to determine how they cluster/segregate with one another. This process was repeated with
different combinations of assigned training and testing samples until all cases had been removed
from probe selection and used for testing once. (See Supplemental Figures)
CLASSIFICATION MODEL
Specificity of the episignature was assessed using the Methylation Variant Pathogenicity
(MVP) score, using all the identified probes. A support vector machine (SVM) used a linear
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kernel for training on ADNP-BIS cases and controls. Once again, a 4:1 ratio of controls to cases
was used to divide both the case and control samples previously matched and used for probe
selection into training and testing cohorts for the SVM. Furthermore, the remaining unselected
samples from the EKD were also divided similarly (75% training, 25% testing) to allow for
comparison and testing of signature robustness against all of the samples in the EKD. Using the
e1071 R package, we performed 10-fold cross validation to determine hyperparameters optimal
for episignature classification. In this process, the training set was divided into ten folds by
random assignment, where the first nine are used for training, and the last used for testing the
accuracy of the model. The mean accuracy over all rounds was then calculated, and
hyperparameters with the best performance by this metric were selected. The model provides a
score ranging from 0-1 for each subject, representing the model’s confidence in predicting
whether the subject has a DNA methylation profile similar to the ADNP-BIS probe set or not.
Conversion of these SVM decision values was done using Platt’s scaling method [19,20], and the
class obtaining the greatest score determined the predicted phenotype. A classification as ADNPBIS was made when a sample received the greatest score for that class (normally greater than
0.5). Finally, the model was applied to both a training set of a large cohort of individuals with
clinical and molecular diagnoses of neurodevelopmental disorders, as well as a group of healthy
controls to determine its effective specificity.
VALIDATION OF CLASSIFICATION
To ensure the model is not susceptible to the batch structure of the methylation
experiment, the classifier was applied to samples assayed on the same batch as the cases used for
training. Using methylation data from individuals without a confirmed diagnosis of ADNP-BIS
within the EKD assayed on the same microarray chip as case samples, methylation profiles were
modeled to ensure the classifier is not confounded by technical artifacts unique to the given
microarray. Specificity was determined by supplying a large number of DNA methylation arrays
from unaffected subjects to the model. To further assess the specificity of the ADNP-BIS
classifier relative to other neurodevelopmental disorder we applied it to cases with other patient
cohorts exhibiting distinct episignatures within the EKD.
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RESULTS
DETECTION AND VERIFICATION OF A SHARED EPISIGNATURE FOR ADNP-BIS
PATIENTS
DNA methylation profiles from the peripheral blood of 15 individuals with confirmed
clinical and molecular presentations of BIS syndrome and 10 individuals classified as ADNP
cases with variants within the bipartite nuclear localization domain, were used to derive the
episignature. Sample filtering steps were performed to measure sample quality, sample type, and
sample’s clustering patterns (samples clustering with controls based on preliminary assessment
are excluded), however no samples required removal . Samples had fewer than 1000 failed
probes and passed quality control requirements. Comparisons were carried out, matching ADNPBIS samples with age, sex and batch-matched controls at a ratio of 4:1 (4 matched controls for
each case sample).
Cases showed significant differences in methylation patterns of 164 probes, which are
visualized using a volcano plot (See Figure 5-1A). Probes with a minimum methylation
difference of 5% between the two cohorts, and a multiple testing corrected p value of <0.01
(limma multivariable regression modeling) were used for the episignature. P values were
adjusted for blood cell type composition to ensure comparability between heterogeneous
peripheral blood sample sources. MDS and heatmap models showed significant overlap in
clustering patterns between the ADNP and BIS cases, with all 25 cases receiving high scores in
the classifier (See Figures 5-1B, 5-1C, and 5-1D), representing the significant degree of overlap
between these conditions. Hierarchical clustering and multiple dimensional scaling (MDS)
demonstrate that the selected probeset strongly separates cases and controls (See Figure 5-1B).
Cross-validation using ADNP-BIS samples was performed to validate the sensitivity of the
episignature, showing in each case that the remaining testing samples clustered with the other
ADNP-BIS samples, and segregated from the controls (See Supplementary Figure 5-1).
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COMPARATIVE ANALYSIS OF EPISIGNATURES
Plotting ADNP-BIS samples alongside other ADNP variants in the central domain of the
protein, not associated with the ADNP-BNL domain, showed distinct clustering of BIS samples,
with some minor overlap with the ADNP-BNL domain variants with other ADNP samples in the
MDS model (Figure 5-2A). Conversely, plotting ADNP-BIS samples alongside ADNP variants
in the terminal domain of the protein (HVDAS_T), not associated with the ADNP-BNL domain,
showed methylation profiles seen in the ADNP-BIS cohort do not match those seen in the
HVDAS_T samples (Figure 5-2B). Similarly, plotting ADNP-BIS samples alongside
SMARCA2 associated BAFopathy-NCBRS cases, showed methylation profiles seen in the
ADNP-BIS cohort do not match those seen in the BAFopathy-NCBRS samples (Figure 5-2C).
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Figure 5-1. ADNP-BIS Episignature Models A. Bimodal distribution plot of mean methylation difference vs -log p-value for each probe,
represented as circles on the plot. Probes highlighted in red indicate the probes chosen following preliminary analysis, wherein the most highly
differentiated probes with statistically significant p-values are selected for representation B. Multidimensional scaling plot representing the
dimensions of variation in methylation signal intensity at informative CpG identified for training using ADNP-NBL and BIS cases. Represents
comparisons of ADNP-NBL and BIS patients against the age and sex matched controls from the EKD. Cases marked in red represent ADNPNBL cases, while orange represent BIS cases, blue indicate Control (training) cases with no phenotypic or genotypic presentation of either case
group, including samples with confirmed presentation of other syndromes. Variant labels are noted on each sample. C. DNA methylation signal
intensity plot comparing confirmed BIS syndrome patients and ADNP-NBL patients against training controls consisting of age and sex matched
controls from the episign knowledge database. Samples are sorted by hierarchical clustering using ward’s method. Cases marked in red atop the
figure represent ADNP-NBL cases, while orange represent BIS cases, blue indicate cases with no phenotypic or genotypic presentation of either
case group, including samples with confirmed presentation of other syndromes. D. SVM classifier model for ADNP-NBL and BIS cases. Each
sample receives scores for the probability of having a DNA methylation profile similar to cases as compared to controls. Higher value on Y axis
indicates that a sample presents a methylation profile more similar to cases compared to controls. All case samples used for probe selection
(n=24) received high scores (>0.95), one ADNP associated HVDAS C sample received an elevated score (0.43), while the remaining samples
within the episign knowledge database received low scores <0.05)
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Figure 5-2. Plotting Additional Sample Types onto ADNP-BIS episignature Models
A. Multidimensional scaling plot representing the dimensions of variation in methylation signal intensity at informative CpG identified for
training using ADNP-NBL and BIS cases. Represents comparisons of ADNP-NBL and BIS patients against the age and sex matched controls
from the EKD as well as central domain ADNP variant associated HVDAS_C cases which were not included in probe selection. Cases marked in
red represent ADNP-NBL cases, while orange represent BIS cases, green indicate HVDAS_C cases that involve variants outside of the bipartite
nuclear localization domain, and blue indicate Control (training) cases with no phenotypic or genotypic presentation of either case group,
including samples with confirmed presentation of other syndromes. B. Multidimensional scaling plot representing the dimensions of variation in
methylation signal intensity at informative CpG identified for training using ADNP-NBL and BIS cases. Represents comparisons of ADNP-NBL
and BIS patients against the age and sex matched controls from the EKD as well as terminal domain associated ADNP variant HVDAS_T cases
which were not included in probe selection. Cases marked in red represent ADNP-NBL cases, while orange represent BIS cases, green indicate
HVDAS_T cases that involve variants outside of the bipartite nuclear localization domain, and blue indicate Control (training) cases with no
phenotypic or genotypic presentation of either case group, including samples with confirmed presentation of other syndromes. C.
Multidimensional scaling plot representing the dimensions of variation in methylation signal intensity at informative CpG identified for training
using ADNP-NBL and BIS cases. Represents comparisons of ADNP-NBL and BIS patients against the age and sex matched controls from the
EKD as well as SMARCA2 associated BAFopathy-NCBRS cases which were not included in probe selection. Cases marked in red represent
ADNP-NBL cases, while orange represent BIS cases, green indicate BAFopathy-NCBRS cases that involve variants outside of the bipartite
nuclear localization domain, and blue indicate Control (training) cases with no phenotypic or genotypic presentation of either case group,
including samples with confirmed presentation of other syndromes.
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DEVELOPMENT OF AN MVP SCORE
ADNP-BIS subjects, matched controls, and a number of samples from syndrome cohorts
previously established in the EKD were used for training a model to test the sensitivity and
specificity of the episignature created through previous probe selection steps. The MVP score
was set to generate a single score from 0-1 for each sample, with 1 being a methylation pattern
highly similar to the case samples, and 0 being a methylation pattern highly similar to matched
control samples. The class obtaining the highest score determined the episignature classification.
These results were validated by a series of tests to validate their reliability. While all ADNP-BIS
samples used for probe selection (not including the 4 BIS samples removed in previous rounds of
analysis) received high scores close to 1, control scores remained near 0, indicating the classifier
has a high sensitivity for the detection of the shared ADNP-BIS episignature (See Figure 5-6,
and Supplemental Figure 5-S2). Furthermore, specificity of the classifier was tested by providing
it with a large number of subjects with confirmed diagnosis of an NDD of various types,
including trinucleotide repeat expansion abnormalities, imprinting defect disorders,
BAFopathies, Mendelian disorders of the epigenetic machinery, down syndrome as well as
subjects with nonsyndromic autism spectrum disorders. The vast majority of EKD samples,
including the ADNP variant associated episignatures for the central and terminal domain
Helsmoortel Van Der AA syndome (HVDAS_C, HVDAS_T), were classified as being highly
similar to controls using the ADNP-BIS classifier, confirming its efficacy as a sensitive and
specific model for the identification of the shared methylation profiles of BIS and ADNP-BNL
cases. One HVDAS C case, involving an ADNP frameshift mutation further downstream from
the bipartite nuclear localization domain received an elevated score (0.43), possibly due to the
close proximity to the domain of interest and having the same variant type. Investigations of this
case did not reveal any evidence of blepharophimosis phenotype.
DISCUSSION
DNA methylation analysis has been used in the analysis of an expanding number of
neurodevelopmental disorders (NDD), implicating the changes in methylation distribution to the
underlying biology of various complex mendelian conditions. Over sixty NDDs have been
identified which exhibit distinct alterations in DNA methylation, referred to as episignatures,
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now used for diagnostic clinical testing [21-32]. This process usually begins with genetic variant
information, which is then used to inform the selection of samples for episignature discovery at
various levels of detail, including gene level, domain specific episignatures and variant type
specific signatures, as well as comparisons across cohorts with specific clinical features. Rarely,
though growing in incidence as the understanding of phenotypic-epigenetic interactions
increases, the process begins with the identification of clinical features that comprise a single
disorder, or multiple. In this work, we expand upon the analytical framework developed via the
continuing work of the EpiSign project, seeking to describe a novel method of identifying an
episiganture for a specific subset of patients with a common phenotype. A common characteristic
of blepharophimosis was noted in a subset of ADNP patients with frameshift mutations within
the bipartite nuclear localization signal domain of the ADNP gene, required for localization to
the nucleus, as well as cellular export and import signals, indicating that this gene has roles
throughout the various cellular compartments. [33-36]. These patients matched the
blepharophimosis phenotype commonly observed in Blepharophimosis intellectual disability
syndrome (BIS), which are associated with variants in SMARCA2. Despite being associated
with variants in two distinct molecular entities, these samples were shown to have a common
methylation profile when analyzed, providing evidence towards potential shared regulatory
pathways which contribute to the shared blepharophimosis. Although the exact mechanism
through which ADNP-BNL mutations lead to the observed phenotype is not fully realized at this
point, it seems to be specific to the effects of this particular truncation in the ADNP protein [7].
This is further supported by the findings in the 2014 paper from helsmoortel et al [37], that found
that despite these frameshift mutations resulting in truncated mRNA transcripts, at least 4
patients were observed to have these transcripts escape nonsense mediated decay. As a result,
lacking the ability to enter the nucleus without the BNL domain [38,39], these proteins could
exert effects elsewhere within the cell, a capability which has been show in further studies of
ADNP’s function in cytoplasmic and extracellular compartments [3,39]. Furthermore, given the
interactions observed between ADNP and SMARCA2 [4], it is possible that the chromatin
remodeling activities of SMARCA2 are at least somewhat reliant on interactions with the ADNP
protein, as variants lacking in the BNL domain and unable to transport into the nucleus of the
cell for chromatin remodeling activity in tandem with SMARCA2’s BAF complex [4,5,11,37],
regulating key stages of embryonic development, potentially resulting in similar phenotypes to
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those observed in patients with SMARCA2 mutations. ADNP’s effect on the embryonic
development stage has been shown in mouse knockout models, wherein the importance of
ADNP was demonstrated with embryonic lethality in complete deficiency models, as well as
significant evidence of chromatin-immunoprecipitation.[4, 33].
Although the blepharophimosis phenotype was not observed in all patients carrying
ADNP-BNL domain disrupting variants, the presence of this phenotype, uncharacteristic of the
presentation seen in the vast majority of other ADNP related HVDAS patients, provided a novel
path towards the derivation of an episignature. Despite a large number of samples recruited for
testing after the identification of blepharophimosis in the original cohort not presenting with
blepharophimosis, the DNA methylation profiles exhibited by these patients continued to match
those seen in SMARCA2 associated BIS patients, providing a novel situation wherein two
distinct molecular entities that are not paralogous, or part of a common protein complex showed
common DNA methylation changes. [4,11]. Further analysis of the changes in DNA methylation,
in tandem with gene expression studies could reveal the source of the variation in phenotype
observed despite the seemingly common variant effect observed in the ADNP cohort.
Furthermore, studies into the exact interactions of the SMARCA2 and ADNP genes will provide
insights into the molecular pathways that dictate their apparent epigenetic and phenotypic
overlap.
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SUPPLEMENTAL FIGURES

Supplemental Figure 5-1. Multidimensional scaling plot for cross validation, representing the
dimensions of variation in methylation signal intensity at informative CpG identified for the
shared SMARCA2-ADNP signature. Represents comparisons of the similarity of methylation
profiles of SMARCA2-ADNP patients, with those chosen for probe selection marked in blue,
and the cross-validation sample marked in red. Control samples (shown in green) include cases
without a confirmed phenotypic and/or genotypic presentation of SMARCA2-ADNP, including
samples with confirmed presentation of other syndromes.
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Supplemental Figure 5-2: ADNP BIS MVP Score ROC Graph: Receiver operating characteristic
curve demonstrating the sensitivity and specificity of the generated MVP scores for the ADNP-BIS cohort and the
remaining EKD samples used for training.
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CONCLUSIONS
This chapter, concerning the identification of a common episignature between two
distinct molecular entities, each associated with their own respective set of NDDs, on the basis of
a shared dysmorphology presents an interesting proposition for the future of episignature
discovery. Within the scope of the EpiSign project, a large number of NDDs have received
highly sensitive and specific episignatures that are capable of differentiating these conditions on
the basis of their DNA methylation profiles. In the vast majority of cases, this process began with
the identification of genomic information, with chromosomal abnormalities, gene variants, and
variant location being used to sort and provide supervised grouping of samples for the SVM
based classifier. This approach led to a large number of gene specific episignatures, as well as
interesting cases wherein episignature assessment led to the derivation of additional
stratifications within groups of samples that have had their own unique DNA methylation
profiles. In the case of HVDAS, associated with variants in the ADNP gene, localization of the
variants within the central or terminal regions of the gene sequence provided two distinct
episignatures [8], and even within this thesis, my third chapter concerning the identification of a
domain specific episignature for K2BNDD provided further evidence of the relatively
unexplored depths of potential episignatures guided by genomic information. With the success of
this approach, as well as the constant emergence of phenotypic trends within various
episignatures discussed within this work, it seems pertinent to discuss the possibility of
phenotype led discovery of episignatures as well.
Led by the observations of Dr Nicola Brunetti and his lab at the Telethon Institute of
Genetics and Medicine, identifying the uncharacteristic appearance of blepharophimosis
phenotypes within a subset of ADNP patients, I began to analyze these samples in tandem with
SMARCA2 associated SMARCA2 variants. As a result, I identified a highly sensitive and specific
episignature that can distinguish samples from both genetic origins, seemingly tied by the
presence of a shared phenotype, opening the door to future work in phenotype led discovery of
shared functional characteristics. Within ClinVar, a large repository of ADNP variants are
classified as variants of unknown significance (56/264, 21%, see Appendix Table 5), which can
potentially be resolved through the episignature analysis pipeline into either the ADNP central or
terminal region signatures, as well as the newly described ADNP-SMARCA2 shared episignature.
Furthermore, SMARCA2 variants also have a large number of variants currently classified as
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VUSs (138/756, 18%, See Appendix Table 6) which can be similarly reclassified using the BAF
complex or shared ADNP-SMARCA2 episignature. The use of functional information such as
DNA methylation is key to the better understanding of these variants which may include effects
in non-coding regions, or splice sites. These are difficult to interpret using traditional genome
based analysis methods which often depend on disturbance of protein structure or stability to
indicate pathogenicity. Through episignature assessment, we can provide a better pathway to
diagnosis when we compare the DNA methylation profiles to assess patterns of overlap in gene
expression.
Although the phenotype observed in the preliminary cohort of patients was not shared by
several of the new subjects used for deriving the episignature, the DNA methylation pattern
derived from this cohort was shared between all subjects. The complex variability associated
with NDDs, and gene regulatory networks can introduce a large amount of difficulty into the
derivation of phenotype based biomarkers, but nonetheless, this study was propagated by
phenotypic findings first, setting it apart from the remaining projects described in previous
chapters. This type of discovery is rapidly gaining prominence in the field of molecular
diagnostics, with various deep phenotyping databases providing significant increase in the ability
to analyze and corroborate the functional evidence derived from analysis of various non-coding
regions of the DNA, expression profiling, and phenotype ontology. In the future, I believe it will
be essential to investigate common phenotypes between disorders, on the basis of functional
information such as DNA methylation profiling, which can better account for the complexity
observed in these conditions. Further investigations of episignatures through the lens of
phenotypic data will assuredly provide novel avenues of understanding into the complex
interactions of the genome, epigenome and ensuing phenotype observed in patients. By
continuing to provide highly robust biomarkers such as the one described in this work to the
expanding landscape of functional annotation databases will allow for disentanglement of the
vast web of molecular interactions that dictate human health.
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Chapter 6: Conclusions

While there have been major advancements in the understanding of human genetic
sequence, , our ability to sequence the entirety of genomic DNA has fallen short of providing
the comprehensive blueprint of the molecular etiology of hereditary neurodevelopmental
disorders. . Moving beyond the one-gene one-disease paradigm [1], researchers have
demonstrated that genetic conditions can be complex, resulting from multifactorial genetic and
environmental causes, with confounding characteristics of incomplete penetrance, variable
expressivity, and overlapping phenotypes.. Global population prevalence of genetic conditions is
2-3% [2], Clinicians and researchers using a myriad of tools from chromosomal microarrays to
whole exome sequencing have attempted to resolve these conditions and provide effective
diagnosis to those living with neurodevelopmental disorders.. Presently, conclusive diagnosis
through NGS in both WES and targeted gene panels provide conclusive diagnosis in
approximately 15-35% of cases [3-8], which despite vast improvements over previous methods,
still means that a significant majority of persons living with neurodevelopmental disorders are
not receiving a conclusive diagnosis. Often, a so-called diagnostic journey must be undertaken to
enable diagnosis, involving extensive molecular testing, clinical phenotypes, and surveys of
behavior and medical history, which can frequently result in inconclusive findings, leaving
patients and their families seeking answers. Development of new diagnostic tools is necessary to
ensure that those living with NDDs receive the accurate diagnosis and level of care they deserve.
As such, my research has focused on the assessment of effectiveness of DNA methylation
profiling in NDDs and my findings demonstrate it to be a powerful method for increasing the
diagnostic yield in this patient population.

Epigenetics and DNA methylation are inherently tied to the function and expression of
the genome, uniting the underlying biology dictated by our sequence of nucleotides, with the
ensuing phenotypic presentation that we observe as phenotypes[9-12]. Epigenetic studies, such
as profiling of patients global DNA methylation patterns, provide a functional link between
disruptions of the genetic sequence and their downstream effects on chromatin.. Our lab has
developed approaches for DNA methylation profiling to improve the diagnosis and
understanding of complex neurodevelopmental disorders. This work has provided effective
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biomarkers for over 70 conditions. The so-called episignatures, representing DNA methylation
profiles at identified CpG dinucleotides which are unique to the patients with specific genetic
disorders [13-23]. Methylation profiling is enabled by comparing data from specific patient
cohorts to the EpiSign knowledge database which currently includes >10,000 methylation
profiles across a growing number of genetic conditions allowing for the development of both
highly sensitive, and specific biomarkers for these disorders. Episignatures can be used for the
reclassification of variants of unknown significance, as they represent functional biological
evidence of pathogenicity, as DNA methylation profiles which match the derived episignature
imply common gene disruption. This enables molecular diagnosis in the absence of traditional
genetic sequence findings [21,24,25].
Our database and catalog of episignatures has grown at an increasing pace since its
inception, as has our understanding of the complexities of DNA methylation profiles in relation
to both phenotype and genotype [13,23, 26, 27]. In my Episignatures are not always a linear one
biomarker to one disorder phenomenon, but instead have a branching network of potential uses
and outcomes, correlating with the gene level disruptions [14,15], as well as sub-gene level
associations such as domain specific episignatures [28]. Furthermore, common episignatures can
be associated with multiple genes, belonging to common molecular pathways or gene networks, ,
as well as shared phenotypes across distinct genetic disorders. My work describes the illustration
of an “Episignature Roadmap” detailing the consequences of DNA methylation perturbations in
relation to NDDs in a variety of genomic and phenotypic contexts.

In the second chapter of this thesis I described the identification of a gene-specific
episignature for Gabriele De Vries syndrome associated with YY1 transcription factor A high
level of sensitivity and specificity was found for this episignature, with all samples with the
exception of one mapping consistently throughout each model, resulting in high MVP scores
(>0.8) in the final classifier model, while the remaining samples within our EKD did not exceed
an MVP score of 0.25, simultaneously demonstrating a high level of sensitivity and specificity.
This was further enforced through a series of leave one out cross validation assessments, where
despite the removal of each sample one by one from case cohort training, samples still received
high MVP scores, indicating that the model is not sensitive to changes in the cohort composition,
and indeed represents an effective method of identifying GADEVs patients through DNA
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methylation. The exceptional case, referred to as YY1-atypical did not fit the episignature
derived for this case cohort adding an interesting level of complexity, and indicates avenues of
future research. The YY1-atypical case presented a distinctly different methylation profile when
compared to other case samples, and upon further assessment of the clinical features, this patient
was identified as having a striking atypical presentation of the disorder, with symptoms of
overgrowth not seen in the rest of the cohort. Furthermore, the unique variant in the YY1-atypical
case was not seen in the remainder of the YY1 cohort, indicating that there is a potential
additional signature tied to phenotypic differences, and domain or variant specific DNA
methylation changes. As such, this chapter provides an example of an effective gene level
episignature, while also exemplifying the necessity of assessing other patients with YY1
mutations for further substratification according to differences in genetic and phenotypic data.
In the third chapter, I continued to explore the possibilities provided by episignature
assessment through the delineation of a KDM2B- related episignature for an as of yet unnamed
disorder we have termed KDM2B related neurodevelopmental disorder, or K2BNDD. Expanding
on the presence of additional subsignatures hinted at in the atypical GADEVs case in the
previous chapter, I discovered not only a sensitive and specific biomarker for patients with
variants the the KDM2B sequence, but an additional sub-signature specific to a key domain in the
KDM2B sequence. Disruption of the CxxC DNA binding motif of the KDM2B gene showed
large changes in methylation not seen in the remainder of the KDM2B cohort, and when
assessed, showed distinct clustering of these samples from both the matched controls and other
KDM2B samples. This result was mirrored in the MVP classifier, with CxxC samples receiving
high scores (>0.8) while the remaining samples scored very low, close to 0, indicating a very
high level of specificity for the methylation changes observed. Additionally, the subsignature
provided evidence of change at the phenotypic level as well, with CxxC patients corresponding
to significant increases in the incidence of congenital anomalies and organ malformations, not
seen in other cases. This demonstrates the effectiveness of these stratified episignatures, to
enable the diagnosis at gene-level, while providing domain specific biomarkers that can explain
differences in phenotype at a higher level of resolution.

In the fourth chapter, I shifted my focus from stratifying signatures from a single genetic
origin, to assessing the effectiveness of comparing genes of multiple distinct origins with
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overlapped episignatures. The first example of this involves the KAT6A/KAT6B homologues. I
demonstrated the existence of shared methylation profiles between these paralogous genes,
which are associated with 3 distinct neurodevelopmental disorders.. These three disorders,
KAT6A syndrome, GTPTS, and SBBYSS provided interesting insights into the effects of
common genetic origin and function in relation to their overlapped DNA methylation profiles
The models showed a significant amount of overlap in differentially methylated probes,
correlated with the shared phenotype observed across these disorders. Samples in each of the
case groups clustered more closely with one another than relative to the age and sex matched
controls. Additionally, these disorders shared a large proportion of the differentially methylated
genes. Interestingly, KAT6A syndrome and GTPTS shared a significantly higher number of
differentially methylated genes (n=11) when compared to those shared between KAT6A
syndrome and SBBYSS (n=1), which could explain some of the trends in shared phenotypes in
these disorders. For example, in both GTPTS and KAT6A syndrome, HEY2 , a gene important in
heart development was differentially methylated, potentially explaining the increased frequency
of heart anomalies in these patients groups (KAT6A syndrome; 53%, GTPTS; 65%) as compared
to SBBYSS (38%) which did not exhibit differential methylation in this gene. These shared
methylation profiles also required a customized strategy in order to derive a specific molecular
classifier. Including the KAT6B samples to the training control cohort, enabled development of
a specific classifier with full differentiation of the KAT6A syndrome samples. Hence, even in the
presence of shared genomic, epigenomic and phenotypic features this approach allowed me to
develop episignatures with a high level of sensitivity and specificity.
The fifth chapter, highlights the shared episignature in patients with ADNP and
SMARCA2 mutations. Here, I explored the effectiveness of a dysmorphology-first approach to
the discovery of an episignature. Common clinical features of blepharophimosis were observed
in a cohort of patients with genetic variants in two genes with unrelated functions, ADNP and
SMARCA2. Although blepharophimosis is commonly associated with patients with SMARCA2
variants in association with Blepharophimosis and Intellectual Development syndrome (BIS), it
is rare to see in patients with ADNP variants commonly associated with Helsmoortel Van Der
AA syndrome. As a result, by assessing patients with the common clinical phenotypesI aimed to
assess evidence of a phenotype-specific DNA methylation episignature that may be common
between these two distinct patient groups. I demonstrated a common, highly sensitive and
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specific episignature biomarker capable of delineating these patients with a common
blepharophimosis phenotype, highlighting the use of such an approach. This provided further
evidence that DNA methylation patterns can be linked to both the genomic and phenotypic
presentations across different genetic disorders, which may affect common molecular pathways.
Overall, my work demonstrates a strong correlation between genetic, epigenetic and
phenotypic patterns observed in patients with genetic neurodevelopmental disorders, along with
providing effective molecular diagnostic biomarkers. Changes in DNA methylation reflect the
intricate network of the underpinning genetic changes and the consequent phenotypes. Several
endeavors are underway already in various laboratories attempting to increase our understanding
of the complex networks of interactions between these three levels of diagnostic evidence,
providing powerful new databases that integrate variant classification information,
transcriptomics, and phenotypic information. The ENCODE project [29] has provided a
searchable database of extensive information of various methods of assessing molecular biology,
including gene expression analysis through assessment of active chromatin states, DNA
methylation levels, and RNA binding, alongside variant information to provide deeper insights
into the interaction of these various molecular mechanisms. This work has provided extensive
improvements to our understanding of the functional elements of the genome including DNA
methylation and histone modifications, and their effects on chromatin accessibility to modulate
gene transcription, transcription factor binding networks, and non-coding RNAs [30,31,32]. This
database provides a powerful refutation of the claim that the majority of our DNA is “junk”
leftover from evolutionary pressures, and instead a vast sea of information for the functional
regulation of the transcribed genome. EpiXCan [33,34] provides similar investigative power,
assessing the transcriptome in relation to gene-trait associations. This database incorporates
epigenomic data alongside variant information, gene expression, and regulatory annotations to
provide a better understanding of transcriptomics, facilitating combination of large existing
databases of genetic variation in coding regions, alongside less well researched non-coding
regions of DNA. Through focusing on trait-associated biological pathways, this project
exemplifies the transition towards a more holistic view of molecular interactions, beyond the
classical one-gene-one disease paradigm... The Human Phenome Ontology (HPO) takes this
work one step further. It includes a standardized vocabulary of phenotypic abnormalities
associated with a specific genetic diseases that can be used by researchers to inform
185

understanding of disparate disorders through a phenotype based view of pathology, by
correlating genetic conditions on the basis of their common clinical presentations related to their
ontological terms [35]. The HPO database synthesizes model organism data, WGS/WES data,
and phenotype ontology terms to network their various interactions, potentially explaining the
common etiology of complex disorders such as NDDs. This “deep-phenotyping” approach, is a
powerful new tool in the assessment of rare complex disorders, and has been adopted by a
number of organizations in their search for pathways that relate to disease etiologies. This work
includes advances in phenotype annotations for various conditions and areas of research, such as
epilepsy disorders, mitochondrial DNA - phenome correlations, neurology, immunology and
even expansion into phenome ontology traits for model organisms such as mouse and zebra fish
[36,37,38,39]. Creation of large scale databases of standardized phenotypic characteristics,
paired with extensive genome and epigenomic data aids in the molecular diagnosis, but can also
be used to further develop ontology terms and their associated disease algorithms, continually
self-refining, similar to how our own EKD operates. As such, the creation of analytical
frameworks through which we can guide the identification and analysis of these complex
disorders and the traits that cause them is paramount in ensuring that we can effectively improve
our ability to diagnose persons living with these conditions, as well as better understand the
underlying biology which unites them.

Numerous other projects have begun addressing additional concerns associated with
transcriptomic reliability and translatability. First and foremost, the effects of different tissue
types on the gene expression networks associated with different conditions is well established,
with epigenetic patterning such as DNA methylation differing extensively from tissue to tissue
within a single organism, in relation to the cell lineage specification of gene expression that
results in the various cell types within our bodies. [40,41,42,43]. Within my research I focused
on peripheral blood, which has been shown to be an effective substrate for the identification of
DNA methylation profiles in relation for disorders where primary clinical phenotypes affect
alternate tissues, namely CNV tissues in the context of the NDDs [25, 44,45, 46] . However it
can be questioned whether or not gene expression profiles from can de reliant in detecting
disorder specific episignatures. Variations in the epigenome arising from germline disruptions in
early embryonic stages are propagated through cell lineage specification and represented across
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multiple tissues in the developed organism [18, 47], arguing that the epigenetic changes in
peripheral blood may represent effective surrogates for the similar disruptions in other tissues.
Analysis of tissue specific epigenetic changes has also been carried out by several entities,
including the gene ORGANizer project and the Genotype-Tissue Expression (GTEx) database.
[48,49]. The Gene ORGANizer project has aided in assessing not only the transcriptomic,
genomic and phenotypic expression of traditional model tissues such as peripheral blood, tumor
samples, or fibroblasts, but more disease relevant tissue sources, including those which are more
difficult to obtain such as brain or CNV tissue, or those which are rarely sampled from (bone,
larynx, spinal cord etc) [49]. This is further complicated by the fact that many tissues can be
assessed at different developmental stages, taken post mortem, and extracted from particular
sections of a given organ.. Gene ORGANizer makes use of several of the databases I have
previously mentioned, including use of HPO for gene-phenotype associations, as well as
ClinVar, and Uniprot for gene-disease associations. In attempting to improve this relatively
unexplored aspect of confounding factors in gene expression analysis, the Gene ORGANizer
project seeks to represent phenotype based associations in relation to genomic traits in a wide
range of human tissues, connecting the expression profiles for the entirety of the human body.
In summary, my research focused on integration of genetic and phenotypic features to
establish the epigenomic correlations and develop diagnostic biomarkers. I hypothesized that
DNA methylation episignatures can be used to provide highly robust biomarkers for the
classification of neurodevelopmental disorders, and further stratification of these signatures can
identify key epigenetic patterns that relate to the phenotypic and genotypic variations seen in
patients with these disorders. To demonstrate this, I identified specific aims related to the
derivation of DNA methylation episignatures in a variety of molecular contexts, defining
syndrome specific, and domain specific episignatures, as well as signatures in the context of
homologous genes, and distinct disorders with shared phenotypic characteristics. In chapter 2, I
hypothesized the existence of a gene specific episignature for Gabriele De Vries Syndrome.
Demonstrated through various models, I found that the methylation patterns displayed by
patients with YY1 disruptions were shared across the cohort, enabling sensitive and specific
identification of this disease group. In chapter 3, analysis of K2BNDD was carried out to derive
a disorder specific episignature, as well as an investigation into the domain specific trends in
DNA methylation caused by disruption of the CxxC DNA binding domain of KDM2B. My
187

results demonstrate a robust signature for the K2BNDD cohort, as well as methylation profiles
for patients with disruptions of the CxxC domain, distinct from the remainder of the cohort.
Chapter 4 demonstrated the derivation of an episignature in the context of the gene homologues,
KAT6A and KAT6B. This provided a sensitive and specific episignature, even in the presence of
highly overlapping molecular and phenotypic characteristics, as well as highlighting potential
pathways which explain these shared characteristics. Finally, chapter 5 discussed the assessment
of two molecularly distinct disorders with a shared phenotype, identifying common DNA
methylation changes between specific ADNP mutations and SMARCA2 associated BIS cases,
demonstrating the effectiveness of episignatures in More focused analyses, such as domain
specific investigations, or the grouping of syndromes with disparate genetic origins, can be used
to demonstrate associations with common phenotypes. My work has provided effective
biomarkers that can enable shortening of the diagnostic odyssey in a number of genetic NDD
conditions, increasing diagnostic yield in the process. Whether it is beginning with gene-level
analysis, or phenotypic observations, distinct episignatures can be derived, revealing a network
of intricate molecular connections.
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APPENDICES
Appendix Table 1. Table of reported variants for YY1, retrieved from ClinVar databases
(https://www.ncbi.nlm.nih.gov/clinvar/?term=YY1%5Bgene%5D&redir=gene)

Name

Clinical significance (Last
reviewed)

GRCh37/hg19
14q32.2(chr14:100704697100706973)x0

Benign(Last reviewed: Dec 1, 2011) VCV000614478

GRCh37/hg19
14q32.2(chr14:100691178100706973)x1

Benign(Last reviewed: Dec 14,
2011)

VCV000614476

NM_003403.5(YY1):c.141G>C
(p.Glu47Asp)

Benign(Last reviewed: Dec 31,
2019)

VCV000716403

GRCh37/hg19
14q32.2(chr14:100704886100706973)x1

Benign(Last reviewed: Feb 16,
2012)

VCV000614479

GRCh37/hg19
14q32.2(chr14:100701417100717821)x1

Benign(Last reviewed: Oct 20,
2010)

VCV000614477

NM_003403.5(YY1):c.30C>T
(p.Ala10=)

Likely benign(Last reviewed: Dec
18, 2018)

VCV000743296

NM_003403.5(YY1):c.306G>A
(p.Glu102=)

Likely benign(Last reviewed: Dec
31, 2019)

VCV000795809

NM_003403.5(YY1):c.842+9T>C

Likely benign(Last reviewed: Jul 16,
2018)
VCV000759598

GRCh37/hg19 14q32.232.33(chr14:98051841107285437)x3

Likely pathogenic

VCV000395888

NM_003403.5(YY1):c.527G>A
(p.Gly176Asp)

Likely pathogenic(Last reviewed:
Dec 11, 2019)

VCV001029703

195

Accession

NM_003403.5(YY1):c.690dup
(p.Asp231fs)

Likely pathogenic(Last reviewed:
Dec 21, 2020)

GRCh37/hg19
14q32.2(chr14:100655021100742092)x1

Likely pathogenic(Last reviewed: Jul
10, 2019)
VCV000980621

NM_003403.5(YY1):c.1118A>G
(p.His373Arg)

Likely pathogenic(Last reviewed: Jul
7, 2020)
VCV000976756

NM_003403.5(YY1):c.1220A>G
(p.His407Arg)

Likely pathogenic(Last reviewed:
Jun 17, 2021)

VCV001184871

NM_003403.5(YY1):c.1015A>C
(p.Lys339Gln)

Likely pathogenic(Last reviewed:
Jun 9, 2017)

VCV000520982

NM_003403.5(YY1):c.550_551del
(p.Ser184fs)

Likely pathogenic(Last reviewed:
May 14, 2018)

VCV000545935

GRCh37/hg19 14q32.2Likely pathogenic(Last reviewed:
32.31(chr14:99737888-101847855) Nov 1, 2018)

VCV000625815

GRCh37/hg19 14q23.232.33(chr14:62493932107285437)x3

Pathogenic

VCV000397361

GRCh37/hg19 14q11.232.33(chr14:19794561107234280)x3

Pathogenic

VCV000395470

GRCh37/hg19 14q32.1332.31(chr14:95871795102457523)x1

Pathogenic(Last reviewed: Apr 1,
2021)

VCV001340262

GRCh38/hg38 14q24.332.33(chr14:73655772106879298)x3

Pathogenic(Last reviewed: Apr 30,
2010)

VCV000144518

GRCh38/hg38 14q24.332.33(chr14:77222795106879298)x3

Pathogenic(Last reviewed: Apr 5,
2012)

VCV000149176

196

VCV001331550

GRCh38/hg38 14q32.232.33(chr14:97938637106855263)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057085

GRCh38/hg38 14q32.1232.33(chr14:91455861106832642)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000058527

GRCh38/hg38 14q31.332.33(chr14:86094030106832642)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000058526

GRCh38/hg38 14q31.232.33(chr14:83912345106855405)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000058525

NM_003403.5(YY1):c.1096C>G
(p.Leu366Val)

Pathogenic(Last reviewed: Aug 17,
2018)

VCV000430619

NM_003403.5(YY1):c.1097T>C
(p.Leu366Pro)

Pathogenic(Last reviewed: Aug 17,
2018)

VCV000430618

NM_003403.5(YY1):c.1138G>T
(p.Asp380Tyr)

Pathogenic(Last reviewed: Dec 1,
2010)

VCV000430617

GRCh37/hg19 14q32.232.33(chr14:96829290107287663)x1

Pathogenic(Last reviewed: Dec 18,
2019)

VCV000929832

GRCh38/hg38 14q11.232.33(chr14:20043514106877229)x3

Pathogenic(Last reviewed: Dec 2,
2014)

VCV000155306

NM_003403.5(YY1):c.1124G>A
(p.Arg375Gln)

Pathogenic(Last reviewed: Dec 21,
2020)

VCV001331552

GRCh38/hg38 14q32.232.31(chr14:99930669101022599)x1

Pathogenic(Last reviewed: Dec 22,
2010)

VCV000154707

GRCh38/hg38 14q32.232.33(chr14:99831655106855263)x1

Pathogenic(Last reviewed: Dec 30,
2009)

VCV000144349

NM_003403.5(YY1):c.385del
(p.Asp129fs)

Pathogenic(Last reviewed: Feb 14,
2019)

VCV000817604

197

GRCh38/hg38 14q32.1232.33(chr14:92540983104863658)x3

Pathogenic(Last reviewed: Feb 16,
2011)

VCV000146638

GRCh37/hg19 14q11.132.33(chr14:19000422107289053)x3

Pathogenic(Last reviewed: Jan 1,
2013)

VCV000601776

GRCh38/hg38 14q11.232.33(chr14:20151149106855263)x3

Pathogenic(Last reviewed: Jan 14,
2011)

VCV000146230

NM_003403.5(YY1):c.690del
(p.Asp231fs)

Pathogenic(Last reviewed: Jan 14,
2021)

VCV001162319

GRCh37/hg19 14q11.232.33(chr14:19280733107287663)x3

Pathogenic(Last reviewed: Jan 5,
2017)

VCV000601777

GRCh37/hg19 14q11.2Pathogenic(Last reviewed: Jul 14,
32.33(chr14:20511673-107285437) 2015)

VCV000443977

NM_003403.5(YY1):c.1111C>T
(p.Arg371Cys)

Pathogenic(Last reviewed: Jul 19,
2019)

VCV001186721

GRCh38/hg38 14q32.232.33(chr14:97638520106855263)x3

Pathogenic(Last reviewed: Jul 30,
2009)

VCV000146074

NM_003403.5(YY1):c.535A>T
(p.Lys179Ter)

Pathogenic(Last reviewed: Jul 7,
2017)

VCV000430621

NM_003403.5(YY1):c.1030C>T
(p.Gln344Ter)

Pathogenic(Last reviewed: Jul 7,
2017)

VCV000430620

GRCh37/hg19 14q32.232.33(chr14:99794230107285437)x3

Pathogenic(Last reviewed: Jun 19,
2017)

VCV000688581

GRCh37/hg19 14q24.232.33(chr14:73750741107285437)x3

Pathogenic(Last reviewed: Jun 22,
2015)

VCV000442718

NM_003403.5(YY1):c.860_864del
(p.Ile287fs)

Pathogenic(Last reviewed: Jun 28,
2017)

VCV000432981

198

GRCh37/hg19 14q32.232.33(chr14:100661319107285437)x1

Pathogenic(Last reviewed: May 18,
2015)
VCV000443644

GRCh37/hg19 14q32.232.33(chr14:100575917107281934)

Pathogenic(Last reviewed: Nov 1,
2018)

VCV000625744

NM_003403.5(YY1):c.1040_1041in
sCGACGGACAACGGCTAGTTTAT
TTTTACTTGCAGCTTCAAAACCG
CCACCTTCCATTGCTTGTCCAGT
GATACGGAGACCTTCCTCGGCA
GCAAAACGAATCAATTCTGCTGT
ACG
(p.Thr348_Gly349insAspGlyGlnArg
LeuValTyrPheTyrLeuGlnLeuGlnAsn Pathogenic(Last reviewed: Nov 27,
ArgHisLeuProLeuLeuValGlnTer)
2019)

VCV001323777

GRCh38/hg38 14q32.232.31(chr14:99794337100944567)x1

Pathogenic(Last reviewed: Oct 1,
2010)

VCV000153097

GRCh38/hg38 14q32.232.33(chr14:99448012106850609)x3

Pathogenic(Last reviewed: Oct 20,
2010)

VCV000146615

NM_003403.5(YY1):c.468_483del
(p.Gly157fs)

Pathogenic(Last reviewed: Oct 23,
2020)

VCV000985223

GRCh37/hg19
14q32.2(chr14:100317190101012999)

Pathogenic(Last reviewed: Oct 26,
2018)

VCV000813332

GRCh37/hg19 14q11.232.33(chr14:19327823107287663)x3

Pathogenic(Last reviewed: Oct 31,
2014)

VCV000601778

GRCh37/hg19 14q32.1232.33(chr14:91969028107285437)x3

Pathogenic(Last reviewed: Oct 4,
2017)

VCV000687996

GRCh38/hg38 14q32.232.31(chr14:100262836102500697)x1

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000150931

199

GRCh38/hg38 14q32.1332.33(chr14:95524407106879501)x1

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000146793

NM_003403.5(YY1):c.1115C>G
(p.Thr372Arg)

Uncertain significance

VCV000091950

NM_003403.5(YY1):c.608A>G
(p.Lys203Arg)

Uncertain significance(Last
reviewed: Apr 7, 2021)

VCV001341784

GRCh38/hg38
14q32.2(chr14:100031805100808500)x1

Uncertain significance(Last
reviewed: Aug 12, 2011)

VCV000058202

NM_003403.5(YY1):c.514G>T
(p.Val172Phe)

Uncertain significance(Last
reviewed: Dec 15, 2018)

VCV001333898

GRCh37/hg19
14q32.2(chr14:98924025101159952)x3

Uncertain significance(Last
reviewed: Dec 6, 2017)

VCV000564133

NM_003403.5(YY1):c.562G>A
(p.Gly188Ser)

Uncertain significance(Last
reviewed: Feb 1, 2019)

VCV001029701

NM_003403.5(YY1):c.1032A>G
(p.Gln344=)

Uncertain significance(Last
reviewed: Feb 13, 2018)

VCV001032129

NM_003403.5(YY1):c.985G>C
(p.Glu329Gln)

Uncertain significance(Last
reviewed: Jun 22, 2021)

VCV001329515

NM_003403.5(YY1):c.-5C>T

Uncertain significance(Last
reviewed: Mar 5, 2019)

VCV001029702

GRCh37/hg19
14q32.2(chr14:100744400100910248)x3

Uncertain significance(Last
reviewed: May 15, 2018)

VCV000685016

NM_003403.5(YY1):c.1114A>G
(p.Thr372Ala)

Uncertain significance(Last
reviewed: May 18, 2018)

VCV001053301

200

NM_003403.5(YY1):c.207CCA[7]
(p.His80dup)

Uncertain significance(Last
reviewed: May 20, 2019)

VCV000931670

NM_003403.5(YY1):c.956C>T
(p.Thr319Ile)

Uncertain significance(Last
reviewed: Nov 10, 2017)

VCV000985282

NM_003403.5(YY1):c.1159_1161de Uncertain significance(Last
l (p.Phe387del)
reviewed: Nov 19, 2018)

VCV000985714

NM_003403.5(YY1):c.742C>T
(p.Pro248Ser)

Uncertain significance(Last
reviewed: Oct 17, 2019)

VCV001309573

NM_003403.5(YY1):c.193C>T
(p.His65Tyr)

Uncertain significance(Last
reviewed: Oct 25, 2019)

VCV000954755

NM_003403.5(YY1):c.1106A>G
(p.Asn369Ser)

Uncertain significance(Last
reviewed: Oct 25, 2021)

VCV001321254

NM_003403.5(YY1):c.202G>A
(p.Ala68Thr)

Uncertain significance(Last
reviewed: Sep 13, 2019)

VCV000996852

GRCh38/hg38
14q32.2(chr14:100236766100743192)x3

Uncertain significance(Last
reviewed: Sep 27, 2013)

VCV000152326

201

Appendix Table 2. Table of reported variants for KDM2B, retrieved from ClinVar databases
(https://www.ncbi.nlm.nih.gov/clinvar/?term=KDM2B%5Bgene%5D&redir=gene)

Name

Clinical significance (Last
reviewed)

Accession

NM_032590.5(KDM2B):c.3522G>T Benign(Last reviewed: Dec 31,
(p.Leu1174=)
2019)

VCV000784262

NM_032590.5(KDM2B):c.1287C>T
(p.Gly429=)

Benign(Last reviewed: Dec 31,
2019)

VCV000776760

NM_032590.5(KDM2B):c.3174C>T
(p.Asp1058=)

Benign(Last reviewed: Dec 31,
2019)

VCV000720488

Benign(Last reviewed: Feb 25,
NM_032590.5(KDM2B):c.397+7C>T 2018)

VCV000715044

NM_032590.5(KDM2B):c.1326C>T
(p.Gly442=)

Benign(Last reviewed: Jan 3, 2019) VCV000773689

202

NM_025126.4(RNF34):c.530G>A
(p.Arg177His)

Benign(Last reviewed: Jun 2, 2018) VCV000778448

NM_032590.5(KDM2B):c.3050G>A
(p.Arg1017His)
Likely benign

VCV000242896

NM_032590.5(KDM2B):c.1605C>T
(p.Pro535=)

Likely benign(Last reviewed: Aug
15, 2017)

VCV000714574

NM_032590.5(KDM2B):c.83_84del
(p.Thr28fs)

Likely benign(Last reviewed: Dec
29, 2019)

VCV000777690

NM_032590.5(KDM2B):c.56A>G
(p.His19Arg)

Likely benign(Last reviewed: Mar
29, 2018)

VCV000770235

NM_032590.5(KDM2B):c.3699C>A Likely benign(Last reviewed: Mar
(p.Ile1233=)
29, 2018)

VCV000738407

GRCh37/hg19 12q24.2224.33(chr12:117461902133841395)x3

Likely pathogenic(Last reviewed:
Nov 1, 2021)

VCV001330196

GRCh38/hg38
12q24.31(chr12:121471000122459718)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057611

GRCh38/hg38
12q24.31(chr12:121325874122505529)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057610

GRCh38/hg38
12q24.31(chr12:120504068122459718)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057609

GRCh38/hg38 12q24.2324.33(chr12:118165459133182322)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057207

GRCh38/hg38 12q24.2124.33(chr12:115131583133166920)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059821

GRCh38/hg38 12q24.3124.32(chr12:120718786127500215)x1

Pathogenic(Last reviewed: Aug 19,
2010)

VCV000154387
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GRCh38/hg38 12q24.3124.33(chr12:120697672133202490)x3

Pathogenic(Last reviewed: Aug 2,
2011)

VCV000148578

GRCh37/hg19 12p13.33q24.33(chr12:173787133777902)x3

Pathogenic(Last reviewed: Dec 2,
2014)

VCV000441983

GRCh37/hg19 12p13.33q24.33(chr12:621220133779118)x3

Pathogenic(Last reviewed: Jan 1,
2013)

VCV000613617

GRCh37/hg19 12p13.33q24.33(chr12:191619133777645)x3

Pathogenic(Last reviewed: Jan 5,
2017)

VCV000613610

GRCh37/hg19 12p13.33q24.33(chr12:173787-133777902)

Pathogenic(Last reviewed: Jul 14,
2015)

VCV000441984

GRCh38/hg38 12q24.2124.33(chr12:114268403133201316)x3

Pathogenic(Last reviewed: Jul 18,
2014)

VCV000155589

GRCh37/hg19 12q24.2324.33(chr12:120367241133777645)x3

Pathogenic(Last reviewed: Jun 27,
2016)

VCV000601434

GRCh37/hg19 12p13.33q24.33(chr12:1-133851895)x3

Pathogenic(Last reviewed: Sep 20,
2016)

VCV000268075

GRCh38/hg38 12p13.33q24.33(chr12:121271133196807)x3

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000150740

GRCh37/hg19
12q24.31(chr12:121441298122107345)x3

Uncertain significance

VCV000394621

GRCh37/hg19
12q24.31(chr12:121882818122666131)x1

Uncertain significance

VCV000395963

GRCh38/hg38 12q24.2324.31(chr12:119286893122638552)x3

Uncertain significance(Last
reviewed: Aug 12, 2011)

VCV000058232
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GRCh37/hg19
12q24.31(chr12:121899406122234599)x3

Uncertain significance(Last
reviewed: Jun 14, 2018)

VCV000815562

NM_032590.5(KDM2B):c.46C>T
(p.Arg16Ter)

Uncertain significance(Last
reviewed: Mar 29, 2016)

VCV000403007

GRCh37/hg19
12q24.31(chr12:121887337123386068)x3

Uncertain significance(Last
reviewed: Mar 3, 2021)

VCV001328462

GRCh37/hg19
12q24.31(chr12:121970346122287290)x1

Uncertain significance(Last
reviewed: May 1, 2021)

VCV001340538

GRCh37/hg19
12q24.31(chr12:121903358122234650)x3

Uncertain significance(Last
reviewed: May 16, 2018)

VCV000686313

GRCh37/hg19
12q24.31(chr12:121931513122059588)x1

Uncertain significance(Last
reviewed: May 3, 2018)

VCV000563906

Appendix Table 3. Table of reported variants for ADNP, retrieved from ClinVar databases
(https://www.ncbi.nlm.nih.gov/clinvar/?term=ADNP%5Bgene%5D&redir=gene)

Name

Clinical significance (Last
reviewed)

Accession

NM_001282531.3(ADNP):c.3236A>
G (p.Asn1079Ser)
Benign(Last reviewed: Apr 1, 2020) VCV001237918

205

NM_001282531.3(ADNP):c.2554A> Benign(Last reviewed: Apr 23,
G (p.Lys852Glu)
2018)

VCV000711607

NM_001282531.3(ADNP):c.1122C> Benign(Last reviewed: Aug 24,
T (p.Asn374=)
2020)

VCV001273051

NM_001282531.3(ADNP):c.108+12 Benign(Last reviewed: Aug 31,
4C>T
2018)

VCV001252442

NM_001282531.3(ADNP):c.1781A> Benign(Last reviewed: Dec 31,
G (p.Gln594Arg)
2019)

VCV000735993

NM_001282531.3(ADNP):c.2943G> Benign(Last reviewed: Dec 31,
T (p.Val981=)
2019)

VCV000712654

NM_001282531.3(ADNP):c.3278_3 Benign(Last reviewed: Feb 11,
279dup (p.Gly1094fs)
2016)

VCV000225224

NM_001282531.3(ADNP):c.2666G> Benign(Last reviewed: Jan 11,
C (p.Ser889Thr)
2021)

VCV000588325

NM_001282531.3(ADNP):c.2743G> Benign(Last reviewed: Jan 14,
A (p.Val915Ile)
2021)

VCV000252698

NM_001282531.3(ADNP):c.*50A>C Benign(Last reviewed: Jul 14, 2021) VCV001189012
NM_001282531.3(ADNP):c.2067C>
T (p.Gly689=)
Benign(Last reviewed: Jul 14, 2021) VCV000587808
NM_001282531.3(ADNP):c.202303G>A

Benign(Last reviewed: Jul 27, 2018) VCV001272506

NM_001282531.3(ADNP):c.108+23
3G>A
Benign(Last reviewed: Jul 3, 2018)

VCV001260648

NM_001282531.3(ADNP):c.2568C>
T (p.Val856=)
Benign(Last reviewed: Jul 3, 2018)

VCV000587839

NM_001282531.3(ADNP):c.909G>A
(p.Met303Ile)
Benign(Last reviewed: Jul 30, 2020) VCV001265979
NM_001282531.3(ADNP):c.2310T> Benign(Last reviewed: Jun 16,
C (p.Phe770=)
2021)
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VCV000747523

NM_001282531.3(ADNP):c.3058C> Benign(Last reviewed: Mar 29,
G (p.Gln1020Glu)
2021)

VCV001278536

NM_001282531.3(ADNP):c.535A>G
(p.Ile179Val)
Benign(Last reviewed: Mar 3, 2021) VCV001236127
NM_001282531.3(ADNP):c.801C>G
(p.Pro267=)
Benign(Last reviewed: Mar 5, 2020) VCV001294552
NM_001282531.3(ADNP):c.3095C>
G (p.Ser1032Cys)
Benign(Last reviewed: May 5, 2021) VCV001287084
NM_001282531.3(ADNP):c.833AG
A[1] (p.Lys279del)

Benign(Last reviewed: Nov 4, 2020) VCV000589741

NM_001282531.3(ADNP):c.108+28
0A>C
Benign(Last reviewed: Oct 5, 2018) VCV001262451
NM_001282531.3(ADNP):c.2076G> Benign(Last reviewed: Sep 14,
A (p.Lys692=)
2018)

VCV000587838

NM_001282531.3(ADNP):c.1163C>
T (p.Ala388Val)
Benign(Last reviewed: Sep 3, 2020) VCV001245671

NM_001282531.3(ADNP):c.1212G> Benign/Likely benign(Last reviewed:
C (p.Ser404=)
Apr 12, 2021)
VCV000588523

NM_001282531.3(ADNP):c.2317A> Benign/Likely benign(Last reviewed:
G (p.Lys773Glu)
Apr 13, 2020)
VCV000777582

NM_001282531.3(ADNP):c.2815A> Benign/Likely benign(Last reviewed:
C (p.Ile939Leu)
Apr 9, 2019)
VCV000722218

NM_001282531.3(ADNP):c.2782G> Benign/Likely benign(Last reviewed:
C (p.Asp928His)
Apr 9, 2021)
VCV000589370

NM_001282531.3(ADNP):c.1075A> Benign/Likely benign(Last reviewed:
G (p.Ile359Val)
Dec 14, 2021)
VCV000718326
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NM_001282531.3(ADNP):c.3185T> Benign/Likely benign(Last reviewed:
C (p.Ile1062Thr)
Dec 15, 2020)
VCV000713739

NM_001282531.3(ADNP):c.2971A> Benign/Likely benign(Last reviewed:
G (p.Met991Val)
Dec 29, 2017)
VCV000588466

NM_001282531.3(ADNP):c.2931A> Benign/Likely benign(Last reviewed:
G (p.Gly977=)
Dec 31, 2019)
VCV000589201

NM_001282531.3(ADNP):c.422_42 Benign/Likely benign(Last reviewed:
4dup (p.Ser141dup)
Dec 31, 2019)
VCV000434092

NM_001282531.3(ADNP):c.1752A> Benign/Likely benign(Last reviewed:
G (p.Gln584=)
Dec 5, 2020)
VCV000588836

NM_001282531.3(ADNP):c.3279C> Benign/Likely benign(Last reviewed:
T (p.Ala1093=)
Jan 27, 2020)
VCV000434090

NM_001282531.3(ADNP):c.2475G> Benign/Likely benign(Last reviewed:
T (p.Gly825=)
Jul 1, 2021)
VCV000587880

NM_001282531.3(ADNP):c.393G>A Benign/Likely benign(Last reviewed:
(p.Pro131=)
Nov 21, 2021)
VCV000588351

NM_001282531.3(ADNP):c.2749C> Benign/Likely benign(Last reviewed:
T (p.Pro917Ser)
Sep 23, 2020)
VCV000723547

Conflicting interpretations of
NM_001282531.3(ADNP):c.2617G> pathogenicity(Last reviewed: Apr 17,
T (p.Asp873Tyr)
2020)
VCV000434095

Conflicting interpretations of
NM_001282531.3(ADNP):c.2772G> pathogenicity(Last reviewed: Dec
C (p.Glu924Asp)
31, 2019)
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VCV000434093

Conflicting interpretations of
NM_001282531.3(ADNP):c.1063G> pathogenicity(Last reviewed: Dec 7,
A (p.Ala355Thr)
2017)
VCV000499359
NM_001282531.3(ADNP):c.3213_3
216del (p.Ser1071fs)
Likely benign

VCV000694537

NM_001282531.3(ADNP):c.2463C> Likely benign(Last reviewed: Apr 1,
T (p.Gly821=)
2021)

VCV000589626

NM_001282531.3(ADNP):c.3092G> Likely benign(Last reviewed: Apr 11,
A (p.Ser1031Asn)
2019)
VCV001336949

NM_001282531.3(ADNP):c.2352A> Likely benign(Last reviewed: Apr 17,
G (p.Arg784=)
2018)
VCV000740826

NM_001282531.3(ADNP):c.2573C> Likely benign(Last reviewed: Apr 2,
G (p.Ala858Gly)
2020)

VCV000931183

NM_001282531.3(ADNP):c.192G>A Likely benign(Last reviewed: Apr 25,
(p.Thr64=)
2018)
VCV000741177

NM_001282531.3(ADNP):c.921C>G Likely benign(Last reviewed: Aug 1,
(p.Leu307=)
2021)
VCV001298870

NM_001282531.3(ADNP):c.2265C> Likely benign(Last reviewed: Aug
T (p.Asp755=)
15, 2018)

VCV000764807

NM_001282531.3(ADNP):c.549C>T Likely benign(Last reviewed: Aug
(p.His183=)
17, 2018)

VCV000764587

NM_001282531.3(ADNP):c.782T>C Likely benign(Last reviewed: Aug
(p.Val261Ala)
18, 2020)

VCV001337659

NM_001282531.3(ADNP):c.609A>G Likely benign(Last reviewed: Aug
(p.Lys203=)
20, 2018)

VCV000762411
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NM_001282531.3(ADNP):c.1754A> Likely benign(Last reviewed: Dec
G (p.Asn585Ser)
17, 2018)

VCV000589686

NM_001282531.3(ADNP):c.1234C> Likely benign(Last reviewed: Dec
G (p.Leu412Val)
18, 2020)

VCV001191415

NM_001282531.3(ADNP):c.1932A> Likely benign(Last reviewed: Dec 2,
G (p.Arg644=)
2017)
VCV000587993

NM_001282531.3(ADNP):c.1635T> Likely benign(Last reviewed: Dec
C (p.Asp545=)
31, 2019)

VCV000797708

NM_001282531.3(ADNP):c.723C>T Likely benign(Last reviewed: Dec
(p.Ile241=)
31, 2019)

VCV000743463

NM_001282531.3(ADNP):c.1428A> Likely benign(Last reviewed: Dec
G (p.Ala476=)
31, 2019)

VCV000729217

NM_001282531.3(ADNP):c.2715C> Likely benign(Last reviewed: Dec
T (p.Asn905=)
31, 2019)

VCV000714188

NM_001282531.3(ADNP):c.2725G> Likely benign(Last reviewed: Dec 4,
A (p.Glu909Lys)
2020)
VCV001193365

NM_001282531.3(ADNP):c.1127G> Likely benign(Last reviewed: Feb
A (p.Arg376Lys)
24, 2021)

VCV001193486

NM_001282531.3(ADNP):c.402C>T Likely benign(Last reviewed: Feb
(p.Ser134=)
27, 2018)

VCV000735278

NM_001282531.3(ADNP):c.1747G> Likely benign(Last reviewed: Feb 3,
T (p.Ala583Ser)
2021)
VCV001195748

NM_001282531.3(ADNP):c.1592T> Likely benign(Last reviewed: Jan 1,
C (p.Met531Thr)
2019)
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VCV000975320

NM_001282531.3(ADNP):c.1123G> Likely benign(Last reviewed: Jan 1,
A (p.Gly375Arg)
2019)

VCV000975319

NM_001282531.3(ADNP):c.886C>T Likely benign(Last reviewed: Jan 1,
(p.Arg296Trp)
2019)

VCV000975318

NM_001282531.3(ADNP):c.627C>A Likely benign(Last reviewed: Jan 11,
(p.Val209=)
2017)
VCV000589486

NM_001282531.3(ADNP):c.142T>C Likely benign(Last reviewed: Jan 12,
(p.Leu48=)
2018)
VCV000732811

NM_001282531.3(ADNP):c.1847A> Likely benign(Last reviewed: Jan 12,
G (p.Lys616Arg)
2022)
VCV001342109

NM_001282531.3(ADNP):c.2157C> Likely benign(Last reviewed: Jan 2,
T (p.Tyr719=)
2019)

VCV000799506

NM_001282531.3(ADNP):c.855A>G Likely benign(Last reviewed: Jan 24,
(p.Pro285=)
2018)
VCV000722164

NM_001282531.3(ADNP):c.1014C> Likely benign(Last reviewed: Jan 27,
G (p.Gly338=)
2017)
VCV000589532

NM_001282531.3(ADNP):c.-5232C>T

Likely benign(Last reviewed: Jan 28,
2019)
VCV001205472

NM_001282531.3(ADNP):c.2561C> Likely benign(Last reviewed: Jan 4,
T (p.Ser854Phe)
2021)

VCV001200985

NM_001282531.3(ADNP):c.1062C> Likely benign(Last reviewed: Jul 18,
T (p.Asn354=)
2018)
VCV000741518

NM_001282531.3(ADNP):c.2406C> Likely benign(Last reviewed: Jul 2,
A (p.Ser802=)
2018)
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VCV000713746

NM_001282531.3(ADNP):c.1683C> Likely benign(Last reviewed: Jul 31,
T (p.Asn561=)
2018)
VCV000761244

NM_001282531.3(ADNP):c.2535A> Likely benign(Last reviewed: Jul 6,
C (p.Leu845=)
2018)

VCV000756768

NM_001282531.3(ADNP):c.1773A> Likely benign(Last reviewed: Jun 1,
C (p.Pro591=)
2017)

VCV000589109

NM_001282531.3(ADNP):c.1704A> Likely benign(Last reviewed: Jun 11,
G (p.Thr568=)
2021)
VCV001327804

NM_001282531.3(ADNP):c.666C>T Likely benign(Last reviewed: Jun 22,
(p.His222=)
2017)
VCV000434091

NM_001282531.3(ADNP):c.3147T> Likely benign(Last reviewed: Jun 8,
C (p.Asn1049=)
2018)

VCV000749518

NM_001282531.3(ADNP):c.2189G> Likely benign(Last reviewed: Mar 1,
A (p.Arg730Gln)
2021)
VCV001300622

NM_001282531.3(ADNP):c.1893A> Likely benign(Last reviewed: Mar
G (p.Leu631=)
29, 2018)

VCV000737800

NM_001282531.3(ADNP):c.1141G> Likely benign(Last reviewed: Mar
C (p.Gly381Arg)
31, 2017)

VCV000389878

NM_001282531.3(ADNP):c.2856A> Likely benign(Last reviewed: May
C (p.Ala952=)
13, 2018)

VCV000789499

NM_001282531.3(ADNP):c.483G>A Likely benign(Last reviewed: May
(p.Glu161=)
17, 2018)

VCV000589614

NM_001282531.3(ADNP):c.2808C> Likely benign(Last reviewed: May
T (p.Tyr936=)
20, 2018)

VCV000745344
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NM_001282531.3(ADNP):c.191C>T Likely benign(Last reviewed: May
(p.Thr64Met)
22, 2021)

VCV001194988

NM_001282531.3(ADNP):c.957C>G Likely benign(Last reviewed: May 4,
(p.Val319=)
2018)
VCV000742535

NM_001282531.3(ADNP):c.1392C> Likely benign(Last reviewed: Nov
T (p.His464=)
13, 2017)

VCV000725817

NM_001282531.3(ADNP):c.2994C> Likely benign(Last reviewed: Nov
T (p.Asp998=)
13, 2020)

VCV001188179

NM_001282531.3(ADNP):c.2574T> Likely benign(Last reviewed: Nov
C (p.Ala858=)
24, 2017)

VCV000728627

NM_001282531.3(ADNP):c.2849A> Likely benign(Last reviewed: Nov
G (p.His950Arg)
29, 2018)

VCV001336819

NM_001282531.3(ADNP):c.356A>G Likely benign(Last reviewed: Oct 20,
(p.Lys119Arg)
2016)
VCV000588925

NM_001282531.3(ADNP):c.285T>C Likely benign(Last reviewed: Oct 24,
(p.Asn95=)
2016)
VCV000588368

NM_001282531.3(ADNP):c.1275T> Likely benign(Last reviewed: Oct 9,
C (p.Ser425=)
2017)

VCV000589712

NM_001282531.3(ADNP):c.2570A> Likely benign(Last reviewed: Sep
G (p.Asn857Ser)
10, 2019)

VCV001210870

NM_001282531.3(ADNP):c.2466G> Likely benign(Last reviewed: Sep
A (p.Val822=)
13, 2017)

VCV001336233

NM_001282531.3(ADNP):c.1584C> Likely benign(Last reviewed: Sep
T (p.Ala528=)
18, 2018)

VCV000751571
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NM_001282531.3(ADNP):c.1597A> Likely benign(Last reviewed: Sep
G (p.Met533Val)
27, 2017)

VCV000589403

NM_001282531.3(ADNP):c.1896A> Likely benign(Last reviewed: Sep
G (p.Lys632=)
30, 2018)

VCV000624198

NM_001282531.3(ADNP):c.673C>T
(p.Arg225Ter)
Likely pathogenic

VCV000374229

NM_001282531.3(ADNP):c.2250_2
274del (p.Val751fs)
Likely pathogenic

VCV000996677

NM_001282531.3(ADNP):c.1717del Likely pathogenic(Last reviewed:
(p.Asp573fs)
Apr 22, 2016)

VCV000438275

NM_001282531.3(ADNP):c.2712du Likely pathogenic(Last reviewed:
p (p.Asn905Ter)
Apr 26, 2021)

VCV001098391

NM_001282531.3(ADNP):c.1754du Likely pathogenic(Last reviewed:
p (p.Asn585fs)
Aug 1, 2016)

VCV000421870

GRCh37/hg19 20q13.13Likely pathogenic(Last reviewed:
13.2(chr20:47726521-50427649)x1 Aug 10, 2015)

VCV000442502

NM_001282531.3(ADNP):c.106dup Likely pathogenic(Last reviewed:
(p.Glu36fs)
Aug 17, 2016)

VCV000421945

NM_001282531.3(ADNP):c.709del
(p.Val237fs)

Likely pathogenic(Last reviewed:
Aug 30, 2017)

VCV000976124

NM_001282531.3(ADNP):c.1046_1 Likely pathogenic(Last reviewed:
047del (p.Leu349fs)
Dec 23, 2015)

VCV000984840

NM_001282531.3(ADNP):c.1179_1 Likely pathogenic(Last reviewed:
180del (p.Leu394fs)
Dec 6, 2017)

VCV000503933
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NM_001282531.3(ADNP):c.2187du Likely pathogenic(Last reviewed:
p (p.Arg730fs)
Feb 2, 2018)

VCV000504292

NM_001282531.3(ADNP):c.1265du Likely pathogenic(Last reviewed:
p (p.Gln423fs)
Feb 5, 2020)

VCV000828170

NM_001282531.3(ADNP):c.2938C> Likely pathogenic(Last reviewed:
T (p.Gln980Ter)
Jan 1, 2019)

VCV000982697

NM_001282531.3(ADNP):c.321del
(p.Asn108fs)

Likely pathogenic(Last reviewed:
Jan 3, 2022)

VCV001333276

NM_001282531.3(ADNP):c.3307du Likely pathogenic(Last reviewed:
p (p.Ter1103LeuextTer?)
Jan 31, 2017)

VCV000545057

NM_001282531.3(ADNP):c.3069_3 Likely pathogenic(Last reviewed:
072del (p.Arg1023fs)
Jun 13, 2016)

VCV000988372

NM_001282531.3(ADNP):c.1310du Likely pathogenic(Last reviewed:
p (p.Gly438fs)
Jun 29, 2021)

VCV001297054

GRCh38/hg38 20q13.13Likely pathogenic(Last reviewed:
13.2(chr20:49989123-51495645)x1 Mar 21, 2011)

VCV000148193

GRCh37/hg19 20q13.13Likely pathogenic(Last reviewed:
13.2(chr20:47682662-49884981)x1 Mar 25, 2014)

VCV000187826

GRCh37/hg19
20q13.13(chr20:4944709049510400)x1

Likely pathogenic(Last reviewed:
Mar 8, 2018)

VCV000564608

NM_001282531.3(ADNP):c.2946du Likely pathogenic(Last reviewed:
p (p.Asp983fs)
Oct 23, 2020)

VCV000987062

NM_001282531.3(ADNP):c.2129du Likely pathogenic(Last reviewed:
p (p.Ser711fs)
Oct 24, 2016)

VCV000984843
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NM_001282531.3(ADNP):c.201G>C Likely pathogenic(Last reviewed:
(p.Gln67His)
Oct 4, 2017)

VCV000521542

NM_001282531.3(ADNP):c.2157del Likely pathogenic(Last reviewed:
(p.Thr718_Tyr719insTer)
Sep 26, 2019)

VCV000800950

NM_001282531.3(ADNP):c.1540T> Likely pathogenic(Last reviewed:
G (p.Cys514Gly)
Sep 27, 2021)

VCV001319913

NM_001282531.3(ADNP):c.82_85d
el (p.Leu28fs)
not provided

VCV000973033

NM_001282531.3(ADNP):c.642_65
1del (p.Asn214fs)
Pathogenic

VCV000981627

NM_001282531.3(ADNP):c.2808del Pathogenic(Last reviewed: Apr 1,
(p.Lys935_Tyr936insTer)
2014)

VCV000139634

NM_001282531.3(ADNP):c.1211C> Pathogenic(Last reviewed: Apr 1,
A (p.Ser404Ter)
2014)

VCV000139633

NM_001282531.3(ADNP):c.733G>T Pathogenic(Last reviewed: Apr 16,
(p.Glu245Ter)
2018)

VCV000619999

NM_001282531.3(ADNP):c.1620_1 Pathogenic(Last reviewed: Apr 18,
630dup (p.Thr544fs)
2016)

VCV000986226

NM_001282531.3(ADNP):c.790C>T Pathogenic(Last reviewed: Apr 27,
(p.Arg264Ter)
2016)

VCV000280535

NM_001282531.3(ADNP):c.2498_2 Pathogenic(Last reviewed: Apr 27,
499del (p.Lys833fs)
2018)

VCV000985962

NM_001282531.3(ADNP):c.655_65 Pathogenic(Last reviewed: Aug 10,
6del (p.Glu218_Ser219insTer)
2021)

VCV001299548

GRCh38/hg38 20q13.13Pathogenic(Last reviewed: Aug 12,
13.2(chr20:49731076-51202566)x1 2011)

VCV000058973

GRCh38/hg38 20q13.13Pathogenic(Last reviewed: Aug 12,
13.2(chr20:49947237-55875406)x3 2011)

VCV000059219
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GRCh38/hg38 20q13.1213.33(chr20:4478770464277321)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059218

NM_001282531.3(ADNP):c.1287du Pathogenic(Last reviewed: Aug 14,
p (p.Ala430fs)
2017)

VCV000451210

NM_001282531.3(ADNP):c.2239G> Pathogenic(Last reviewed: Aug 15,
T (p.Glu747Ter)
2017)

VCV000489048

NM_001282531.3(ADNP):c.2213C> Pathogenic(Last reviewed: Aug 19,
A (p.Ser738Ter)
2021)

VCV000984838

NM_001282531.3(ADNP):c.2213C> Pathogenic(Last reviewed: Aug 2,
G (p.Ser738Ter)
2017)

VCV000391218

NM_001282531.3(ADNP):c.2287du Pathogenic(Last reviewed: Aug 25,
p (p.Ser763fs)
2017)

VCV000522015

NM_001282531.3(ADNP):c.190dup Pathogenic(Last reviewed: Aug 30,
(p.Thr64fs)
2021)

VCV000280557

NM_001282531.3(ADNP):c.1239_1 Pathogenic(Last reviewed: Dec 1,
240del (p.Gln414fs)
2016)

VCV000973124

NM_001282531.3(ADNP):c.1184du Pathogenic(Last reviewed: Dec 1,
p (p.Ser396fs)
2017)

VCV000973125

NM_001282531.3(ADNP):c.67_70d Pathogenic(Last reviewed: Dec 1,
el (p.Leu23fs)
2018)

VCV000973123

GRCh37/hg19 20p13q13.33(chr20:61569-62915555)x3

Pathogenic(Last reviewed: Dec 2,
2014)

VCV000443340

NM_001282531.3(ADNP):c.2318du Pathogenic(Last reviewed: Dec 8,
p (p.Tyr774fs)
2016)

VCV000374212

NM_001282531.3(ADNP):c.712C>T Pathogenic(Last reviewed: Feb 1,
(p.Gln238Ter)
2018)

VCV000872736

NM_001282531.3(ADNP):c.2157C> Pathogenic(Last reviewed: Feb 1,
A (p.Tyr719Ter)
2018)

VCV000280623
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NM_001282531.3(ADNP):c.845del
(p.Gly282fs)

Pathogenic(Last reviewed: Feb 3,
2017)

VCV000423279

NM_001282531.3(ADNP):c.940_94 Pathogenic(Last reviewed: Feb 4,
1del (p.Leu314fs)
2019)

VCV000984839

NM_001282531.3(ADNP):c.331del
(p.Tyr111fs)

Pathogenic(Last reviewed: Feb 6,
2019)

VCV000985605

NM_001282531.3(ADNP):c.916C>T Pathogenic(Last reviewed: Feb 8,
(p.Arg306Ter)
2019)

VCV000817538

GRCh37/hg19 20p13q13.33(chr20:63244-62961294)x3

Pathogenic(Last reviewed: Jan 1,
2013)

VCV000604423

NM_001282531.3(ADNP):c.280C>T Pathogenic(Last reviewed: Jan 1,
(p.Arg94Cys)
2019)

VCV000975321

NM_001282531.3(ADNP):c.898dup Pathogenic(Last reviewed: Jan 1,
(p.Ser300fs)
2020)

VCV001174075

NM_001282531.3(ADNP):c.539_54 Pathogenic(Last reviewed: Jan 1,
2del (p.Val180fs)
2021)

VCV000373314

NM_001282531.3(ADNP):c.56_57d Pathogenic(Last reviewed: Jan 14,
el (p.Val19fs)
2022)

VCV000817018

NM_001282531.3(ADNP):c.1033C> Pathogenic(Last reviewed: Jan 15,
T (p.Gln345Ter)
2016)

VCV000984841

NM_001282531.3(ADNP):c.2157C> Pathogenic(Last reviewed: Jan 3,
G (p.Tyr719Ter)
2022)

VCV000139635

NM_001282531.3(ADNP):c.819del
(p.Lys274fs)

Pathogenic(Last reviewed: Jan 4,
2017)

VCV000280262

NM_001282531.3(ADNP):c.1235del Pathogenic(Last reviewed: Jan 5,
(p.Leu412fs)
2016)

VCV000280199

GRCh37/hg19 20p13q13.33(chr20:63244-62948788)x3

VCV000604422

Pathogenic(Last reviewed: Jan 5,
2017)
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GRCh37/hg19 20p13q13.33(chr20:61569-62915555)

Pathogenic(Last reviewed: Jul 14,
2015)

VCV000443339

NM_001282531.3(ADNP):c.2496_2 Pathogenic(Last reviewed: Jul 21,
499del (p.Asn832fs)
2021)

VCV000139632

NM_001282531.3(ADNP):c.2287del Pathogenic(Last reviewed: Jul 5,
(p.Ser763fs)
2016)

VCV000521175

NM_001282531.3(ADNP):c.70del
(p.Ser24fs)

Pathogenic(Last reviewed: Jun 15,
2015)

VCV000419147

NM_001282531.3(ADNP):c.1807_1 Pathogenic(Last reviewed: Jun 17,
808dup (p.Pro604fs)
2021)

VCV001184924

NM_001282531.3(ADNP):c.2175del Pathogenic(Last reviewed: Jun 21,
(p.Leu726fs)
2017)

VCV000432980

NM_001282531.3(ADNP):c.337_34 Pathogenic(Last reviewed: Jun 26,
0del (p.Thr113fs)
2017)

VCV000450110

NM_001282531.3(ADNP):c.69dup
(p.Ser24Ter)

VCV001335928

Pathogenic(Last reviewed: Jun 26,
2017)

NM_001282531.3(ADNP):c.1106_1 Pathogenic(Last reviewed: Jun 6,
108delinsCTGT (p.Leu369fs)
2016)

VCV000265590

NM_001282531.3(ADNP):c.1222_1 Pathogenic(Last reviewed: Mar 12,
223del (p.Lys408fs)
2015)

VCV000190279

NM_001282531.3(ADNP):c.1936_1 Pathogenic(Last reviewed: Mar 18,
937del (p.Arg646fs)
2016)

VCV000619994

GRCh38/hg38 20q13.13Pathogenic(Last reviewed: Mar 21,
13.2(chr20:50781990-52792847)x1 2011)

VCV000148190

NM_001282531.3(ADNP):c.2865_2 Pathogenic(Last reviewed: Mar 23,
868del (p.Ser955fs)
2016)

VCV000984844

NM_001282531.3(ADNP):c.2230G> Pathogenic(Last reviewed: Mar 27,
T (p.Glu744Ter)
2020)

VCV000489245
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NM_001282531.3(ADNP):c.517C>T Pathogenic(Last reviewed: Mar 27,
(p.Arg173Ter)
2020)

VCV000431117

NM_001282531.3(ADNP):c.177_17 Pathogenic(Last reviewed: Mar 9,
8dup (p.Asp60fs)
2017)

VCV000620048

NM_001282531.3(ADNP):c.2195del Pathogenic(Last reviewed: May 18,
(p.Lys731_Leu732insTer)
2017)

VCV000430071

NM_001282531.3(ADNP):c.57dup
(p.Lys20fs)

Pathogenic(Last reviewed: May 2,
2017)

VCV000429255

NM_001282531.3(ADNP):c.1337G> Pathogenic(Last reviewed: May 2,
A (p.Trp446Ter)
2017)

VCV000521765

NM_001282531.3(ADNP):c.-51G>C

Pathogenic(Last reviewed: May 28,
2019)

VCV000803615

NM_001282531.3(ADNP):c.2157_2 Pathogenic(Last reviewed: May 28,
159del (p.Tyr719_Glu720delinsTer) 2019)

VCV000803614

NM_001282531.3(ADNP):c.2499del Pathogenic(Last reviewed: May 9,
(p.Val834fs)
2016)

VCV000520984

NM_001282531.3(ADNP):c.1132du Pathogenic(Last reviewed: Nov 1,
p (p.Tyr378fs)
2019)

VCV000872735

GRCh37/hg19 20q13.13Pathogenic(Last reviewed: Nov 12,
13.2(chr20:47627844-52045480)x1 2013)

VCV000443773

NM_001282531.3(ADNP):c.1876_1 Pathogenic(Last reviewed: Nov 27,
892del (p.Leu626fs)
2017)

VCV000503886

NM_001282531.3(ADNP):c.2454C> Pathogenic(Last reviewed: Nov 4,
G (p.Tyr818Ter)
2021)

VCV001334645

NM_001282531.3(ADNP):c.2491_2 Pathogenic(Last reviewed: Nov 5,
494del (p.Leu831fs)
2021)

VCV000139631

GRCh38/hg38 20p13q13.33(chr20:99557-64277321)x3

VCV000146596

Pathogenic(Last reviewed: Oct 19,
2010)
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NM_001282531.3(ADNP):c.1652_1 Pathogenic(Last reviewed: Oct 23,
653del (p.Asp551fs)
2020)

VCV000987470

NM_001282531.3(ADNP):c.1666C> Pathogenic(Last reviewed: Oct 23,
T (p.Gln556Ter)
2020)

VCV000987411

NM_001282531.3(ADNP):c.2327du Pathogenic(Last reviewed: Oct 23,
p (p.Asn776fs)
2020)

VCV000987168

NM_001282531.3(ADNP):c.2187del Pathogenic(Last reviewed: Oct 23,
(p.Lys729fs)
2020)

VCV000987030

NM_001282531.3(ADNP):c.2194_2 Pathogenic(Last reviewed: Oct 3,
197del (p.Leu732fs)
2017)

VCV000452597

GRCh37/hg19 20p13q13.33(chr20:63244-62912463)x3

Pathogenic(Last reviewed: Oct 31,
2014)

VCV000604421

NM_001282531.3(ADNP):c.484C>T Pathogenic(Last reviewed: Sep 15,
(p.Gln162Ter)
2016)

VCV000984842

NM_001282531.3(ADNP):c.330dup Pathogenic(Last reviewed: Sep 16,
(p.Tyr111fs)
2016)

VCV000280876

NM_001282531.3(ADNP):c.2387G> Pathogenic(Last reviewed: Sep 23,
A (p.Trp796Ter)
2021)

VCV001338860

NM_001282531.3(ADNP):c.2268du Pathogenic(Last reviewed: Sep 30,
p (p.Lys757fs)
2016)

VCV000280907

NM_001282531.3(ADNP):c.2378T> Pathogenic(Last reviewed: Sep 30,
G (p.Leu793Ter)
2016)

VCV000280874

NM_001282531.3(ADNP):c.64dup
(p.Ile22fs)

Pathogenic/Likely pathogenic(Last
reviewed: Apr 26, 2021)

VCV000931423

NM_001282531.3(ADNP):c.2188C> Pathogenic/Likely pathogenic(Last
T (p.Arg730Ter)
reviewed: Jun 17, 2021)

VCV000279598

NM_001282531.3(ADNP):c.2156du Pathogenic/Likely pathogenic(Last
p (p.Tyr719Ter)
reviewed: Oct 23, 2020)

VCV000190278
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NM_001282531.3(ADNP):c.583C>T
(p.Pro195Ser)
Uncertain significance

VCV000813652

NM_001282531.3(ADNP):c.1931G>
A (p.Arg644Gln)
Uncertain significance

VCV000813555

NM_001282531.3(ADNP):c.1721C> Uncertain significance(Last
T (p.Ala574Val)
reviewed: Apr 1, 2019)

VCV000809260

NM_001282531.3(ADNP):c.283A>G Uncertain significance(Last
(p.Asn95Asp)
reviewed: Apr 1, 2020)

VCV000932382

Uncertain significance(Last
reviewed: Apr 13, 2018)

VCV000560064

NM_001282531.3(ADNP):c.953G>T Uncertain significance(Last
(p.Gly318Val)
reviewed: Apr 16, 2019)

VCV001305248

NM_001282531.3(ADNP):c.197A>G Uncertain significance(Last
(p.Asn66Ser)
reviewed: Apr 25, 2018)

VCV001336506

NM_001282531.3(ADNP):c.108+6T Uncertain significance(Last
>C
reviewed: Apr 26, 2018)

VCV000816876

NM_001282531.3(ADNP):c.2165T> Uncertain significance(Last
C (p.Met722Thr)
reviewed: Apr 5, 2017)

VCV000426751

NM_001282531.3(ADNP):c.298G>T Uncertain significance(Last
(p.Asp100Tyr)
reviewed: Apr 7, 2021)

VCV001300678

NM_001282531.3(ADNP):c.2669G> Uncertain significance(Last
A (p.Gly890Asp)
reviewed: Aug 1, 2019)

VCV001304829

NM_001282531.3(ADNP):c.2083A> Uncertain significance(Last
G (p.Asn695Asp)
reviewed: Aug 14, 2019)

VCV001304872

Single allele
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NM_001282531.3(ADNP):c.638C>T Uncertain significance(Last
(p.Ser213Leu)
reviewed: Aug 22, 2019)

VCV001027973

NM_001282531.3(ADNP):c.2474G> Uncertain significance(Last
A (p.Gly825Glu)
reviewed: Dec 1, 2016)

VCV000973122

NM_001282531.3(ADNP):c.2632A> Uncertain significance(Last
G (p.Ser878Gly)
reviewed: Dec 13, 2016)

VCV000589464

NM_001282531.3(ADNP):c.1345T> Uncertain significance(Last
C (p.Cys449Arg)
reviewed: Dec 27, 2019)

VCV001311337

NM_001282531.3(ADNP):c.2012A> Uncertain significance(Last
G (p.Tyr671Cys)
reviewed: Dec 6, 2019)

VCV001310944

NM_001282531.3(ADNP):c.3302A> Uncertain significance(Last
G (p.Gln1101Arg)
reviewed: Feb 18, 2020)

VCV001312755

NM_001282531.3(ADNP):c.2116C> Uncertain significance(Last
A (p.Leu706Ile)
reviewed: Jan 1, 2018)

VCV000546901

NM_001282531.3(ADNP):c.391C>G Uncertain significance(Last
(p.Pro131Ala)
reviewed: Jan 1, 2020)

VCV001174100

NM_001282531.3(ADNP):c.2572G> Uncertain significance(Last
A (p.Ala858Thr)
reviewed: Jan 12, 2018)

VCV000976094

NM_001282531.3(ADNP):c.481G>A Uncertain significance(Last
(p.Glu161Lys)
reviewed: Jan 2, 2020)

VCV001027972

NM_001282531.3(ADNP):c.872C>G Uncertain significance(Last
(p.Ala291Gly)
reviewed: Jan 25, 2018)

VCV001031904

NM_001282531.3(ADNP):c.2143G> Uncertain significance(Last
A (p.Val715Met)
reviewed: Jan 5, 2016)

VCV000434094
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NM_001282531.3(ADNP):c.985C>G Uncertain significance(Last
(p.Gln329Glu)
reviewed: Jan 6, 2016)

VCV000285662

NM_001282531.3(ADNP):c.839G>A Uncertain significance(Last
(p.Ser280Asn)
reviewed: Jul 1, 2018)

VCV000624199

NM_001282531.3(ADNP):c.2600A> Uncertain significance(Last
G (p.Asn867Ser)
reviewed: Jul 10, 2019)

VCV001337284

NM_001282531.3(ADNP):c.2716_2 Uncertain significance(Last
718del (p.Asp906del)
reviewed: Jul 15, 2020)

VCV001306884

NM_001282531.3(ADNP):c.3056T> Uncertain significance(Last
C (p.Met1019Thr)
reviewed: Jul 27, 2020)

VCV001027971

NM_001282531.3(ADNP):c.1133A> Uncertain significance(Last
G (p.Tyr378Cys)
reviewed: Jul 28, 2016)

VCV000588109

NM_001282531.3(ADNP):c.1102C> Uncertain significance(Last
T (p.Gln368Ter)
reviewed: Jun 14, 2016)

VCV000338748

NM_001282531.3(ADNP):c.1677C> Uncertain significance(Last
A (p.His559Gln)
reviewed: Jun 20, 2016)

VCV000387173

NM_001282531.3(ADNP):c.2059T> Uncertain significance(Last
C (p.Cys687Arg)
reviewed: Jun 26, 2017)

VCV001052737

NM_001282531.3(ADNP):c.3040A> Uncertain significance(Last
C (p.Lys1014Gln)
reviewed: Jun 29, 2021)

VCV001334498

NM_001282531.3(ADNP):c.669C>T Uncertain significance(Last
(p.Cys223=)
reviewed: Jun 5, 2017)

VCV000432769

NM_001282531.3(ADNP):c.650A>G Uncertain significance(Last
(p.Glu217Gly)
reviewed: Mar 24, 2021)

VCV001331626

224

NM_001282531.3(ADNP):c.736C>T Uncertain significance(Last
(p.Arg246Cys)
reviewed: Mar 3, 2020)

VCV001251938

NM_001282531.3(ADNP):c.-51G>A

Uncertain significance(Last
reviewed: Mar 8, 2017)

VCV000423847

NM_001282531.3(ADNP):c.208C>T Uncertain significance(Last
(p.Arg70Trp)
reviewed: May 1, 2021)

VCV001176428

NM_001282531.3(ADNP):c.2749C> Uncertain significance(Last
G (p.Pro917Ala)
reviewed: May 14, 2020)

VCV001301725

NM_001282531.3(ADNP):c.1855G> Uncertain significance(Last
T (p.Val619Phe)
reviewed: May 16, 2017)

VCV000386594

NM_001282531.3(ADNP):c.2918_2 Uncertain significance(Last
932del (p.Glu973_Ser978delinsAla) reviewed: May 17, 2018)

VCV000546231

NM_001282531.3(ADNP):c.2056C> Uncertain significance(Last
G (p.His686Asp)
reviewed: May 17, 2021)

VCV001303971

NM_001282531.3(ADNP):c.344A>G Uncertain significance(Last
(p.Asn115Ser)
reviewed: May 2, 2016)

VCV000589274

NM_001282531.3(ADNP):c.3248du Uncertain significance(Last
p (p.Val1084fs)
reviewed: May 21, 2018)

VCV000546371

NM_001282531.3(ADNP):c.775A>C Uncertain significance(Last
(p.Asn259His)
reviewed: May 26, 2017)

VCV000589645

NM_001282531.3(ADNP):c.3097T> Uncertain significance(Last
C (p.Tyr1033His)
reviewed: May 29, 2019)

VCV001306158

NM_001282531.3(ADNP):c.724G>A Uncertain significance(Last
(p.Glu242Lys)
reviewed: May 5, 2017)

VCV000589090
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NM_001282531.3(ADNP):c.121T>C Uncertain significance(Last
(p.Phe41Leu)
reviewed: Nov 14, 2019)

VCV001310439

NM_001282531.3(ADNP):c.1180C> Uncertain significance(Last
G (p.Leu394Val)
reviewed: Nov 20, 2019)

VCV001030496

NM_001282531.3(ADNP):c.2189G> Uncertain significance(Last
C (p.Arg730Pro)
reviewed: Nov 5, 2019)

VCV001309778

NM_001282531.3(ADNP):c.2971_2 Uncertain significance(Last
979del (p.Met991_Pro993del)
reviewed: Nov 5, 2019)

VCV000966928

NM_001282531.3(ADNP):c.3304G> Uncertain significance(Last
A (p.Ala1102Thr)
reviewed: Oct 24, 2019)

VCV000931701

NM_001282531.3(ADNP):c.499T>C Uncertain significance(Last
(p.Cys167Arg)
reviewed: Oct 27, 2020)

VCV001304715

NM_001282531.3(ADNP):c.2150G> Uncertain significance(Last
A (p.Arg717His)
reviewed: Oct 30, 2019)

VCV000958481

NM_001282531.3(ADNP):c.1142G> Uncertain significance(Last
T (p.Gly381Val)
reviewed: Sep 13, 2017)

VCV000588833
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Appendix Table 4. Table of reported variants for SMARCA2, retrieved from ClinVar databases
(https://www.ncbi.nlm.nih.gov/clinvar/?term=SMARCA2%5Bgene%5D&redir=gene)

Name

Clinical significance (Last
reviewed)

Accession

NM_003070.5(SMARCA2):c.329345T>C

Benign(Last reviewed: Apr 13,
2020)

VCV001249804

NM_003070.5(SMARCA2):c.4199+ Benign(Last reviewed: Apr 17,
41G>C
2020)

VCV001224862

NM_003070.5(SMARCA2):c.97C>T Benign(Last reviewed: Apr 18,
(p.Pro33Ser)
2019)

VCV000366193

NM_003070.5(SMARCA2):c.425418G>C

VCV001281533

Benign(Last reviewed: Apr 20,
2021)
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NM_003070.5(SMARCA2):c.3125+ Benign(Last reviewed: Apr 29,
47T>A
2020)

VCV001289555

NM_003070.5(SMARCA2):c.1080A
>G (p.Glu360=)
Benign(Last reviewed: Apr 3, 2020) VCV001265175
NM_003070.5(SMARCA2):c.231C>
T (p.Ile77=)
Benign(Last reviewed: Apr 3, 2020) VCV000588510
NM_003070.5(SMARCA2):c.2883+
37T>C
Benign(Last reviewed: Apr 9, 2020) VCV001221707
NM_003070.5(SMARCA2):c.3684+ Benign(Last reviewed: Aug 10,
104A>C
2018)

VCV001287712

NM_003070.5(SMARCA2):c.1047217C>T

Benign(Last reviewed: Aug 10,
2018)

VCV001278462

NM_003070.5(SMARCA2):c.2883+ Benign(Last reviewed: Aug 10,
90A>C
2018)

VCV001270974

NM_003070.5(SMARCA2):c.3762+ Benign(Last reviewed: Aug 10,
194A>C
2018)

VCV001266909

NM_003070.5(SMARCA2):c.299274G>A

Benign(Last reviewed: Aug 10,
2018)

VCV001229665

NM_003070.5(SMARCA2):c.2770109A>C

Benign(Last reviewed: Aug 10,
2018)

VCV001228268

NM_003070.5(SMARCA2):c.4738316dup

Benign(Last reviewed: Aug 10,
2019)

VCV001243486

NM_003070.5(SMARCA2):c.4359+ Benign(Last reviewed: Aug 11,
178C>T
2018)

VCV001263334

NM_003070.5(SMARCA2):c.2348+ Benign(Last reviewed: Aug 11,
311_2348+312dup
2019)

VCV001269133

NM_003070.5(SMARCA2):c.2883+ Benign(Last reviewed: Aug 11,
269_2883+281dup
2019)

VCV001181773

NM_003070.5(SMARCA2):c.3510G Benign(Last reviewed: Aug 11,
>T (p.Arg1170=)
2021)

VCV001304563
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NM_003070.5(SMARCA2):c.3981+ Benign(Last reviewed: Aug 20,
22C>T
2020)

VCV001258850

NM_003070.5(SMARCA2):c.1827A Benign(Last reviewed: Aug 21,
>G (p.Pro609=)
2018)

VCV000126345

NM_003070.5(SMARCA2):c.356220del

Benign(Last reviewed: Aug 21,
2019)

VCV001282930

NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: Aug 21,
175TG[22]
2019)

VCV001282148

NM_003070.5(SMARCA2):c.3078+ Benign(Last reviewed: Aug 21,
88dup
2019)

VCV001233837

NM_003070.5(SMARCA2):c.22620A>G

Benign(Last reviewed: Aug 22,
2020)

VCV001249904

NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: Aug 23,
175TG[17]
2019)

VCV001182066

NM_003070.5(SMARCA2):c.3125+ Benign(Last reviewed: Aug 24,
43G>T
2020)

VCV001276859

NM_003070.5(SMARCA2):c.3078+ Benign(Last reviewed: Aug 26,
89C>A
2019)

VCV001222148

NM_003070.5(SMARCA2):c.436014A>T

Benign(Last reviewed: Aug 27,
2021)

VCV001254119

NM_003070.5(SMARCA2):c.398240C>T

Benign(Last reviewed: Aug 28,
2020)

VCV001288554

NM_003070.5(SMARCA2):c.695A> Benign(Last reviewed: Aug 30,
C (p.Gln232Pro)
2019)

VCV000366200

NM_003070.5(SMARCA2):c.4594+ Benign(Last reviewed: Aug 31,
102_4594+103insT
2018)

VCV001236852

NM_003070.5(SMARCA2):c.4253+ Benign(Last reviewed: Aug 31,
53C>T
2018)

VCV001232653

NM_003070.5(SMARCA2):c.791133del

Benign(Last reviewed: Aug 6, 2019) VCV001289984

229

NM_003070.5(SMARCA2):c.3078+
82A>T
Benign(Last reviewed: Aug 6, 2019) VCV001266423
NM_003070.5(SMARCA2):c.791133dup

Benign(Last reviewed: Aug 6, 2019) VCV001266002

NM_003070.5(SMARCA2):c.2348+
312GT[21]
Benign(Last reviewed: Aug 7, 2019) VCV001223916
NM_003070.5(SMARCA2):c.1522231G>A

Benign(Last reviewed: Aug 8, 2018) VCV001296691

NM_003070.5(SMARCA2):c.193655A>T

Benign(Last reviewed: Aug 8, 2018) VCV001270525

NM_003070.5(SMARCA2):c.376380T>C

Benign(Last reviewed: Aug 8, 2018) VCV001259756

NM_003070.5(SMARCA2):c.252725G>A

Benign(Last reviewed: Aug 8, 2018) VCV001257198

NM_003070.5(SMARCA2):c.-3645A>G

Benign(Last reviewed: Aug 8, 2018) VCV001251909

NM_003070.5(SMARCA2):c.-36230T>G

Benign(Last reviewed: Aug 8, 2018) VCV001231248

NM_003070.5(SMARCA2):c.152248T>C

Benign(Last reviewed: Aug 8, 2018) VCV001178694

NM_003070.5(SMARCA2):c.177G>
A (p.Thr59=)
Benign(Last reviewed: Aug 8, 2018) VCV000126344
NM_003070.5(SMARCA2):c.4594+
16C>T
Benign(Last reviewed: Dec 1, 2020) VCV001249925
NM_003070.5(SMARCA2):c.4199+
47G>C
Benign(Last reviewed: Dec 1, 2020) VCV001240429
NM_003070.5(SMARCA2):c.1935+ Benign(Last reviewed: Dec 13,
35T>G
2020)

VCV001249356

NM_003070.5(SMARCA2):c.459541T>A

VCV001288135

Benign(Last reviewed: Dec 15,
2020)

230

NM_003070.5(SMARCA2):c.669GC Benign(Last reviewed: Dec 18,
A[14] (p.Gln238dup)
2019)

VCV000436797

NM_003070.5(SMARCA2):c.462G> Benign(Last reviewed: Dec 23,
A (p.Gly154=)
2021)

VCV000126348

NM_003070.5(SMARCA2):c.27707C>G

VCV000366213

Benign(Last reviewed: Dec 31,
2019)

NM_003070.5(SMARCA2):c.2931G
>A (p.Leu977=)
Benign(Last reviewed: Dec 6, 2021) VCV001327235
NM_003070.5(SMARCA2):c.234915T>A

Benign(Last reviewed: Dec 6, 2021) VCV001327234

NM_003070.5(SMARCA2):c.3292+
24C>T
Benign(Last reviewed: Dec 7, 2020) VCV001243685
NM_003070.5(SMARCA2):c.1266T
>A (p.Thr422=)
Benign(Last reviewed: Dec 7, 2020) VCV001227377
NM_003070.5(SMARCA2):c.4594+
80_4594+98del
Benign(Last reviewed: Dec 9, 2019) VCV001279806
NM_003070.5(SMARCA2):c.4247G Benign(Last reviewed: Jan 12,
>C (p.Gly1416Ala)
2018)

VCV000914998

NM_003070.5(SMARCA2):c.517C> Benign(Last reviewed: Jan 12,
T (p.Pro173Ser)
2018)

VCV000914908

NM_003070.5(SMARCA2):c.*716A> Benign(Last reviewed: Jan 12,
G
2018)

VCV000366342

NM_003070.5(SMARCA2):c.*698T> Benign(Last reviewed: Jan 12,
C
2018)

VCV000366341

NM_003070.5(SMARCA2):c.*620T> Benign(Last reviewed: Jan 12,
C
2018)

VCV000366339

NM_003070.5(SMARCA2):c.*324G Benign(Last reviewed: Jan 12,
>C
2018)

VCV000366335

NM_003070.5(SMARCA2):c.3939C Benign(Last reviewed: Jan 12,
>T (p.Asp1313=)
2018)

VCV000366222

231

NM_003070.5(SMARCA2):c.36856C>A

Benign(Last reviewed: Jan 12,
2018)

VCV000366221

NM_003070.5(SMARCA2):c.2991+ Benign(Last reviewed: Jan 12,
10G>A
2018)

VCV000366216

NM_003070.5(SMARCA2):c.1675A Benign(Last reviewed: Jan 13,
>C (p.Arg559=)
2018)

VCV000914438

NM_003070.5(SMARCA2):c.734A> Benign(Last reviewed: Jan 13,
T (p.Gln245Leu)
2018)

VCV000912952

NM_003070.5(SMARCA2):c.*726T> Benign(Last reviewed: Jan 13,
C
2018)

VCV000366343

NM_003070.5(SMARCA2):c.*431G Benign(Last reviewed: Jan 13,
>A
2018)

VCV000366337

NM_003070.5(SMARCA2):c.*181C
>T

Benign(Last reviewed: Jan 13,
2018)

VCV000366333

NM_003070.5(SMARCA2):c.*138C
>T

Benign(Last reviewed: Jan 13,
2018)

VCV000366332

NM_003070.5(SMARCA2):c.4679G Benign(Last reviewed: Jan 13,
>A (p.Arg1560Gln)
2018)

VCV000366321

NM_003070.5(SMARCA2):c.4584A Benign(Last reviewed: Jan 13,
>G (p.Ser1528=)
2018)

VCV000366254

NM_003070.5(SMARCA2):c.4516A Benign(Last reviewed: Jan 13,
>T (p.Ile1506Phe)
2018)

VCV000366251

NM_003070.5(SMARCA2):c.2907C Benign(Last reviewed: Jan 13,
>T (p.Asp969=)
2018)

VCV000366214

NM_003070.5(SMARCA2):c.1877+ Benign(Last reviewed: Jan 13,
9T>A
2018)

VCV000366209

NM_003070.5(SMARCA2):c.716C> Benign(Last reviewed: Jan 23,
T (p.Pro239Leu)
2021)

VCV001249161

NM_003070.5(SMARCA2):c.4737+ Benign(Last reviewed: Jan 26,
18G>A
2021)

VCV001269049
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NM_003070.5(SMARCA2):c.4737+ Benign(Last reviewed: Jan 27,
13G>A
2021)

VCV000912462

NM_003070.5(SMARCA2):c.708A> Benign(Last reviewed: Jan 27,
G (p.Gln236=)
2021)

VCV000366202

NM_003070.5(SMARCA2):c.483G>
A (p.Pro161=)
Benign(Last reviewed: Jan 9, 2021) VCV001278061
NM_003070.5(SMARCA2):c.436079A>G

Benign(Last reviewed: Jul 14, 2021) VCV001185431

NM_003070.5(SMARCA2):c.1347+
16_1347+17insT
Benign(Last reviewed: Jul 14, 2021) VCV001185430
NM_003070.5(SMARCA2):c.4253+
40G>C
Benign(Last reviewed: Jul 14, 2021) VCV000802456
NM_003070.5(SMARCA2):c.307925T>A

Benign(Last reviewed: Jul 15, 2021) VCV001271266

NM_003070.5(SMARCA2):c.4199+
46C>T
Benign(Last reviewed: Jul 15, 2021) VCV001226808
NM_003070.5(SMARCA2):c.4199+
183T>C
Benign(Last reviewed: Jul 26, 2018) VCV001288648
NM_003070.5(SMARCA2):c.3456+
164A>G
Benign(Last reviewed: Jul 26, 2018) VCV001287511
NM_003070.5(SMARCA2):c.2416331A>G

Benign(Last reviewed: Jul 26, 2018) VCV001286901

NM_003070.5(SMARCA2):c.2185224A>T

Benign(Last reviewed: Jul 26, 2018) VCV001283518

NM_003070.5(SMARCA2):c.790+7
3C>T
Benign(Last reviewed: Jul 26, 2018) VCV001276752
NM_003070.5(SMARCA2):c.1347+
191A>C
Benign(Last reviewed: Jul 26, 2018) VCV001271351
NM_003070.5(SMARCA2):c.3292+
256T>G
Benign(Last reviewed: Jul 26, 2018) VCV001248990

233

NM_003070.5(SMARCA2):c.3079136G>A

Benign(Last reviewed: Jul 26, 2018) VCV001242782

NM_003070.5(SMARCA2):c.174750G>C

Benign(Last reviewed: Jul 26, 2018) VCV001233896

NM_003070.5(SMARCA2):c.3763196A>G

Benign(Last reviewed: Jul 27, 2018) VCV001296611

NM_003070.5(SMARCA2):c.2184+
112A>G
Benign(Last reviewed: Jul 27, 2018) VCV001283777
NM_003070.5(SMARCA2):c.3763188G>A

Benign(Last reviewed: Jul 27, 2018) VCV001277473

NM_003070.5(SMARCA2):c.1047188C>T

Benign(Last reviewed: Jul 27, 2018) VCV001272405

NM_003070.5(SMARCA2):c.3079248G>A

Benign(Last reviewed: Jul 27, 2018) VCV001272260

NM_003070.5(SMARCA2):c.3763284G>A

Benign(Last reviewed: Jul 27, 2018) VCV001243769

NM_003070.5(SMARCA2):c.1348158T>C

Benign(Last reviewed: Jul 3, 2018)

VCV001296716

NM_003070.5(SMARCA2):c.1935+
216C>T
Benign(Last reviewed: Jul 3, 2018)

VCV001296708

NM_003070.5(SMARCA2):c.1174109G>A

Benign(Last reviewed: Jul 3, 2018)

VCV001296650

NM_003070.5(SMARCA2):c.3078+
114C>T
Benign(Last reviewed: Jul 3, 2018)

VCV001289266

NM_003070.5(SMARCA2):c.3981+
203C>T
Benign(Last reviewed: Jul 3, 2018)

VCV001288601

NM_003070.5(SMARCA2):c.2184+
99T>C
Benign(Last reviewed: Jul 3, 2018)

VCV001286658

NM_003070.5(SMARCA2):c.3762+
73C>G
Benign(Last reviewed: Jul 3, 2018)

VCV001281323
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NM_003070.5(SMARCA2):c.3126225A>C

Benign(Last reviewed: Jul 3, 2018)

VCV001278660

NM_003070.5(SMARCA2):c.459520T>C

Benign(Last reviewed: Jul 3, 2018)

VCV001278359

NM_003070.5(SMARCA2):c.790+8
3A>C
Benign(Last reviewed: Jul 3, 2018)

VCV001270376

NM_003070.5(SMARCA2):c.1935+
85G>T
Benign(Last reviewed: Jul 3, 2018)

VCV001258233

NM_003070.5(SMARCA2):c.312653T>C

Benign(Last reviewed: Jul 3, 2018)

VCV001257336

NM_003070.5(SMARCA2):c.4737+
317C>T
Benign(Last reviewed: Jul 3, 2018)

VCV001249269

NM_003070.5(SMARCA2):c.4461+
48G>A
Benign(Last reviewed: Jul 3, 2018)

VCV001248205

NM_003070.5(SMARCA2):c.355+1
01A>C
Benign(Last reviewed: Jul 3, 2018)

VCV001244769

NM_003070.5(SMARCA2):c.4595285T>G

Benign(Last reviewed: Jul 3, 2018)

VCV001240618

NM_003070.5(SMARCA2):c.187852A>T

Benign(Last reviewed: Jul 3, 2018)

VCV001236919

NM_003070.5(SMARCA2):c.459577G>T

Benign(Last reviewed: Jul 3, 2018)

VCV001236353

NM_003070.5(SMARCA2):c.226107G>A

Benign(Last reviewed: Jul 3, 2018)

VCV001235432

NM_003070.5(SMARCA2):c.225+2
07C>A
Benign(Last reviewed: Jul 3, 2018)

VCV001232226

NM_003070.5(SMARCA2):c.356253A>G

Benign(Last reviewed: Jul 3, 2018)

VCV001228940

NM_003070.5(SMARCA2):c.4738299A>G

Benign(Last reviewed: Jul 3, 2018)

VCV001183914
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NM_003070.5(SMARCA2):c.4594+
232T>C
Benign(Last reviewed: Jul 3, 2018)

VCV001182132

NM_003070.5(SMARCA2):c.4461+
195T>C
Benign(Last reviewed: Jul 3, 2018)

VCV001177711

NM_003070.5(SMARCA2):c.4638C
>G (p.Asp1546Glu)
Benign(Last reviewed: Jul 3, 2018)

VCV000126349

NM_003070.5(SMARCA2):c.-5G>A Benign(Last reviewed: Jul 3, 2018)

VCV000126341

NM_003070.5(SMARCA2):c.234910del

Benign(Last reviewed: Jul 30, 2020) VCV001277235

NM_003070.5(SMARCA2):c.3672G
>A (p.Glu1224=)
Benign(Last reviewed: Jul 31, 2018) VCV000126346
NM_003070.5(SMARCA2):c.683A>
C (p.Gln228Pro)
Benign(Last reviewed: Jul 31, 2018) VCV000126351
NM_003070.5(SMARCA2):c.3762+ Benign(Last reviewed: Jun 16,
47C>T
2020)

VCV001250497

NM_003070.5(SMARCA2):c.3292+ Benign(Last reviewed: Jun 16,
25G>A
2021)

VCV001247000

GRCh37/hg19
9p24.3(chr9:2143543-2151371)x0

Benign(Last reviewed: Jun 21,
2012)

VCV000611461

NM_003070.5(SMARCA2):c.4218G Benign(Last reviewed: Jun 24,
>A (p.Val1406=)
2019)

VCV001337262

NM_003070.5(SMARCA2):c.225+2 Benign(Last reviewed: Jun 25,
8C>G
2020)

VCV001273778

NM_003070.5(SMARCA2):c.218544C>G

Benign(Last reviewed: Jun 29,
2020)

VCV001236102

NM_003070.5(SMARCA2):c.1806C Benign(Last reviewed: Jun 30,
>T (p.Thr602=)
2021)

VCV000366208

NM_003070.5(SMARCA2):c.689A>
C (p.Gln230Pro)
Benign(Last reviewed: Mar 1, 2021) VCV000912949
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NM_003070.5(SMARCA2):c.1422G Benign(Last reviewed: Mar 14,
>A (p.Gln474=)
2019)

VCV000366205

NM_003070.5(SMARCA2):c.459533C>T

Benign(Last reviewed: Mar 19,
2020)

VCV001229573

NM_003070.5(SMARCA2):c.4736G Benign(Last reviewed: Mar 20,
>A (p.Arg1579His)
2018)

VCV000912460

NM_003070.5(SMARCA2):c.45957G>C

Benign(Last reviewed: Mar 20,
2020)

VCV000366320

NM_003070.5(SMARCA2):c.234922G>T

Benign(Last reviewed: Mar 21,
2020)

VCV001243045

NM_003070.5(SMARCA2):c.1510C Benign(Last reviewed: Mar 22,
>A (p.Arg504=)
2021)

VCV001294473

NM_003070.5(SMARCA2):c.597C> Benign(Last reviewed: Mar 26,
T (p.Pro199=)
2018)

VCV000914909

NM_003070.5(SMARCA2):c.312617C>T

Benign(Last reviewed: Mar 26,
2020)

VCV001252991

NM_003070.5(SMARCA2):c.459522A>G

Benign(Last reviewed: Mar 27,
2020)

VCV001175587

NM_003070.5(SMARCA2):c.1521+ Benign(Last reviewed: Mar 31,
21G>A
2020)

VCV001256677

NM_003070.5(SMARCA2):c.1962G Benign(Last reviewed: Mar 31,
>A (p.Gln654=)
2020)

VCV000366210

NM_003070.5(SMARCA2):c.750A> Benign(Last reviewed: May 13,
G (p.Gln250=)
2021)

VCV000366203

NM_003070.5(SMARCA2):c.1188G Benign(Last reviewed: May 14,
>T (p.Val396=)
2021)

VCV001276895

NM_003070.5(SMARCA2):c.376347C>A

Benign(Last reviewed: May 15,
2021)

VCV001281331

NM_003070.5(SMARCA2):c.669GC Benign(Last reviewed: May 17,
A[16] (p.Gln236_Gln238dup)
2021)

VCV000587963
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NM_003070.5(SMARCA2):c.2348+ Benign(Last reviewed: May 20,
31G>A
2020)

VCV001230826

NM_003070.5(SMARCA2):c.51G>C Benign(Last reviewed: May 24,
(p.Pro17=)
2019)

VCV001245835

NM_003070.5(SMARCA2):c.104735C>A

Benign(Last reviewed: May 29,
2020)

VCV001294504

NM_003070.5(SMARCA2):c.104732C>T

Benign(Last reviewed: May 30,
2020)

VCV001278581

NM_003070.5(SMARCA2):c.174748G>C

Benign(Last reviewed: May 31,
2020)

VCV001270992

NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: May 31,
13A>G
2020)

VCV001243855

NM_003070.5(SMARCA2):c.2883+ Benign(Last reviewed: May 31,
46A>G
2020)

VCV001174411

NM_003070.5(SMARCA2):c.1046+
45C>T
Benign(Last reviewed: May 4, 2020) VCV001236579
NM_003070.5(SMARCA2):c.1046+ Benign(Last reviewed: Nov 10,
275G>C
2018)

VCV001234193

NM_003070.5(SMARCA2):c.376348C>A

Benign(Last reviewed: Nov 11,
2020)

VCV001268759

NM_003070.5(SMARCA2):c.1983C Benign(Last reviewed: Nov 23,
>A (p.Leu661=)
2020)

VCV001269159

NM_003070.5(SMARCA2):c.473828C>G

Benign(Last reviewed: Nov 25,
2020)

VCV001283447

NM_003070.5(SMARCA2):c.645G> Benign(Last reviewed: Nov 26,
A (p.Leu215=)
2021)

VCV001326519

NM_003070.5(SMARCA2):c.420047G>A

Benign(Last reviewed: Nov 4, 2020) VCV001236464

NM_003070.5(SMARCA2):c.3078+
65del
Benign(Last reviewed: Nov 7, 2019) VCV001235860
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NM_003070.5(SMARCA2):c.790+4
5G>A
Benign(Last reviewed: Nov 7, 2020) VCV001263993
NM_003070.5(SMARCA2):c.2883+
275_2883+281dup
Benign(Last reviewed: Oct 1, 2019) VCV001241962
NM_003070.5(SMARCA2):c.355+4 Benign(Last reviewed: Oct 13,
9A>C
2020)

VCV001251903

NM_003070.5(SMARCA2):c.4590C Benign(Last reviewed: Oct 15,
>T (p.Ser1530=)
2021)

VCV000126347

NM_003070.5(SMARCA2):c.376358G>A

Benign(Last reviewed: Oct 17,
2018)

VCV001286142

NM_003070.5(SMARCA2):c.29928G>A

Benign(Last reviewed: Oct 17,
2018)

VCV000366217

NM_003070.5(SMARCA2):c.187830C>T

Benign(Last reviewed: Oct 21,
2018)

VCV001256925

NM_003070.5(SMARCA2):c.567T> Benign(Last reviewed: Oct 27,
C (p.Tyr189=)
2021)

VCV001302893

NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: Oct 29,
175TG[25]
2019)

VCV001269625

NM_003070.5(SMARCA2):c.4359+ Benign(Last reviewed: Oct 31,
98G>C
2018)

VCV001280456

NM_003070.5(SMARCA2):c.4462122A>C

VCV001224274

Benign(Last reviewed: Oct 31,
2018)

NM_003070.5(SMARCA2):c.1521+
44G>A
Benign(Last reviewed: Oct 9, 2018) VCV001282827
NM_003070.5(SMARCA2):c.2037185G>T

Benign(Last reviewed: Sep 1, 2018) VCV001274285

NM_003070.5(SMARCA2):c.345779T>C

Benign(Last reviewed: Sep 1, 2018) VCV001271671

NM_003070.5(SMARCA2):c.376334T>G

Benign(Last reviewed: Sep 1, 2018) VCV001267888
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NM_003070.5(SMARCA2):c.174786C>G

Benign(Last reviewed: Sep 1, 2018) VCV001247753

NM_003070.5(SMARCA2):c.187884A>G

Benign(Last reviewed: Sep 1, 2018) VCV001230525

NM_003070.5(SMARCA2):c.376335C>T

Benign(Last reviewed: Sep 1, 2018) VCV001181741

NM_003070.5(SMARCA2):c.1428C Benign(Last reviewed: Sep 14,
>G (p.Leu476=)
2021)

VCV001302814

NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: Sep 18,
175TG[18]
2020)

VCV001268087

NM_003070.5(SMARCA2):c.2883+
270_2883+281dup
Benign(Last reviewed: Sep 2, 2019) VCV001246625
NM_003070.5(SMARCA2):c.2526+ Benign(Last reviewed: Sep 20,
175TG[21]
2019)

VCV001273314

NM_003070.5(SMARCA2):c.3078+ Benign(Last reviewed: Sep 23,
88del
2019)

VCV001282504

NM_003070.5(SMARCA2):c.2991+ Benign(Last reviewed: Sep 23,
10G>T
2020)

VCV001275606

NM_003070.5(SMARCA2):c.4359+ Benign(Last reviewed: Sep 23,
46G>A
2021)

VCV001300281

NM_003070.5(SMARCA2):c.23493T>C

Benign(Last reviewed: Sep 29,
2021)

VCV000366211

GRCh37/hg19
9p24.3(chr9:2149063-2151371)x1

Benign(Last reviewed: Sep 30,
2010)

VCV000611462

NM_003070.5(SMARCA2):c.3684+
341G>A
Benign(Last reviewed: Sep 4, 2018) VCV001296684
NM_003070.5(SMARCA2):c.4200134G>A

Benign(Last reviewed: Sep 4, 2018) VCV001228734

NM_003070.5(SMARCA2):c.174G>
A (p.Pro58=)
Benign(Last reviewed: Sep 4, 2018) VCV000126343
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NM_003070.5(SMARCA2):c.717G>
A (p.Pro239=)
Benign(Last reviewed: Sep 5, 2018) VCV000126354
NM_003070.5(SMARCA2):c.2526+
175TG[24]
Benign(Last reviewed: Sep 8, 2019) VCV001244021
NM_003070.5(SMARCA2):c.2883+
274_2883+281dup
Benign(Last reviewed: Sep 9, 2019) VCV001274602
NM_003070.5(SMARCA2):c.234910dup

Benign(Last reviewed: Sep 9, 2019) VCV001183167

NM_003070.5(SMARCA2):c.669GC Benign/Likely benign(Last reviewed:
A[17] (p.Gln235_Gln238dup)
Apr 15, 2021)
VCV000588473

NM_003070.5(SMARCA2):c.677A> Benign/Likely benign(Last reviewed:
C (p.Gln226Pro)
Apr 2, 2019)
VCV000366199

NM_003070.5(SMARCA2):c.4257A Benign/Likely benign(Last reviewed:
>C (p.Ser1419=)
Apr 25, 2021)
VCV000366236

NM_003070.5(SMARCA2):c.210G> Benign/Likely benign(Last reviewed:
A (p.Met70Ile)
Apr 30, 2020)
VCV000588943

NM_003070.5(SMARCA2):c.1737G Benign/Likely benign(Last reviewed:
>A (p.Pro579=)
Apr 7, 2021)
VCV000366206

NM_003070.5(SMARCA2):c.669GC Benign/Likely benign(Last reviewed:
A[12] (p.Gln238del)
Aug 12, 2019)
VCV000126353

NM_003070.5(SMARCA2):c.7917C>T

Benign/Likely benign(Last reviewed:
Aug 25, 2020)
VCV000366204

NM_003070.5(SMARCA2):c.4029T Benign/Likely benign(Last reviewed:
>G (p.Leu1343=)
Dec 1, 2020)
VCV000366231
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NM_003070.5(SMARCA2):c.246C> Benign/Likely benign(Last reviewed:
T (p.Asp82=)
Dec 12, 2019)
VCV000366195

NM_003070.5(SMARCA2):c.459G> Benign/Likely benign(Last reviewed:
A (p.Pro153=)
Dec 2, 2020)
VCV000914397

NM_003070.5(SMARCA2):c.4717G Benign/Likely benign(Last reviewed:
>A (p.Asp1573Asn)
Dec 31, 2019)
VCV000366324

NM_003070.5(SMARCA2):c.1122C Benign/Likely benign(Last reviewed:
>G (p.Thr374=)
Dec 4, 2020)
VCV000126342

NM_003070.5(SMARCA2):c.669GC Benign/Likely benign(Last reviewed:
A[10] (p.Gln236_Gln238del)
Feb 1, 2022)
VCV000212231

NM_003070.5(SMARCA2):c.2733A Benign/Likely benign(Last reviewed:
>G (p.Gln911=)
Feb 10, 2022)
VCV000588361

NM_003070.5(SMARCA2):c.4440G Benign/Likely benign(Last reviewed:
>A (p.Thr1480=)
Feb 19, 2020)
VCV000366243

NM_003070.5(SMARCA2):c.4761G Benign/Likely benign(Last reviewed:
>A (p.Thr1587=)
Feb 4, 2020)
VCV000366327

NM_003070.5(SMARCA2):c.680A> Benign/Likely benign(Last reviewed:
C (p.Gln227Pro)
Jan 13, 2018)
VCV000588909

NM_003070.5(SMARCA2):c.3438C Benign/Likely benign(Last reviewed:
>T (p.Ser1146=)
Jan 18, 2019)
VCV000366220

NM_003070.5(SMARCA2):c.669G> Benign/Likely benign(Last reviewed:
A (p.Gln223=)
Jan 18, 2019)
VCV000366198

NM_003070.5(SMARCA2):c.666A> Benign/Likely benign(Last reviewed:
G (p.Gln222=)
Jan 4, 2019)
VCV000366197
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NM_003070.5(SMARCA2):c.3282A Benign/Likely benign(Last reviewed:
>G (p.Leu1094=)
Jul 8, 2019)
VCV000588468

NM_003070.5(SMARCA2):c.483G> Benign/Likely benign(Last reviewed:
T (p.Pro161=)
Jun 1, 2021)
VCV000366196

NM_003070.5(SMARCA2):c.513C> Benign/Likely benign(Last reviewed:
A (p.Pro171=)
Jun 10, 2019)
VCV000212229

NM_003070.5(SMARCA2):c.2136G Benign/Likely benign(Last reviewed:
>A (p.Val712=)
Jun 26, 2019)
VCV000588159

NM_003070.5(SMARCA2):c.4479C Benign/Likely benign(Last reviewed:
>T (p.Ile1493=)
Mar 1, 2021)
VCV000914528

NM_003070.5(SMARCA2):c.4207G Benign/Likely benign(Last reviewed:
>A (p.Val1403Met)
Mar 11, 2020)
VCV000366232

NM_003070.5(SMARCA2):c.3843C Benign/Likely benign(Last reviewed:
>T (p.Pro1281=)
Mar 25, 2021)
VCV000588558

NM_003070.5(SMARCA2):c.42004G>A

Benign/Likely benign(Last reviewed:
Mar 5, 2020)
VCV000588141

NM_003070.5(SMARCA2):c.685_68 Benign/Likely benign(Last reviewed:
6insCGC (p.Gln229_Gln230insPro) May 9, 2020)
VCV000588299

NM_003070.5(SMARCA2):c.4646G Benign/Likely benign(Last reviewed:
>A (p.Arg1549Gln)
Nov 2, 2018)
VCV000915171

NM_003070.5(SMARCA2):c.669GC Benign/Likely benign(Last reviewed:
A[15] (p.Gln237_Gln238dup)
Nov 20, 2020)
VCV000436800

NM_003070.5(SMARCA2):c.669GC Benign/Likely benign(Last reviewed:
A[8] (p.Gln234_Gln238del)
Nov 5, 2018)
VCV000212230
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NM_003070.5(SMARCA2):c.4699G Benign/Likely benign(Last reviewed:
>C (p.Val1567Leu)
Oct 10, 2019)
VCV000366322

NM_003070.5(SMARCA2):c.4731T Benign/Likely benign(Last reviewed:
>C (p.Asp1577=)
Oct 14, 2020)
VCV000588668

Conflicting interpretations of
NM_003070.5(SMARCA2):c.844G> pathogenicity(Last reviewed: Aug 2,
A (p.Ala282Thr)
2019)
VCV000588156

Conflicting interpretations of
NM_003070.5(SMARCA2):c.876C> pathogenicity(Last reviewed: Dec 2,
T (p.Pro292=)
2020)
VCV000913314

Conflicting interpretations of
NM_003070.5(SMARCA2):c.2810G pathogenicity(Last reviewed: Feb
>A (p.Arg937His)
18, 2022)

VCV000827774

Conflicting interpretations of
NM_003070.5(SMARCA2):c.669GC pathogenicity(Last reviewed: Jan 1,
A[19] (p.Gln233_Gln238dup)
2019)
VCV000126352

Conflicting interpretations of
NM_003070.5(SMARCA2):c.175A> pathogenicity(Last reviewed: Jan
T (p.Thr59Ser)
13, 2018)

VCV000366194

Conflicting interpretations of
NM_003070.5(SMARCA2):c.3229T pathogenicity(Last reviewed: Jan 3,
>A (p.Ser1077Thr)
2020)
VCV001311593

Conflicting interpretations of
NM_003070.5(SMARCA2):c.2361C pathogenicity(Last reviewed: Jun
>A (p.Asn787Lys)
10, 2021)
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VCV000694693

Conflicting interpretations of
NM_003070.5(SMARCA2):c.2348C pathogenicity(Last reviewed: Jun
>T (p.Ser783Leu)
10, 2021)

VCV000561113

Conflicting interpretations of
NM_003070.5(SMARCA2):c.1514G pathogenicity(Last reviewed: Mar
>A (p.Arg505Gln)
25, 2020)

VCV000829813

Conflicting interpretations of
NM_003070.5(SMARCA2):c.1854C pathogenicity(Last reviewed: May
>T (p.Asp618=)
13, 2021)

VCV000212224

NM_003070.5(SMARCA2):c.225+1 Likely benign(Last reviewed: Apr 1,
45G>A
2019)

VCV001185805

NM_003070.5(SMARCA2):c.3492G Likely benign(Last reviewed: Apr 15,
>A (p.Gly1164=)
2021)
VCV001309084

NM_003070.5(SMARCA2):c.400G> Likely benign(Last reviewed: Apr 21,
A (p.Val134Ile)
2017)
VCV000589374

NM_003070.5(SMARCA2):c.2883+ Likely benign(Last reviewed: Apr 29,
203G>A
2019)
VCV001210931

NM_003070.5(SMARCA2):c.669GC Likely benign(Last reviewed: Apr 4,
A[11] (p.Gln237_Gln238del)
2018)

VCV000587879

NM_003070.5(SMARCA2):c.1935+ Likely benign(Last reviewed: Apr 5,
23G>T
2021)

VCV001300815

NM_003070.5(SMARCA2):c.4716C Likely benign(Last reviewed: Apr 7,
>T (p.Ser1572=)
2021)

VCV001301136
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NM_003070.5(SMARCA2):c.218593A>G

Likely benign(Last reviewed: Apr 9,
2019)

VCV001213498

NM_003070.5(SMARCA2):c.1408G Likely benign(Last reviewed: Aug 1,
>T (p.Ala470Ser)
2019)
VCV000810344

NM_003070.5(SMARCA2):c.420057G>A

Likely benign(Last reviewed: Aug
10, 2018)

VCV001180191

NM_003070.5(SMARCA2):c.3078+ Likely benign(Last reviewed: Aug
65dup
10, 2019)

VCV001215316

NM_003070.5(SMARCA2):c.2348+ Likely benign(Last reviewed: Aug
312GT[23]
10, 2019)

VCV001204968

NM_003070.5(SMARCA2):c.2348+ Likely benign(Last reviewed: Aug
312GT[19]
11, 2019)

VCV001215668

NM_003070.5(SMARCA2):c.226234AAAC[7]

Likely benign(Last reviewed: Aug
13, 2019)

VCV001219596

NM_003070.5(SMARCA2):c.4253+ Likely benign(Last reviewed: Aug
135G>A
17, 2018)

VCV001219728

NM_003070.5(SMARCA2):c.-36205T>C

Likely benign(Last reviewed: Aug
17, 2018)

VCV001191112

NM_003070.5(SMARCA2):c.902C> Likely benign(Last reviewed: Aug
T (p.Ala301Val)
25, 2021)

VCV001254900

NM_003070.5(SMARCA2):c.704_70
5insACAACAGCAGCC
Likely benign(Last reviewed: Aug
(p.236QQQP[3])
26, 2021)

VCV001254928

NM_003070.5(SMARCA2):c.4479C Likely benign(Last reviewed: Aug 3,
>G (p.Ile1493Met)
2020)
VCV001337600
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NM_003070.5(SMARCA2):c.3882C Likely benign(Last reviewed: Aug
>G (p.Leu1294=)
30, 2016)

VCV000589368

NM_003070.5(SMARCA2):c.398224G>A

Likely benign(Last reviewed: Aug
31, 2018)

VCV001219608

NM_003070.5(SMARCA2):c.4461+ Likely benign(Last reviewed: Aug
204G>A
31, 2018)

VCV001206728

NM_003070.5(SMARCA2):c.226123T>C

Likely benign(Last reviewed: Aug 8,
2018)
VCV001209526

NM_003070.5(SMARCA2):c.4359+ Likely benign(Last reviewed: Aug 8,
126G>A
2018)
VCV001201328

NM_003070.5(SMARCA2):c.1348113C>G

Likely benign(Last reviewed: Aug 8,
2018)
VCV001197819

NM_003070.5(SMARCA2):c.2883+ Likely benign(Last reviewed: Aug 8,
107G>C
2018)
VCV001194879

NM_003070.5(SMARCA2):c.1522182G>A

Likely benign(Last reviewed: Dec 1,
2018)
VCV001218462

NM_003070.5(SMARCA2):c.1348150G>C

Likely benign(Last reviewed: Dec 1,
2018)
VCV001195815

NM_003070.5(SMARCA2):c.1201C Likely benign(Last reviewed: Dec 1,
>T (p.Arg401Cys)
2020)
VCV001197110

NM_003070.5(SMARCA2):c.2929C Likely benign(Last reviewed: Dec
>T (p.Leu977=)
14, 2021)

VCV001327749

NM_003070.5(SMARCA2):c.436016C>G

VCV001217641

Likely benign(Last reviewed: Dec
17, 2018)
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NM_003070.5(SMARCA2):c.3457319T>C

Likely benign(Last reviewed: Dec
17, 2018)

VCV001199594

NM_003070.5(SMARCA2):c.1174122T>C

Likely benign(Last reviewed: Dec
17, 2018)

VCV001197362

NM_003070.5(SMARCA2):c.1173+ Likely benign(Last reviewed: Dec
130G>C
17, 2018)

VCV001191289

NM_003070.5(SMARCA2):c.2036+ Likely benign(Last reviewed: Dec
217T>C
17, 2018)

VCV001187328

NM_003070.5(SMARCA2):c.666_68 Likely benign(Last reviewed: Dec
3del (p.Gln233_Gln238del)
17, 2021)

VCV001328645

NM_003070.5(SMARCA2):c.2805C Likely benign(Last reviewed: Dec
>T (p.Ile935=)
23, 2016)

VCV000588587

NM_003070.5(SMARCA2):c.681G> Likely benign(Last reviewed: Dec
A (p.Gln227=)
26, 2019)

VCV001188115

NM_003070.5(SMARCA2):c.3192G Likely benign(Last reviewed: Dec
>A (p.Ala1064=)
30, 2015)

VCV000436799

NM_003070.5(SMARCA2):c.2185234C>G

Likely benign(Last reviewed: Dec 5,
2018)
VCV001190753

NM_003070.5(SMARCA2):c.2526+ Likely benign(Last reviewed: Dec 5,
52T>G
2020)
VCV001197473

NM_003070.5(SMARCA2):c.2154C Likely benign(Last reviewed: Dec 8,
>G (p.Leu718=)
2020)
VCV001320537

NM_003070.5(SMARCA2):c.3267G Likely benign(Last reviewed: Feb
>A (p.Arg1089=)
13, 2020)
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VCV000366219

NM_003070.5(SMARCA2):c.3555C Likely benign(Last reviewed: Feb
>T (p.Leu1185=)
23, 2021)

VCV000588117

NM_003070.5(SMARCA2):c.2184+ Likely benign(Last reviewed: Jan 1,
5T>C
2017)

VCV000562022

NM_003070.5(SMARCA2):c.3230C Likely benign(Last reviewed: Jan 1,
>G (p.Ser1077Cys)
2019)

VCV000982924

NM_003070.5(SMARCA2):c.4461+ Likely benign(Last reviewed: Jan 1,
3C>G
2019)

VCV000982825

NM_003070.5(SMARCA2):c.4080T Likely benign(Last reviewed: Jan 12,
>G (p.Asp1360Glu)
2018)
VCV000914996

NM_003070.5(SMARCA2):c.750A> Likely benign(Last reviewed: Jan 12,
T (p.Gln250His)
2018)
VCV000913313

NM_003070.5(SMARCA2):c.*29C> Likely benign(Last reviewed: Jan 12,
T
2018)
VCV000366331

NM_003070.5(SMARCA2):c.4206C Likely benign(Last reviewed: Jan 13,
>T (p.Asn1402=)
2018)
VCV000914997

NM_003070.5(SMARCA2):c.957C> Likely benign(Last reviewed: Jan 13,
G (p.Leu319=)
2018)
VCV000913316

NM_003070.5(SMARCA2):c.4725G Likely benign(Last reviewed: Jan 13,
>A (p.Glu1575=)
2018)
VCV000366325

NM_003070.5(SMARCA2):c.4029T Likely benign(Last reviewed: Jan 13,
>A (p.Leu1343=)
2018)
VCV000366230

NM_003070.5(SMARCA2):c.1746+ Likely benign(Last reviewed: Jan 13,
10C>T
2018)
VCV000366207
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NM_003070.5(SMARCA2):c.174711C>A

Likely benign(Last reviewed: Jan 25,
2021)
VCV001193234

NM_003070.5(SMARCA2):c.1521+ Likely benign(Last reviewed: Jan 28,
55A>G
2019)
VCV001210650

NM_003070.5(SMARCA2):c.2762G Likely benign(Last reviewed: Jan 8,
>T (p.Gly921Val)
2021)

VCV001337248

NM_003070.5(SMARCA2):c.35655T>C

Likely benign(Last reviewed: Jul 26,
2018)
VCV001211670

NM_003070.5(SMARCA2):c.187827C>T

Likely benign(Last reviewed: Jul 27,
2020)
VCV001209310

NM_003070.5(SMARCA2):c.704A> Likely benign(Last reviewed: Jul 29,
C (p.Gln235Pro)
2021)
VCV001219703

NM_003070.5(SMARCA2):c.2883+ Likely benign(Last reviewed: Jul 7,
37dup
2020)

VCV001206659

NM_003070.5(SMARCA2):c.*355du Likely benign(Last reviewed: Jun 14,
p
2016)
VCV000366336

NM_003070.5(SMARCA2):c.701A> Likely benign(Last reviewed: Jun 14,
C (p.Gln234Pro)
2016)
VCV000366201

NM_003070.5(SMARCA2):c.4509G Likely benign(Last reviewed: Jun 16,
>A (p.Arg1503=)
2021)
VCV001328668

NM_003070.5(SMARCA2):c.4595261_4595-254del

Likely benign(Last reviewed: Jun 17,
2020)
VCV001189961

NM_003070.5(SMARCA2):c.667_66 Likely benign(Last reviewed: Jun 17,
8insCAG (p.Gln223delinsProGlu)
2021)
VCV001328660
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NM_003070.5(SMARCA2):c.744G> Likely benign(Last reviewed: Jun 18,
A (p.Thr248=)
2016)
VCV000589294

NM_003070.5(SMARCA2):c.682_68 Likely benign(Last reviewed: Jun 22,
3insCGC (p.Gln228_Gln229insPro) 2021)
VCV001329651

NM_003070.5(SMARCA2):c.459548C>T

Likely benign(Last reviewed: Jun 24,
2021)
VCV001329774

NM_003070.5(SMARCA2):c.4738281del

Likely benign(Last reviewed: Jun 5,
2019)

VCV001202877

NM_003070.5(SMARCA2):c.4462312A>G

Likely benign(Last reviewed: Jun 5,
2019)

VCV001187510

NM_003070.5(SMARCA2):c.3729T Likely benign(Last reviewed: Mar 1,
>A (p.Ile1243=)
2018)
VCV000810347

NM_003070.5(SMARCA2):c.3191C Likely benign(Last reviewed: Mar
>T (p.Ala1064Val)
12, 2021)

VCV001254664

NM_003070.5(SMARCA2):c.1676G Likely benign(Last reviewed: Mar
GA[3] (p.Arg562del)
13, 2020)

VCV001218335

NM_003070.5(SMARCA2):c.669GC Likely benign(Last reviewed: Mar
A[18] (p.Gln234_Gln238dup)
17, 2021)

VCV001209185

NM_003070.5(SMARCA2):c.3292+ Likely benign(Last reviewed: Mar
35C>G
19, 2019)

VCV001197398

Likely benign(Last reviewed: Mar
NM_003070.5(SMARCA2):c.*9G>C 20, 2020)

VCV000366329

NM_003070.5(SMARCA2):c.7916C>T

VCV000680332

Likely benign(Last reviewed: Mar
21, 2018)
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NM_003070.5(SMARCA2):c.1664A Likely benign(Last reviewed: Mar
GA[3] (p.Lys558del)
25, 2020)

VCV001198505

NM_003070.5(SMARCA2):c.2991+ Likely benign(Last reviewed: Mar
40A>G
27, 2021)

VCV001300383

NM_003070.5(SMARCA2):c.3963G Likely benign(Last reviewed: Mar
>A (p.Thr1321=)
29, 2017)

VCV000588973

NM_003070.5(SMARCA2):c.4254319_4254-317dup

VCV001199480

Likely benign(Last reviewed: Mar
29, 2019)

NM_003070.5(SMARCA2):c.669GC Likely benign(Last reviewed: Mar 3,
A[9] (p.Gln235_Gln238del)
2021)
VCV000588716

NM_003070.5(SMARCA2):c.2883+ Likely benign(Last reviewed: Mar
27G>T
31, 2020)

VCV001207787

NM_003070.5(SMARCA2):c.695_71 Likely benign(Last reviewed: Mar 9,
5del (p.Gln232_Gln238del)
2020)
VCV001182585

NM_003070.5(SMARCA2):c.4764T Likely benign(Last reviewed: Mar 9,
>A (p.Asp1588Glu)
2021)
VCV001342724

NM_003070.5(SMARCA2):c.2532G Likely benign(Last reviewed: Mar 9,
>A (p.Arg844=)
2021)
VCV001300851

NM_003070.5(SMARCA2):c.2244C Likely benign(Last reviewed: May
>T (p.Ala748=)
18, 2021)

VCV001327195

NM_003070.5(SMARCA2):c.669GC Likely benign(Last reviewed: May
A[3] (p.Gln229_Gln238del)
24, 2021)

VCV001338913

NM_003070.5(SMARCA2):c.4595182C>G

VCV001213233

Likely benign(Last reviewed: May
26, 2019)
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NM_003070.5(SMARCA2):c.2211C Likely benign(Last reviewed: May 5,
>T (p.Ser737=)
2021)
VCV001327677

NM_003070.5(SMARCA2):c.1347+ Likely benign(Last reviewed: May 8,
206dup
2020)
VCV001207419

NM_003070.5(SMARCA2):c.1035G Likely benign(Last reviewed: Nov 1,
>A (p.Glu345=)
2021)
VCV001335724

NM_003070.5(SMARCA2):c.1890C Likely benign(Last reviewed: Nov
>T (p.Ala630=)
11, 2020)

VCV001301177

NM_003070.5(SMARCA2):c.1173+ Likely benign(Last reviewed: Nov
299G>T
22, 2018)

VCV001202248

NM_003070.5(SMARCA2):c.3762+ Likely benign(Last reviewed: Nov
250A>G
25, 2018)

VCV001200301

NM_003070.5(SMARCA2):c.226234AAAC[8]

Likely benign(Last reviewed: Nov 3,
2019)
VCV001194512

NM_003070.5(SMARCA2):c.669GC Likely benign(Last reviewed: Nov 9,
A[6] (p.Gln232_Gln238del)
2020)
VCV000587833

NM_003070.5(SMARCA2):c.4594+ Likely benign(Last reviewed: Oct 14,
165C>T
2018)
VCV001204791

NM_003070.5(SMARCA2):c.1047129G>A

Likely benign(Last reviewed: Oct 16,
2018)
VCV001214208

NM_003070.5(SMARCA2):c.2184+ Likely benign(Last reviewed: Oct 16,
45A>G
2018)
VCV001190752

NM_003070.5(SMARCA2):c.152219G>A

Likely benign(Last reviewed: Oct 16,
2018)
VCV001186042
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NM_003070.5(SMARCA2):c.3126285T>C

Likely benign(Last reviewed: Oct 17,
2018)
VCV001198678

NM_003070.5(SMARCA2):c.3079139C>T

Likely benign(Last reviewed: Oct 17,
2018)
VCV001179267

NM_003070.5(SMARCA2):c.4200131_4200-130insCTT

Likely benign(Last reviewed: Oct 20,
2020)
VCV001194536

NM_003070.5(SMARCA2):c.3684+ Likely benign(Last reviewed: Oct 21,
24A>T
2018)
VCV001205159

NM_003070.5(SMARCA2):c.2348+ Likely benign(Last reviewed: Oct 28,
312GT[20]
2019)
VCV001203724

NM_003070.5(SMARCA2):c.1521+ Likely benign(Last reviewed: Oct 31,
48G>A
2018)
VCV001200685

NM_003070.5(SMARCA2):c.3981+ Likely benign(Last reviewed: Oct 5,
235G>A
2018)

VCV001208309

NM_003070.5(SMARCA2):c.708_72 Likely benign(Last reviewed: Oct 6,
2del (p.Gln238_Gln242del)
2020)

VCV001211740

NM_003070.5(SMARCA2):c.3274C Likely benign(Last reviewed: Oct 7,
>G (p.Leu1092Val)
2019)

VCV001202936

NM_003070.5(SMARCA2):c.3292+ Likely benign(Last reviewed: Oct 9,
99T>C
2018)

VCV001203402

NM_003070.5(SMARCA2):c.1173+ Likely benign(Last reviewed: Oct 9,
274T>C
2018)

VCV001195577

NM_003070.5(SMARCA2):c.4738271T>G

Likely benign(Last reviewed: Sep 1,
2018)
VCV001180080
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NM_003070.5(SMARCA2):c.2416143C>G

Likely benign(Last reviewed: Sep 2,
2019)
VCV001218779

NM_003070.5(SMARCA2):c.3384T Likely benign(Last reviewed: Sep
>C (p.Ala1128=)
26, 2018)

VCV001336892

NM_003070.5(SMARCA2):c.666_68 Likely benign(Last reviewed: Sep
6del (p.Gln232_Gln238del)
26, 2020)

VCV001212093

NM_003070.5(SMARCA2):c.356220dup

VCV001192109

Likely benign(Last reviewed: Sep
30, 2019)

NM_003070.5(SMARCA2):c.3762+ Likely benign(Last reviewed: Sep 4,
182G>A
2018)
VCV001213430

NM_003070.5(SMARCA2):c.4594+ Likely benign(Last reviewed: Sep 4,
95C>A
2018)
VCV001212574

NM_003070.5(SMARCA2):c.2036+ Likely benign(Last reviewed: Sep 4,
64T>C
2018)
VCV001196254

NM_003070.5(SMARCA2):c.4594+ Likely benign(Last reviewed: Sep 4,
152G>T
2018)
VCV001193834

NM_003070.5(SMARCA2):c.2185271C>T

Likely benign(Last reviewed: Sep 4,
2018)
VCV001185727

NM_003070.5(SMARCA2):c.791134_791-133del

Likely benign(Last reviewed: Sep 5,
2019)
VCV001186369

NM_003070.5(SMARCA2):c.2526+ Likely benign(Last reviewed: Sep 6,
214_2526+215insGGTGTG
2019)
VCV001220119

NM_003070.5(SMARCA2):c.2883+ Likely benign(Last reviewed: Sep 8,
271_2883+281dup
2019)
VCV001219783
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NM_001289396.1:c.[3495G>C(;)39
17G>A]
Likely pathogenic

VCV000374221

NM_003070.5(SMARCA2):c.1538G
>T (p.Gly513Val)
Likely pathogenic

VCV000829812

NM_003070.5(SMARCA2):c.2809C
>T (p.Arg937Cys)
Likely pathogenic

VCV000827771

NM_003070.5(SMARCA2):c.1600G
>A (p.Asp534Asn)
Likely pathogenic

VCV000827769

GRCh37/hg19 9p24.324.1(chr9:1232387-4611862)x1

VCV000396183

Likely pathogenic

NM_003070.5(SMARCA2):c.787T> Likely pathogenic(Last reviewed:
A (p.Ser263Thr)
Apr 1, 2020)

VCV000978583

NM_003070.5(SMARCA2):c.2834T Likely pathogenic(Last reviewed:
>G (p.Phe945Cys)
Apr 11, 2017)

VCV000449924

NM_003070.5(SMARCA2):c.3490G Likely pathogenic(Last reviewed:
>A (p.Gly1164Arg)
Aug 1, 2021)

VCV001299136

NM_003070.5(SMARCA2):c.3612T Likely pathogenic(Last reviewed:
>G (p.Phe1204Leu)
Aug 24, 2016)

VCV000430455

NM_003070.5(SMARCA2):c.1600G Likely pathogenic(Last reviewed:
>C (p.Asp534His)
Aug 24, 2016)

VCV000988516

NM_003070.5(SMARCA2):c.34572A>T

Likely pathogenic(Last reviewed:
Aug 7, 2020)

VCV000981460

GRCh37/hg19 9p24.311.2(chr9:204193-44259464)x4

Likely pathogenic(Last reviewed:
Dec 19, 2016)

VCV000559575

NM_003070.5(SMARCA2):c.3021C Likely pathogenic(Last reviewed:
>G (p.Asn1007Lys)
Dec 29, 2015)

VCV000265528
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NM_003070.5(SMARCA2):c.3849G Likely pathogenic(Last reviewed:
>T (p.Trp1283Cys)
Dec 8, 2016)

VCV000373701

NM_003070.5(SMARCA2):c.3236T Likely pathogenic(Last reviewed:
>C (p.Met1079Thr)
Feb 12, 2016)

VCV000432081

NM_003070.5(SMARCA2):c.1600G Likely pathogenic(Last reviewed: Jul
>T (p.Asp534Tyr)
22, 2014)
VCV000217002

NM_003070.5(SMARCA2):c.2639C Likely pathogenic(Last reviewed:
>A (p.Thr880Asn)
Jun 1, 2021)

VCV001176897

NM_003070.5(SMARCA2):c.2254G Likely pathogenic(Last reviewed:
>A (p.Gly752Arg)
Jun 10, 2021)

VCV001032869

NM_003070.5(SMARCA2):c.3599A Likely pathogenic(Last reviewed:
>C (p.Gln1200Pro)
Jun 24, 2016)

VCV000976221

NM_003070.5(SMARCA2):c.3482A Likely pathogenic(Last reviewed:
>G (p.His1161Arg)
Jun 3, 2014)

VCV000217001

NM_003070.5(SMARCA2):c.473del Likely pathogenic(Last reviewed:
(p.Pro158fs)
Mar 8, 2019)

VCV000817478

NM_003070.5(SMARCA2):c.3441C Likely pathogenic(Last reviewed:
>A (p.Asp1147Glu)
Mar 9, 2020)

VCV000988739

NM_003070.5(SMARCA2):c.3314G Likely pathogenic(Last reviewed:
>T (p.Arg1105Leu)
May 1, 2019)

VCV000810345

NM_003070.5(SMARCA2):c.3587A Likely pathogenic(Last reviewed:
>C (p.Gln1196Pro)
May 28, 2019)

VCV000802455

NM_003070.5(SMARCA2):c.2737T Likely pathogenic(Last reviewed:
>C (p.Phe913Leu)
May 31, 2016)

VCV000521074
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NM_003070.5(SMARCA2):c.1553T Likely pathogenic(Last reviewed:
>C (p.Ile518Thr)
May 6, 2020)

VCV000992996

NM_003070.5(SMARCA2):c.3456G Likely pathogenic(Last reviewed:
>C (p.Gln1152His)
May 8, 2017)

VCV000429419

NM_003070.5(SMARCA2):c.3562G Likely pathogenic(Last reviewed:
>A (p.Ala1188Thr)
Nov 10, 2016)

VCV000369656

NM_003070.5(SMARCA2):c.1601A Likely pathogenic(Last reviewed:
>G (p.Asp534Gly)
Nov 3, 2021)

VCV001319165

NM_003070.5(SMARCA2):c.1540T Likely pathogenic(Last reviewed:
>C (p.Tyr514His)
Oct 12, 2017)

VCV000452666

NM_003070.5(SMARCA2):c.3493C Likely pathogenic(Last reviewed:
>A (p.Gln1165Lys)
Oct 24, 2014)

VCV000212227

NM_003070.5(SMARCA2):c.3962C Likely pathogenic(Last reviewed:
>T (p.Thr1321Met)
Oct 26, 2020)

VCV001285425

NM_003070.5(SMARCA2):c.2648C Likely pathogenic(Last reviewed:
>A (p.Pro883Gln)
Oct 31, 2018)

VCV000436804

NM_003070.5(SMARCA2):c.2326T Likely pathogenic(Last reviewed:
>C (p.Tyr776His)
Oct 4, 2016)

VCV000521300

NM_003070.5(SMARCA2):c.2342C Likely pathogenic(Last reviewed:
>G (p.Pro781Arg)
Sep 10, 2020)

VCV000981428

NM_003070.5(SMARCA2):c.3623C Likely pathogenic(Last reviewed:
>G (p.Ser1208Cys)
Sep 10, 2020)

VCV000981388

NM_003070.5(SMARCA2):c.2348C Likely pathogenic(Last reviewed:
>G (p.Ser783Trp)
Sep 10, 2020)

VCV000436803
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NM_003070.5(SMARCA2):c.1574G Likely pathogenic(Last reviewed:
>A (p.Arg525His)
Sep 10, 2020)

VCV000829814

NM_003070.5(SMARCA2):c.2786A Likely pathogenic(Last reviewed:
>T (p.Glu929Val)
Sep 10, 2020)

VCV000827770

NM_003070.5(SMARCA2):c.1538G Likely pathogenic(Last reviewed:
>A (p.Gly513Asp)
Sep 16, 2020)

VCV000979174

NM_003070.5(SMARCA2):c.2552A Likely pathogenic(Last reviewed:
>G (p.Asp851Gly)
Sep 2, 2016)

VCV000267266

GRCh37/hg19 9p24.323(chr9:203861-10700288)x3

Likely pathogenic(Last reviewed:
Sep 22, 2014)

VCV000443400

NM_003070.5(SMARCA2):c.3602C Likely pathogenic(Last reviewed:
>A (p.Ala1201Glu)
Sep 22, 2019)

VCV001206691

NM_003070.5(SMARCA2):c.1529A Likely pathogenic(Last reviewed:
>G (p.Asp510Gly)
Sep 30, 2020)

VCV000982400

NM_003070.5(SMARCA2):c.3495G no interpretation for the single
>C (p.Gln1165His)
variant

VCV000374406

NM_003070.5(SMARCA2):c.3917G no interpretation for the single
>A (p.Arg1306Lys)
variant

VCV000374405

NM_003070.5(SMARCA2):c.3614A
>G (p.Asp1205Gly)
not provided

VCV000068774

NM_003070.5(SMARCA2):c.3562G
>C (p.Ala1188Pro)
not provided

VCV000068773

NM_003070.5(SMARCA2):c.3436A
>C (p.Ser1146Arg)
not provided

VCV000068772

NM_003070.5(SMARCA2):c.3404T
>C (p.Leu1135Pro)
not provided

VCV000068771

NM_003070.5(SMARCA2):c.3314G
>C (p.Arg1105Pro)
not provided

VCV000068770
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NM_003070.5(SMARCA2):c.2838A
>T (p.Leu946Phe)
not provided

VCV000068768

NM_003070.5(SMARCA2):c.2837T
>C (p.Leu946Ser)
not provided

VCV000068767

NM_003070.5(SMARCA2):c.2641G
>C (p.Gly881Arg)
not provided

VCV000068766

NM_003070.5(SMARCA2):c.2556A
>C (p.Glu852Asp)
not provided

VCV000068763

NM_003070.5(SMARCA2):c.2551G
>C (p.Asp851His)
not provided

VCV000068761

NM_003070.5(SMARCA2):c.2264A
>G (p.Lys755Arg)
not provided

VCV000068759

NM_003070.5(SMARCA2):c.2561A
>G (p.His854Arg)
not provided

VCV000068764

NM_003070.5(SMARCA2):c.2563C
>G (p.Arg855Gly)
Pathogenic

VCV000068765

GRCh37/hg19 9p24.324.2(chr9:213161-3497920)x1

Pathogenic

VCV000395051

GRCh37/hg19 9p24.324.1(chr9:203861-5909152)x1

Pathogenic

VCV000396782

GRCh37/hg19 9p24.323(chr9:203861-11414732)x1

Pathogenic

VCV000396960

GRCh37/hg19 9p24.324.1(chr9:203861-8735462)x1

Pathogenic

VCV000395984

GRCh37/hg19 9p24.322.3(chr9:203861-14322268)x1

Pathogenic

VCV000395946

GRCh37/hg19 9p24.322.3(chr9:203861-15211277)x1

Pathogenic

VCV000396532

GRCh37/hg19 9p24.322.2(chr9:203861-16670878)x1

Pathogenic

VCV000396784
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GRCh37/hg19 9p24.322.2(chr9:203861-16856907)x1

Pathogenic

VCV000396028

GRCh37/hg19 9p24.322.2(chr9:203861-16925108)x1

Pathogenic

VCV000396012

GRCh37/hg19 9p24.322.2(chr9:204193-18073357)x1

Pathogenic

VCV000981212

GRCh37/hg19 9p24.322.2(chr9:213161-17496750)x1

Pathogenic

VCV000394262

GRCh37/hg19 9p24.313.1(chr9:32396-39140211)

Pathogenic

VCV000394346

GRCh37/hg19 9p24.3q13(chr9:203861-67983174)x4

Pathogenic

VCV000396847

GRCh37/hg19 9p24.3q13(chr9:203861-68188391)x4

Pathogenic

VCV000396397

GRCh37/hg19 9p24.3q21.11(chr9:203861-69002883)x3

Pathogenic

VCV000396594

GRCh37/hg19 9p24.3q21.11(chr9:13997-70919878)x4

Pathogenic

VCV000393860

GRCh37/hg19 9p24.3q34.3(chr9:203861-141020389)x3

Pathogenic

VCV000397469

GRCh37/hg19 9p24.3q34.3(chr9:203864-141020389)x3

Pathogenic

VCV000396494

NM_003070.5(SMARCA2):c.3395G Pathogenic(Last reviewed: Apr 1,
>A (p.Gly1132Asp)
2012)

261

VCV000031687

GRCh38/hg38 9p24.324.1(chr9:204104-5695507)x1

Pathogenic(Last reviewed: Apr 14,
2011)

VCV000148301

GRCh38/hg38 9p24.323(chr9:204104-11610300)x3

Pathogenic(Last reviewed: Apr 14,
2011)

VCV000148307

GRCh37/hg19 9p24.323(chr9:203861-14080419)x1

Pathogenic(Last reviewed: Apr 2,
2019)

VCV000815189

NM_003070.5(SMARCA2):c.3650T Pathogenic(Last reviewed: Apr 20,
>C (p.Leu1217Pro)
2018)

VCV000280814

GRCh37/hg19 9p24.3q21.33(chr9:203861-88189913)x3

Pathogenic(Last reviewed: Apr 22,
2014)

VCV000442489

GRCh38/hg38 9p24.324.1(chr9:204104-8266492)x1

Pathogenic(Last reviewed: Apr 27,
2011)

VCV000148381

GRCh38/hg38 9p24.323(chr9:204193-10164955)x1

Pathogenic(Last reviewed: Apr 29,
2013)

VCV000144246

GRCh38/hg38 9p24.313.1(chr9:203861-38381642)

Pathogenic(Last reviewed: Apr 29,
2013)

VCV000155344

GRCh38/hg38 9p24.324.1(chr9:185579-7635806)x1

Pathogenic(Last reviewed: Apr 30,
2011)

VCV000152906

GRCh38/hg38 9p24.324.1(chr9:211086-7444397)x1

Pathogenic(Last reviewed: Apr 30,
2011)

VCV000151916

GRCh38/hg38 9p24.323(chr9:211086-11457340)x1

Pathogenic(Last reviewed: Apr 30,
2011)

VCV000152907

GRCh37/hg19 9p24.3q34.3(chr9:62525-141006407)

Pathogenic(Last reviewed: Apr 30,
2011)

VCV000395707
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GRCh38/hg38 9p24.324.1(chr9:204104-5426099)x3

Pathogenic(Last reviewed: Apr 8,
2011)

VCV000148264

GRCh38/hg38 9p24.324.2(chr9:204193-3468435)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059837

GRCh38/hg38 9p24.324.2(chr9:220253-3793376)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057352

GRCh38/hg38 9p24.324.2(chr9:280255-3905421)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059066

GRCh38/hg38 9p24.324.1(chr9:220253-5140455)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059063

GRCh38/hg38 9p24.324.1(chr9:220253-6073001)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059062

GRCh38/hg38 9p24.324.1(chr9:211086-6106482)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060440

GRCh38/hg38 9p24.324.1(chr9:220253-6968724)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059065

GRCh38/hg38 9p24.323(chr9:1592306-12387899)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057027

GRCh38/hg38 9p24.323(chr9:204193-10340779)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060431

GRCh38/hg38 9p24.323(chr9:211086-11867480)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060441

GRCh38/hg38 9p24.323(chr9:195399-11081440)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060416
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GRCh38/hg38 9p24.323(chr9:203993-12621562)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060427

GRCh38/hg38 9p24.323(chr9:211087-13754567)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059060

GRCh38/hg38 9p24.323(chr9:204193-13974100)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057180

GRCh38/hg38 9p24.322.3(chr9:111216-14650762)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000060415

GRCh38/hg38 9p24.322.1(chr9:1242978-18957216)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059067

GRCh38/hg38 9p24.322.2(chr9:220253-18073359)x1

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059064

GRCh38/hg38 9p24.321.3(chr9:204193-22086858)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059836

GRCh38/hg38 9p24.313.3(chr9:204193-33284638)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059839

GRCh38/hg38 9p24.313.1(chr9:220253-38815419)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059876

GRCh38/hg38 9p24.313.1(chr9:204193-38815478)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000160921

GRCh38/hg38 9p24.313.1(chr9:203993-38815619)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059835

GRCh38/hg38 9p24.313.1(chr9:204193-38741440)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000057406
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GRCh38/hg38 9p24.3q34.3(chr9:193412-138114463)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059875

GRCh38/hg38 9p24.3q34.3(chr9:193412-138124532)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000059874

GRCh38/hg38 9p24.3q34.3(chr9:193412-138179445)x3

Pathogenic(Last reviewed: Aug 12,
2011)

VCV000160862

GRCh37/hg19 9p24.321.3(chr9:46587-22012051)x3

Pathogenic(Last reviewed: Aug 12,
2014)

VCV000611426

GRCh38/hg38 9p24.324.2(chr9:204193-4210335)x1

Pathogenic(Last reviewed: Aug 18,
2010)

VCV000144708

GRCh38/hg38 9p24.323(chr9:204104-14182668)x1

Pathogenic(Last reviewed: Aug 19,
2011)

VCV000148598

GRCh38/hg38 9p24.313.3(chr9:204104-34151476)x3

Pathogenic(Last reviewed: Aug 2,
2012)

VCV000150116

GRCh38/hg38 9p24.3q21.11(chr9:204104-66233120)x4

Pathogenic(Last reviewed: Aug 2,
2012)

VCV000148823

GRCh38/hg38 9p24.3q21.31(chr9:193412-79877816)x3

Pathogenic(Last reviewed: Aug 20,
2012)

VCV000154945

GRCh37/hg19 9p24.323(chr9:46587-13708607)x1

Pathogenic(Last reviewed: Aug 22,
2014)

VCV000611425

GRCh37/hg19 9p24.324.1(chr9:203861-7007586)x1

Pathogenic(Last reviewed: Aug 25,
2017)

VCV000563673

GRCh38/hg38 9p24.3q34.3(chr9:193412-138179445)x3

Pathogenic(Last reviewed: Aug 27,
2010)

VCV000033205
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GRCh37/hg19 9p24.323(chr9:203861-9306658)x1

Pathogenic(Last reviewed: Aug 28,
2017)

VCV000563675

GRCh37/hg19 9p24.3q21.11(chr9:203861-70985795)x4

Pathogenic(Last reviewed: Aug 30,
2017)

VCV000563686

GRCh38/hg38 9p24.323(chr9:204104-11298187)x1

Pathogenic(Last reviewed: Aug 5,
2011)

VCV000146684

GRCh38/hg38 9p24.322.1(chr9:204104-18882281)x1

Pathogenic(Last reviewed: Aug 5,
2011)

VCV000146394

GRCh38/hg38 9p24.313.1(chr9:204193-38815478)x3

Pathogenic(Last reviewed: Aug 5,
2011)

VCV000032288

NM_003070.5(SMARCA2):c.2648C Pathogenic(Last reviewed: Aug 6,
>T (p.Pro883Leu)
2021)

VCV000030016

GRCh37/hg19 9p24.324.1(chr9:46587-5486856)x1

Pathogenic(Last reviewed: Dec 18,
2014)

VCV000611423

GRCh37/hg19 9p24.321.3(chr9:203861-20653468)x3

Pathogenic(Last reviewed: Dec 18,
2017)

VCV000563681

GRCh37/hg19 9p24.321.2(chr9:203861-26397133)x3

Pathogenic(Last reviewed: Dec 18,
2017)

VCV000563682

GRCh38/hg38 9p24.324.1(chr9:220253-7733826)x1

Pathogenic(Last reviewed: Dec 22,
2010)

VCV000154621

NM_003070.5(SMARCA2):c.3220C Pathogenic(Last reviewed: Dec 23,
>G (p.Gln1074Glu)
2019)

VCV000984920

NM_003070.5(SMARCA2):c.3439G Pathogenic(Last reviewed: Dec 3,
>A (p.Asp1147Asn)
2021)

VCV000279980
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GRCh38/hg38 9p24.322.2(chr9:204193-18073359)x1

Pathogenic(Last reviewed: Dec 30,
2009)

VCV000144343

NM_003070.5(SMARCA2):c.3313C Pathogenic(Last reviewed: Dec 7,
>T (p.Arg1105Cys)
2020)

VCV000068769

GRCh38/hg38 9p24.322.1(chr9:220253-18708805)x1

Pathogenic(Last reviewed: Feb 18,
2011)

VCV000146356

NM_003070.5(SMARCA2):c.2815C Pathogenic(Last reviewed: Feb 26,
>T (p.His939Tyr)
2012)

VCV000030018

NM_003070.5(SMARCA2):c.3476G Pathogenic(Last reviewed: Feb 26,
>T (p.Arg1159Leu)
2012)

VCV000030015

NM_003070.5(SMARCA2):c.2642G Pathogenic(Last reviewed: Feb 26,
>T (p.Gly881Val)
2012)

VCV000030013

NM_003070.5(SMARCA2):c.3473A Pathogenic(Last reviewed: Feb 26,
>T (p.Asp1158Val)
2012)

VCV000030011

NM_003070.5(SMARCA2):c.3604G Pathogenic(Last reviewed: Feb 26,
>T (p.Gly1202Cys)
2012)

VCV000030009

NM_003070.5(SMARCA2):c.3637C Pathogenic(Last reviewed: Feb 26,
>T (p.Arg1213Trp)
2012)

VCV000030008

NM_003070.5(SMARCA2):c.2255G Pathogenic(Last reviewed: Feb 26,
>C (p.Gly752Ala)
2012)

VCV000030019

GRCh38/hg38 9p24.3q34.3(chr9:204193-138179445)

Pathogenic(Last reviewed: Feb 28,
2010)

VCV000144309

GRCh37/hg19 9p24.323(chr9:203861-13486759)x1

Pathogenic(Last reviewed: Feb 29,
2016)

VCV000442671

GRCh37/hg19 9p24.3q34.3(chr9:10590-141122247)x3

Pathogenic(Last reviewed: Jan 1,
2013)

VCV000611419
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GRCh38/hg38 9p24.324.1(chr9:204193-6968724)x1

Pathogenic(Last reviewed: Jan 14,
2011)

VCV000146231

NM_003070.5(SMARCA2):c.3446A Pathogenic(Last reviewed: Jan 20,
>G (p.Asn1149Ser)
2016)

VCV000379917

GRCh37/hg19 9p24.323(chr9:13997-11376705)x1

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253580

GRCh37/hg19 9p24.322.1(chr9:213161-19450250)x3

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253670

GRCh37/hg19 9p24.313.1(chr9:213161-39092820)x3

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253667

GRCh37/hg19 9p24.313.1(chr9:163131-38763958)x3

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253633

GRCh37/hg19 9p24.311.2(chr9:213161-47212321)x4

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253592

GRCh37/hg19 9p24.3q34.3(chr9:163131-141122114)x3

Pathogenic(Last reviewed: Jan 20,
2016)

VCV000253402

GRCh38/hg38 9p24.324.1(chr9:204104-5657733)x1

Pathogenic(Last reviewed: Jan 23,
2012)

VCV000149059

GRCh38/hg38 9p24.323(chr9:204104-10023901)x1

Pathogenic(Last reviewed: Jan 23,
2012)

VCV000149060

GRCh38/hg38 9p24.323(chr9:204193-10852686)x1

Pathogenic(Last reviewed: Jan 24,
2011)

VCV000146254

GRCh38/hg38 9p24.324.2(chr9:266045-3346702)x1

Pathogenic(Last reviewed: Jan 27,
2011)

VCV000154563
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GRCh37/hg19 9p24.323(chr9:203861-14103730)x1

Pathogenic(Last reviewed: Jan 29,
2019)

VCV000815188

GRCh38/hg38 9p24.323(chr9:204193-10473327)x1

Pathogenic(Last reviewed: Jan 30,
2010)

VCV000144391

NM_003070.5(SMARCA2):c.3479C Pathogenic(Last reviewed: Jan 30,
>G (p.Ala1160Gly)
2022)

VCV001320261

GRCh37/hg19 9p24.3q34.3(chr9:46587-141066491)x3

Pathogenic(Last reviewed: Jan 5,
2017)

VCV000611427

NM_003070.5(SMARCA2):c.3298A Pathogenic(Last reviewed: Jan 5,
>C (p.Thr1100Pro)
2022)

VCV001334325

GRCh38/hg38 9p24.3q34.3(chr9:203861-138125937)x3

Pathogenic(Last reviewed: Jul 1,
2013)

VCV000153518

GRCh37/hg19 9p24.322.2(chr9:203861-17789410)x1

Pathogenic(Last reviewed: Jul 11,
2018)

VCV000815186

GRCh37/hg19 9p24.3q34.3(chr9:203862-141020389)

Pathogenic(Last reviewed: Jul 14,
2015)

VCV000443986

NM_003070.5(SMARCA2):c.3313C Pathogenic(Last reviewed: Jul 14,
>G (p.Arg1105Gly)
2016)

VCV000280726

GRCh38/hg38 9p24.3q22.1(chr9:203861-88130444)x4

Pathogenic(Last reviewed: Jul 16,
2013)

VCV000153561

GRCh38/hg38 9p24.324.1(chr9:203861-5094461)x1

Pathogenic(Last reviewed: Jul 18,
2014)

VCV000155570

NM_003070.5(SMARCA2):c.3386G Pathogenic(Last reviewed: Jul 23,
>A (p.Gly1129Asp)
2019)

VCV000390604
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GRCh38/hg38 9p24.324.1(chr9:220253-8866675)x1

Pathogenic(Last reviewed: Jul 30,
2009)

VCV000146111

GRCh37/hg19 9p24.313.1(chr9:203861-38472979)x3

Pathogenic(Last reviewed: Jul 30,
2018)

VCV000687476

GRCh38/hg38 9p24.3q21.11(chr9:204104-67549861)x3

Pathogenic(Last reviewed: Jul 5,
2011)

VCV000150341

GRCh38/hg38 9p11.2q34.3(chr9:193412-138159073)x3

Pathogenic(Last reviewed: Jul 5,
2011)

VCV000150340

GRCh38/hg38 9p24.313.1(chr9:204104-38768294)x3

Pathogenic(Last reviewed: Jul 9,
2012)

VCV000150242

GRCh37/hg19 9p24.323(chr9:46587-12532584)x1

Pathogenic(Last reviewed: Jul 9,
2016)

VCV000611424

NM_003070.5(SMARCA2):c.2564G Pathogenic(Last reviewed: Jun 10,
>A (p.Arg855Gln)
2021)

VCV001177355

NM_003070.5(SMARCA2):c.2554G Pathogenic(Last reviewed: Jun 10,
>C (p.Glu852Gln)
2021)

VCV001177354

NM_003070.5(SMARCA2):c.3476G Pathogenic(Last reviewed: Jun 10,
>A (p.Arg1159Gln)
2021)

VCV000030010

GRCh37/hg19 9p24.3q13(chr9:203861-67986965)x3

Pathogenic(Last reviewed: Jun 13,
2017)

VCV000685107

NM_003070.5(SMARCA2):c.3464A Pathogenic(Last reviewed: Jun 18,
>C (p.Gln1155Pro)
2018)

VCV000419659

GRCh38/hg38 9p24.3q34.3(chr9:203862-138125937)x3

VCV000155409

Pathogenic(Last reviewed: Jun 22,
2015)
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GRCh37/hg19 9p24.322.2(chr9:203861-17125893)x1

Pathogenic(Last reviewed: Jun 23,
2014)

VCV000441876

GRCh37/hg19 9p24.322.2(chr9:203861-17655298)x1

Pathogenic(Last reviewed: Jun 23,
2014)

VCV000442304

GRCh38/hg38 9p24.323(chr9:204090-13146846)x1

Pathogenic(Last reviewed: Jun 30,
2010)

VCV000144686

GRCh37/hg19 9p24.313.1(chr9:203861-38787480)x3

Pathogenic(Last reviewed: Mar 10,
2016)

VCV000443177

GRCh37/hg19 9p24.322.1(chr9:204193-18654812)

Pathogenic(Last reviewed: Mar 15,
2021)

VCV001047891

SMARCA2, 55-KB DEL

Pathogenic(Last reviewed: Mar 18,
2012)

VCV000030020

GRCh38/hg38 9p24.324.2(chr9:203861-4585050)x1

Pathogenic(Last reviewed: Mar 18,
2014)

VCV000154196

GRCh38/hg38 9p24.324.2(chr9:204104-3367760)x1

Pathogenic(Last reviewed: Mar 21,
2011)

VCV000148184

GRCh37/hg19 9p24.323(chr9:203861-9924905)x1

Pathogenic(Last reviewed: Mar 23,
2018)

VCV000563677

GRCh38/hg38 9p24.321.1(chr9:203861-31423873)x4

Pathogenic(Last reviewed: Mar 24,
2014)

VCV000153184

GRCh38/hg38 9p24.323(chr9:204193-11277770)x1

Pathogenic(Last reviewed: Mar 30,
2010)

VCV000144441

GRCh37/hg19 9p24.3q13(chr9:203861-67983174)x4

Pathogenic(Last reviewed: Mar 8,
2018)

VCV000563684
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GRCh37/hg19 9p24.3q21.12(chr9:203861-72717793)x3

Pathogenic(Last reviewed: May 15,
2018)

VCV000563687

GRCh37/hg19 9p24.324.1(chr9:203861-5081516)x1

Pathogenic(Last reviewed: May 16,
2014)

VCV000442111

GRCh37/hg19 9p24.323(chr9:203861-11028975)x1

Pathogenic(Last reviewed: May 19,
2017)

VCV000687390

GRCh37/hg19 9p24.3q21.11(chr9:203861-70984588)x3

Pathogenic(Last reviewed: May 20,
2019)

VCV000815190

NM_003070.5(SMARCA2):c.2554G Pathogenic(Last reviewed: May 24,
>A (p.Glu852Lys)
2017)

VCV000068762

GRCh37/hg19 9p24.324.2(chr9:204090-2430905)x1

Pathogenic(Last reviewed: May 28,
2020)

VCV000983185

GRCh38/hg38 9p24.321.1(chr9:220257-29424848)x3

Pathogenic(Last reviewed: May 30,
2010)

VCV000144555

GRCh38/hg38 9p24.3q34.3(chr9:193412-138159073)x3

Pathogenic(Last reviewed: May 7,
2012)

VCV000150050

GRCh37/hg19 9p24.323(chr9:203861-11033228)x1

Pathogenic(Last reviewed: May 9,
2017)

VCV000687364

GRCh37/hg19 9p24.3q34.3(chr9:10590-141107672)x3

Pathogenic(Last reviewed: Nov 1,
2010)

VCV000611417

GRCh37/hg19 9p24.3q13(chr9:203861-68262804)x3,4

Pathogenic(Last reviewed: Nov 1,
2017)

VCV000563685

GRCh37/hg19 9p24.313.1(chr9:214309-39156958)

Pathogenic(Last reviewed: Nov 1,
2018)

VCV000625636
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NM_003070.5(SMARCA2):c.2383T Pathogenic(Last reviewed: Nov 10,
>C (p.Trp795Arg)
2017)

VCV000981747

NM_003070.5(SMARCA2):c.3484C Pathogenic(Last reviewed: Nov 12,
>T (p.Arg1162Cys)
2021)

VCV000373431

GRCh37/hg19 9p24.324.2(chr9:203861-2978707)x1

Pathogenic(Last reviewed: Nov 13,
2017)

VCV000689070

GRCh37/hg19 9p24.313.1(chr9:203861-38787480)x3

Pathogenic(Last reviewed: Nov 2,
2018)

VCV000563683

GRCh37/hg19 9p24.3q34.3(chr9:10590-141114095)x2

Pathogenic(Last reviewed: Nov 23,
2011)

VCV000611418

NM_003070.5(SMARCA2):c.2561A Pathogenic(Last reviewed: Nov 23,
>T (p.His854Leu)
2016)

VCV000981748

GRCh38/hg38 9p24.322.2(chr9:204193-16897580)x1

Pathogenic(Last reviewed: Nov 30,
2009)

VCV000146719

GRCh38/hg38 9p24.3q21.13(chr9:193412-74615913)x3

Pathogenic(Last reviewed: Nov 30,
2009)

VCV000146703

GRCh38/hg38 9p24.3q21.11(chr9:13997-68401065)x3

Pathogenic(Last reviewed: Nov 30,
2010)

VCV000146018

GRCh38/hg38 9p24.324.2(chr9:204104-3755031)x1

Pathogenic(Last reviewed: Nov 4,
2011)

VCV000148849

NM_003070.5(SMARCA2):c.3475C Pathogenic(Last reviewed: Nov 4,
>G (p.Arg1159Gly)
2019)

VCV000030012

GRCh37/hg19 9p24.323(chr9:203861-10666419)x1

VCV000815187

Pathogenic(Last reviewed: Oct 1,
2018)
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GRCh37/hg19 9p24.323(chr9:203861-11271239)x1

Pathogenic(Last reviewed: Oct 11,
2017)

VCV000563678

NM_003070.5(SMARCA2):c.3602C Pathogenic(Last reviewed: Oct 12,
>T (p.Ala1201Val)
2021)

VCV000030017

NM_003070.5(SMARCA2):c.2486C Pathogenic(Last reviewed: Oct 13,
>T (p.Thr829Ile)
2017)

VCV000212225

GRCh38/hg38 9p24.322.3(chr9:214367-16307944)x1

Pathogenic(Last reviewed: Oct 14,
2010)

VCV000147703

GRCh38/hg38 9p24.324.1(chr9:204104-6322471)x1

Pathogenic(Last reviewed: Oct 15,
2012)

VCV000151712

GRCh38/hg38 9p24.322.3(chr9:322690-16401656)x1

Pathogenic(Last reviewed: Oct 15,
2012)

VCV000152943

GRCh38/hg38 9p24.3q21.12(chr9:193412-70630731)x3

Pathogenic(Last reviewed: Oct 20,
2010)

VCV000146931

NM_003070.5(SMARCA2):c.3593T Pathogenic(Last reviewed: Oct 21,
>G (p.Val1198Gly)
2016)

VCV000521357

GRCh37/hg19 9p24.322.1(chr9:203861-19448473)x3

Pathogenic(Last reviewed: Sep 10,
2018)

VCV000684956

GRCh38/hg38 9p24.324.1(chr9:204104-7133443)x1

Pathogenic(Last reviewed: Sep 12,
2011)

VCV000148677

NM_003070.5(SMARCA2):c.1573C Pathogenic(Last reviewed: Sep 15,
>T (p.Arg525Cys)
2021)

VCV000829811

GRCh38/hg38 9p24.323(chr9:204193-11435662)x1

VCV000147839

Pathogenic(Last reviewed: Sep 16,
2011)

NM_003070.5(SMARCA2):c.3314G Pathogenic(Last reviewed: Sep 2,
>A (p.Arg1105His)
2020)
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VCV000982859

NM_003070.5(SMARCA2):c.1585C Pathogenic(Last reviewed: Sep 2,
>G (p.Leu529Val)
2020)

VCV000829810

GRCh37/hg19 9p24.324.1(chr9:203861-4959039)x1

Pathogenic(Last reviewed: Sep 20,
2017)

VCV000563670

GRCh38/hg38 9p24.324.1(chr9:204090-4970154)x3

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000154749

GRCh38/hg38 9p24.323(chr9:204090-9282864)x1

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000150751

GRCh38/hg38 9p24.322.3(chr9:204090-15260600)x1

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000154897

GRCh38/hg38 9p24.321.3(chr9:459131-24207894)x3

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000149484

GRCh38/hg38 9p24.3q34.3(chr9:193412-138124524)x3

Pathogenic(Last reviewed: Sep 21,
2012)

VCV000149828

GRCh38/hg38 9p24.324.1(chr9:203861-8172957)x1

Pathogenic(Last reviewed: Sep 23,
2013)

VCV000153821

GRCh37/hg19 9p24.3q34.3(chr9:203861-141020388)x3

Pathogenic(Last reviewed: Sep 28,
2018)

VCV000685192

GRCh38/hg38 9p24.321.2(chr9:204104-27963369)x3

Pathogenic(Last reviewed: Sep 4,
2012)

VCV000150819

GRCh37/hg19 9p24.322.3(chr9:203861-14744606)x1

Pathogenic(Last reviewed: Sep 6,
2017)

VCV000563679

NM_003070.5(SMARCA2):c.2853G Pathogenic(Last reviewed: Sep 7,
>C (p.Lys951Asn)
2016)

VCV000436805
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NM_003070.5(SMARCA2):c.2810G Pathogenic/Likely pathogenic(Last
>T (p.Arg937Leu)
reviewed: Apr 30, 2021)

VCV000827773

NM_003070.5(SMARCA2):c.3485G Pathogenic/Likely pathogenic(Last
>A (p.Arg1162His)
reviewed: Sep 1, 2018)

VCV000030014

NM_003070.5(SMARCA2):c.2156T
>C (p.Leu719Pro)
Uncertain significance

VCV000827775

NM_003070.5(SMARCA2):c.2795T
>C (p.Ile932Thr)
Uncertain significance

VCV000827828

NM_003070.5(SMARCA2):c.3040A
>G (p.Lys1014Glu)
Uncertain significance

VCV000827772

NM_003070.5(SMARCA2):c.4666A
>G (p.Lys1556Glu)
Uncertain significance

VCV000813686

NM_003070.5(SMARCA2):c.1450C
>A (p.His484Asn)
Uncertain significance

VCV000374228

NM_003070.5(SMARCA2):c.1279C Uncertain significance(Last
>T (p.Arg427Cys)
reviewed: Apr 1, 2020)

VCV000916365

NM_003070.5(SMARCA2):c.2425G Uncertain significance(Last
>C (p.Ala809Pro)
reviewed: Apr 1, 2021)

VCV001176896

NM_003070.5(SMARCA2):c.182G> Uncertain significance(Last
C (p.Gly61Ala)
reviewed: Apr 10, 2019)

VCV000449800

NM_003070.5(SMARCA2):c.4370G Uncertain significance(Last
>A (p.Arg1457His)
reviewed: Apr 12, 2019)

VCV001305007

NM_003070.5(SMARCA2):c.3412G Uncertain significance(Last
>C (p.Ala1138Pro)
reviewed: Apr 14, 2018)

VCV000985482

NM_003070.5(SMARCA2):c.3519G Uncertain significance(Last
>T (p.Arg1173Ser)
reviewed: Apr 16, 2019)

VCV001305100

NM_003070.5(SMARCA2):c.3615C Uncertain significance(Last
>G (p.Asp1205Glu)
reviewed: Apr 16, 2019)

VCV001305099
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NM_003070.5(SMARCA2):c.3940G Uncertain significance(Last
>A (p.Val1314Met)
reviewed: Apr 16, 2021)

VCV001314521

GRCh37/hg19 9p24.324.2(chr9:2180509-3128422)x3

Uncertain significance(Last
reviewed: Apr 28, 2017)

VCV000686138

NM_003070.5(SMARCA2):c.4262G Uncertain significance(Last
>A (p.Arg1421Gln)
reviewed: Apr 30, 2020)

VCV001047931

GRCh38/hg38 9p24.324.2(chr9:1845513-3022547)x3

Uncertain significance(Last
reviewed: Apr 4, 2013)

VCV000152115

NM_003070.5(SMARCA2):c.344A> Uncertain significance(Last
T (p.Gln115Leu)
reviewed: Apr 5, 2019)

VCV001308470

Uncertain significance(Last
reviewed: Apr 9, 2019)

VCV000635963

NM_003070.5(SMARCA2):c.3379A Uncertain significance(Last
>G (p.Arg1127Gly)
reviewed: Aug 1, 2017)

VCV000810346

NM_003070.5(SMARCA2):c.47387C>T

Uncertain significance(Last
reviewed: Aug 1, 2019)

VCV000872500

NM_003070.5(SMARCA2):c.4103G Uncertain significance(Last
>A (p.Arg1368Lys)
reviewed: Aug 1, 2019)

VCV000872499

GRCh38/hg38 9p24.3(chr9:839152- Uncertain significance(Last
2094920)x3
reviewed: Aug 12, 2011)

VCV000057235

GRCh38/hg38 9p24.324.2(chr9:1998911-2925112)x3

Uncertain significance(Last
reviewed: Aug 12, 2011)

VCV000058462

NM_003070.5(SMARCA2):c.3265C Uncertain significance(Last
>T (p.Arg1089Trp)
reviewed: Aug 7, 2019)

VCV001307583

Single allele
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NM_003070.5(SMARCA2):c.919G> Uncertain significance(Last
A (p.Val307Met)
reviewed: Dec 11, 2019)

VCV000931617

NM_003070.5(SMARCA2):c.1534G Uncertain significance(Last
>A (p.Glu512Lys)
reviewed: Dec 11, 2020)

VCV000992210

NM_003070.5(SMARCA2):c.3448C Uncertain significance(Last
>G (p.Pro1150Ala)
reviewed: Dec 13, 2019)

VCV001029502

NM_003070.5(SMARCA2):c.31C>A Uncertain significance(Last
(p.Pro11Thr)
reviewed: Dec 18, 2017)

VCV000522971

NM_003070.5(SMARCA2):c.497A> Uncertain significance(Last
G (p.Gln166Arg)
reviewed: Dec 20, 2019)

VCV001311425

NM_003070.5(SMARCA2):c.3389G Uncertain significance(Last
>A (p.Gly1130Asp)
reviewed: Dec 30, 2017)

VCV000623322

NM_003070.5(SMARCA2):c.209T> Uncertain significance(Last
A (p.Met70Lys)
reviewed: Dec 31, 2019)

VCV001311613

NM_003070.5(SMARCA2):c.583G> Uncertain significance(Last
C (p.Gly195Arg)
reviewed: Dec 6, 2019)

VCV001311059

NM_003070.5(SMARCA2):c.3638G Uncertain significance(Last
>C (p.Arg1213Pro)
reviewed: Feb 1, 2018)

VCV000495133

NM_003070.5(SMARCA2):c.482C> Uncertain significance(Last
T (p.Pro161Leu)
reviewed: Feb 14, 2014)

VCV000126350

NM_003070.5(SMARCA2):c.669GC Uncertain significance(Last
A[5] (p.Gln231_Gln238del)
reviewed: Feb 2, 2017)

VCV000436801

NM_003070.5(SMARCA2):c.4486C Uncertain significance(Last
>A (p.Gln1496Lys)
reviewed: Feb 3, 2017)

VCV000521478
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NM_003070.5(SMARCA2):c.50C>T Uncertain significance(Last
(p.Pro17Leu)
reviewed: Feb 4, 2022)

VCV001186796

NM_003070.5(SMARCA2):c.1211C Uncertain significance(Last
>T (p.Thr404Met)
reviewed: Feb 5, 2021)

VCV001314105

NM_003070.5(SMARCA2):c.*587T> Uncertain significance(Last
C
reviewed: Jan 12, 2018)

VCV000915202

NM_003070.5(SMARCA2):c.2070C Uncertain significance(Last
>G (p.Ser690Arg)
reviewed: Jan 12, 2018)

VCV000914955

NM_003070.5(SMARCA2):c.20374C>A

Uncertain significance(Last
reviewed: Jan 12, 2018)

VCV000914954

NM_003070.5(SMARCA2):c.3981+ Uncertain significance(Last
11C>G
reviewed: Jan 12, 2018)

VCV000914487

NM_003070.5(SMARCA2):c.*489A> Uncertain significance(Last
G
reviewed: Jan 12, 2018)

VCV000913964

NM_003070.5(SMARCA2):c.*80T>
C

Uncertain significance(Last
reviewed: Jan 12, 2018)

VCV000913578

NM_003070.5(SMARCA2):c.890C> Uncertain significance(Last
A (p.Pro297Gln)
reviewed: Jan 12, 2018)

VCV000913315

NM_003070.5(SMARCA2):c.25273T>C

Uncertain significance(Last
reviewed: Jan 12, 2018)

VCV000913001

NM_003070.5(SMARCA2):c.699G> Uncertain significance(Last
A (p.Gln233=)
reviewed: Jan 12, 2018)

VCV000912951

NM_003070.5(SMARCA2):c.*876G Uncertain significance(Last
>C
reviewed: Jan 12, 2018)

VCV000912496
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NM_003070.5(SMARCA2):c.*537T> Uncertain significance(Last
C
reviewed: Jan 12, 2018)

VCV000366338

NM_003070.5(SMARCA2):c.*197A> Uncertain significance(Last
G
reviewed: Jan 12, 2018)

VCV000366334

Uncertain significance(Last
NM_003070.5(SMARCA2):c.*5T>C reviewed: Jan 12, 2018)

VCV000366328

NM_003070.5(SMARCA2):c.2933A Uncertain significance(Last
>T (p.Tyr978Phe)
reviewed: Jan 12, 2018)

VCV000366215

NM_003070.5(SMARCA2):c.*670A> Uncertain significance(Last
G
reviewed: Jan 13, 2018)

VCV000915203

NM_003070.5(SMARCA2):c.4673C Uncertain significance(Last
>G (p.Pro1558Arg)
reviewed: Jan 13, 2018)

VCV000915172

NM_003070.5(SMARCA2):c.1812G Uncertain significance(Last
>A (p.Lys604=)
reviewed: Jan 13, 2018)

VCV000914439

NM_003070.5(SMARCA2):c.1599C Uncertain significance(Last
>T (p.Thr533=)
reviewed: Jan 13, 2018)

VCV000914437

NM_003070.5(SMARCA2):c.399C> Uncertain significance(Last
T (p.His133=)
reviewed: Jan 13, 2018)

VCV000914396

NM_003070.5(SMARCA2):c.324T> Uncertain significance(Last
A (p.Pro108=)
reviewed: Jan 13, 2018)

VCV000914395

NM_003070.5(SMARCA2):c.105A> Uncertain significance(Last
G (p.Pro35=)
reviewed: Jan 13, 2018)

VCV000914394

NM_003070.5(SMARCA2):c.*230T> Uncertain significance(Last
C
reviewed: Jan 13, 2018)

VCV000913962
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NM_003070.5(SMARCA2):c.*204G Uncertain significance(Last
>A
reviewed: Jan 13, 2018)

VCV000913961

NM_003070.5(SMARCA2):c.*192G Uncertain significance(Last
>C
reviewed: Jan 13, 2018)

VCV000913960

NM_003070.5(SMARCA2):c.*101A> Uncertain significance(Last
C
reviewed: Jan 13, 2018)

VCV000913579

NM_003070.5(SMARCA2):c.3768G Uncertain significance(Last
>A (p.Met1256Ile)
reviewed: Jan 13, 2018)

VCV000913366

NM_003070.5(SMARCA2):c.3633C Uncertain significance(Last
>T (p.His1211=)
reviewed: Jan 13, 2018)

VCV000913365

NM_003070.5(SMARCA2):c.3216C Uncertain significance(Last
>T (p.Phe1072=)
reviewed: Jan 13, 2018)

VCV000913364

NM_003070.5(SMARCA2):c.990C> Uncertain significance(Last
T (p.Pro330=)
reviewed: Jan 13, 2018)

VCV000913318

NM_003070.5(SMARCA2):c.961C> Uncertain significance(Last
T (p.Leu321=)
reviewed: Jan 13, 2018)

VCV000913317

NM_003070.5(SMARCA2):c.693G> Uncertain significance(Last
A (p.Gln231=)
reviewed: Jan 13, 2018)

VCV000912950

NM_003070.5(SMARCA2):c.*782G Uncertain significance(Last
>A
reviewed: Jan 13, 2018)

VCV000912495

NM_003070.5(SMARCA2):c.*765T> Uncertain significance(Last
G
reviewed: Jan 13, 2018)

VCV000912494

NM_003070.5(SMARCA2):c.4737+ Uncertain significance(Last
12C>T
reviewed: Jan 13, 2018)

VCV000912461

281

NM_003070.5(SMARCA2):c.*694T> Uncertain significance(Last
G
reviewed: Jan 13, 2018)

VCV000366340

NM_003070.5(SMARCA2):c.*16T>
C

Uncertain significance(Last
reviewed: Jan 13, 2018)

VCV000366330

NM_003070.5(SMARCA2):c.47389T>C

Uncertain significance(Last
reviewed: Jan 13, 2018)

VCV000366326

NM_003070.5(SMARCA2):c.4701G Uncertain significance(Last
>A (p.Val1567=)
reviewed: Jan 13, 2018)

VCV000366323

NM_003070.5(SMARCA2):c.4499A Uncertain significance(Last
>C (p.Lys1500Thr)
reviewed: Jan 13, 2018)

VCV000366250

NM_003070.5(SMARCA2):c.3165T Uncertain significance(Last
>C (p.Leu1055=)
reviewed: Jan 13, 2018)

VCV000366218

NM_003070.5(SMARCA2):c.2452C Uncertain significance(Last
>T (p.Leu818=)
reviewed: Jan 13, 2018)

VCV000366212

NM_003070.5(SMARCA2):c.4765G Uncertain significance(Last
>C (p.Asp1589His)
reviewed: Jan 24, 2018)

VCV001032871

NM_003070.5(SMARCA2):c.1931A Uncertain significance(Last
>C (p.Glu644Ala)
reviewed: Jan 27, 2020)

VCV001314988

NM_003070.5(SMARCA2):c.1436C Uncertain significance(Last
>T (p.Ala479Val)
reviewed: Jan 28, 2020)

VCV001315067

NM_003070.5(SMARCA2):c.4364G Uncertain significance(Last
>C (p.Arg1455Thr)
reviewed: Jul 1, 2016)

VCV000374420

NM_003070.5(SMARCA2):c.459511T>A

VCV001306417

Uncertain significance(Last
reviewed: Jul 1, 2019)

282

NM_003070.5(SMARCA2):c.4212G Uncertain significance(Last
>T (p.Glu1404Asp)
reviewed: Jul 10, 2019)

VCV001304869

NM_003070.5(SMARCA2):c.2932T Uncertain significance(Last
>C (p.Tyr978His)
reviewed: Jul 19, 2019)

VCV001304600

NM_003070.5(SMARCA2):c.274G> Uncertain significance(Last
A (p.Gly92Arg)
reviewed: Jul 21, 2018)

VCV001032870

NM_003070.5(SMARCA2):c.1625A Uncertain significance(Last
>G (p.Asn542Ser)
reviewed: Jul 22, 2019)

VCV001211033

NM_003070.5(SMARCA2):c.2852A Uncertain significance(Last
>G (p.Lys951Arg)
reviewed: Jul 27, 2018)

VCV000976071

NM_003070.5(SMARCA2):c.4696G Uncertain significance(Last
>A (p.Val1566Ile)
reviewed: Jul 27, 2020)

VCV001029503

NM_003070.5(SMARCA2):c.1333C Uncertain significance(Last
>T (p.Arg445Cys)
reviewed: Jul 29, 2021)

VCV001319926

NM_003070.5(SMARCA2):c.4414A Uncertain significance(Last
>C (p.Met1472Leu)
reviewed: Jul 7, 2017)

VCV000976210

NM_003070.5(SMARCA2):c.4275A Uncertain significance(Last
>G (p.Glu1425=)
reviewed: Jun 1, 2019)

VCV000810348

NM_003070.5(SMARCA2):c.2794A Uncertain significance(Last
>T (p.Ile932Leu)
reviewed: Jun 10, 2020)

VCV000430530

NM_003070.5(SMARCA2):c.2267C Uncertain significance(Last
>T (p.Thr756Ile)
reviewed: Jun 10, 2021)

VCV000068760

NM_003070.5(SMARCA2):c.2878G Uncertain significance(Last
>A (p.Glu960Lys)
reviewed: Jun 11, 2019)

VCV001303289

283

NM_003070.5(SMARCA2):c.508G> Uncertain significance(Last
C (p.Gly170Arg)
reviewed: Jun 11, 2021)

VCV001327907

NM_003070.5(SMARCA2):c.2329C Uncertain significance(Last
>G (p.Leu777Val)
reviewed: Jun 17, 2014)

VCV000377393

NM_003070.5(SMARCA2):c.3252T Uncertain significance(Last
>A (p.Asp1084Glu)
reviewed: Jun 19, 2019)

VCV000976144

NM_003070.5(SMARCA2):c.4164C Uncertain significance(Last
>T (p.Asn1388=)
reviewed: Jun 25, 2015)

VCV000212228

NM_003070.5(SMARCA2):c.117410T>C

Uncertain significance(Last
reviewed: Jun 25, 2019)

VCV001337253

NM_003070.5(SMARCA2):c.4157_4 Uncertain significance(Last
166del (p.Gln1386fs)
reviewed: Jun 27, 2019)

VCV001306761

NC_000009.11:g.(?_2029023)_(530 Uncertain significance(Last
0444_?)dup
reviewed: Jun 30, 2020)

VCV001042801

NM_003070.5(SMARCA2):c.795G> Uncertain significance(Last
A (p.Pro265=)
reviewed: Mar 17, 2016)

VCV000436798

NM_003070.5(SMARCA2):c.*307C
>T

Uncertain significance(Last
reviewed: Mar 2, 2018)

VCV000913963

NM_003070.5(SMARCA2):c.4696G Uncertain significance(Last
>C (p.Val1566Leu)
reviewed: Mar 2, 2021)

VCV001342463

NM_003070.5(SMARCA2):c.915C> Uncertain significance(Last
G (p.Pro305=)
reviewed: Mar 24, 2016)

VCV000436802

NM_003070.5(SMARCA2):c.2348+ Uncertain significance(Last
8A>C
reviewed: Mar 26, 2021)

VCV001342334

284

NM_003070.5(SMARCA2):c.56G>A

Uncertain significance(Last
reviewed: Mar 30, 2018)

VCV000913279

NM_003070.5(SMARCA2):c.4508G Uncertain significance(Last
>A (p.Arg1503Gln)
reviewed: May 1, 2018)

VCV000810349

NM_003070.5(SMARCA2):c.880G> Uncertain significance(Last
A (p.Ala294Thr)
reviewed: May 12, 2020)

VCV001098643

NM_003070.5(SMARCA2):c.887A> Uncertain significance(Last
C (p.Gln296Pro)
reviewed: May 18, 2017)

VCV000588983

NM_003070.5(SMARCA2):c.869C> Uncertain significance(Last
T (p.Ala290Val)
reviewed: May 24, 2019)

VCV001302166

NM_003070.5(SMARCA2):c.2082T Uncertain significance(Last
>G (p.Ser694Arg)
reviewed: May 26, 2021)

VCV001326395

NM_003070.5(SMARCA2):c.929C> Uncertain significance(Last
A (p.Pro310Gln)
reviewed: May 28, 2019)

VCV000802454

NM_003070.5(SMARCA2):c.3796C Uncertain significance(Last
>G (p.Arg1266Gly)
reviewed: May 31, 2017)

VCV000589167

NM_003070.5(SMARCA2):c.1232A Uncertain significance(Last
>G (p.Asn411Ser)
reviewed: Nov 15, 2019)

VCV001187925

NM_003070.5(SMARCA2):c.2032A Uncertain significance(Last
>G (p.Ile678Val)
reviewed: Nov 18, 2020)

VCV001333848

NM_003070.5(SMARCA2):c.1226C Uncertain significance(Last
>G (p.Ala409Gly)
reviewed: Nov 21, 2019)

VCV001310623

GRCh37/hg19
9p24.3(chr9:2130392-2185324)x1

VCV000563563

Uncertain significance(Last
reviewed: Nov 3, 2017)

285

NM_003070.5(SMARCA2):c.1325G Uncertain significance(Last
>A (p.Arg442Lys)
reviewed: Oct 1, 2018)

VCV000810343

NM_003070.5(SMARCA2):c.1240G Uncertain significance(Last
>A (p.Ala414Thr)
reviewed: Oct 10, 2019)

VCV000451242

NM_003070.5(SMARCA2):c.39824A>T

Uncertain significance(Last
reviewed: Oct 13, 2020)

VCV001304125

NM_003070.5(SMARCA2):c.1296G Uncertain significance(Last
>C (p.Leu432=)
reviewed: Oct 31, 2014)

VCV000212223

NM_003070.5(SMARCA2):c.1064C Uncertain significance(Last
>G (p.Ala355Gly)
reviewed: Oct 4, 2019)

VCV001308897

NM_003070.5(SMARCA2):c.3754de Uncertain significance(Last
l (p.Leu1252fs)
reviewed: Sep 10, 2020)

VCV000981424

NM_003070.5(SMARCA2):c.1458C Uncertain significance(Last
>G (p.Asn486Lys)
reviewed: Sep 10, 2020)

VCV000827829

NM_003070.5(SMARCA2):c.334C> Uncertain significance(Last
T (p.Pro112Ser)
reviewed: Sep 12, 2019)

VCV001308195

NM_003070.5(SMARCA2):c.1586T Uncertain significance(Last
>G (p.Leu529Arg)
reviewed: Sep 13, 2017)

VCV000522058

NM_003070.5(SMARCA2):c.3385G Uncertain significance(Last
>C (p.Gly1129Arg)
reviewed: Sep 23, 2014)

VCV000212226

NM_003070.5(SMARCA2):c.2420C Uncertain significance(Last
>T (p.Thr807Ile)
reviewed: Sep 8, 2017)

VCV000451779

286

Appendix Table 5. Table of reported variants for KAT6A, retrieved from ClinVar databases
(https://www.ncbi.nlm.nih.gov/clinvar/?term=KDM2B%5Bgene%5D&redir=gene)
Name

Clinical significance (Last reviewed)

Accession

NM_006766.5(
KAT6A):c.3392
G>A
(p.Arg1131His) Benign(Last reviewed: Apr 12, 2021)

VCV001221162

NM_006766.5(
KAT6A):c.1364
-9T>A
Benign(Last reviewed: Apr 26, 2021)

VCV001271402

NM_006766.5(
KAT6A):c.2533
C>T
(p.Arg845Cys) Benign(Last reviewed: Apr 5, 2019)

VCV001263118

NM_006766.5(
KAT6A):c.3660
C>T
(p.Pro1220=)
Benign(Last reviewed: Apr 8, 2021)

VCV000730577

NM_006766.5(
KAT6A):c.1996
+62G>A
Benign(Last reviewed: Aug 10, 2019)

VCV001274664

NM_006766.5(
KAT6A):c.1996
+98A>G
Benign(Last reviewed: Aug 10, 2019)

VCV001272501

NM_006766.5(
KAT6A):c.1996
+90_1996+99d
el
Benign(Last reviewed: Aug 10, 2019)

VCV001270393

NM_006766.5(
KAT6A):c.1598
+263dup
Benign(Last reviewed: Aug 10, 2019)

VCV001178308

NM_006766.5(
KAT6A):c.1996
+100A>G
Benign(Last reviewed: Aug 11, 2019)

VCV001277202

NM_006766.5(
KAT6A):c.1996
+61_1996+62in
sTA
Benign(Last reviewed: Aug 13, 2019)

VCV001289176

287

NM_006766.5(
KAT6A):c.1996
+88_1996+99d
el
Benign(Last reviewed: Aug 13, 2019)

VCV001277059

NM_006766.5(
KAT6A):c.1740
+294ATG[11]
Benign(Last reviewed: Aug 13, 2019)

VCV001267606

NM_006766.5(
KAT6A):c.1740
+294ATG[10]
Benign(Last reviewed: Aug 20, 2019)

VCV001258284

NM_006766.5(
KAT6A):c.1996
+94_1996+101
del
Benign(Last reviewed: Aug 21, 2019)

VCV001263963

NM_006766.5(
KAT6A):c.1599
-8G>A
Benign(Last reviewed: Aug 24, 2020)

VCV000786120

NM_006766.5(
KAT6A):c.1044
-57A>G
Benign(Last reviewed: Aug 3, 2018)

VCV001250240

NM_006766.5(
KAT6A):c.1740
+294ATG[8]
Benign(Last reviewed: Aug 6, 2019)

VCV001232892

NM_006766.5(
KAT6A):c.1740
+294ATG[12]
Benign(Last reviewed: Aug 7, 2019)

VCV001291825

NM_006766.5(
KAT6A):c.4707
C>T
(p.Tyr1569=)
Benign(Last reviewed: Dec 15, 2020)

VCV001252501

NM_006766.5(
KAT6A):c.4149
C>T
(p.Ser1383=)
Benign(Last reviewed: Dec 19, 2019)

VCV001272650

NM_006766.5(
KAT6A):c.1599
-9C>T
Benign(Last reviewed: Dec 31, 2019)

VCV000770571

NM_006766.5(
KAT6A):c.3353
-31C>A
Benign(Last reviewed: Feb 10, 2021)

VCV001278127

NM_006766.5(
KAT6A):c.1364
-11T>C
Benign(Last reviewed: Feb 27, 2020)

VCV001281888

NM_006766.5(
KAT6A):c.5036
C>T
(p.Pro1679Leu) Benign(Last reviewed: Feb 6, 2020)

VCV001248835

NM_006766.5(
KAT6A):c.2672 Benign(Last reviewed: Feb 7, 2021)

VCV001285736

288

C>T
(p.Thr891Met)
NM_006766.5(
KAT6A):c.3352
+20C>T
Benign(Last reviewed: Feb 9, 2021)

VCV001223126

NM_006766.5(
KAT6A):c.2869
G>T
(p.Ala957Ser) Benign(Last reviewed: Jan 11, 2018)

VCV000731757

NM_006766.5(
KAT6A):c.1996
+49T>C
Benign(Last reviewed: Jan 13, 2021)

VCV001244907

NM_006766.5(
KAT6A):c.3764
C>G
(p.Ala1255Gly) Benign(Last reviewed: Jan 14, 2020)

VCV001281676

NM_006766.5(
KAT6A):c.2437
-318T>C
Benign(Last reviewed: Jul 17, 2018)

VCV001290657

NM_006766.5(
KAT6A):c.1902
+96T>G
Benign(Last reviewed: Jul 17, 2018)

VCV001267389

NM_006766.5(
KAT6A):c.1043
+233C>T
Benign(Last reviewed: Jul 17, 2018)

VCV001259092

NM_006766.5(
KAT6A):c.*185
C>G
Benign(Last reviewed: Jul 17, 2018)

VCV001247574

NM_006766.5(
KAT6A):c.-325129A>G
Benign(Last reviewed: Jul 17, 2018)

VCV001183258

NM_006766.5(
KAT6A):c.2982
G>A
(p.Pro994=)
Benign(Last reviewed: Jul 17, 2018)

VCV000587818

NM_006766.5(
KAT6A):c.401T
>C
(p.Leu134Ser) Benign(Last reviewed: Jul 20, 2018)

VCV000587821

NM_006766.5(
KAT6A):c.4455
C>T
(p.Ser1485=)
Benign(Last reviewed: Jul 20, 2018)

VCV000587817

NM_006766.5(
KAT6A):c.1445
T>A
(p.Met482Lys) Benign(Last reviewed: Jul 26, 2019)

VCV001178084

289

NM_006766.5(
KAT6A):c.3039
+158C>A
Benign(Last reviewed: Jul 3, 2018)

VCV001276014

NM_006766.5(
KAT6A):c.199T>A
Benign(Last reviewed: Jul 3, 2018)

VCV001245822

NM_006766.5(
KAT6A):c.1902
+20G>A
Benign(Last reviewed: Jul 3, 2018)

VCV001242874

NM_006766.5(
KAT6A):c.82658C>T
Benign(Last reviewed: Jul 3, 2018)

VCV001182953

NM_006766.5(
KAT6A):c.4914
C>T
(p.Cys1638=) Benign(Last reviewed: Jul 3, 2018)

VCV000587956

NM_006766.5(
KAT6A):c.4872
C>G
(p.Val1624=)
Benign(Last reviewed: Jul 3, 2018)

VCV000587916

NM_006766.5(
KAT6A):c.3192
G>A
(p.Thr1064=)
Benign(Last reviewed: Jul 5, 2018)

VCV000587815

NM_006766.5(
KAT6A):c.2226
C>T
(p.Asp742=)
Benign(Last reviewed: Mar 11, 2020)

VCV001258419

NM_006766.5(
KAT6A):c.600+
5G>T
Benign(Last reviewed: Mar 13, 2020)

VCV000716531

NM_006766.5(
KAT6A):c.1996
+48C>G
Benign(Last reviewed: Mar 25, 2020)

VCV001177720

NM_006766.5(
KAT6A):c.5241
A>G
(p.Pro1747=)
Benign(Last reviewed: May 29, 2020)

VCV001262345

NM_006766.5(
KAT6A):c.5379
G>A
(p.Gln1793=)
Benign(Last reviewed: Nov 19, 2021)

VCV000588207

NM_006766.5(
KAT6A):c.4394
A>G
(p.Asp1465Gly) Benign(Last reviewed: Oct 1, 2021)

VCV001300277

NM_006766.5(
KAT6A):c.71014C>G
Benign(Last reviewed: Oct 1, 2021)

VCV001300266

290

NM_006766.5(
KAT6A):c.2694
A>G
(p.Gln898=)
Benign(Last reviewed: Oct 21, 2018)

VCV000587932

NM_006766.5(
KAT6A):c.5597
C>G
(p.Ser1866Cys) Benign(Last reviewed: Oct 21, 2019)

VCV001287491

NM_006766.5(
KAT6A):c.1482
+6G>A
Benign(Last reviewed: Oct 23, 2020)

VCV001222349

NM_006766.5(
KAT6A):c.1902
+268G>C
Benign(Last reviewed: Sep 22, 2018)

VCV001224567

NM_006766.5(
KAT6A):c.3576
C>T
(p.Ile1192=)
Benign(Last reviewed: Sep 28, 2020)

VCV001273565

NM_006766.5(
KAT6A):c.600+
283T>A
Benign(Last reviewed: Sep 30, 2019)

VCV001286870

NM_006766.5(
KAT6A):c.2627
A>C
(p.Gln876Pro) Benign(Last reviewed: Sep 6, 2021)

VCV001269461

NM_006766.5(
KAT6A):c.3440
A>T
(p.Lys1147Ile) Benign(Last reviewed: Sep 6, 2021)

VCV001049560

NM_006766.5(
KAT6A):c.2487
A>G
(p.Val829=)
Benign(Last reviewed: Sep 8, 2021)

VCV000587953

NM_006766.5(
KAT6A):c.2373
A>C
(p.Glu791Asp) Benign/Likely benign(Last reviewed: Apr 1, 2019)

VCV000588282

NM_006766.5(
KAT6A):c.4779
G>A
(p.Ser1593=)
Benign/Likely benign(Last reviewed: Apr 1, 2021)

VCV000721663

NM_006766.5(
KAT6A):c.3561
C>T
(p.Cys1187=) Benign/Likely benign(Last reviewed: Apr 11, 2019)

VCV000588050

NM_006766.5(
KAT6A):c.4146
G>A
(p.Thr1382=)
Benign/Likely benign(Last reviewed: Apr 16, 2020)

VCV000588065

291

NM_006766.5(
KAT6A):c.3242
C>G
(p.Pro1081Arg) Benign/Likely benign(Last reviewed: Apr 19, 2021)

VCV000719038

NM_006766.5(
KAT6A):c.4940
AGC[5]
(p.Gln1650dup) Benign/Likely benign(Last reviewed: Aug 10, 2020)

VCV000588016

NM_006766.5(
KAT6A):c.3321
AGA[2]
(p.Glu1109del) Benign/Likely benign(Last reviewed: Aug 4, 2020)

VCV000588354

NM_006766.5(
KAT6A):c.3577
G>A
(p.Val1193Ile) Benign/Likely benign(Last reviewed: Dec 10, 2020)

VCV000587853

NM_006766.5(
KAT6A):c.5259
A>G
(p.Leu1753=)
Benign/Likely benign(Last reviewed: Dec 2, 2020)

VCV000589656

NM_006766.5(
KAT6A):c.5526
G>A
(p.Thr1842=)
Benign/Likely benign(Last reviewed: Dec 23, 2020)

VCV000588011

NM_006766.5(
KAT6A):c.5994
C>T
(p.Asn1998=) Benign/Likely benign(Last reviewed: Dec 27, 2019)

VCV000588777

NM_006766.5(
KAT6A):c.1477
C>T
(p.Leu493=)
Benign/Likely benign(Last reviewed: Dec 31, 2019)

VCV000588369

NM_006766.5(
KAT6A):c.4956
A>G
(p.Pro1652=)
Benign/Likely benign(Last reviewed: Jul 18, 2019)

VCV000589069

NM_006766.5(
KAT6A):c.1134
A>G
(p.Ser378=)
Benign/Likely benign(Last reviewed: Jul 22, 2021)

VCV000589524

NM_006766.5(
KAT6A):c.4953
_4976del
(p.Pro1652_Pro
1659del)
Benign/Likely benign(Last reviewed: Jul 3, 2019)

VCV000588080

NM_006766.5(
KAT6A):c.4611
C>T
(p.Ser1537=)
Benign/Likely benign(Last reviewed: Jul 8, 2020)

VCV000589286

292

NM_006766.5(
KAT6A):c.5913
C>T
(p.Asn1971=) Benign/Likely benign(Last reviewed: Jun 10, 2019)

VCV000588835

NM_006766.5(
KAT6A):c.648A
>G (p.Lys216=) Benign/Likely benign(Last reviewed: Jun 4, 2021)

VCV000589011

NM_006766.5(
KAT6A):c.1157
G>A
(p.Arg386Gln) Benign/Likely benign(Last reviewed: May 1, 2021)

VCV000588950

NM_006766.5(
KAT6A):c.1029
G>T
(p.Lys343Asn) Benign/Likely benign(Last reviewed: May 18, 2020)

VCV000726877

NM_006766.5(
KAT6A):c.5040
_5051del
(p.1677_1680Q
QPQ[1])
Benign/Likely benign(Last reviewed: May 28, 2019)

VCV000589281

NM_006766.5(
KAT6A):c.4952
C>T
(p.Pro1651Leu) Benign/Likely benign(Last reviewed: May 28, 2019)

VCV000445624

NM_006766.5(
KAT6A):c.1741
-10A>G
Benign/Likely benign(Last reviewed: May 9, 2021)

VCV000711395

NM_006766.5(
KAT6A):c.3010
A>G
(p.Ile1004Val) Benign/Likely benign(Last reviewed: Nov 8, 2020)

VCV000589512

NM_006766.5(
KAT6A):c.1185
T>G
(p.Asp395Glu) Benign/Likely benign(Last reviewed: Oct 1, 2019)

VCV000588308

NM_006766.5(
KAT6A):c.5967
T>C
(p.Ala1989=)
Benign/Likely benign(Last reviewed: Oct 25, 2020)

VCV000588426

NM_006766.5(
KAT6A):c.4324
G>A
(p.Ala1442Thr) Benign/Likely benign(Last reviewed: Oct 27, 2020)

VCV000445863

NM_006766.5(
KAT6A):c.3505
C>T
Conflicting interpretations of pathogenicity(Last reviewed: Apr 20,
(p.Arg1169Ter) 2020)

VCV000280873

NM_006766.5( Conflicting interpretations of pathogenicity(Last reviewed: Feb 10,
KAT6A):c.5740 2020)

VCV000445654

293

A>G
(p.Met1914Val)
NM_006766.5(
KAT6A):c.3855
G>T
Conflicting interpretations of pathogenicity(Last reviewed: Feb 7,
(p.Gln1285His) 2021)

VCV000588899

NM_006766.5(
KAT6A):c.893C
>T
Conflicting interpretations of pathogenicity(Last reviewed: Jan 1,
(p.Thr298Ile)
2019)

VCV000634490

NM_006766.5(
KAT6A):c.3859
GAG[2]
Conflicting interpretations of pathogenicity(Last reviewed: Nov 10,
(p.Glu1289del) 2020)

VCV000377124

NM_006766.5(
KAT6A):c.4968
_4982dup
(p.Gln1657_Pro Conflicting interpretations of pathogenicity(Last reviewed: Oct 1,
1661dup)
2020)

VCV000587892

NM_006766.5(
KAT6A):c.1342
A>G
Conflicting interpretations of pathogenicity(Last reviewed: Oct 11,
(p.Ser448Gly) 2017)

VCV000497669

NM_006766.5(
KAT6A):c.5525
C>G
(p.Thr1842Arg) Likely benign

VCV000265767

NM_006766.5(
KAT6A):c.3802
C>T
(p.Pro1268Ser) Likely benign

VCV001206121

NM_006766.5(
KAT6A):c.1997
-6C>T
Likely benign(Last reviewed: Apr 1, 2018)

VCV000624322

NM_006766.5(
KAT6A):c.709+
330A>C
Likely benign(Last reviewed: Apr 10, 2019)

VCV001198545

NM_006766.5(
KAT6A):c.4982
C>T
(p.Pro1661Leu) Likely benign(Last reviewed: Apr 13, 2021)

VCV001300918

NM_006766.5(
KAT6A):c.5601
G>A
(p.Ala1867=)
Likely benign(Last reviewed: Apr 2, 2021)

VCV001213003

NM_006766.5(
KAT6A):c.1065
A>T
(p.Lys355Asn) Likely benign(Last reviewed: Apr 6, 2021)

VCV001300971
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NM_006766.5(
KAT6A):c.4722
C>T
(p.Gly1574=)
Likely benign(Last reviewed: Apr 8, 2020)

VCV001199128

NM_006766.5(
KAT6A):c.3039
+30C>T
Likely benign(Last reviewed: Aug 10, 2018)

VCV001204582

NM_006766.5(
KAT6A):c.1996
+61_1996+62in
sTGTA
Likely benign(Last reviewed: Aug 10, 2019)

VCV001188463

NM_006766.5(
KAT6A):c.1996
+61_1996+62in
sTGTGTGTA
Likely benign(Last reviewed: Aug 13, 2019)

VCV001194085

NM_006766.5(
KAT6A):c.1996
+50GT[23]
Likely benign(Last reviewed: Aug 15, 2019)

VCV001215549

NM_006766.5(
KAT6A):c.1996
+50G>C
Likely benign(Last reviewed: Aug 15, 2020)

VCV001187219

NM_006766.5(
KAT6A):c.1996
+94_1996+99d
el
Likely benign(Last reviewed: Aug 21, 2019)

VCV001191182

NM_006766.5(
KAT6A):c.4962
G>A
(p.Pro1654=)
Likely benign(Last reviewed: Aug 22, 2017)

VCV000776322

NM_006766.5(
KAT6A):c.1996
+92_1996+101
del
Likely benign(Last reviewed: Aug 23, 2019)

VCV001211380

NM_006766.5(
KAT6A):c.4768
G>A
(p.Gly1590Ser) Likely benign(Last reviewed: Aug 25, 2018)

VCV000588852

NM_006766.5(
KAT6A):c.3742
G>A
(p.Glu1248Lys) Likely benign(Last reviewed: Aug 3, 2016)

VCV000377054

NM_006766.5(
KAT6A):c.1996
+50GT[22]
Likely benign(Last reviewed: Aug 7, 2019)

VCV001204751

NM_006766.5(
KAT6A):c.603G
>A (p.Pro201=) Likely benign(Last reviewed: Dec 1, 2020)

VCV000589173

NM_006766.5(
KAT6A):c.1741
-182A>C
Likely benign(Last reviewed: Dec 12, 2018)

VCV001188190
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NM_006766.5(
KAT6A):c.1996
+8T>A
Likely benign(Last reviewed: Dec 19, 2017)

VCV000730438

NM_006766.5(
KAT6A):c.2517
T>C
(p.Ala839=)
Likely benign(Last reviewed: Dec 2, 2020)

VCV001201486

NM_006766.5(
KAT6A):c.5586
G>A
(p.Ala1862=)
Likely benign(Last reviewed: Dec 22, 2020)

VCV001207709

NM_006766.5(
KAT6A):c.5601
G>T
(p.Ala1867=)
Likely benign(Last reviewed: Dec 31, 2019)

VCV000719150

NM_006766.5(
KAT6A):c.4188
C>G
(p.His1396Gln) Likely benign(Last reviewed: Dec 8, 2020)

VCV001186435

NM_006766.5(
KAT6A):c.2864
C>T
(p.Pro955Leu) Likely benign(Last reviewed: Feb 1, 2021)

VCV000710644

NM_006766.5(
KAT6A):c.5730
T>C
(p.Asn1910=) Likely benign(Last reviewed: Feb 18, 2021)

VCV000719218

NM_006766.5(
KAT6A):c.4977
_4985dup
(p.Gln1660_Pro
1662dup)
Likely benign(Last reviewed: Feb 2, 2018)

VCV000724518

NM_006766.5(
KAT6A):c.4182
C>T
(p.Asp1394=) Likely benign(Last reviewed: Feb 21, 2020)

VCV001194144

NM_006766.5(
KAT6A):c.4767
C>T
(p.Tyr1589=)
Likely benign(Last reviewed: Feb 22, 2017)

VCV000588810

NM_006766.5(
KAT6A):c.4222
G>A
(p.Glu1408Lys) Likely benign(Last reviewed: Feb 26, 2021)

VCV001254829

NM_006766.5(
KAT6A):c.5027
A>C
(p.Gln1676Pro) Likely benign(Last reviewed: Jan 1, 2019)

VCV000975258

NM_006766.5(
KAT6A):c.1662 Likely benign(Last reviewed: Jan 1, 2019)

VCV000975257
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G>T
(p.Gln554His)
NM_006766.5(
KAT6A):c.5572
C>T
(p.Arg1858Cys) Likely benign(Last reviewed: Jan 1, 2019)

VCV000975256

NM_006766.5(
KAT6A):c.2710
G>A
(p.Glu904Lys) Likely benign(Last reviewed: Jan 1, 2019)

VCV000975255

NM_006766.5(
KAT6A):c.5666
G>A
(p.Arg1889His) Likely benign(Last reviewed: Jan 12, 2018)

VCV000734321

NM_006766.5(
KAT6A):c.958C
>G
(p.Leu320Val) Likely benign(Last reviewed: Jan 12, 2022)

VCV001254827

NM_006766.5(
KAT6A):c.3040
-8T>C
Likely benign(Last reviewed: Jan 13, 2021)

VCV001187477

NM_006766.5(
KAT6A):c.1903
-206C>T
Likely benign(Last reviewed: Jan 28, 2019)

VCV001217129

NM_006766.5(
KAT6A):c.1043
T>G
(p.Val348Gly) Likely benign(Last reviewed: Jan 31, 2018)

VCV000589247

NM_006766.5(
KAT6A):c.1599
-10T>C
Likely benign(Last reviewed: Jan 5, 2021)

VCV001329611

NM_006766.5(
KAT6A):c.5185
A>T
(p.Ile1729Leu) Likely benign(Last reviewed: Jul 14, 2020)

VCV001198558

NM_006766.5(
KAT6A):c.4503
C>T
(p.Asn1501=) Likely benign(Last reviewed: Jul 26, 2016)

VCV000588093

NM_006766.5(
KAT6A):c.4512
C>T
(p.Ala1504=)
Likely benign(Last reviewed: Jun 1, 2021)

VCV001176883

NM_006766.5(
KAT6A):c.4119
C>T
(p.Ser1373=)
Likely benign(Last reviewed: Jun 4, 2021)

VCV001327333

NM_006766.5(
KAT6A):c.5494 Likely benign(Last reviewed: Mar 1, 2019)

VCV001209314
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A>G
(p.Met1832Val)
NM_006766.5(
KAT6A):c.5019
A>G
(p.Pro1673=)
Likely benign(Last reviewed: Mar 21, 2017)

VCV000587796

NM_006766.5(
KAT6A):c.17A>G
Likely benign(Last reviewed: Mar 31, 2019)

VCV001206802

NM_006766.5(
KAT6A):c.2983
G>A
(p.Glu995Lys) Likely benign(Last reviewed: Mar 5, 2018)

VCV000548600

NM_006766.5(
KAT6A):c.2760
G>C
(p.Leu920=)
Likely benign(Last reviewed: Mar 9, 2017)

VCV000589558

NM_006766.5(
KAT6A):c.2505
A>G
(p.Pro835=)
Likely benign(Last reviewed: May 12, 2021)

VCV001321557

NM_006766.5(
KAT6A):c.4988
C>T
(p.Pro1663Leu) Likely benign(Last reviewed: May 14, 2018)

VCV000589048

NM_006766.5(
KAT6A):c.4150
G>A
(p.Val1384Met) Likely benign(Last reviewed: May 26, 2021)

VCV001197725

NM_006766.5(
KAT6A):c.2633
G>A
(p.Arg878His) Likely benign(Last reviewed: May 27, 2020)

VCV001198352

NM_006766.5(
KAT6A):c.5776
C>G
(p.Arg1926Gly) Likely benign(Last reviewed: May 28, 2019)

VCV000802401

NM_006766.5(
KAT6A):c.2241
C>A (p.Ile747=) Likely benign(Last reviewed: May 5, 2021)

VCV001321530

NM_006766.5(
KAT6A):c.4560
C>T
(p.Ser1520=)
Likely benign(Last reviewed: Nov 1, 2021)

VCV001335709

NM_006766.5(
KAT6A):c.5668
G>A
(p.Ala1890Thr) Likely benign(Last reviewed: Nov 15, 2017)

VCV000725886
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NM_006766.5(
KAT6A):c.3833
G>A
(p.Arg1278His) Likely benign(Last reviewed: Nov 24, 2020)

VCV001218506

NM_006766.5(
KAT6A):c.1363
+65T>C
Likely benign(Last reviewed: Nov 25, 2018)

VCV001199783

NM_006766.5(
KAT6A):c.5683
C>T
(p.Arg1895Cys) Likely benign(Last reviewed: Nov 25, 2020)

VCV001207257

NM_006766.5(
KAT6A):c.5549
C>T
(p.Pro1850Leu) Likely benign(Last reviewed: Nov 30, 2017)

VCV000787620

NM_006766.5(
KAT6A):c.3040
-83A>G
Likely benign(Last reviewed: Nov 5, 2018)

VCV001205810

NM_006766.5(
KAT6A):c.3936
C>T
(p.Asp1312=) Likely benign(Last reviewed: Nov 6, 2020)

VCV001193761

NM_006766.5(
KAT6A):c.3040
-9A>G
Likely benign(Last reviewed: Oct 13, 2020)

VCV001211647

NM_006766.5(
KAT6A):c.1010
G>A
(p.Arg337His) Likely benign(Last reviewed: Oct 15, 2020)

VCV001254687

NM_006766.5(
KAT6A):c.1996
+278T>G
Likely benign(Last reviewed: Oct 16, 2018)

VCV001219902

NM_006766.5(
KAT6A):c.1482
+238dup
Likely benign(Last reviewed: Oct 17, 2018)

VCV001208341

NM_006766.5(
KAT6A):c.2437
-267A>G
Likely benign(Last reviewed: Oct 17, 2018)

VCV001195547

NM_006766.5(
KAT6A):c.1044
-280C>T
Likely benign(Last reviewed: Oct 5, 2018)

VCV001195795

NM_006766.5(
KAT6A):c.3225
T>C
(p.Asp1075=) Likely benign(Last reviewed: Oct 5, 2020)

VCV001208736

NM_006766.5(
KAT6A):c.3264
G>T
(p.Leu1088Phe
)
Likely benign(Last reviewed: Oct 8, 2020)

VCV001223761
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NM_006766.5(
KAT6A):c.1996
+90_1996+101
del
Likely benign(Last reviewed: Oct 9, 2019)

VCV001191665

NM_006766.5(
KAT6A):c.2986
A>G
(p.Ser996Gly) Likely benign(Last reviewed: Sep 17, 2019)

VCV001189464

NM_006766.5(
KAT6A):c.1044
-180G>T
Likely benign(Last reviewed: Sep 19, 2019)

VCV001204832

NM_006766.5(
KAT6A):c.336G
>C
(p.Glu112Asp) Likely benign(Last reviewed: Sep 2, 2019)

VCV001204805

NM_006766.5(
KAT6A):c.1996
+50GT[25]
Likely benign(Last reviewed: Sep 2, 2019)

VCV001199080

NM_006766.5(
KAT6A):c.5101
C>T
(p.Pro1701Ser) Likely benign(Last reviewed: Sep 23, 2020)

VCV000984622

NM_006766.5(
KAT6A):c.3256
C>T
(p.Arg1086Cys) Likely benign(Last reviewed: Sep 24, 2020)

VCV001198511

NM_006766.5(
KAT6A):c.825+
53G>C
Likely benign(Last reviewed: Sep 26, 2018)

VCV001216193

NM_006766.5(
KAT6A):c.826236_826232del
Likely benign(Last reviewed: Sep 26, 2018)

VCV001201893

NM_006766.5(
KAT6A):c.192G>C
Likely benign(Last reviewed: Sep 26, 2018)

VCV001195781

NM_006766.5(
KAT6A):c.710215G>A
Likely benign(Last reviewed: Sep 26, 2018)

VCV001193899

NM_006766.5(
KAT6A):c.601183C>T
Likely benign(Last reviewed: Sep 26, 2018)

VCV001191337

NM_006766.5(
KAT6A):c.2965
GAG[4]
(p.Glu993del) Likely benign(Last reviewed: Sep 29, 2021)

VCV001300574

NM_006766.5(
KAT6A):c.5644
G>A
(p.Val1882Ile) Likely benign(Last reviewed: Sep 3, 2019)

VCV001186257
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NM_006766.5(
KAT6A):c.5019
ACC[3]
(p.Pro1675dup) Likely benign(Last reviewed: Sep 8, 2021)

VCV000589573

NM_006766.5(
KAT6A):c.3921
_3922del
(p.Glu1307fs) Likely pathogenic

VCV001334428

NM_006766.5(
KAT6A):c.1582
C>T
(p.Pro528Ser) Likely pathogenic

VCV000996682

NM_006766.5(
KAT6A):c.2007
del
(p.Leu669fs)
Likely pathogenic(Last reviewed: Apr 1, 2018)

VCV000624321

NM_006766.5(
KAT6A):c.4688
_4689del
(p.Asn1562_Ty
r1563insTer)
Likely pathogenic(Last reviewed: Apr 7, 2015)

VCV000559923

NM_006766.5(
KAT6A):c.296G
>A
(p.Trp99Ter)
Likely pathogenic(Last reviewed: Aug 1, 2017)

VCV000493478

NM_006766.5(
KAT6A):c.4399
C>T
(p.Gln1467Ter) Likely pathogenic(Last reviewed: Aug 7, 2019)

VCV000422237

NM_006766.5(
KAT6A):c.4861
C>T
(p.Gln1621Ter) Likely pathogenic(Last reviewed: Dec 9, 2021)

VCV001334703

NM_006766.5(
KAT6A):c.4070
del
(p.Gln1357fs) Likely pathogenic(Last reviewed: Jan 1, 2019)

VCV000982773

NM_006766.5(
KAT6A):c.4666
A>T
(p.Ile1556Phe) Likely pathogenic(Last reviewed: Jan 1, 2019)

VCV000975406

NM_006766.5(
KAT6A):c.5123
del
(p.Asn1708fs) Likely pathogenic(Last reviewed: Jan 3, 2022)

VCV001333695

NM_006766.5(
KAT6A):c.2437
-3C>G
Likely pathogenic(Last reviewed: Jan 9, 2017)

VCV000392057

NM_006766.5(
KAT6A):c.3596 Likely pathogenic(Last reviewed: Jul 11, 2017)

VCV000559924
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del
(p.Gly1199fs)
NM_006766.5(
KAT6A):c.4037
del
(p.Gly1346fs)
Likely pathogenic(Last reviewed: Jul 18, 2018)

VCV000817161

NM_006766.5(
KAT6A):c.3040
-1G>T
Likely pathogenic(Last reviewed: Jun 17, 2016)

VCV000985644

NM_006766.5(
KAT6A):c.5701
del
(p.Val1901fs)
Likely pathogenic(Last reviewed: Jun 3, 2021)

VCV001321924

NM_006766.5(
KAT6A):c.3039
+1G>T
Likely pathogenic(Last reviewed: Mar 1, 2017)

VCV000444748

NM_006766.5(
KAT6A):c.5248
_5257del
(p.Ala1749_Thr
1750insTer)
Likely pathogenic(Last reviewed: Mar 20, 2018)

VCV000523923

NM_006766.5(
KAT6A):c.3184
G>T
(p.Glu1062Ter) Likely pathogenic(Last reviewed: Mar 20, 2018)

VCV000523839

NM_006766.5(
KAT6A):c.4085
del
(p.Lys1362fs) Likely pathogenic(Last reviewed: May 1, 2021)

VCV001176884

NM_006766.5(
KAT6A):c.4664
G>A
(p.Ser1555Asn) Likely pathogenic(Last reviewed: May 26, 2020)

VCV000976788

NM_006766.5(
KAT6A):c.5645
_5646delinsGC
TGGCCGTA
(p.Val1882fs)
Likely pathogenic(Last reviewed: May 26, 2020)

VCV000817979

NM_006766.5(
KAT6A):c.1280
G>T
(p.Arg427Leu) Likely pathogenic(Last reviewed: Nov 19, 2015)

VCV000430275

NM_006766.5(
KAT6A):c.3039
+1del
Likely pathogenic(Last reviewed: Oct 19, 2017)

VCV000453041

NM_006766.5(
KAT6A):c.2437
-1G>A
Likely pathogenic(Last reviewed: Oct 23, 2020)

VCV000986888
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NM_006766.5(
KAT6A):c.1907
_1908del
(p.Lys636fs)
Likely pathogenic(Last reviewed: Oct 5, 2020)

VCV000988723

NM_006766.5(
KAT6A):c.3212
A>C
(p.Glu1071Ala) Likely pathogenic(Last reviewed: Sep 13, 2015)

VCV000429660

NM_006766.5(
KAT6A):c.4819
C>T
(p.Gln1607Ter) Likely pathogenic(Last reviewed: Sep 19, 2017)

VCV000451851

NM_006766.5(
KAT6A):c.4348
_4349del
(p.Leu1450fs) Likely pathogenic(Last reviewed: Sep 25, 2020)

VCV000988752

NM_006766.5(
KAT6A):c.5736
T>G
(p.Asn1912Lys) not provided

VCV000818162

NM_006766.5(
KAT6A):c.1506
del
(p.Asp503fs)
Pathogenic

VCV001172592

GRCh37/hg19
8p11.2111.1(chr8:4069
019843388233)x3
Pathogenic

VCV000394062

GRCh37/hg19
8p23.111.1(chr8:1258
013243388233)x3
Pathogenic

VCV000394647

GRCh37/hg19
8p23.311.1(chr8:1580
4843786723)x3
Pathogenic

VCV000397117

GRCh37/hg19
8p23.3q24.3(chr8:158
991146280828)x3 Pathogenic

VCV000394884

NM_006766.5(
KAT6A):c.3039
+1G>A
Pathogenic(Last reviewed: Apr 10, 2020)

VCV000984972

NM_006766.5(
KAT6A):c.4398
_4399del
(p.Gln1467fs) Pathogenic(Last reviewed: Apr 14, 2020)

VCV001323134
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NM_006766.5(
KAT6A):c.1786
_1787del
(p.Leu596fs)
Pathogenic(Last reviewed: Apr 20, 2020)

VCV000978867

NM_006766.5(
KAT6A):c.4069
C>T
(p.Gln1357Ter) Pathogenic(Last reviewed: Apr 20, 2020)

VCV000978866

NM_006766.5(
KAT6A):c.3703
G>T
(p.Glu1235Ter) Pathogenic(Last reviewed: Apr 20, 2020)

VCV000978865

NM_006766.5(
KAT6A):c.1569
C>A
(p.Tyr523Ter) Pathogenic(Last reviewed: Apr 20, 2020)

VCV000978864

NM_006766.5(
KAT6A):c.3432
dup
(p.Pro1145fs) Pathogenic(Last reviewed: Apr 25, 2016)

VCV000280545

NM_006766.5(
KAT6A):c.2127
del
(p.Lys709fs)
Pathogenic(Last reviewed: Apr 25, 2017)

VCV000985477

NM_006766.5(
KAT6A):c.4945
C>T
(p.Gln1649Ter) Pathogenic(Last reviewed: Apr 3, 2020)

VCV000984649

GRCh38/hg38
8p11.21q11.21(chr8:41
84569947893948)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059786

GRCh38/hg38
8p11.2111.1(chr8:3998
142443532444)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059784

GRCh38/hg38
8p11.2311.21(chr8:378
9943042371734)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059782

GRCh38/hg38
8p11.22q11.21(chr8:39
83063349209461)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059783
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GRCh38/hg38
8p1211.21(chr8:343
1225043158901)x1
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000057114

GRCh38/hg38
8p12q11.21(chr8:29
71989748521849)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000057312

GRCh38/hg38
8p21.2q11.21(chr8:25
83213048521849)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000057237

GRCh38/hg38
8p23.111.21(chr8:126
0997542085703)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000161033

GRCh38/hg38
8p22q11.21(chr8:14
94011047929925)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059769

GRCh38/hg38
8p23.111.1(chr8:1272
890443673207)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000161019

GRCh38/hg38
8p23.111.1(chr8:1275
079643532444)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059766

GRCh38/hg38
8p23.111.1(chr8:1260
997543336172)x3
Pathogenic(Last reviewed: Aug 12, 2011)

VCV000059764

GRCh38/hg38
8p23.3q24.3(chr8:241
530145049449)x3 Pathogenic(Last reviewed: Aug 12, 2011)

VCV000057496

NM_006766.5(
KAT6A):c.442C
>T
(p.Arg148Ter) Pathogenic(Last reviewed: Aug 13, 2018)

VCV000589472
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GRCh37/hg19
8p23.1q24.3(chr8:124
90999146295771)x3 Pathogenic(Last reviewed: Aug 15, 2014)

VCV000443619

GRCh38/hg38
8p23.111.1(chr8:1264
612343686843)x3
Pathogenic(Last reviewed: Aug 2, 2011)

VCV000151014

GRCh38/hg38
8p23.3q24.3(chr8:208
048145070385)x3 Pathogenic(Last reviewed: Aug 2, 2013)

VCV000153413

NM_006766.5(
KAT6A):c.1085
_1089dup
(p.Arg364fs)
Pathogenic(Last reviewed: Aug 21, 2017)

VCV000451609

NM_006766.5(
KAT6A):c.4361
dup
(p.Thr1455fs)
Pathogenic(Last reviewed: Aug 22, 2015)

VCV000419571

GRCh38/hg38
8p21.3q24.3(chr8:212
91522145070385)x3 Pathogenic(Last reviewed: Aug 26, 2013)

VCV000153737

NM_006766.5(
KAT6A):c.2463
del
(p.Asn821fs)
Pathogenic(Last reviewed: Aug 29, 2018)

VCV001034308

GRCh38/hg38
8p23.3q24.3(chr8:226
452145068712)x3 Pathogenic(Last reviewed: Dec 10, 2012)

VCV000154791

NM_006766.5(
KAT6A):c.4228
_4232del
(p.Lys1410fs) Pathogenic(Last reviewed: Dec 13, 2018)

VCV000524135

GRCh38/hg38
8p11.2111.1(chr8:3996
053143673207)x3
Pathogenic(Last reviewed: Dec 22, 2010)

VCV000154596

GRCh38/hg38
8p23.111.1(chr8:1272
890443673207)x3
Pathogenic(Last reviewed: Dec 22, 2010)

VCV000032941

306

GRCh38/hg38
8p23.111.1(chr8:1260
997543673207)x3
Pathogenic(Last reviewed: Dec 22, 2010)

VCV000146507

GRCh38/hg38
8p23.111.1(chr8:1218
242143673207)x3
Pathogenic(Last reviewed: Dec 22, 2010)

VCV000148174

NM_006766.5(
KAT6A):c.1176
del
(p.Cys393fs)
Pathogenic(Last reviewed: Feb 27, 2018)

VCV000504378

GRCh37/hg19
8p23.3q24.3(chr8:102
13146293414)x3 Pathogenic(Last reviewed: Jan 1, 2013)

VCV000610612

NM_006766.5(
KAT6A):c.3034
C>T
(p.Arg1012Ter) Pathogenic(Last reviewed: Jan 1, 2019)

VCV000975405

NM_006766.5(
KAT6A):c.1663
del
(p.Gln555fs)
Pathogenic(Last reviewed: Jan 1, 2019)

VCV000975259

NM_006766.5(
KAT6A):c.3385
C>T
(p.Arg1129Ter) Pathogenic(Last reviewed: Jan 1, 2019)

VCV000180229

NM_006766.5(
KAT6A):c.4025
del
(p.Lys1342fs) Pathogenic(Last reviewed: Jan 10, 2018)

VCV000419562

NM_006766.5(
KAT6A):c.3306
del
(p.Lys1103fs) Pathogenic(Last reviewed: Jan 16, 2020)

VCV000807616

NM_006766.5(
KAT6A):c.805C
>T
(p.Arg269Ter) Pathogenic(Last reviewed: Jan 23, 2019)

VCV000620554

GRCh38/hg38
8p23.111.1(chr8:1238
358443673207)x3
Pathogenic(Last reviewed: Jan 24, 2011)

VCV000146257

NM_006766.5(
KAT6A):c.1473 Pathogenic(Last reviewed: Jan 4, 2019)

VCV000817975

307

_1476dup
(p.Leu493fs)
GRCh37/hg19
8p23.3q24.3(chr8:164
984146293414)x3 Pathogenic(Last reviewed: Jan 5, 2017)

VCV000610618

NM_006766.5(
KAT6A):c.5566
del
(p.Ser1856fs) Pathogenic(Last reviewed: Jan 7, 2019)

VCV000817973

NM_006766.5(
KAT6A):c.5546
_5555del
(p.Met1849fs) Pathogenic(Last reviewed: Jan 8, 2016)

VCV000280240

NM_006766.5(
KAT6A):c.856C
>T
(p.Arg286Ter) Pathogenic(Last reviewed: Jul 13, 2018)

VCV000598767

NM_006766.5(
KAT6A):c.4381
C>T
(p.Gln1461Ter) Pathogenic(Last reviewed: Jul 2, 2020)

VCV000391696

GRCh37/hg19
8p12q24.3(chr8:319
36551146295771)x3 Pathogenic(Last reviewed: Jul 25, 2018)

VCV000687493

NM_006766.5(
KAT6A):c.3318
_3319insCT
(p.Glu1107fs) Pathogenic(Last reviewed: Jun 11, 2019)

VCV000807615

NM_006766.5(
KAT6A):c.1096
C>T
(p.Arg366Ter) Pathogenic(Last reviewed: Jun 18, 2018)

VCV000620229

NM_006766.5(
KAT6A):c.3182
T>G
(p.Leu1061Ter) Pathogenic(Last reviewed: Jun 21, 2016)

VCV000280659

NM_006766.5(
KAT6A):c.3928
C>T
(p.Gln1310Ter) Pathogenic(Last reviewed: Jun 28, 2016)

VCV000985176

NM_006766.5(
KAT6A):c.5639
C>A
(p.Ser1880Ter) Pathogenic(Last reviewed: Jun 29, 2017)

VCV000489019

308

NM_006766.5(
KAT6A):c.3353
-3_3353dup
Pathogenic(Last reviewed: Jun 30, 2017)

VCV000450319

NM_006766.5(
KAT6A):c.1903
-5_1903-2del
Pathogenic(Last reviewed: Mar 1, 2019)

VCV000692079

NM_006766.5(
KAT6A):c.3443
del
(p.Lys1148fs) Pathogenic(Last reviewed: Mar 22, 2018)

VCV000559638

NM_006766.5(
KAT6A):c.3553
C>T
(p.Gln1185Ter) Pathogenic(Last reviewed: Mar 29, 2016)

VCV000280462

NM_006766.5(
KAT6A):c.1146
_1147insG
(p.Tyr383fs)
Pathogenic(Last reviewed: Mar 29, 2021)

VCV001048764

NM_006766.5(
KAT6A):c.3692
del
(p.Ala1231fs)
Pathogenic(Last reviewed: Mar 30, 2020)

VCV000985843

NM_006766.5(
KAT6A):c.3879
dup
(p.Glu1294fs) Pathogenic(Last reviewed: Mar 5, 2015)

VCV000180678

GRCh37/hg19
8p23.3q24.3(chr8:158
049146295771)x3 Pathogenic(Last reviewed: Mar 5, 2015)

VCV000442201

NM_006766.5:c
.3411del
Pathogenic(Last reviewed: May 14, 2021)

VCV001082502

NM_006766.5(
KAT6A):c.1928
A>G
(p.Asn643Ser) Pathogenic(Last reviewed: May 14, 2021)

VCV000626907

NM_006766.5(
KAT6A):c.1900
A>T
(p.Lys634Ter) Pathogenic(Last reviewed: May 18, 2017)

VCV000985898

NM_006766.5(
KAT6A):c.3780
del
(p.Pro1261fs) Pathogenic(Last reviewed: May 2, 2018)

VCV000545910

NM_006766.5(
KAT6A):c.3782
del
(p.Pro1261fs) Pathogenic(Last reviewed: May 2, 2018)

VCV000524127

309

NM_006766.5(
KAT6A):c.3395
_3396del
(p.Asp1132fs) Pathogenic(Last reviewed: May 23, 2016)

VCV000985124

GRCh37/hg19
8p11.22q12.3(chr8:395
5565764049089)x3
Pathogenic(Last reviewed: May 26, 2017)

VCV000685558

GRCh38/hg38
8p23.111.21(chr8:126
0997542085703)x3
Pathogenic(Last reviewed: May 27, 2010)

VCV000034276

NM_006766.5(
KAT6A):c.1536
dup
(p.Glu513Ter) Pathogenic(Last reviewed: May 27, 2016)

VCV000280641

GRCh37/hg19
8p23.111.1(chr8:1193
502343824035)x3
Pathogenic(Last reviewed: May 5, 2014)

VCV000443194

NM_006766.5(
KAT6A):c.3116
_3117del
(p.Ile1038_Ser
1039insTer)
Pathogenic(Last reviewed: May 5, 2016)

VCV000162616

NM_006766.5(
KAT6A):c.1312
C>T
(p.Arg438Ter) Pathogenic(Last reviewed: Nov 21, 2021)

VCV001325410

NM_006766.5(
KAT6A):c.4256
_4260dup
(p.Asp1421fs) Pathogenic(Last reviewed: Nov 23, 2018)

VCV000817328

NM_006766.5(
KAT6A):c.1405
C>T
(p.Arg469Ter) Pathogenic(Last reviewed: Nov 23, 2021)

VCV001285569

NM_006766.5(
KAT6A):c.4210
dup
(p.Glu1404fs) Pathogenic(Last reviewed: Nov 24, 2016)

VCV000373672

NM_006766.5(
KAT6A):c.4254
_4257del
(p.Glu1419fs) Pathogenic(Last reviewed: Nov 30, 2015)

VCV000369686

GRCh37/hg19
8p11.21(chr8:4 Pathogenic(Last reviewed: Nov 30, 2017)

VCV000687703

310

176181342107108)x1
NM_006766.5(
KAT6A):c.3661
G>T
(p.Glu1221Ter) Pathogenic(Last reviewed: Nov 7, 2019)

VCV000280246

GRCh37/hg19
8p23.311.1(chr8:1768
14-43396776) Pathogenic(Last reviewed: Oct 1, 2020)

VCV000997076

NM_006766.5(
KAT6A):c.3055
C>T
(p.Arg1019Ter) Pathogenic(Last reviewed: Oct 12, 2019)

VCV000489088

NM_006766.5(
KAT6A):c.4372
_4373del
(p.Ser1458fs) Pathogenic(Last reviewed: Oct 15, 2019)

VCV000817759

GRCh38/hg38
8p23.3q24.3(chr8:241
530145054634)x3 Pathogenic(Last reviewed: Oct 19, 2010)

VCV000059738

NM_006766.5(
KAT6A):c.3973
G>T
(p.Glu1325Ter) Pathogenic(Last reviewed: Oct 23, 2020)

VCV000987501

NM_006766.5(
KAT6A):c.1465
_1471del
(p.Gln489fs)
Pathogenic(Last reviewed: Oct 23, 2020)

VCV000987373

NM_006766.5(
KAT6A):c.3286
dup
(p.Cys1096fs) Pathogenic(Last reviewed: Oct 9, 2016)

VCV000985670

NM_006766.5(
KAT6A):c.3412
del
(p.Glu1139fs) Pathogenic(Last reviewed: Oct 9, 2017)

VCV000452579

NM_006766.5(
KAT6A):c.907+
1del
Pathogenic(Last reviewed: Sep 18, 2017)

VCV000620010

GRCh37/hg19
8p23.3q24.3(chr8:158
048146295771)x3 Pathogenic(Last reviewed: Sep 18, 2018)

VCV000687787

311

GRCh38/hg38
8p12q12.1(chr8:365
8010359618998)x3
Pathogenic(Last reviewed: Sep 21, 2012)

VCV000150770

GRCh38/hg38
8p23.3q24.3(chr8:241
605145054781)x3 Pathogenic(Last reviewed: Sep 21, 2012)

VCV000149660

NM_006766.5(
KAT6A):c.658C
>T
(p.Arg220Ter) Pathogenic(Last reviewed: Sep 5, 2018)

VCV000620356

NM_006766.5(
KAT6A):c.931C
>T
(p.Arg311Ter) Pathogenic(Last reviewed: Sep 6, 2019)

VCV000419207

GRCh37/hg19
8p23.3q24.3(chr8:158
049146295771)
Pathogenic(Last reviewed: Sep 9, 2015)

VCV000442200

NM_006766.5(
KAT6A):c.3070
C>T
(p.Arg1024Ter) Pathogenic(Last reviewed: Sep 9, 2021)

VCV000180230

NM_006766.5(
KAT6A):c.3353
-1G>A
Pathogenic/Likely pathogenic(Last reviewed: Apr 26, 2021)

VCV000449582

NM_006766.5(
KAT6A):c.2218
del
(p.Arg740fs)
Pathogenic/Likely pathogenic(Last reviewed: Feb 5, 2020)

VCV000828153

NM_006766.5(
KAT6A):c.4645
G>A
(p.Gly1549Ser) Pathogenic/Likely pathogenic(Last reviewed: Jan 3, 2022)

VCV000419627

NM_006766.5(
KAT6A):c.4038
del
(p.Val1347fs)
Pathogenic/Likely pathogenic(Last reviewed: Jul 18, 2018)

VCV000617516

NM_006766.5(
KAT6A):c.949C
>T
(p.Arg317Ter) Pathogenic/Likely pathogenic(Last reviewed: Oct 23, 2020)

VCV000489323

GRCh37/hg19
8p21.2q12.1(chr8:247
7206424813176)x3
Uncertain significance

VCV000393993

312

NM_006766.5(
KAT6A):c.4804
A>G
(p.Ser1602Gly) Uncertain significance(Last reviewed: Apr 12, 2021)

VCV001303206

NM_006766.5(
KAT6A):c.6013C>T
Uncertain significance(Last reviewed: Apr 15, 2020)

VCV001013743

NM_006766.5(
KAT6A):c.4776
GTC[1]
(p.Ser1597del) Uncertain significance(Last reviewed: Apr 18, 2018)

VCV000588522

NM_006766.5(
KAT6A):c.5974
G>C
(p.Val1992Leu) Uncertain significance(Last reviewed: Apr 20, 2018)

VCV000452008

NM_006766.5(
KAT6A):c.5366
C>G
(p.Thr1789Arg) Uncertain significance(Last reviewed: Apr 23, 2019)

VCV001305371

NM_006766.5(
KAT6A):c.5560
C>T
(p.His1854Tyr) Uncertain significance(Last reviewed: Apr 27, 2019)

VCV000638390

NM_006766.5(
KAT6A):c.4108
G>T
(p.Glu1370Ter) Uncertain significance(Last reviewed: Apr 8, 2013)

VCV000162180

NM_006766.5(
KAT6A):c.4594
A>T
(p.Met1532Leu) Uncertain significance(Last reviewed: Aug 16, 2019)

VCV001307891

NM_006766.5(
KAT6A):c.2004
G>C
(p.Leu668Phe) Uncertain significance(Last reviewed: Aug 2, 2019)

VCV001307349

NM_006766.5(
KAT6A):c.96A>
G (p.Ile32Met) Uncertain significance(Last reviewed: Aug 24, 2019)

VCV000937075

NM_006766.5(
KAT6A):c.4210
G>A
(p.Glu1404Lys) Uncertain significance(Last reviewed: Aug 26, 2016)

VCV000589359

NM_006766.5(
KAT6A):c.2806
C>A
(p.Pro936Thr) Uncertain significance(Last reviewed: Aug 26, 2021)

VCV001342810

NM_006766.5(
KAT6A):c.2135
G>A
(p.Ser712Asn) Uncertain significance(Last reviewed: Aug 27, 2021)

VCV001328184

313

NM_006766.5(
KAT6A):c.4058
A>G
(p.Asp1353Gly) Uncertain significance(Last reviewed: Dec 1, 2018)

VCV000810280

NM_006766.5(
KAT6A):c.824C
>T
(p.Ala275Val) Uncertain significance(Last reviewed: Dec 12, 2019)

VCV001310917

NM_006766.5(
KAT6A):c.5135
C>T
(p.Thr1712Ile) Uncertain significance(Last reviewed: Dec 17, 2019)

VCV001310411

NM_006766.5(
KAT6A):c.5809
C>T
(p.His1937Tyr) Uncertain significance(Last reviewed: Dec 26, 2019)

VCV001310678

NM_006766.5(
KAT6A):c.4445
C>T
(p.Pro1482Leu) Uncertain significance(Last reviewed: Dec 7, 2019)

VCV001028557

NM_006766.5(
KAT6A):c.4520
G>T
(p.Ser1507Ile) Uncertain significance(Last reviewed: Dec 8, 2017)

VCV000589580

NM_006766.5(
KAT6A):c.107T
>C (p.Val36Ala) Uncertain significance(Last reviewed: Feb 1, 2019)

VCV000810281

NM_006766.5(
KAT6A):c.638T
>A
(p.Leu213His) Uncertain significance(Last reviewed: Feb 14, 2020)

VCV001311988

NM_006766.5(
KAT6A):c.406G
>A
(p.Gly136Arg) Uncertain significance(Last reviewed: Feb 15, 2021)

VCV001223701

NM_006766.5(
KAT6A):c.250A
>G
(p.Lys84Glu)
Uncertain significance(Last reviewed: Feb 17, 2020)

VCV001303125

NM_006766.5(
KAT6A):c.5594
C>T
(p.Pro1865Leu) Uncertain significance(Last reviewed: Feb 7, 2020)

VCV001311705

NM_006766.5(
KAT6A):c.3778
A>G
(p.Ser1260Gly) Uncertain significance(Last reviewed: Jan 2, 2020)

VCV001028556

NM_006766.5(
KAT6A):c.4841 Uncertain significance(Last reviewed: Jan 26, 2021)

VCV001331663

314

G>A
(p.Ser1614Asn)
NM_006766.5(
KAT6A):c.2843
G>A
(p.Arg948Gln) Uncertain significance(Last reviewed: Jan 28, 2020)

VCV000983321

NM_006766.5(
KAT6A):c.752G
>A
(p.Arg251Gln) Uncertain significance(Last reviewed: Jan 28, 2021)

VCV001285505

NM_006766.5(
KAT6A):c.4837
_4854dup
(p.Gly1613_Me
t1618dup)
Uncertain significance(Last reviewed: Jan 29, 2020)

VCV001206430

NM_006766.5(
KAT6A):c.2140
AAG[1]
(p.Lys715del) Uncertain significance(Last reviewed: Jan 31, 2018)

VCV000504267

NM_006766.5(
KAT6A):c.571G
>T
(p.Val191Leu) Uncertain significance(Last reviewed: Jan 4, 2021)

VCV000389090

NM_006766.5(
KAT6A):c.2496
A>G
(p.Glu832=)
Uncertain significance(Last reviewed: Jan 6, 2021)

VCV001313851

NM_006766.5(
KAT6A):c.2869
G>C
(p.Ala957Pro) Uncertain significance(Last reviewed: Jul 1, 2017)

VCV000493477

NM_006766.5(
KAT6A):c.3040
-9_3040-8del
Uncertain significance(Last reviewed: Jul 1, 2017)

VCV000493476

NM_006766.5(
KAT6A):c.3485
A>T
(p.His1162Leu) Uncertain significance(Last reviewed: Jul 1, 2020)

VCV001013578

NM_006766.5(
KAT6A):c.3187
C>T
(p.Pro1063Ser) Uncertain significance(Last reviewed: Jul 12, 2019)

VCV001307027

NM_006766.5(
KAT6A):c.1097
G>A
(p.Arg366Gln) Uncertain significance(Last reviewed: Jul 6, 2016)

VCV000588013

NM_006766.5(
KAT6A):c.4697
C>G
(p.Pro1566Arg) Uncertain significance(Last reviewed: Jul 8, 2019)

VCV000985405

315

NM_006766.5(
KAT6A):c.254C
>T
(p.Pro85Leu)
Uncertain significance(Last reviewed: Jul 9, 2021)

VCV001341746

NM_006766.5(
KAT6A):c.4420
T>A
(p.Cys1474Ser) Uncertain significance(Last reviewed: Jun 1, 2021)

VCV001013577

NM_006766.5(
KAT6A):c.5339
A>G
(p.Tyr1780Cys) Uncertain significance(Last reviewed: Jun 11, 2019)

VCV001219823

NM_006766.5(
KAT6A):c.4529
C>T
(p.Thr1510Ile) Uncertain significance(Last reviewed: Jun 17, 2021)

VCV001328779

NM_006766.5(
KAT6A):c.1433
C>T
(p.Thr478Ile)
Uncertain significance(Last reviewed: Jun 20, 2017)

VCV000432911

NM_006766.5(
KAT6A):c.3670
_3675del
(p.Lys1224_Glu
1225del)
Uncertain significance(Last reviewed: Jun 20, 2019)

VCV001302094

NM_006766.5(
KAT6A):c.2989
C>T
(p.Pro997Ser) Uncertain significance(Last reviewed: Jun 21, 2019)

VCV001028555

NM_006766.5(
KAT6A):c.2459
A>G
(p.Glu820Gly) Uncertain significance(Last reviewed: Jun 23, 2017)

VCV000445391

NM_006766.5(
KAT6A):c.5966
C>G
(p.Ala1989Gly) Uncertain significance(Last reviewed: Jun 26, 2019)

VCV001306757

NM_006766.5(
KAT6A):c.2911
C>T
(p.Arg971Cys) Uncertain significance(Last reviewed: Jun 29, 2020)

VCV001184331

NM_006766.5(
KAT6A):c.2008
T>C
(p.Ser670Pro) Uncertain significance(Last reviewed: Jun 3, 2021)

VCV001306132

NM_006766.5(
KAT6A):c.3989
A>G
(p.Lys1330Arg) Uncertain significance(Last reviewed: Jun 5, 2019)

VCV001306017

316

NM_006766.5(
KAT6A):c.1212
G>C
(p.Lys404Asn) Uncertain significance(Last reviewed: Jun 8, 2021)

VCV001327765

NM_006766.5(
KAT6A):c.2696
A>G
(p.Tyr899Cys) Uncertain significance(Last reviewed: Mar 1, 2021)

VCV001342656

NM_006766.5(
KAT6A):c.3299
C>G
(p.Ser1100Cys) Uncertain significance(Last reviewed: Mar 2, 2017)

VCV000589549

NM_006766.5(
KAT6A):c.2791
G>A
(p.Gly931Arg) Uncertain significance(Last reviewed: Mar 2, 2019)

VCV001028553

NM_006766.5(
KAT6A):c.2947
G>T
(p.Gly983Cys) Uncertain significance(Last reviewed: Mar 25, 2019)

VCV001028554

NM_006766.5(
KAT6A):c.458G
>A
(p.Arg153His) Uncertain significance(Last reviewed: Mar 8, 2017)

VCV000424162

NM_006766.5(
KAT6A):c.3353
-4A>G
Uncertain significance(Last reviewed: May 17, 2017)

VCV000588978

NM_006766.5(
KAT6A):c.523A
>G
(p.Asn175Asp) Uncertain significance(Last reviewed: May 17, 2021)

VCV001254350

NM_006766.5(
KAT6A):c.2915
G>C
(p.Arg972Pro) Uncertain significance(Last reviewed: May 19, 2016)

VCV000589262

NM_006766.5(
KAT6A):c.248C
>G
(p.Pro83Arg)
Uncertain significance(Last reviewed: May 24, 2021)

VCV001326554

NM_006766.5(
KAT6A):c.5921
G>A
(p.Gly1974Glu) Uncertain significance(Last reviewed: May 31, 2017)

VCV000589125

NM_006766.5(
KAT6A):c.5299
C>G
(p.His1767Asp) Uncertain significance(Last reviewed: May 4, 2020)

VCV001028560

NM_006766.5(
KAT6A):c.3830 Uncertain significance(Last reviewed: May 5, 2014)

VCV000162181

317

_3831insTT
(p.Arg1278fs)
NM_006766.5(
KAT6A):c.5207
C>T
(p.Pro1736Leu) Uncertain significance(Last reviewed: May 5, 2020)

VCV001028559

NM_006766.5(
KAT6A):c.4235
A>G
(p.Glu1412Gly) Uncertain significance(Last reviewed: May 6, 2016)

VCV000587871

NM_006766.5(
KAT6A):c.5630
G>A
(p.Arg1877His) Uncertain significance(Last reviewed: Nov 1, 2017)

VCV000547034

NM_006766.5(
KAT6A):c.26A>
G (p.Tyr9Cys) Uncertain significance(Last reviewed: Nov 1, 2021)

VCV001335710

NM_006766.5(
KAT6A):c.247C
>T
(p.Pro83Ser)
Uncertain significance(Last reviewed: Nov 18, 2016)

VCV000373381

NM_006766.5(
KAT6A):c.2366
A>G
(p.Glu789Gly) Uncertain significance(Last reviewed: Nov 19, 2019)

VCV001304714

NM_006766.5(
KAT6A):c.3032
A>C
(p.Lys1011Thr) Uncertain significance(Last reviewed: Nov 26, 2019)

VCV001310343

NM_006766.5(
KAT6A):c.3026
C>T
(p.Thr1009Met) Uncertain significance(Last reviewed: Nov 29, 2017)

VCV000595202

NM_006766.5(
KAT6A):c.766C
>T
(p.Arg256Trp) Uncertain significance(Last reviewed: Nov 29, 2019)

VCV000976403

NM_006766.5(
KAT6A):c.4949
A>C
(p.Gln1650Pro) Uncertain significance(Last reviewed: Nov 3, 2021)

VCV001319833

NM_006766.5(
KAT6A):c.2422
G>A
(p.Glu808Lys) Uncertain significance(Last reviewed: Nov 4, 2019)

VCV001309699

NM_006766.5(
KAT6A):c.4292
dup
(p.Leu1431fs) Uncertain significance(Last reviewed: Nov 6, 2013)

VCV000162182

318

NM_006766.5(
KAT6A):c.4598
T>C
(p.Met1533Thr) Uncertain significance(Last reviewed: Nov 8, 2018)

VCV001034309

NM_006766.5(
KAT6A):c.3412
C>T
(p.Leu1138Phe
)
Uncertain significance(Last reviewed: Oct 1, 2019)

VCV000871561

NM_006766.5(
KAT6A):c.4688
A>T
(p.Tyr1563Phe) Uncertain significance(Last reviewed: Oct 1, 2019)

VCV000871560

NM_006766.5(
KAT6A):c.3982
A>G
(p.Lys1328Glu) Uncertain significance(Last reviewed: Oct 12, 2016)

VCV000376989

NM_006766.5(
KAT6A):c.4752
G>C
(p.Gln1584His) Uncertain significance(Last reviewed: Oct 22, 2020)

VCV001313294

NM_006766.5(
KAT6A):c.5878
A>C
(p.Ser1960Arg) Uncertain significance(Last reviewed: Oct 23, 2018)

VCV000388829

NM_006766.5(
KAT6A):c.68A>
G (p.Gln23Arg) Uncertain significance(Last reviewed: Oct 25, 2019)

VCV001309657

NM_006766.5(
KAT6A):c.4960
C>A
(p.Pro1654Thr) Uncertain significance(Last reviewed: Oct 3, 2019)

VCV001028558

NC_000008.10:
g.(?_41905876)
_(42188497_?)
dup
Uncertain significance(Last reviewed: Oct 7, 2020)

VCV001061009

NM_006766.5(
KAT6A):c.5817
C>A
(p.Asn1939Lys) Uncertain significance(Last reviewed: Sep 1, 2019)

VCV001303386

NM_006766.5(
KAT6A):c.5270
A>G
(p.Gln1757Arg) Uncertain significance(Last reviewed: Sep 1, 2021)

VCV001013576

NM_006766.5(
KAT6A):c.205A
>C
(p.Asn69His)
Uncertain significance(Last reviewed: Sep 16, 2020)

VCV000992311

319

GRCh37/hg19
8p1211.1(chr8:3609
442143822214)x3
Uncertain significance(Last reviewed: Sep 17, 2018)

320

VCV000688131

